<SEC-DOCUMENT>0001641172-25-017647.txt : 20250929
<SEC-HEADER>0001641172-25-017647.hdr.sgml : 20250929
<ACCEPTANCE-DATETIME>20250702195034
<PRIVATE-TO-PUBLIC>
ACCESSION NUMBER:		0001641172-25-017647
CONFORMED SUBMISSION TYPE:	DRS
PUBLIC DOCUMENT COUNT:		4
FILED AS OF DATE:		20250703
<PUBLIC-REL-DATE>20250929
DATE AS OF CHANGE:		20250702

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			PALISADE BIO, INC.
		CENTRAL INDEX KEY:			0001357459
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		ORGANIZATION NAME:           	03 Life Sciences
		EIN:				522007292
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		DRS
		SEC ACT:		1933 Act
		SEC FILE NUMBER:	377-08174
		FILM NUMBER:		251103398

	BUSINESS ADDRESS:	
		STREET 1:		7750 EL CAMINO REAL, SUITE 5200
		CITY:			CARLSBAD
		STATE:			CA
		ZIP:			92009
		BUSINESS PHONE:		(858) 704-4900

	MAIL ADDRESS:	
		STREET 1:		7750 EL CAMINO REAL, SUITE 5200
		CITY:			CARLSBAD
		STATE:			CA
		ZIP:			92009

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Seneca Biopharma, Inc.
		DATE OF NAME CHANGE:	20200127

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Neuralstem, Inc.
		DATE OF NAME CHANGE:	20060324
</SEC-HEADER>
<DOCUMENT>
<TYPE>DRS
<SEQUENCE>1
<FILENAME>filename1.htm
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>As
confidentially submitted to the Securities and Exchange Commission on July 2, 2025. This draft registration statement has not been publicly
filed with the Securities and Exchange Commission and all information herein remains strictly confidential.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Registration
No. 333-</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 4pt solid; border-bottom: Black 1pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: right"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 18pt"><B>UNITED
STATES</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 18pt"><B>SECURITIES
AND EXCHANGE COMMISSION</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 12pt"><B>WASHINGTON,
D.C. 20549</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 18pt"><B>FORM
S-1</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>REGISTRATION
STATEMENT</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>UNDER</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>THE
SECURITIES ACT OF 1933</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 18pt"><B>Palisade
Bio, Inc.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>(Exact
Name of Registrant as Specified in Its Charter)</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center; width: 32%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Delaware</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center; width: 32%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>2834</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center; width: 32%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>52-2007292</B></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>(State
    or Other Jurisdiction of<BR>
    Incorporation or Organization)</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>(Primary
    Standard Industrial<BR>
    Classification Code Number)</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>(I.R.S.
    Employer<BR>
    Identification Number)</B></FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Palisade
Bio, Inc.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>7750
El Camino Real, Suite 2A</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Carlsbad,
CA 92009</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>(858)
704-4900</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>(Address,
including zip code, and telephone number, including area code of registrant&rsquo;s principal executive offices)</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Palisade
Bio, Inc.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>JD
Finley</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Chief
Executive Officer</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>7750
El Camino Real, Suite 2A</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Carlsbad,
CA 92009</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>(858)
704-4900</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>(Name,
address, including zip code, and telephone number, including area code, of agent for service)</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Copies
to:</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 50%"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Jeffrey
                                            C. Thacker</B></FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Ryan
    J. Gunderson</B></FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>John
    E. Maciejewski</B></FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Gunderson
    Dettmer Stough Villeneuve</B></FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Franklin
    &amp; Hachigian, LLP</B></FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>3570
    Carmel Mountain Road, Suite 200</B></FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>San
    Diego, California 92130</B></FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>(858)
    436-8000</B></FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"></P></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 50%"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Michael
                                            Nertney</B></FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Ellenoff
    Grossman &amp; Schole LLP</B></FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>1345
    Avenue of the Americas</B></FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>New
    York, NY 10105</B></FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>(212)
    370-1300</B></FONT></P></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Approximate
date of commencement of proposed sale to the public: As soon as practicable after the effective date of this registration statement.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
any of the securities being registered on this Form are to be offered on a delayed or continuous basis pursuant to Rule 415 under the
Securities Act of 1933 check the following box. &#9746;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 12.5pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
this Form is filed to register additional securities for an offering pursuant to Rule 462(b) under the Securities Act, please check the
following box and list the Securities Act registration statement number of the earlier effective registration statement for the same
offering. &#9744;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
this Form is a post-effective amendment filed pursuant to Rule 462(c) under the Securities Act, check the following box and list the
Securities Act registration statement number of the earlier effective registration statement for the same offering. &#9744;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
this Form is a post-effective amendment filed pursuant to Rule 462(d) under the Securities Act, check the following box and list the
Securities Act registration statement number of the earlier effective registration statement for the same offering. &#9744;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Indicate
by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company,
or an emerging growth company. See the definitions of &ldquo;large accelerated filer,&rdquo; &ldquo;accelerated filer,&rdquo; &ldquo;smaller
reporting company,&rdquo; and &ldquo;emerging growth company&rdquo; in Rule 12b-2 of the Exchange Act.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 12.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 45%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Large
    accelerated filer</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 5%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9744;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 45%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Accelerated
    filer</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right; width: 5%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9744;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Non-accelerated
    filer</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9746;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Smaller
    reporting company</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9746;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Emerging
    growth company</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9744;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying
with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. &#9744;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>The
registrant hereby amends this registration statement on such date or dates as may be necessary to delay its effective date until the
registrant shall file a further amendment which specifically states that this registration statement shall thereafter become effective
in accordance with section 8(a) of the Securities Act of 1933 or until the registration statement shall become effective on such date
as the Securities and Exchange Commission, acting pursuant to said section 8(a), may determine.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid; border-bottom: Black 4pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; color: red"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>The
information in this preliminary prospectus is not complete and may be changed. We may not sell these securities until the registration
statement filed with the Securities and Exchange Commission is effective. This preliminary prospectus is not an offer to sell these securities
and it is not soliciting an offer to buy these securities in any state where the offer or sale is not permitted.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 12.5pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>SUBJECT
TO COMPLETION, DATED, &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2025</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif"><IMG SRC="formdrs_001.jpg" ALT=""></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Units
consisting of&nbsp;&nbsp;&nbsp; shares of common stock or pre-funded warrants to purchase up to &nbsp;&nbsp;&nbsp;&nbsp;shares
of common stock, Series 1 warrants to purchase up to &#8239;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares of common stock and Series 2 warrants
to purchase up to &nbsp;&nbsp;&nbsp;&nbsp;shares of common stock</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Representative
Warrant to purchase up to &nbsp;&nbsp;&nbsp;&nbsp;shares of common stock</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>(and
up to &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares of common stock underlying pre-funded warrants, Series 1 warrants, Series 2 warrants, and
Representative Warrants)</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are offering &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;units (the &ldquo;Units&rdquo;), with each Unit consisting of one share of our
common stock, par value $0.01 per share (the &ldquo;common stock&rdquo;), together with one Series 1 warrant and one Series 2 warrant,
in each case to purchase one share of common stock. The Series 1 warrants will be exercisable until the earlier of (i) the one year anniversary
of the Initial Exercise Date (as defined below) and (ii) within 30 days of reporting positive clinical data from a cohort of fibrostenotic
Crohn&rsquo;s (&ldquo;FSCD&rdquo;) patients in our ongoing Phase 1 study, and the Series 2 warrants will be exercisable until the five
year anniversary of the Initial Exercise Date (the Series 1 warrants and the Series 2 warrants are collectively referred to herein as,
the &ldquo;warrants&rdquo;) at an assumed public offering price of $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; per Unit (the last
reported sale price of our Common Stock on The Nasdaq Capital Market (&ldquo;Nasdaq&rdquo;) on &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;,
2025). Each Series 1 warrant and Series 2 warrant included in the Units entitles its holder to purchase one share of common stock at
an exercise price per share of $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; . The warrants will be exercisable upon receipt of such stockholder approval
as may be required by the applicable rules and regulations of The Nasdaq Stock Market (the &ldquo;Warrant Stockholder Approval&rdquo;)
provided however, if the Pricing Conditions (as defined below) are met, the Warrant Stockholder Approval will not be required and the
warrants will be exercisable upon issuance (the &ldquo;Initial Exercise Date&rdquo;). As used herein &ldquo;Pricing Conditions&rdquo;
means that the combined offering price per Unit is such that the Warrant Stockholder Approval is not required under Nasdaq rules because
either (i) the offering is an at-the-market offering under Nasdaq rules and such price equals or exceeds the sum of (a) the applicable
&ldquo;Minimum Price&rdquo; per share under Nasdaq rule 5635(d) plus (b) $0.125 per whole share of common stock underlying the warrants
or (ii) the offering is a discounted offering where the pricing and discount (including attributing a value of $0.125 per whole share
underlying the warrants) meet the pricing requirements under the Nasdaq rules. In the event the Pricing Conditions are not met and we
are unable to obtain the Warrant Stockholder Approval, the warrants will not be exercisable, and therefore the warrants may not have
any value.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are also offering to certain purchasers whose purchase of Units in this offering would otherwise result in the purchaser, together with
its affiliates and certain related parties, beneficially owning more than 4.99% (or, at the election of the purchaser, 9.99%) of our
outstanding common stock immediately following the consummation of this offering, the opportunity to purchase, if any such purchaser
so chooses, Units consisting of pre-funded warrants to purchase shares of common stock, in lieu of Units consisting of shares of common
stock. The purchase price of each Unit consisting of pre-funded warrants will be equal to the public offering price for the common stock
in this offering, minus $0.0001. Each pre-funded warrant is exercisable for one (1) share of our common stock and has an exercise price
of $0.0001 per share. For each pre-funded warrant that we sell, the number of shares of common stock we are offering will be reduced
on a one-for-one basis. This prospectus also relates to the offering of common stock issuable upon exercise of the pre-funded warrants.
We collectively refer to the shares of common stock, pre-funded warrants and warrants offered hereby and the shares of common stock underlying
the pre-funded warrants and warrants as the &ldquo;securities.&rdquo;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Units have no stand-alone rights and will not be certificated or issued as stand-alone securities. The shares of common stock, pre-funded
warrants, if any, and warrants comprising such units are immediately separable and will be issued separately in this offering. The underwriters
have the option to purchase an additional &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares of common stock and/or an additional
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Series 1 warrants to purchase shares of common stock and/or an additional Series
2 warrants to purchase shares of common stock solely to cover over-allotments, if any, at the price to the public, less the underwriting
discounts and commissions. The over-allotment option may be used to purchase shares of common stock, Series 1 warrants and/or Series
2 warrants, or any combination thereof, as determined by the underwriters, but such purchases cannot exceed an aggregate of 15% of the
number of shares of common stock and pre-funded warrants, if any, and/or Series 1 warrants and/or Series 2 warrants sold in this offering.
The over-allotment option is exercisable for 45 days from the date of this prospectus.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
common stock is listed on The Nasdaq Capital Market under the symbol &ldquo;PALI.&rdquo; On&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
, 2025, the last reported sale price of our common stock was $ per share. The assumed public offering price used throughout this prospectus
may not be indicative of the final public offering price. The final public offering price will be determined through negotiation between
us and the underwriters based upon a number of factors, including our history and our prospects, the industry in which we operate, our
past and present operating results and the general condition of the securities markets at the time of this offering and may be at a discount
to the current market price. We do not intend to apply for listing of the warrants or pre-funded warrants offered hereby on any securities
exchange or trading system.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Investing
in our securities involves a high degree of risk. Before making an investment decision, please read the information under &ldquo;<A HREF="#ar_005">Risk
Factors</A>&rdquo; beginning on page 13 of this prospectus and under similar headings in any amendment or supplement to this prospectus
or in any filing with the Securities and Exchange Commission that is incorporated by reference herein.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" ALIGN="CENTER" STYLE="border-collapse: collapse; width: 80%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="padding-bottom: 1pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-weight: bold; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">Per
    Unit</FONT></TD><TD STYLE="padding-bottom: 1pt; font-weight: bold"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-weight: bold; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Total</B></FONT></TD><TD STYLE="padding-bottom: 1pt; font-weight: bold"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 60%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Public offering price(1)</FONT></TD><TD STYLE="width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="width: 16%; text-align: right"></TD><TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="width: 16%; text-align: right"></TD><TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Underwriting discount and commissions(2)</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="text-align: right"></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="text-align: right"></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Proceeds, before expenses, to us (3)</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    public offering price corresponds to (i) a public offering price per share of common stock of $ ($ net of the underwriting discount),
    (ii) a public offering price per pre-funded warrant of $ ($ net of the underwriting discount), (iii) a public offering price per
    Series 1 warrant of $ ($ net of the underwriting discount), and (iv) a public offering price per Series 2 warrant of $ ($ net of
    the underwriting discount).</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">See
    &ldquo;Underwriting&rdquo; for a complete description of the compensation payable to the underwriters in connection with this offering.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(3)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    above summary of offering proceeds does not give effect to any proceeds from the exercise of any pre-funded warrants being issued
    in this offering.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have agreed to issue to the representative of the underwriters warrants to purchase the number of shares of common stock equal to 6.0%
of the aggregate number of shares of common stock and/or pre-funded warrants sold in this offering (the &ldquo;Representative Warrants&rdquo;).
The Representative Warrants will have an exercise price of $&emsp;and be exercisable for five years from the commencement of sales of
the offering.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
underwriters have the option to purchase up to an additional&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; shares from us at the public
offering price, less the underwriting discount, for 45 days after the date of this prospectus.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
underwriters expect to deliver the securities to purchasers in the offering on or about &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2025.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 12.5pt; text-align: justify; text-indent: 22pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>NEITHER
THE SECURITIES AND EXCHANGE COMMISSION NOR ANY STATE SECURITIES COMMISSION HAS APPROVED OR DISAPPROVED OF THESE SECURITIES OR DETERMINED
IF THIS PROSPECTUS IS TRUTHFUL OR COMPLETE. ANY REPRESENTATION TO THE CONTRARY IS A CRIMINAL OFFENSE.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"></P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 14pt"><B>Ladenburg
Thalmann</B></FONT></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 12.5pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 12.5pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>The
date of this prospectus is&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; , 2025.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 12.5pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 3 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 12.5pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>TABLE
OF CONTENTS</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Page</B></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#ar_001">About
    this Prospectus</A></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#ar_002">Prospectus
    Summary</A></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">2</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#ar_003">The
    Offering</A></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">8</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#ar_004">Risk
    Factors Summary</A></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">11</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#ar_005">Risk
    Factors</A></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">13</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#sk_001">Special Note Regarding Forward-Looking Statements</A></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">35</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#sk_002">Use of Proceeds</A></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">36</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#sk_004">Dividend Policy</A></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">38</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#sk_005">Capitalization</A></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">39</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#sk_006">Dilution</A></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">41</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#sk_007">Certain Relationships and Related Party Transactions</A></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">43</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#sk_008">Security Ownership of Certain Beneficial Owners and Management</A></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">44</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#sk_009">Description of Capital Stock</A></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">45</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#sk_010">Description of Securities We are Offering</A></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">49</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#sk_011">Underwriting</A></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">53</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#sk_012">Legal Matters</A></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">57</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#sk_013">Experts</A></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">58</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#sk_014">Where You Can Find More Information</A></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">59</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#sk_015">Incorporation of Certain Information by Reference</A></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">60</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 4 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: LowerRoman; Name: PageNo -->i<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><A NAME="ar_001"></A>ABOUT
THIS PROSPECTUS</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 12.5pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
incorporate by reference important information into this prospectus. You may obtain the information incorporated by reference without
charge by following the instructions under &ldquo;Incorporation of Certain Information by Reference.&rdquo; You should carefully read
this prospectus as well as additional information described under &ldquo;Incorporation of Certain Information by Reference,&rdquo; before
deciding to invest in our securities.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 12.5pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Neither
we nor the underwriters have authorized anyone to provide you with additional information or information different from that contained
or incorporated by reference in this prospectus or in any free writing prospectus that we have authorized for use in connection with
this offering. We take no responsibility for and cannot provide any assurance as to the reliability of, any other information that others
may give you. This prospectus does not constitute an offer to sell to any person, or a solicitation of an offer to purchase from any
person, the securities offered by this prospectus in any jurisdiction in which it is unlawful to make such offer or solicitation of an
offer.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
underwriters are offering to sell, and seeking offers to buy, our securities only in jurisdictions where offers and sales are permitted.
The information contained in this prospectus and any free writing prospectus that we have authorized for use in connection with this
offering is accurate only as of the respective dates thereof, and the information in the documents incorporated by reference in this
prospectus is accurate only as of the date of those respective documents, regardless of the time of delivery of this prospectus or of
any sale of our securities. Our business, financial condition, results of operations, and prospects may have changed since such dates.
It is important for you to read and consider all information contained or incorporated by reference in this prospectus in making your
investment decision. You should read both this prospectus, as well as the documents incorporated by reference into this prospectus and
the additional information described under &ldquo;Incorporation of Certain Information by Reference&rdquo; in this prospectus before
investing in our securities.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Unless
otherwise indicated, information contained in or incorporated by reference into this prospectus concerning our business and the industry
and markets in which we operate, including with respect to our business prospects, our market position and opportunity, and the competitive
landscape, is based on information from our management&rsquo;s estimates, as well as from industry publications, surveys, and studies
conducted by third parties. Our management&rsquo;s estimates are derived from publicly available information, their knowledge of our
business and industry, and assumptions based on such information and knowledge, which they believe to be reasonable. In addition, while
we believe that information contained in the industry publications, surveys, and studies has been obtained from reliable sources, we
have not independently verified any of the data contained in these third-party sources, and the accuracy and completeness of the information
contained in these sources is not guaranteed.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Although
we are not aware of any misstatements regarding the market and industry data presented in this prospectus and the documents incorporated
herein by reference, these estimates involve risks and uncertainties and are subject to change based on various factors, including those
discussed under the heading &ldquo;Risk Factors&rdquo; in this prospectus and any related free writing prospectus, and under similar
headings in the other documents that are incorporated by reference into this prospectus, including in our Annual Report on Form 10-K
filed with the Securities and Exchange Commission (the &ldquo;SEC&rdquo;) on March 24, 2025. Accordingly, you should not place undue
reliance on this information.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
investors outside the United States: We and the underwriters have not done anything that would permit this offering or the possession
or distribution of this prospectus in any jurisdiction where action for those purposes is required, other than in the United States.
Persons outside the United States who come into possession of this prospectus must inform themselves about, and observe any restrictions
relating to, the offering of the securities and the distribution of this prospectus outside of the United States.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 5; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&nbsp;</p></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><A NAME="ar_002"></A>PROSPECTUS
SUMMARY</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.3in; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>This
summary highlights certain information about us, this offering and selected information contained elsewhere in or incorporated by reference
into this prospectus. This summary is not complete and does not contain all of the information that you should consider before making
an investment decision. For a more complete understanding of our company, you should read and consider carefully the more detailed information
included or incorporated by reference in this prospectus and any applicable prospectus supplement, including the factors described under
the heading &ldquo;Risk Factors&rdquo; beginning on page 13 of this prospectus, and in our Annual Report on Form 10-K filed with the
SEC on March 24, 2025, together with any free writing prospectus we have authorized for use in connection with this offering and the
financial statements and all other information incorporated by reference in this prospectus. When used in this prospectus, except where
the context otherwise requires, the terms the &ldquo;Company,&rdquo; &ldquo;we,&rdquo; &ldquo;us,&rdquo; &ldquo;our,&rdquo; &ldquo;Palisade,&rdquo;
or similar terms refer to Palisade Bio, Inc.</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Company
Overview</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are a clinical-stage biopharmaceutical company focused on developing and advancing novel therapeutics for patients living with autoimmune,
inflammatory, and fibrotic diseases. Our lead product candidate, PALI-2108, is being developed as a treatment for patients living with
inflammatory bowel disease (&ldquo;IBD&rdquo;), including fibrostenotic Crohn&rsquo;s disease (&ldquo;FSCD&rdquo;) and ulcerative colitis
(&ldquo;UC&rdquo;).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Our
Pipeline</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">We
are currently advancing clinical trials of PALI-2108 for the treatment of IBD, including UC and FSCD. The following table summarizes
the current stages of our clinical an</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">d research programs:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif"><IMG SRC="formdrs_002.jpg" ALT=""><FONT STYLE="font-size: 10pt">&nbsp;</FONT></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center; color: Red"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Our
Precision Medicine Approach</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are developing a biomarker-based patient selection approach that we believe may aid clinicians in identifying patients who may better
respond to PALI-2108, thereby improving the rate of clinical response previously demonstrated with enzyme phosphodiesterase-4 (&ldquo;PDE4&rdquo;)
inhibitors. Our approach involves the use of clinical and multiomics data from large patient populations to identify PDE4-related biomarkers
that are correlated with IBD, its severity, and which are modified with local PDE4-inhibitor therapy in the colon. Based on our research,
we have initiated the development of corresponding biomarker assays for these PDE4-related biomarkers that we expect to use in our current
and future clinical studies with the aim of developing regulatory approved tests for selecting potential responders to PALI-2108.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 6; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&nbsp;</p></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>PALI-2108</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
lead product candidate, PALI-2108, is a prodrug inhibitor designed to help treat UC and FSCD by targeting the key PDE4 in colon tissues
and preventing it from breaking down cyclic Adenosine Monophosphate (&ldquo;cAMP&rdquo;) molecules which regulate inflammation in the
body. By inhibiting PDE4, intracellular cAMP molecule levels become elevated, which may lead to a reduction of inflammatory molecules
and an increase of anti-inflammatory molecules within tissues of the colon. Additionally, we believe that PALI-2108 may help prevent
the movement of inflammatory cells from the blood into colon tissues, thereby lowering the activity of certain proteins that contribute
to fibrosis (a type of tissue scarring).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">With
a glucuronic-derived sugar moiety, PALI-2108 remains minimally absorbed until activated by the colonic bacterium enzyme &beta;-glucuronidase.
We believe that localized bioactivation may help focus the effects of PALI-2108 where it would be most beneficial to a patient suffering
from IBD.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>PALI-2108
for FSCD</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Studies
have shown that patients with intestinal fibrosis exhibit elevated PDE4 B and D enzyme levels in intestinal tissues. Also, preclinical
research using a chronic DSS-induced mouse model of intestinal fibrosis shows similarly decreased PDE4 enzyme levels and demonstrated
that systemic administration of PDE4 inhibitors improve clinical symptoms and reduce known biomarkers of fibrosis associated with FSCD.
In these studies, systemically delivered PDE4 inhibitors significantly improved clinical outcomes, including body weight, disease activity,
colon length, and key biomarkers of intestinal fibrosis, such as &alpha;-SMA and MMPs, with these markers returning to baseline levels
upon treatment. Additionally, PDE4 inhibition was found to prevent the breakdown of cAMP, which in turn inhibits fibroblast functions,
including tissue remodeling. Further research indicates that TGF-beta, a key driver of fibrosis, modulates cAMP levels, and PDE4 inhibition
exerts particularly strong anti-fibrotic effects when TGF-beta-induced fibroblast stimulation is present.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
conducted a study evaluating the anti-inflammatory and anti-fibrotic effects of PALI-2108, a locally bioactivated PDE4 inhibitor, in
an acute DSS-induced mouse model. Treatment with PALI-2108 resulted in dose-dependent improvements in clinical outcomes, including disease
activity and colon length. Additionally, PDE4B expression in colon tissues was reduced in a dose-dependent manner, intracellular cAMP
levels increased, and TNF-alpha levels in colon tissues were normalized in most of the mice treated.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Bioinformatics
analysis of colon biopsy gene expression data (RNA-seq) further supports the effects of PALI-2108. The analysis reveals a dose-dependent
modulation of 187 genes associated with four major fibrotic pathways in IBD. Furthermore, the treatment shows a dose-dependent improvement
in fibrosis enrichment scores for FSCD markers. These findings suggest that PALI-2108 is a promising dual-acting drug candidate, with
both anti-inflammatory and anti-fibrotic properties, for the treatment of FSCD.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>PALI-2108
for UC</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
UC mouse models, we have demonstrated the dose-dependent efficacy of PALI-2108. Specifically, we utilized Dextran Sodium Sulfate (&ldquo;DSS&rdquo;)-induced
UC mouse models and target engagement in oxazolone-induced colitis. Thus, based on the research conducted on these mouse models, we demonstrated
that PALI-2108 has preferential colon activation. This preferential colon activation offers a unique approach to delivering the PDE4
inhibitor locally within the colon. The local bioactivation of PALI-2108 prodrug is designed to prevent the systemic toxicity inherent
with immunosuppression and avoid the known tolerability issues of PDE4 inhibitors.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 7; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&nbsp;</p></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><IMG SRC="formdrs_003.jpg" ALT=""></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center; color: Red"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Phase
I Clinical Study of PALI-2108</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>&nbsp;</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
October 9, 2024<FONT STYLE="background-color: white">, Health Canada issued a No Objection Letter for our Phase 1 human clinical study
of PALI-2108 for the treatment of UC. We officially began studying on November 7, 2024. As of the date of this prospectus, we have completed
the dosing of 89 subjects across all cohorts of the study. Each of the five SAD cohorts and the four MAD cohorts consisted of eight subjects,
with six subjects receiving the drug and two subjects receiving a placebo. The FE study included two cohorts each of six subjects, of
which one cohort was in a fasted state and the other cohort in a fed state. Finally, we have completed the dosing of all five UC patients
in the UC cohort of the study, with topline results from the UC cohort expected in July 2025.</FONT></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
May 27, 2025, we announced positive results from the SAD, MAD and FE cohorts in healthy volunteers. The clinical study successfully met
its primary endpoints of safety, tolerability, and PK. Based on these results, we plan to initiate an additional safety, tolerability,
and PK/PD exploratory Phase 1b cohort in FSCD while we complete longer-term chronic safety and toxicology studies. This will be followed
by the initiation of Phase 2 clinical programs to assess PALI-2108&rsquo;s efficacy, safety, and tolerability in patients with FSCD as
well as those with moderate to severe UC. The planned Phase 1b cohort is expected to evaluate multiple dosing strategies to define optimal
therapeutic exposure and patient response, and the planned Phase 2 studies are expected to evaluate clinically meaningful endpoints for
patients with FSCD and UC.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Our
Strategy</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
objective is to establish ourselves as a leader in the development of differentiated product candidates targeting the autoimmune, inflammatory,
and fibrotic disease markets, which we believe will address a large, well-established need among patients living with autoimmune and
inflammatory diseases.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 8; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&nbsp;</p></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
believe the key elements of our strategy include:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">advancing
    our lead product candidate, PALI-2108 through human clinical trials;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">leveraging
    our drug development platform infrastructure to identify product candidates that target autoimmune, inflammatory, and fibrotic diseases;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">pursuing
    strategic partnerships to further expand our programs and maximize the worldwide potential of our product candidates and platform;
    and</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">pursuing
    strategy of in-licensing/acquisition or out-licensing/sale of our product candidates.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Market</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
believe that if developed and approved for marketing, PALI-2108 could be an effective treatment for IBD. Our initial indications for
PALI-2108 are:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Fibrostenotic
Crohn&rsquo;s Disease</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>&nbsp;</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Crohn&rsquo;s
disease (&ldquo;CD&rdquo;) is an IBD that can affect any part of the gastrointestinal tract, from the mouth to the anus. It is characterized
by inflammation that can penetrate deep into the layers of the affected bowel tissue, leading to a range of symptoms including abdominal
pain, severe diarrhea, fatigue, weight loss, and malnutrition. In the eight major markets (&ldquo;8MM&rdquo;), diagnosed incident cases
of CD are expected to increase from 118,885 cases in 2022 to 122,175 cases by 2032, reflecting an AGR of 0.28%. The U.S. is projected
to have the highest number of diagnosed incident cases of CD in 2032, with 68,815 cases, while France is projected to report the fewest
at 4,560 cases. Additionally, diagnosed prevalent cases of CD are anticipated to rise from 1,626,752 in 2022 to 1,695,580 in 2032, with
an AGR of 0.42%. The U.S. is again projected to lead in prevalence in 2032, with 755,802 cases, whereas Japan is projected to have the
fewest diagnosed prevalent cases of CD at 44,732. These increases in diagnosed cases are attributed to changes in population dynamics
across these markets. The global market for CD treatments was valued at $13.9 billion in 2022 and is projected to grow to approximately
$25.5 billion in 2032 at a CAGR of approximately 6%. This market growth is fueled by the rising prevalence of the disease, improved diagnostic
techniques, and ongoing advancements in research and development activities for new drug therapies.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">FSCD,
a severe form of CD, is characterized by the formation of fibrotic tissue, or strictures, in the bowel, which can result in obstruction
and significant complications. Approximately half of CD patients will develop stricture formation within the first 10 years of diagnosis.
Currently, treatment options for FSCD are limited, with no approved therapies specifically addressing this indication. Existing treatment
approaches are primarily invasive, including balloon dilation, strictureplasty, and, in more severe cases, bowel resection. These procedures,
while necessary, pose significant risks and can greatly impact the quality of life.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Given
the lack of effective treatment options, we believe PALI-2108 has the potential to provide a much needed first-in-class therapy for these
patients. PDE4 inhibitors are a clinically and commercially proven dual-acting anti-inflammatory and anti-fibrotic candidate, offering
a unique approach to addressing both the inflammatory and fibrotic components of CD. With its innovative mechanism of action, PALI-2108
has the potential to transform the lives of individuals suffering from FSCD by providing a less invasive and more effective treatment
alternative.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Ulcerative
Colitis</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>&nbsp;</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">UC
is a chronic IBD that primarily affects the colon and rectum, leading to long-lasting inflammation and ulcers in the digestive tract.
Common symptoms include abdominal pain, diarrhea, and rectal bleeding. The prevalence of UC is estimated to range from 156 to 291 cases
per 100,000 people globally. In the 8MM, diagnosed incident cases of UC are projected to increase from 160,122 cases in 2021 to 168,467
cases by 2031, reflecting an annual growth rate (&ldquo;AGR&rdquo;) of 0.52%. The U.S. is expected to have the highest number of diagnosed
incident cases in 2031, totaling 104,795, while France will have the fewest at 2,972 cases. Additionally, diagnosed prevalent cases are
anticipated to rise from 1,946,428 in 2021 to 2,069,770 in 2031, with an AGR of 0.63%. The U.S. is again projected to lead in prevalence
in 2031 with 655,317 cases, whereas Canada is projected to report the lowest with 91,186 cases. This growth in diagnosed cases is largely
attributed to changes in population dynamics across these markets. The market for 8MM for UC treatments was valued at approximately $7.3
billion in 2021 and is expected to grow to over $9.5 billion in 2031 at a compound annual growth rate (&ldquo;CAGR&rdquo;) of approximately
2.78%. Market expansion is driven by the increasing prevalence of the disease, advancements in diagnostic techniques, and the development
of more effective and targeted therapies.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 9; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&nbsp;</p></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Unmet
Needs in IBD</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>&nbsp;</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Despite
the availability of various treatments, there are significant unmet needs in managing IBD. These challenges impact patient outcomes and
overall disease management. We believe improvements to key existing therapies in IBD are necessary.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Inadequate
    Primary Response to Medical Treatment <I>- Many patients experience low rates of clinical response to initial medical treatments.
    </I></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Secondary
    Loss of Clinical Response or Drug Intolerance <I>&ndash; A portion of patients initially respond well to treatment but later experience
    a loss of clinical response or develop intolerance to currently available drugs.</I></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Patient
    Selection <I>- Identifying patients likely to respond to specific drugs is critical. </I></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Safety
    Concerns and Long-Term Medication Use <I>- Existing drugs may have side effects and safety concerns, including black box warnings,
    associated with prolonged use.</I></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Limited
    Options for Refractory or Severe Disease &ndash; <I>A portion of patients face refractory or severe disease that does not respond
    adequately to available treatments.</I></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Enhancing
    Treatment Adherence <B><I>&mdash;</I></B><I>Frequent or inconvenient dosing regimens, including infusions and injections, can hinder
    patient adherence. </I></FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Based
on our clinical research and development, we believe that PALI-2108 has the potential to address many of these areas of needed improvement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Intellectual
Property</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Patents</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have exclusively licensed a worldwide patent portfolio from Giiant consisting of pending patent applications related to the assets licensed,
including PALI-2108. In the U.S., we have exclusive rights to one pending patent application (Application no. 17927827). Internationally,
we have exclusive rights to seven patent applications pending (Application Nos. (i) 2021280418, (ii) 3174137, (iii) 2021800586815, (iv)
21813912.9, (v) 2022-573665, (vi) 1020227045933, and (vii) MX/a/2022/014416).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
pending patents all relate to (i) the methods of making pharmaceutical composition, (ii) the pharmaceutical compositions, and (iii) the
methods of using the pharmaceutical composition of PALI-2108 and the other assets licensed from Giiant.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have also filed a provisional patent application No. 63/733,390 (Personalized Methods of Administering PDE4 inhibitors) relating to personalized
PALI-2108 treatment.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
success will depend in part on our ability to obtain and maintain patent and other intellectual property protection in the U.S. and other
countries with respect to our technology, including PALI-2108 and the other assets licensed from Giiant. We also rely in part on trade
secret, copyright and trademark laws, and confidentiality, licensing and other agreements with employees and third parties, all of which
offer only limited protection. We seek to protect our proprietary position by filing and prosecuting patent applications in the U.S.
and abroad related to our technology and product candidates.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 10; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&nbsp;</p></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition to our pending patents related to PALI-2108, we also maintain a portfolio of patents related to LB1148. This remaining LB1148
portfolio of patents is directed to a composition comprising three components of LB1148 and their therapeutic use in treating shock.
This patent portfolio includes a patent in Europe, four granted patents in the U.S., and granted patents in Korea (KR 1820977) and Canada
(CA 2812299), all of which are co-owned, under the name of Leading Biosciences, Inc., with The Regents of the University of California.
In addition, this patent portfolio includes a granted patent in China that we previously assigned to Newsoara to support our co-development
agreement. The expected expiration date of the issued patents is 2031, excluding any adjustments or extensions of patent term that may
be available.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Notice
of Nasdaq Listing Deficiency</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
April 30, 2025, we received notice (the &ldquo;Notice&rdquo;) from The Nasdaq Stock Market LLC (&ldquo;Nasdaq&rdquo;) advising us that
for 30 consecutive trading days preceding the date of the Notice, the bid price of our common stock had closed below the $1.00 per share
minimum required for continued listing on The Nasdaq Capital Market pursuant to Nasdaq Listing Rule 5550(a)(2) (the &ldquo;Minimum Bid
Price Requirement&rdquo;).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Notice has no effect on the listing of our common stock at this time, and our common stock continues to trade on The Nasdaq Capital Market
under the symbol &ldquo;PALI.&rdquo;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Under
Nasdaq Listing Rule 5810(c)(3)(A), we have 180 calendar days following the date of the Notice, or until October 27, 2025, to regain compliance
with the Minimum Bid Price Requirement (the &ldquo;Compliance Period&rdquo;). If at any time during the Compliance Period the closing
bid price of our common stock is at least $1.00 for a minimum of 10 consecutive business days, we will regain compliance with the Minimum
Bid Price Requirement and our common stock will continue to be eligible for listing on The Nasdaq Capital Market absent noncompliance
with any other requirement for continued listing.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
we do not regain compliance with the Minimum Bid Price Requirement by the end of the Compliance Period, we may be afforded an additional
180 calendar days to regain compliance with the Minimum Bid Price Requirement (the &ldquo;Additional Compliance Period&rdquo;) if on
the last day of the Compliance Period we are in compliance with the market value of publicly held shares requirement for continued listing
as well as all other standards for initial listing of its common stock on The Nasdaq Capital Market (other than the Minimum Bid Price
Requirement), unless we do not indicate our intent to cure the deficiency, or if it appears to Nasdaq that it is not possible for us
to cure the deficiency.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
we do not regain compliance with the Minimum Bid Price Requirement by the end of the Compliance Period, or the Additional Compliance
Period, if applicable, our common stock will be subject to delisting. We intend to monitor the closing bid price of our common stock
and may, if appropriate, consider implementing available options to regain compliance with the Minimum Bid Price Requirement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Implications
of Being a Smaller Reporting Company</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are a &ldquo;smaller reporting company&rdquo; as defined in Item 10(f)(1) of Regulation S-K. Smaller reporting companies may take advantage
of certain reduced disclosure obligations, including, among other things, providing only two years of audited financial statements. We
will remain a smaller reporting company until the last day of any fiscal year for so long as either (1) the market value of our shares
of common stock held by non-affiliates does not equal or exceed $250.0 million as of the prior June 30th, or (2) our annual revenues
did not equal or exceed $100.0 million during such completed fiscal year and the market value of our shares of common stock held by non-affiliates
did not equal or exceed $700.0 million as of the prior June 30th. To the extent we take advantage of any reduced disclosure obligations,
it may make comparison of our financial statements with other public companies difficult or impossible.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Corporate
Information</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
were originally incorporated in 2001 in the State of Delaware under the name Neuralstem, Inc. In October of 2019, we changed our name
to Seneca Biopharma, Inc. (&ldquo;Seneca&rdquo;). In April of 2021, we effected a merger with Leading BioSciences, Inc. (the &ldquo;Merger&rdquo;),
whereby Leading BioSciences, Inc. (&ldquo;LBS&rdquo;) became a wholly owned subsidiary of Seneca. In April of 2021, we changed our name
from Seneca Biopharma, Inc. to Palisade Bio, Inc. Our principal executive offices are located at 7750 El Camino Real, Suite 2A, Carlsbad,
California 92009, our telephone number is (858) 704-4900 and our website address is www.palisadebio.com.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
information on our website is not incorporated by reference in this prospectus or in any other filings we make with the SEC.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Subsidiaries</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have two wholly owned subsidiaries, Suzhou Neuralstem Biopharmaceutical Co., Ltd. (&ldquo;Suzhou&rdquo;), organized under the laws of
the People&rsquo;s Republic of China, and LBS. Suzhou was established by Seneca to sponsor the non-GDP Phase 2 clinical trial of NSI-566
that was conducted between 2013 and 2016 in Beijing, China. As of December 31, 2024, Suzhou has no employees or other operations. We
are currently in the process of dissolving the Suzhou subsidiary. Our other subsidiary is LBS, which is our operating entity.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 11; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&nbsp;</p></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><A NAME="ar_003"></A>THE
OFFERING</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 2.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Units
    we are offering</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.15in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Units.
    Each Unit consists of one share of common stock, one Series 1 warrant and one Series 2 warrant, each to purchase one share of our
    common stock (together with the shares of common stock underlying such warrants). Certain purchasers whose purchase of Units in this
    offering would otherwise result in the purchaser, together with its affiliates and certain related parties, beneficially owning more
    than 4.99% (or, at the election of the purchaser, 9.99%) of our outstanding common stock immediately following the closing of this
    offering, the opportunity to purchase, if such purchasers so choose, Units consisting of pre-funded warrants to purchase shares of
    common stock, in lieu of Units consisting of shares of common stock that would otherwise result in any such purchaser&rsquo;s beneficial
    ownership exceeding 4.99% (or, at the election of the purchaser, 9.99%) of our outstanding common stock. Each pre-funded warrant
    is exercisable for one share of our common stock. The purchase price of each Unit consisting of pre-funded warrants is equal to the
    price at which a Unit consisting of a share of common stock is being sold to the public in this offering, minus $0.0001, and the
    exercise price of each pre-funded warrant is $0.0001 per share. The pre-funded warrants are exercisable immediately and may be exercised
    at any time until all of the pre-funded warrants are exercised in full. This offering also relates to the shares of common stock
    issuable upon exercise of any pre-funded warrants sold in this offering. For each pre-funded warrant that we sell, the number of
    shares of common stock that we are offering will be reduced on a one-for-one basis.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Public
    offering price per Unit</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$
    per Unit, based on assumed public offering price of $ &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, the closing price of our common stock on Nasdaq
    on &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2025.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Underwriters&rsquo;
    option to purchase additional shares</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
    have granted the underwriters an option for a period of 45 days from the date of this prospectus to purchase up to an additional
    &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares of our common stock, and/or an additional &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Series
    1 warrants to purchase shares of common stock, and/or an additional Series 2 warrants to purchase shares of common stock solely to
    cover over-allotments, if any, at the price per each security less the underwriting discounts and commissions. The over-allotment
    option may be used to purchase shares of common stock, Series 1 warrants or Series 2 warrants, or any combination thereof, as determined
    by the underwriters, but such purchases cannot exceed an aggregate of 15% of the number of shares of common stock and pre-funded
    warrants, Series 1 warrants and Series 2 warrants sold in the offering.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Warrants</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Under
    Nasdaq listing rules, the Series 1 warrants and Series 2 warrants are not exercisable without Warrant Stockholder Approval; provided
    however, if the Pricing Conditions are met, the warrants will be exercisable upon the Initial Exercise Date. If the Pricing Conditions
    are not met, we intend to promptly seek, after this offering, the Warrant Stockholder Approval for issuances of shares of common
    stock issuable upon exercise of the warrants. If applicable, we have agreed to hold a meeting to obtain Warrant Stockholder Approval
    as soon as practicable following the closing of this offering, but no later than days following the closing of this offering, and
    further agreed to cause an additional stockholder meeting to be held every days thereafter until such Warrant Stockholder Approval
    is obtained or the warrants are no longer outstanding. We cannot assure you that we will be able to obtain this requisite approval.
    The Series 1 warrants and Series 2 warrants will be exercisable beginning on the date the Warrant Stockholder Approval is obtained,
    if at all, or the Initial Exercise Date and expire on the earlier of (i) one year anniversary of the Initial Exercise Date and (ii)
    within 30 days of reporting positive clinical data from a cohort of FSCD patients in our ongoing Phase 1 study, in the case of Series
    1 warrants, or five year anniversary of the Initial Exercise Date, in the case of the Series 2 warrants, at an initial exercise price
    per share equal to $ , subject to appropriate adjustment in the event of recapitalization events, stock dividends, stock splits,
    stock combinations, reclassifications, reorganizations or similar events affecting our common stock. In the event that the Pricing
    Conditions are not met and we are not able to obtain the Warrant Stockholder Approval, the warrants will not be exercisable and therefore
    have no value. This offering also relates to the shares of common stock issuable upon exercise of any warrants sold in this offering.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 12; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&nbsp;</p></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 2.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Common
    stock outstanding immediately before this offering </B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.15in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4,800,247
    shares.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Common
    stock outstanding immediately after this offering</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares,
    or shares if the underwriters exercise their option to purchase additional shares of common stock in full, and assuming full exercise
    of the pre-funded warrants and none of the warrants issued in this offering are exercised.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Use
    of proceeds</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
    estimate that the net proceeds to us from this offering will be approximately $ million, based on an assumed public offering price
    of $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; per Unit (the closing price of our common stock on The Nasdaq Capital Market on &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;,
    2025), or $ &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;million if the underwriters exercise their option to purchase additional shares in
    full, after deducting the underwriting discounts and commissions and estimated offering expenses payable by us. We intend to use
    the net proceeds from this offering to, among other things, advance PALI-2108 through preclinical and clinical development and into
    INDs or their equivalent in foreign jurisdictions, fund our research and development activities and for general working capital needs.
    See &ldquo;<I>Use of Proceeds</I>&rdquo; for additional information.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Lock-Up
    Agreements</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We,
    and each of our officers and directors are subject to certain lock-up restrictions as set forth in more detail in the &ldquo;<I>Underwriting</I>&rdquo;
    section.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Reverse
    Stock Split</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Promptly
    after this offering, we intend to seek stockholder approval to effect a reverse stock split (the &ldquo;Reverse Split&rdquo;) of
    our shares of common stock at a ratio to be determined by our board of directors.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Risk
    Factors</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">An
    investment in our securities involves a high degree of risk. See &ldquo;<I>Risk Factors</I>&rdquo; beginning on page 13 of this prospectus
    and the other information included and incorporated by reference in this prospectus for a discussion of the risk factors you should
    carefully consider before deciding to invest in our securities.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Nasdaq
    Symbol</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
    common stock is listed on The Nasdaq Capital Market under the symbol &ldquo;PALI.&rdquo; There is no established trading market for
    the pre-funded warrants or warrants and we do not expect a market to develop. In addition, we do not intend to apply for the listing
    of the pre-funded warrants or warrants on any national securities exchange or other trading market. Without an active trading market,
    the liquidity of the pre-funded warrants and warrants will be limited.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></P>


<!-- Field: Page; Sequence: 13; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&nbsp;</p></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Unless
otherwise indicated, the number of shares of common stock to be outstanding immediately after this offering is based on 4,396,646 shares
of common stock which were outstanding as of March 31, 2025, adjusted for an aggregate of 399,000 shares that were issued subsequent
to March 31, 2025 pursuant to the exercise of pre-funded warrants issued in our December 2024 underwritten offering and for an aggregate
of 4,601 shares that were issued pursuant to our 2021 Employee Stock Purchase Plan, or the ESPP, for an aggregate of 4,800,247 shares
of common stock outstanding as of June 30, 2025, but excludes:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">shares
    of common stock issuable upon the exercise of pre-funded warrants issued in this offering;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">shares
    of common stock issuable upon the exercise of Representative Warrants issued in this offering;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">shares
    of common stock issuable upon the exercise of Series 1 warrants issued in this offering;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">shares
    of common stock issuable upon the exercise of Series 2 warrants issued in this offering;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">427
    shares of common stock issuable upon exercise of outstanding stock options as of June 30, 2025 granted under the LBS 2013 Amended
    and Restated Employee, Director, and Consultant Equity Incentive Plan, as amended and restated, or the 2013 Plan, with a weighted-average
    exercise price of $15,144.99 per share;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">146,155
    shares of common stock issuable upon exercise of outstanding stock options as of June 30, 2025, granted under the 2021 Equity Incentive
    Plan, as amended, or the 2021 Plan, with a weighted-average exercise price of $12.89 per share;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">12,679
    shares of common stock issuable upon exercise of outstanding stock options as of June 30, 2025 granted under the 2021 Inducement
    Plan, with a weighted average exercise price of $11.72 per share;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">89,400
    shares of common stock issuable upon vesting of restricted stock units outstanding as of June 30, 2025, all of which were issued
    under the 2021 Plan and vest in equal amounts on an annual basis over three years from the date of grant;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2,952
    shares of common stock issuable upon vesting of restricted performance stock units outstanding as of June 30, 2025, all of which
    were issued under the 2021 Plan and vest subject to certain milestones;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">49,834
    shares of common stock reserved for future issuances under the 2021 Plan as of June 30, 2025, as well as any future automatic increases
    in the number of shares of common stock reserved for future issuance under the 2021 Plan;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">43,394
    shares of common stock reserved for future issuance under the ESPP, as of June 30, 2025, as well as any automatic increases in the
    number of shares of common stock reserved for future issuance under the ESPP;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">50,341
    shares of common stock reserved for issuance under the 2021 Inducement Plan as of June 30, 2025;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4,717,538
    shares of common stock issuable upon exercise of outstanding warrants as of June 30, 2025 with a weighted-average exercise price
    of $5.64 per share; and</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">8
    shares of common stock issuable upon conversion of the 200,000 outstanding shares of our Series A 4.5% Convertible Preferred Stock
    as of June 30, 2025, as well as any future shares of common stock issuable upon conversion of additional shares of Series A 4.5%
    Convertible Preferred Stock that may be issued as payment-in-kind dividends thereon in accordance with their terms.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 14; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&nbsp;</p></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><A NAME="ar_004"></A>RISK
FACTORS SUMMARY</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>The
Company faces many risks and uncertainties, as more fully described in this prospectus. Some of these risks and uncertainties are summarized
below. The summary below does not contain all of the information that may be important to you, and you should read this summary together
with the more detailed discussion of these risks and uncertainties contained in the Section entitled &ldquo;Risk Factors.&rdquo;</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Risks
Related to This Offering</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Sales
    of a substantial number of our common stock in the public market could cause our share price to fall.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
    management will have broad discretion in the use of the net proceeds from this offering and may allocate the net proceeds from this
    offering in ways that you and other stockholders may not approve.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    market price of our common stock has been, and will likely continue to be, volatile, and you could lose all or part of your investment.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
    we are required to obtain Warrant Stockholder Approval, the warrants will not be exercisable until we are able to receive such approval,
    and if we are unable to obtain such approval, the warrants will have no value.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Risks
Related to Our Development, Commercialization and Regulatory Approval of Our Product Candidates</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
    business depends on the successful clinical development, regulatory approval, and commercialization of our therapeutic compounds,
    including our lead asset PALI-2108.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">There
    are substantial risks in drug development, and, as a result, we may not be able to successfully develop any product candidate, including
    our lead product candidate, PALI-2108.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
    depend on our license agreement with Giiant Pharma Inc. (&ldquo;Giiant&rdquo;) to permit us to use patents and patent applications
    relating to PALI-2108. Termination of these rights or the failure to comply with our obligations under the license agreement could
    materially harm our business and prevent us from developing or commercializing PALI-2108, our lead product candidate.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
    are currently conducting a Phase 1 clinical trial of PALI-2108 in Canada, and the U.S. Food and Drug Administration (&ldquo;FDA&rdquo;)
    or applicable foreign regulatory authorities may not accept data from such trials, or any other trial we conduct outside of the U.S.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
    may find it difficult to enroll patients in our clinical trials, which could delay or prevent us from proceeding with clinical trials
    of our product candidates.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
    expect that our operations and development of PALI-2108 will require substantially more capital than we currently have, and we cannot
    guarantee when or if we will be able to secure such additional funding.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
    product candidates, including our lead product candidate PALI-2108, may cause undesirable side effects or have other unexpected properties
    that could delay or prevent their regulatory approval, limit the commercial profile of an approved label, or result in post-approval
    regulatory action.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">There
    can be no assurance that our product candidates will obtain regulatory approval.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
    clinical studies of PALI-2108 do not yield successful results, we may discontinue the development of PALI-2108.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">It
    may take us longer than we estimate to complete clinical trials, and we may not be able to complete them at all.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Even
    if PALI-2108 is approved for commercialization, future regulatory reviews or inspections may result in its suspension or withdrawal,
    closure of a facility or substantial fines.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    successful commercialization of PALI-2108, if approved, will depend in part on the extent to which government authorities and health
    insurers establish adequate reimbursement levels and pricing policies.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
    face potential product liability exposure, and if successful claims are brought against us, we may incur substantial liability for
    a product candidate and we may need to limit our commercialization.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Even
    if a product candidate obtains regulatory approval, it may fail to achieve the broad degree of physician and patient adoption and
    use necessary for commercial success.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 15; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&nbsp;</p></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Risks
Related to Our Business</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
    have a limited operating history and have never generated any revenues from product sales.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
    business model assumes revenue from, among other activities, marketing or out-licensing the products we develop. PALI-2108 is in
    the early stages of clinical development, and because we have a short development history with PALI-2108, there is a limited amount
    of information about us upon which you can evaluate our business and prospects.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
    may choose to discontinue the development or commercialization of any of our product candidates, or may choose not to commercialize
    product candidates in approved indications, at any time during development or after approval, which could adversely affect us and
    our operations.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
    inability to successfully in-license, acquire, develop and market additional product candidates or approved products could impair
    our ability to grow our business.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Changes
    in funding for the FDA and, other government agencies or comparable foreign regulatory authorities could hinder their ability to
    hire and retain key leadership and other personnel, or otherwise prevent new products and services from being developed or commercialized
    in a timely manner or otherwise prevent these agencies or authorities from performing normal business functions on which the operations
    of our business may rely, which could negatively impact our business.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Risks
Related to Our Dependence on Third Parties</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
    anticipate relying on third-party Contract Research Organizations (&ldquo;CROs&rdquo;) and other third parties to conduct and oversee
    our clinical trials. If these third parties do not meet our requirements or otherwise conduct the trials as required, we may not
    be able to satisfy our contractual obligations for, obtain regulatory approval for, or commercialize our product candidates.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
    depend on two qualified suppliers for the active pharmaceutical ingredient used in the clinical trials of PALI-2108. Insufficient
    availability of the API or other raw materials necessary to manufacture PALI-2108, or the inability of our suppliers to manufacture
    and supply our products on commercially reasonable terms, could adversely impact our business, results of operations and financial
    condition.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
    expect to rely on collaborations with third parties for the successful development and commercialization of our product candidates.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
    currently rely on third-party contractors to supply, manufacture and distribute clinical drug supplies for our product candidates.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Risks
Related to Our Financial Operations</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
    have expressed substantial doubt about our ability to continue as a going concern.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
    have a history of net operating losses, and we expect to continue to incur net operating losses and may never achieve profitability.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Failure
    to remediate a material weakness in internal controls over financial reporting could result in material misstatements in our consolidated
    financial statements.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Risks
Related to Our Intellectual Property</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
    may not be able to obtain, maintain or enforce global patent rights or other intellectual property rights that cover our product
    candidates and technologies that are of sufficient breadth to prevent third parties from competing against us.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
    we fail to comply with our obligations under our intellectual property license agreements, we could lose license rights that are
    important to our business.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Other
Risks Related to Our Securities</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
    common stock could be delisted from the Nasdaq Stock Market if we are unable to maintain compliance with the Nasdaq Stock Market&rsquo;s
    continued listing standards.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 49pt; text-align: justify; text-indent: -24.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 16; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&nbsp;</p></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><A NAME="ar_005"></A>RISK
FACTORS</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Investing
in our securities involves a high degree of risk. Before investing in our securities, you should carefully consider the risks and uncertainties
discussed under &ldquo;Risk Factors&rdquo; in our latest annual report on Form 10-K and subsequent quarterly reports on Form 10-Q and
current reports on Form 8-K, which are incorporated by reference herein in their entirety. Before making an investment decision, you
should carefully consider each of the following risks described below, together with all other information set forth in or incorporated
in this prospectus, including the financial statements and the related notes. The risks described in this prospectus or incorporated
by reference into this prospectus are not the only ones we face, but those that we consider to be material. Additional risks not presently
known to us or that we currently believe are immaterial may also significantly impair our business operations and could result in a complete
loss of your investment. Past financial performance may not be a reliable indicator of future performance, and historical trends should
not be used to anticipate results or trends in future periods. If any of the following risks actually occur, our business, financial
condition, results of operations or cash flow could be seriously harmed. This could cause the market price of our common stock to decline,
and you could lose all or part of your investment.</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Risks
Related to This Offering</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Sales
of a substantial number of our common stock in the public market could cause our share price to fall.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
market price of our common stock could decline as a result of sales of a large number of shares of our common stock in the market, and
the perception that these sales could occur may also depress the market price of our common stock. In addition, our daily trading volume
may be limited and significantly less than the amount of shares available for sale. In the event that the number of our common stock
shares offered for sale on any given day exceeds the existing demand for our shares, it may cause our stock price to fall.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
may also issue additional shares of our common stock, convertible securities or other equity, including pursuant to our equity compensation
plans. Such issuances could be dilutive to investors and could cause the price of shares of our common stock to decline. New investors
in such issuances could also receive rights senior to those of holders of shares of our common stock.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
above factors may make it more difficult for us to sell equity securities in the future at a time and at a price that we deem appropriate.
Any such sales also could cause the market price of our common stock to fall and make it more difficult for you to sell shares of our
common stock.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Our
management will have broad discretion in the use of the net proceeds from this offering and may allocate the net proceeds from this offering
in ways that you and other stockholders may not approve.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
management will have broad discretion in the use of the net proceeds, including for any of the purposes described in the section entitled
&ldquo;Use of Proceeds,&rdquo; and you will not have the opportunity as part of your investment decision to assess whether the net proceeds
are being used appropriately. The failure of our management to use these funds effectively could harm our business. Pending their use,
we intend to invest the net proceeds from this offering in short- and intermediate-term, interest-bearing obligations, investment-grade
instruments, certificates of deposit or direct or guaranteed obligations of the U.S. government. These investments may not yield a favorable
return to our stockholders.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 17; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&nbsp;</p></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>The
market price of our common stock has been, and will likely continue to be, volatile, and you could lose all or part of your investment.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Prior
to the listing of our common stock, there was no public market for shares of our common stock. Since we began trading on the Nasdaq Stock
Market, the stock price of our common stock has experienced very high volatility and the market prices of securities of other public
companies have historically been highly volatile. The market price of our common stock could be subject to wide fluctuations in response
to various factors, some of which are beyond our control and may not be related to our operating performance. Fluctuations in the price
of our common stock could cause you to lose all or part of your investment because you may be unable to sell your shares at or above
the price you paid. Factors that could cause fluctuations in the market price of our common stock include the following:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">price
    and volume fluctuations in the overall stock market from time to time;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">volatility
    in the market prices and trading volumes of biotechnology stocks;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">changes
    in operating performance and stock market valuations of other biotechnology companies generally or those in our industry in particular;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">sales
    of shares of our common stock by us or our stockholders;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">failure
    of securities analysts to maintain coverage of us, changes in financial estimates by securities analysts who follow us, or our failure
    to meet these estimates or the expectations of investors;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    financial projections we may provide to the public, any changes in those projections or our failure to meet those projections;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">announcements
    by us or our competitors of new products or services;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    public&rsquo;s reaction to our press releases, other public announcements, and filings with the Securities and Exchange Commission;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">rumors
    and market speculation involving us or other companies in our industry;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">actual
    or anticipated changes in our operating results or fluctuations in our operating results;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">actual
    or anticipated developments in our business, our competitors&rsquo; businesses, or the competitive landscape generally;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">litigation
    involving us, our industry, or both, or investigations by regulators into our operations or those of our competitors;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">announced
    or completed acquisitions of businesses or technologies by us or our competitors;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">new
    laws or regulations or new interpretations of existing laws or regulations applicable to our business;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">changes
    in accounting standards, policies, guidelines, interpretations, or principles;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">outbreaks
    of war or other hostilities;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">any
    significant change in our management;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">a
    return of pandemic conditions; and</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">general
    economic conditions and slow or negative growth of our markets.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>If
you purchase our common stock, warrants or pre-funded warrants in this offering, you will incur immediate and substantial dilution in
the book value of your shares.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
public offering price in this offering is substantially higher than the net tangible book value per share of our common stock. Investors
purchasing common stock, warrants or pre-funded warrants in this offering will pay a price per share that substantially exceeds the book
value of our tangible assets after subtracting our liabilities. As a result, investors purchasing common stock, warrants or pre-funded
warrants in this offering will incur immediate dilution of $ &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;per share, based on the assumed
public offering price of $ &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;per Unit.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 18; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&nbsp;</p></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
a result of the dilution to investors purchasing securities in this offering, investors may receive significantly less than the purchase
price paid in this offering, if anything, in the event of our liquidation. For a further description of the dilution that you will incur
as a result of purchasing securities in this offering, see &ldquo;Dilution.&rdquo;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>There
is no public market for the pre-funded warrants, Series 1 warrants or Series 2 warrants being offered in this offering.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">There
is no established public trading market for the pre-funded warrants, Series 1 warrants or Series 2 warrants being offered in this offering,
and we do not expect a market to develop. In addition, we do not intend to apply to list the pre-funded warrants, Series 1 warrants or
Series 2 warrants on any securities exchange or nationally recognized trading system, including The Nasdaq Stock Market. Without an active
market, the liquidity of the pre-funded warrants and warrants will be limited.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Holders
of our pre-funded warrants, Series 1 warrants and Series 2 warrants will have no rights as a common stockholder until they acquire our
common stock.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Until
holders of our pre-funded warrants, Series 1 warrants and Series 2 warrants sold in this offering acquire shares of our common stock
upon exercise of the pre-funded warrants, Series 1 warrants and Series 2 warrants, the holders will have no rights with respect to shares
of our common stock issuable upon exercise of pre-funded warrants, Series 1 warrants and Series 2 warrants. Upon exercise of the pre-funded
warrants and warrants, holders will be entitled to exercise the rights of a common stockholder only as to matters for which the record
date occurs after the exercise date.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>The
warrants are speculative in nature.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
warrants do not confer any rights of common stock ownership on their holders, such as voting rights or the right to receive dividends,
but rather merely represent the right to acquire shares of common stock at a fixed price for a limited period of time. Moreover, following
this offering, the market value of the warrants, if any, will be uncertain and there can be no assurance that the market value of the
warrants will equal or exceed their imputed offering price. The warrants will not be listed or quoted for trading on any market or exchange.
There can be no assurance that the market price of our common stock will ever equal or exceed the exercise price of the warrants, and
consequently, the warrants may expire valueless.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>If
we are required to obtain Warrant Stockholder Approval, the warrants will not be exercisable until we are able to receive such approval,
and if we are unable to obtain such approval, the warrants will have no value.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
we are required to obtain Warrant Stockholder Approval, the warrants will not be exercisable until, and unless, we obtain the Warrant
Stockholder Approval from our stockholders. While we intend to promptly seek stockholder approval, if required, there is no guarantee
that the Warrant Stockholder Approval will be obtained. If we are unable to obtain the Warrant Stockholder Approval, the warrants will
not be exercisable and thus have no value. In addition, we will incur substantial costs, and management will devote substantial time
and attention, in attempting to obtain the Warrant Stockholder Approval.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Risks
Related to Our Development, Commercialization and Regulatory Approval of Our Product Candidates</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Our
business depends on the successful clinical development, regulatory approval, and commercialization of our therapeutic compounds, including
our lead asset PALI-2108.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
October 9, 2024, Health Canada approved our Canadian Clinical Trial Application (&ldquo;CTA&rdquo;) to commence a Phase 1 clinical trial
for PALI-2108 in Canada. On November 7, 2024, we commenced the Phase 1 clinical trial of PALI-2108 and on May 27, 2025, we announced
positive results from the SAD, MAD and FE cohorts in healthy volunteers. The clinical study successfully met its primary endpoints of
safety, tolerability, and PK. Our success depends on the development and clinical success of PALI-2108, which is subject to a number
of risks, including:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    continued enforceability of our research collaboration and license agreement with Giiant;</FONT></TD></TR>
</TABLE>

<P STYLE="margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></P>


<!-- Field: Page; Sequence: 19; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&nbsp;</p></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></P>

<P STYLE="margin: 0"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">timely
    and successful completion of required clinical trials, which may be significantly slower or costlier than we anticipate and/or produces
    results that do not achieve the primary or secondary endpoints of the trial(s);</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
    ability to develop and implement clinical trial designs and protocols;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    successful initiation and completion of our current planned clinical trials and any additionally required preclinical studies, if
    any;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
    ability to retain third-party CROs on terms acceptable to us for the conduct and oversight of our anticipated clinical trials, including
    our Phase 1 clinical trial for PALI-2108;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
    ability to fund the development costs related to PALI-2108&rsquo;s clinical development;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    approval by Health Canada or other regulatory authorities to commence the marketing of our product candidates;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    ability for us and third-parties, if applicable, to achieve and maintain compliance with our contractual obligations and applicable
    regulatory requirements;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    ability of our contract manufacturers to manufacture sufficient supply of our product candidates to meet the required clinical trial
    supplies and any additional required preclinical studies;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    ability of our contract manufacturers to remain in good standing with regulatory agencies and to develop, validate and maintain commercially
    viable manufacturing facilities and processes that are compliant with cGMP regulations;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
    ability to obtain favorable labeling for our product candidates through regulators that allows for successful commercialization;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">acceptance
    by physicians, insurers, payors, and patients of the beneficial quality, safety and efficacy of our product candidates, if approved,
    including relative to alternative and competing treatments;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
    ability to price our product candidates to recover our development costs and applicable milestone or royalty payments, and generate
    a satisfactory profit margin; and</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
    ability and our applicable collaboration and licensing partners&rsquo; ability to establish and enforce intellectual property rights
    related to our product candidates and technologies.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
we do not achieve one or more of these factors, many of which are beyond our control, in a timely manner or at all, we could experience
significant delays or an inability to obtain regulatory approvals or commercialize our proposed product candidates. Even if successfully
completed, we must complete a number of additional clinical trials prior to obtaining regulatory approval to commercialize our product
candidates. Accordingly, we cannot make assurances that we will ever be able to generate sufficient revenue through the sale of any product
candidates, if approved, to internally fund our business.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>There
are substantial risks in drug development, and, as a result, we may not be able to successfully develop any product candidate, including
our lead product candidate, PALI-2108.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have initiated a Phase 1 clinical trial of PALI-2108 in our target indication of inflammatory bowel disease, or IBD. Drug development
requires a significant amount of capital and can take a long time to reach commercial viability, if it can be achieved at all. During
the development process, we may experience technological barriers that we may be unable to overcome. Further, certain underlying premises
in our development programs have not been proven. Because of these and similar uncertainties, it is possible that our product candidates
will not reach commercialization. If we are unable to successfully develop and commercialize our product candidates, including our lead
product candidate, PALI-2108, we will be unable to generate revenue or build a sustainable or profitable business.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>We
depend on our license agreement with Giiant to permit us to use patents and patent applications relating to PALI-2108. Termination of
these rights or the failure to comply with our obligations under the license agreement could materially harm our business and prevent
us from developing or commercializing PALI-2108, our lead product candidate.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are a party to the Giiant License Agreement under which we have been granted rights to patents and patent applications that are important
to our business. We rely on this license agreement to be able to use various proprietary technologies that are material to our business,
including patents, and patent applications that cover PALI-2108. Our rights to PALI-2108 are subject to the continuation of, and our
compliance with, the terms of the Giiant License Agreement. If we fail to comply with any of our obligations under the Giiant License
Agreement, Giiant may have the right to terminate the Giiant License agreement, in which event we would not be able to continue the development
or our proposed commercialization of PALI-2108. Additionally, disputes may arise under the Giiant License Agreement regarding the intellectual
property that is subject to such agreement. If disputes over intellectual property that we have licensed, or in the future may license,
prevent or impair our ability to maintain any of our license agreements, including the Giiant License Agreement, on acceptable terms,
we may be unable to successfully develop and commercialize the affected product candidates and technologies.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 20; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&nbsp;</p></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Clinical
drug development is expensive, time-consuming and uncertain.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
clinical development of product candidates is very expensive, time-consuming, difficult to design and implement, and the outcomes are
inherently uncertain. Most product candidates that commence clinical trials are never approved by regulatory authorities for commercialization
and of those that are approved, many do not generate sufficient revenue to cover their costs of development. In addition, we, any partner
with which we may collaborate, Health Canada, any similar regulatory authority, state and local agencies, counterpart agencies in foreign
countries, or the applicable Institutional Review Board (&ldquo;IRB&rdquo;) at our trial sites, may suspend, delay, require modifications
to or terminate our clinical trials, once begun, at any time.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>We
are currently conducting a Phase 1 clinical trial of PALI-2108 in Canada, and the FDA or applicable foreign regulatory authorities may
not accept data from such trials, or any other trial we conduct outside of the U.S.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are conducting a Phase 1 clinical trial for ulcerative colitis in Canada. However, we have not received approval from the FDA to commence
any clinical trials in the U.S., and there is no guarantee that we will be able to obtain such approval in a timely manner, if at all.
If our Phase 1 clinical trial is successful and we seek to initiate a Phase 2 clinical trial in the U.S., there is no certainty that
the FDA will accept the data generated from our Canadian trial. The FDA&rsquo;s acceptance of foreign clinical data is subject to certain
conditions, including whether the trial was conducted in accordance with good clinical practices (&ldquo;GCP&rdquo;) and whether the
FDA can validate the trial data through on-site inspections or other means. Moreover, the FDA will assess whether the trial design, patient
population, endpoints, and other factors meet the standards expected for clinical trials conducted within the U.S.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition, regulatory approval for clinical trials and eventual drug approval in the U.S. is a complex process, influenced by several
factors, including:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    adequacy and relevance of the Phase 1 trial data in supporting progression to Phase 2, as evaluated by the FDA;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    ability of the trial to meet safety, efficacy, and other scientific requirements set by the FDA, which may differ from those of Health
    Canada;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">whether
    the foreign clinical trial was conducted under an FDA-recognized regulatory authority, and whether FDA oversight is possible through
    monitoring or inspection of clinical sites; and</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    FDA&rsquo;s consideration of the risk-benefit ratio for continuing clinical development in the U.S., particularly based on data from
    a non-U.S. population.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Furthermore,
while the FDA does have the ability to approve drugs that have undergone clinical trials in foreign jurisdictions, including Canada,
approval is generally contingent on demonstrating that the trial data align with FDA standards and regulatory expectations. It is also
possible that we may be required to conduct additional trials in the U.S. to address any concerns regarding the applicability of the
foreign trial data to the U.S. population or regulatory environment. There can be no assurance that we will successfully obtain FDA approval
to initiate a Phase 1 clinical trial in the U.S. or that if our Canadian trial is successful, a subsequent Phase 2 trial.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>We
may find it difficult to enroll patients in our clinical trials, which could delay or prevent us from proceeding with clinical trials
of our product candidates.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Identifying
and qualifying subjects to participate in our current and anticipated future clinical trials is critical to our success. Our inability
to enroll patients in our clinical trials on a timely basis could result in the trials being delayed or never completed.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 21; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&nbsp;</p></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Patient
enrollment and trial completion are affected by numerous additional factors, including the:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">process
    for identifying patients;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">design
    of the trial protocol;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">eligibility
    and exclusion criteria;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">perceived
    risks and benefits of the product candidate under study;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">availability
    of competing therapies and clinical trials;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">severity
    of the disease under investigation;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">proximity
    and availability of clinical trial sites for prospective patients;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">ability
    to obtain and maintain patients&rsquo; consents;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">risk
    that enrolled patients will drop out before completion of the clinical trial;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">patient
    referral practices of physicians; and,</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">ability
    to monitor patients adequately during and after treatment.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
we have difficulty enrolling a sufficient number of patients to conduct our clinical trials as planned, we may need to delay, limit or
terminate ongoing or planned clinical trials, any of which would have an adverse effect on our business, financial condition, results
of operations and prospects. There can be no assurances that we will be able to complete enrollment for our anticipated Phase 1 clinical
trial for PALI-2108, and if we fail to do so, we may not be able to complete the trial on a timely basis, or at all.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>We
expect that our operations and development of PALI-2108 will require substantially more capital than we currently have, and we cannot
guarantee when or if we will be able to secure such additional funding</I></B>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have historically funded our operations and prior development efforts through the sale of our securities. Based on our existing cash
resources and our current business plan, we do not have adequate capital to fund our anticipated operations through the completion of
the development of PALI-2108. As a result, we will need to secure additional funding. If we are not able to obtain additional capital
in the future or on acceptable terms, we may need to curtail our anticipated clinical trials as well as our operations.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Our
product candidates, including our lead product candidate, PALI-2108, may cause undesirable side effects or have other unexpected properties
that could delay or prevent their regulatory approval, limit the commercial profile of an approved label, or result in post-approval
regulatory action.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Unforeseen
side effects from PALI-2108 could arise either during clinical development or, if approved, after it has been marketed. Undesirable side
effects could cause us, any partners with which we may collaborate, or regulatory authorities to interrupt, extend, modify, delay or
halt clinical trials and could result in a more restrictive or narrower label or the delay or denial of regulatory approval by Health
Canada, or comparable regulatory authorities like the FDA.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Results
of clinical trials could reveal a high and unacceptable severity and prevalence of side effects. In such an event, trials could be suspended
or terminated, and Health Canada or comparable regulatory authorities, like the FDA, could order us to cease further development of or
deny approval of a product candidate for any or all targeted indications. The drug-related side effects could affect patient recruitment
or the ability of enrolled patients to complete the trial or result in product liability claims. Any of these occurrences may have an
adverse material effect on our business, financial condition, operating results and prospects.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Additionally,
if we or others identify undesirable side effects, or other previously unknown problems, caused by a product after obtaining regulatory
approval, a number of potentially negative consequences could result, which could prevent us or our potential partners from achieving
or maintaining market acceptance of the product and could substantially increase the costs of commercializing such product.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 22; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&nbsp;</p></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>There
can be no assurance that our product candidates will obtain regulatory approval.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
sale of human therapeutic products in the U.S. and foreign jurisdictions is subject to extensive and time-consuming regulatory approval,
which requires, among other things:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">preclinical
    data required for the submission of an IND or CTA;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">controlled
    research and human clinical testing;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">establishment
    of the safety and efficacy of the proposed product candidate;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">government
    review and approval of a submission containing manufacturing, preclinical and clinical data; and</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">adherence
    to cGMP regulations during production and storage.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">PALI-2108
will require significant development, clinical testing, possibly additional preclinical studies, and the investment of significant funds
to gain regulatory approval before it can be commercialized. Although we commenced a Phase 1 clinical trial in Canada, there can be no
assurances that gaining regulatory approval in Canada will result in regulatory approval from any other regulatory agency, including
the FDA of the U.S. The results of our human clinical testing of PALI-2108 may not meet applicable regulatory requirements. If approved
in a jurisdiction, PALI-2108 may also require the completion of post-market studies. The process of completing clinical testing and obtaining
the required approvals is expected to take a number of years and require the use of substantial resources. Further, there can be no assurance
that PALI-2108 will be shown to be safe and effective throughout our clinical trials or receive applicable regulatory approvals.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
June 28, 2024, the U.S. Supreme Court issued an opinion holding that courts reviewing agency action pursuant to the Administrative Procedure
Act &ldquo;must exercise their independent judgment&rdquo; and &ldquo;may not defer to an agency interpretation of the law simply because
a statute is ambiguous.&rdquo; The decision will have a significant impact on how lower courts evaluate challenges to agency interpretations
of law, including those by the FDA and other agencies with significant oversight of the biopharmaceutical industry. The new framework
is likely to increase both the frequency of such challenges and their odds of success by eliminating one way in which the government
previously prevailed in such cases. As a result, significant regulatory policies will be subject to increased litigation and judicial
scrutiny.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
we fail to obtain regulatory approvals, or if there are significant changes in regulatory policies that result in increased litigation
and judicial scrutiny leading to unexpected delays and increased cost, we may not be able to market PALI-2108 and our operations will
be adversely affected.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>If
clinical studies of PALI-2108 do not yield successful results, we may discontinue the development of PALI-2108.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
must demonstrate that PALI-2108 is safe and efficacious in humans through extensive clinical testing. We may experience numerous unforeseen
events during, or as a result of, the testing process that could delay or prevent commercialization of any products, including the following:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    results of preclinical studies that we have completed may not be indicative of results that will be obtained in human clinical trials;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">safety
    and efficacy results attained in preclinical studies may not be indicative of results that are obtained in our clinical trials;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">after
    reviewing early clinical trial results, we may abandon projects that we previously believed to be promising;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">we
    or our regulators may suspend or terminate our clinical trials because the participating subjects or patients are being exposed to
    unacceptable health risks; and</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">PALI-2108
    may not have the desired effects or may include undesirable side effects or other characteristics that preclude regulatory approval
    or limit their commercial use if approved.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>It
may take us longer than we estimate to complete clinical trials, and we may not be able to complete them at all.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Although
for planning purposes we project the commencement, continuation and completion of our clinical trials; a number of factors, including
scheduling conflicts with participating researchers and/or CROs, clinicians and research or clinical institutions, and difficulties in
identifying or enrolling patients who meet trial eligibility criteria, may cause significant delays. Even if we were to commence and
complete our clinical trials involving PALI-2108 as currently contemplated, they may not be successful.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 23; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&nbsp;</p></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Even
if PALI-2108 is approved for commercialization, future regulatory reviews or inspections may result in its suspension or withdrawal,
closure of a facility or substantial fines.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
regulatory approval to market and commercialize PALI-2108 is received, regulatory agencies will subject PALI-2108, as well as the manufacturing
facilities, to continual review and periodic inspection. If previously unknown problems with a product or manufacturing and laboratory
facility are discovered, or we fail to comply with applicable regulatory approval requirements, a regulatory agency may impose restrictions
on PALI-2108 or us. The agency may require the withdrawal of PALI-2108 from the market, closure of the facility or substantial fines.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>The
successful commercialization of PALI-2108, if approved, will depend in part on the extent to which government authorities and health
insurers establish adequate reimbursement levels and pricing policies.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Sales
of any approved drug candidate will depend in part on the availability of coverage and reimbursement from third-party payers such as
government insurance programs in the applicable jurisdiction, including, for example, Medicare and Medicaid in the U.S., private health
insurers, health maintenance organizations and other health care related organizations, who are increasingly challenging the price of
medical products and services. Accordingly, coverage and reimbursement may be uncertain. Adoption of any drug by the medical community
may be limited if third-party payers will not offer coverage. Additionally, significant uncertainty exists as to the reimbursement status
of newly approved drugs. Cost control initiatives may decrease coverage and payment levels for any drug and, in turn, the price that
we will be able to charge and/or the volume of our sales. We are unable to predict all changes to the coverage or reimbursement methodologies
that will be applied by private or government payers. Any denial of private or government payer coverage or inadequate reimbursement
could harm our business or future revenues, if any. If we partner with third parties with respect to any of our product candidates, we
may be reliant on that partner to obtain reimbursement from government and private payors for the drug, if approved, and any failure
of that partner to establish adequate reimbursement could have a negative impact on our revenues and profitability.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition, both the federal and state governments in the U.S. and foreign governments continue to propose and pass new legislation, regulations,
and policies affecting coverage and reimbursement rates, which are designed to contain or reduce the cost of health care. Further federal
and state proposals and healthcare reforms are likely, which could limit the prices that can be charged for the product candidates that
we develop and may further limit our commercial opportunity. There may be future changes that result in reductions in potential coverage
and reimbursement levels for our product candidates, if approved and commercialized, and we cannot predict the scope of any future changes
or the impact that those changes would have on our operations.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
future reimbursement for PALI-2108, subject to approval, is substantially less than projected, or rebate obligations associated with
them are substantially greater than expected, our future net revenue and profitability, if any, could be materially diminished.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>We
face potential product liability exposure, and if successful claims are brought against us, we may incur substantial liability for a
product candidate and we may need to limit our commercialization.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
use of our product candidates in clinical trials and the sale of any products for which we obtain marketing approval exposes us to the
risk of product liability claims. Product liability claims might be brought against us by clinical trial participants, consumers, health-care
providers, pharmaceutical companies, or others selling our products. If we cannot successfully defend ourselves against these claims,
we may incur substantial liabilities. Regardless of merit or eventual outcomes of such claims, product liability claims may result in:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">decreased
    demand for our product candidates;</FONT></TD></TR>

<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">impairment
    of our business reputation;</FONT></TD></TR>

<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">withdrawal
    of clinical trial participants;</FONT></TD></TR>

<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">costs
    of litigation;</FONT></TD></TR>

<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">substantial
    monetary awards to patients or other claimants; and</FONT></TD></TR>

<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">loss
    of revenues.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 24; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->20<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&nbsp;</p></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
insurance coverage may not be sufficient to reimburse us for all expenses or losses we may suffer. Moreover, insurance coverage is becoming
increasingly expensive, and, in the future, we may not be able to maintain insurance coverage at a reasonable cost or in sufficient amounts
to protect us against losses.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Even
if a product candidate obtains regulatory approval, it may fail to achieve the broad degree of physician and patient adoption and use
necessary for commercial success.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
commercial success of our product candidates, if approved, will depend significantly on attaining broad adoption and use of the drug
by physicians and patients. The degree and rate of physician and patient adoption of a product, if approved, will depend on a number
of factors, including but not limited to:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">patient
    demand for approved products that treat the indication for which they are approved;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    effectiveness of a product compared to other available therapies or treatment regimens;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    availability of coverage and adequate reimbursement from managed care plans and other healthcare payors;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    cost of treatment in relation to alternative treatments and willingness to pay on the part of patients;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">insurers&rsquo;
    willingness to see the applicable indication as a disease worth treating;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">proper
    administration by physicians or patients;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">patient
    satisfaction with the results, administration and overall treatment experience;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">limitations
    or contraindications, warnings, precautions or approved indications for use different than those sought by us that are contained
    in the final approved labeling;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">any
    requirement of an authoritative regulatory body to undertake a risk evaluation and mitigation strategy;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    effectiveness of our sales, marketing, pricing, reimbursement and access, government affairs, and distribution efforts;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">adverse
    publicity about a product or favorable publicity about competitive products;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">new
    government regulations and programs, including price controls and/or limits or prohibitions on ways to commercialize drugs, such
    as increased scrutiny on direct-to-consumer advertising of pharmaceuticals; and</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">potential
    product liability claims or other product-related litigation.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
any of our product candidates are approved for use but fail to achieve the broad degree of physician and patient adoption necessary for
commercial success, our operating results and financial condition will be adversely affected, which may delay, prevent or limit our ability
to generate revenue and continue our business.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Risks
Related to Our Business</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>We
have a limited operating history and have never generated any revenues from product sales.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are a biopharmaceutical company with a limited operating history that may make it difficult to evaluate the success of our business and
to assess our future viability. While we were initially formed in 2001, our operations, have historically been limited to business planning,
raising capital and other research and development activities related to our product candidates. We additionally adopted a new business
plan in September 2023 upon entering into the Giiant License Agreement. Since that time, we have not yet demonstrated an ability to successfully
complete any clinical trials and have never completed the development of any product candidate, nor have we ever generated any revenue
from product sales. Consequently, we have no meaningful operations upon which to evaluate our business, and predictions about our future
success or viability may not be as accurate as they could be if we had a longer operating history or a history of successfully developing
and commercializing biopharmaceutical products.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Our
business model assumes revenue from, among other activities, marketing or out-licensing the products we develop. PALI-2108 is in the
early stages of clinical development and because we have a short development history with PALI-2108, there is a limited amount of information
about us upon which you can evaluate our business and prospects.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have no approved drugs and thus have not begun to market or generate revenues from the commercialization of any products. We only have
a limited history upon which we can evaluate our ability to develop PALI-2108. We commenced our initial Phase 1 clinical trial of PALI-2108
in November of 2024. Thus, we have limited experience and have not yet demonstrated an ability to successfully overcome many of the risks
and uncertainties frequently encountered by companies in new and rapidly evolving fields, particularly in the biopharmaceutical area.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 25; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->21<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&nbsp;</p></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
example, to execute our business plan, we will need to:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">execute
    product development activities using unproven technologies;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">build,
    maintain, and protect a strong intellectual property portfolio;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">demonstrate
    safety and efficacy of our drug candidates in multiple human clinical studies;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">receive
    approval from Health Canada and/or approval from similar foreign regulatory bodies, such as the FDA;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Retain
    qualified CROs to oversee and manage for the continued development of PALI-2108 through current and future clinical trials;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">gain
    market acceptance for the development and commercialization of any drugs we develop;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">ensure
    our products are reimbursed by commercial and/or government payors at a rate that permits commercial viability;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">develop
    and maintain successful strategic relationships with suppliers, distributors, and commercial licensing partners;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">manage
    our spending and cash requirements as our expenses will increase in the near term if we add programs and additional preclinical and
    clinical trials; and</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">effectively
    market any products for which we obtain marketing approval.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
we are unsuccessful in accomplishing these objectives, we may not be able to develop our proposed products, raise capital, expand our
business or continue our operations.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Our
success depends on attracting and retaining senior management and scientists with relevant expertise.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
future success depends to a significant extent on the continued services of our key employees, including our senior scientific, technical
and managerial personnel. We do not maintain key person life insurance for any of our executives. Competition for qualified employees
in the pharmaceutical industry is high, and our ability to execute our strategy will depend in part on our ability to continue to attract
and retain qualified scientists and management. If we are unable to find, hire, and retain qualified individuals, we may be unable to
execute our business plan in a timely manner, if at all.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>We
may choose to discontinue development or commercialization any of our product candidates, or may choose not to commercialize product
candidates in approved indications, at any time during development or after approval, which could adversely affect us and our operations.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">At
any time, we may decide to discontinue the development of, or temporarily pause the development of, any of our product candidates then
in existence for a variety of reasons, including the appearance of new technologies that make our product candidates obsolete, competition
from competing product(s) or changes in or failure to comply with applicable regulatory requirements. If we temporarily pause or terminate
a program in which we have invested significant resources, we will not receive any return on our investment and we will have missed the
opportunity to have allocated those resources to potentially more productive uses, which could have an adverse effect on us and our business.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Our
inability to successfully in-license, acquire, develop and market additional product candidates or approved products could impair our
ability to grow our business.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">PALI-2108
is currently our only product candidate being actively developed. We may in-license, acquire, develop and market additional products
and product candidates. Since our internal research and development capabilities are limited, we may be dependent on pharmaceutical companies,
academic or government scientists and other researchers to sell or license products or technology to us. The success of this strategy
depends partly on our ability to identify and select promising pharmaceutical product candidates and approved products, negotiate licensing
or acquisition agreements with their current owners, and finance these arrangements.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
process of identifying, negotiating and implementing a license or acquisition of a product candidate or approved product is lengthy and
complex. Other companies, including some with substantially greater financial, marketing, sales and other resources, may compete with
us for the license or acquisition of product candidates and approved products. Moreover, we may devote resources to potential acquisitions
or licensing opportunities that are never completed, or we may fail to realize the anticipated benefits of such efforts. We may not be
able to acquire the rights to additional approved products or product candidates on terms that we find acceptable, or at all.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 26; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->22<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&nbsp;</p></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Further,
any product candidate that we acquire or license may require additional development efforts prior to commercial sale, including preclinical
or clinical testing and approval by the applicable regulatory authorities. All product candidates are prone to risks of failure typical
of pharmaceutical product development, including the possibility that a product candidate will not be shown to be sufficiently safe and
effective for approval by regulatory authorities. In addition, we cannot provide assurance that any approved products that we acquire
will be manufactured or sold profitably or achieve market acceptance.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Changes
in funding for the FDA and, other government agencies or comparable foreign regulatory authorities could hinder their ability to hire
and retain key leadership and other personnel, or otherwise prevent new products and services from being developed or commercialized
in a timely manner or otherwise prevent these agencies or authorities from performing normal business functions on which the operations
of our business may rely, which could negatively impact our business.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
ability of the FDA or comparable foreign regulatory authorities to review and approve new products, to provide feedback on clinical trials
and development programs, to meet with sponsors and to otherwise review regulatory submissions can be affected by a variety of factors,
including government budget and funding levels, ability to hire and retain key leadership and other personnel, the sufficiency of user
fees, and statutory, regulatory, and policy changes. Average review times at the agency have fluctuated in recent years as a result.
In addition, government funding of other government agencies or comparable foreign regulatory authorities on which our operations may
rely, including those that fund research and development activities is subject to the political process, which is inherently fluid and
unpredictable.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Disruptions
at the FDA and other, other government agencies or comparable foreign regulatory authorities may also slow the time necessary for new
drugs to be reviewed or approved by necessary government agencies, which would adversely affect our business. For example, over the last
several years, the U.S. government has shut down several times and certain regulatory agencies, such as the FDA, have had to furlough
critical employees and stop critical activities. If a prolonged government shutdown occurs, it could significantly impact the ability
of the FDA to timely review and process our regulatory submissions, which could have a material adverse effect on our business.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Risks
Related to Our Dependence on Third Parties</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>We
anticipate relying on third-party CROs and other third parties to conduct and oversee our clinical trials. If these third parties do
not meet our requirements or otherwise conduct the trials as required, we may not be able to satisfy our contractual obligations for
obtain regulatory approval for, or commercialize our product candidates.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have retained a CRO to oversee our Phase 1 clinical trial for PALI-2108 in Canada. We are likely to rely on third-party CROs to conduct
and oversee our other anticipated clinical trials and other aspects of product development. We also expect to rely on various medical
institutions, clinical investigators and contract laboratories to conduct our trials in accordance with our clinical protocols and all
applicable regulatory requirements, including the FDA&rsquo;s regulations and GCP requirements, which are an international standard meant
to protect the rights and health of patients and to define the roles of clinical trial sponsors, administrators and monitors, and state
regulations governing the handling, storage, security and recordkeeping for drug and biologic products. These CROs and other third parties
are expected to play a significant role in the conduct of these trials and the subsequent collection and analysis of data from the clinical
trials. We expect to rely heavily on these parties for the execution of our clinical trials and any additionally required preclinical
studies and will control only certain aspects of their activities. We and our CROs and other third-party contractors will be required
to comply with GCP and GLP regulations, which are regulations and guidelines enforced by the FDA and comparable foreign regulatory authorities,
such as Health Canada, with respect to our Phase 1 clinical trial for PALI-2108. Regulatory authorities enforce these GCP or GLP regulations
through periodic inspections of trial sponsors, principal investigators and trial sites. If we or any of these third parties fail to
comply with applicable GCP and GLP regulations, or reveal noncompliance from an audit or inspection, any clinical data generated in our
clinical trials may be deemed unreliable, and the FDA or other regulatory authorities may require us to perform additional clinical trials
before approving our or our partners&rsquo; marketing applications. We cannot assure that upon inspection by a given regulatory authority
such regulatory authority will determine whether any of our clinical trials comply with applicable GCP or GLP regulations. In addition,
our clinical trials generally must be conducted with compounds produced under cGMP regulations. Our failure to comply with these regulations
and policies may require us to repeat clinical trials, which would be costly and delay the regulatory approval process. In the event
that we are unable to retain a qualified CRO for our Phase 1 clinical trial for PALI-2108, or any other anticipated clinical trial, it
would delay planned clinical operations and result in additional cost and expense. Additionally, if our current CRO for our Phase 1 clinical
trial in Canada or if any of our CROs that we retain in the future were to terminate their involvement with us, there is no assurance
that we would be able to enter into arrangements with alternative CROs or do so on commercially reasonable terms.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>We
depend on two qualified suppliers for the active pharmaceutical ingredient used in the clinical trials of PALI-2108. Insufficient availability
of the API or other raw materials necessary to manufacture PALI-2108, or the inability of our suppliers to manufacture and supply our
products on commercially reasonable terms, could adversely impact our business, results of operations and financial condition.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have two qualified suppliers for the API used in PALI-2108. We do not have, and we do not intend to establish in the foreseeable future,
internal manufacturing capabilities. Instead, we intend to use the facilities of third-party manufacturers to produce the materials used
in our clinical trials. Our dependence on third parties for the supply and manufacture of PALI-2108 and any future product candidates
may adversely affect our ability to obtain our products in a timely or competitive manner, if at all.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Any
supply shortages, quality concerns, or failure to obtain sufficient API, excipients, or components from our suppliers, including disruptions
caused by, among other things, supply chain delays, public health emergencies, climate events, or political unrest would adversely affect
our business, results of operations and financial condition. In particular, our suppliers may be impacted by epidemics, pandemics or
other disease outbreaks or public health emergencies and general macroeconomic conditions, including inflationary pressures, economic
slowdown or recession, relatively high interest rates, imposed tariffs, changes in monetary policy, potential U.S. federal government
shutdowns, geopolitical conflicts and financial institution instability, all of which may result in supply delays and cost increases.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 27; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->23<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&nbsp;</p></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
manufacturing process for pharmaceutical products is highly regulated, and regulatory agencies may from time to time shut down facilities
that they believe do not comply with regulations. Our third-party manufacturers and suppliers are subject to numerous FDA and Health
Canada regulations, including those governing manufacturing processes, stability testing, record keeping, product serialization, and
quality standards. Similar regulations apply in other jurisdictions where we may conduct business. Our third-party manufacturers and
suppliers are independent entities who are subject to their own operational and financial risks which are out of our control.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
we, our third-party manufacturers, or our suppliers fail to comply with these regulations, our ability to deliver adequate supplies of
PALI-2108 for clinical trials in a timely and cost-effective manner may be adversely affected. Should any of these risks materialize
and adversely affect such third-party manufacturers&rsquo; and/or suppliers&rsquo; performance obligations to us, and we are unable to
secure sufficient of the API used in the manufacture of PALI-2108 on commercially acceptable terms, or if we encounter delays and difficulties
in our relationships with manufacturers or suppliers, our business, results of operations and financial condition could be adversely
affected.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>We
expect to rely on collaborations with third parties for the successful development and commercialization of our product candidates.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
currently rely on and expect to continue to rely upon the efforts of third parties for the successful development and commercialization
of our product candidates. The clinical and commercial success of our product candidates may depend upon maintaining successful relationships
with third-party partners, which are subject to a number of significant risks, including the following:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
    partners&rsquo; ability to execute their responsibilities in a timely, cost-efficient and compliant manner;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">reduced
    control over delivery and manufacturing schedules;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">price
    increases;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">manufacturing
    deviations from internal or regulatory specifications;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">quality
    incidents;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    failure of partners to perform their obligations for technical, market or other reasons;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">misappropriation
    of our product candidates; and</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">other
    risks in potentially meeting our product commercialization schedule or satisfying the requirements of our end-users.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
cannot provide any assurance that we will be able to establish or maintain third-party relationships in order to successfully develop
and commercialize our product candidates.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>We
currently rely on third-party contractors to supply, manufacture and distribute clinical drug supplies for our product candidates.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
do not currently have, nor do we currently plan to acquire, the infrastructure or capability to supply, store, manufacture or distribute
clinical or commercial quantities of drug substances or products. Although we have entered into a commercial supply agreement to provide
us with such drug substances or products for our current Phase 1 clinical trial, our future ability to develop and commercialize, if
approved, our product candidates is dependent on our ability to obtain the APIs and other substances and materials used in our product
candidates successfully from third parties and to have finished products manufactured by third parties in accordance with regulatory
requirements and in sufficient quantities for preclinical and clinical testing and commercialization. If we fail to develop and maintain
supply and other technical relationships with these third parties, we may be unable to continue to develop or commercialize our products
and product candidates, which could adversely affect us and our business.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are dependent on our contract suppliers and manufacturers for day-to-day compliance with applicable laws and cGMP regulations for production
of our proposed products and API. If the safety or quality of any product or product candidate or component is compromised due to a failure
to adhere to applicable laws or for other reasons, we may not be able to commercialize or obtain regulatory approval for the affected
product or product candidates successfully, and we may be held liable as a result.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
expect to continue to depend on third-party contract suppliers and manufacturers. Our supply and manufacturing agreements do not guarantee
that a contract supplier or manufacturer will provide services adequate for our needs. Additionally, any damage to or destruction of
our third-party manufacturers&rsquo; or suppliers&rsquo; facilities or equipment, even by force majeure, may significantly impair our
ability to have our products and product candidates manufactured on a timely basis. Our reliance on contract manufacturers and suppliers
further exposes us to the possibility that they, or third parties with access to their facilities, may misappropriate our trade secrets
or other proprietary information. Furthermore, the manufacturing facilities of our suppliers are located outside of the U.S. This may
give rise to difficulties in importing our products or product candidates or their components into the U.S. or other countries.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
currently have agreements in place with foreign third parties in China and other countries to provide the necessary clinical supply of
our API. Termination of or limitations on our relationships with foreign third parties that manufacture the API used in PALI-2108 may
arise if U.S. legislation, tariffs, sanctions, trade restrictions, or other U.S. and foreign regulatory requirements, or prohibitions
restrict our ability to engage with these foreign third parties. Further, any such actions could adversely impact our current and future
arrangements with our foreign suppliers, including our current Chinese drug manufacturer, which could increase the cost or reduce the
supply of material available to us or delay the procurement or supply of such material used in our clinical trial.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 28; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->24<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&nbsp;</p></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Risks
Related to Our Financial Operations</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>We
have expressed substantial doubt about our ability to continue as a going concern.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Management
has determined that there is substantial doubt about our ability to continue as a going concern for a period of one year following the
issuance of our most recent financial statements. This determination was based on conditions and events, considered in the aggregate,
that raise substantial doubt about our ability to continue as a going concern within one year after the date that the consolidated financial
statements are issued, including our available cash as of the date of this filing, which is not sufficient to fund our anticipated level
of operations for the next 12 months. Our future consolidated financial statements may include a similar qualification about our ability
to continue as a going concern. Our year-end and interim consolidated financial statements were prepared assuming that we will continue
as a going concern and do not include any adjustments that may result from the outcome of this uncertainty.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
we seek additional financing to fund our business activities in the future and there remains substantial doubt about our ability to continue
as a going concern, investors or other financing sources may be unwilling to provide additional funding to us on commercially reasonable
terms or at all.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>We
have a history of net losses, and we expect to continue to incur net losses and may never achieve profitability.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have incurred net losses since our inception. We expect that our operating losses will continue for the foreseeable future as we continue
our drug development and discovery efforts. To achieve profitability, we must, either directly or through licensing and/or partnering
relationships, meet certain milestones, successfully develop and obtain regulatory approval for one or more drug candidates and effectively
manufacture, market and sell any drugs we successfully develop. Even if we are able to successfully commercialize product candidates
that receive regulatory approval, we may not be able to realize revenues at a level that would allow us to achieve or sustain profitability.
Accordingly, we may never generate significant revenue and, even if we generate significant revenue, we may never achieve profitability.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Failure
to remediate a material weakness in internal controls over financial reporting could result in material misstatements in our consolidated
financial statements.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
management has identified a material weakness in our internal control over financial reporting. The material weakness was due to a lack
of controls in the financial closing and reporting process, including a lack of segregation of duties and the documentation and design
of formalized processes and procedures surrounding the creation and posting of journal entries and account reconciliations.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
our remaining material weakness, which management concluded is still present as of the date of these financial statements, is not remediated,
or if we identify further material weaknesses in our internal controls, our failure to establish and maintain effective disclosure controls
and procedures and internal control over financial reporting could result in material misstatements in our consolidated financial statements
and a failure to meet our reporting and financial obligations.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Risks
Related to Our Intellectual Property</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>We
may not be able to obtain, maintain or enforce global patent rights or other intellectual property rights that cover our product candidates
and technologies that are of sufficient breadth to prevent third parties from competing against us.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
success with respect to our current and future product candidates will depend, in part, on our ability to obtain and maintain patent
protection in both the U.S. and other countries, to preserve our trade secrets and to prevent third parties from infringing on our proprietary
rights. Our ability to protect our product candidates from unauthorized or infringing use by third parties depends in substantial part
on our ability to obtain and maintain valid and enforceable patents in certain countries.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
patent application process, also known as patent prosecution, is expensive and time-consuming, and we and our current or future licensors
and licensees may not be able to prepare, file and prosecute all necessary or desirable patent applications at a reasonable cost or in
a timely manner in all the countries that are desirable. It is also possible that we or our current, or future licensors and licensees
will fail to identify patentable aspects of inventions made in the course of development and commercialization activities before it is
too late to obtain patent protection on them. Therefore, these and any of our patents and applications may not be prosecuted and enforced
in a manner consistent with the best interests of our business. Moreover, our competitors independently may develop equivalent knowledge,
methods and know-how or discover workarounds to our patents that would not constitute infringement. Any of these outcomes could impair
our ability to enforce the exclusivity of any issued or pending patents we may have or the ability to obtain future patent protections,
which may have an adverse impact on our business, financial condition and operating results.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 29; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->25<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&nbsp;</p></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
ability to obtain, maintain and/or enforce patents is uncertain and involves complex legal and factual questions, especially across varying
countries. Accordingly, rights under any existing patents or any patents we might obtain or license may not cover our product candidates
or may not provide us with sufficient protection for our product candidates to afford a sustainable commercial advantage against competitive
products or processes, including those from branded, generic and over-the-counter pharmaceutical companies. In addition, we cannot guarantee
that any patents or other intellectual property rights will be issued from any pending or future patent or other similar applications
owned by or licensed to us. Even if patents or other intellectual property rights have issued or will issue, we cannot guarantee that
the claims of these patents and other rights are or will be held valid or enforceable by the courts, through injunction or otherwise,
or will provide us with any significant protection against competitive products or otherwise be commercially valuable to us in every
country of commercial significance that we may target.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
ability to obtain and maintain valid and enforceable patents depends on whether the differences between our technology and prior art
make it patentable. We do not have outstanding issued patents covering all of the recent developments in our technology and we are unsure
of the patent protection that we will be successful in obtaining, if any. Even if the patents are successfully issued, third parties
may design around or challenge the validity, enforceability or scope of such issued patents or any other issued patents we own or license,
which may result in such patents being narrowed, invalidated or held unenforceable. If the breadth or strength of protection provided
by the patents we hold or pursue with respect to our product candidates are challenged, it could dissuade companies from collaborating
with us to develop or threaten our ability to commercialize or finance our product candidates.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
laws of some foreign jurisdictions do not provide intellectual property rights to the same extent or duration as in the U.S., and many
companies have encountered significant difficulties in acquiring, maintaining, protecting, defending and especially enforcing such rights
in foreign jurisdictions. If we encounter such difficulties in protecting or are otherwise precluded from effectively protecting our
intellectual property in foreign jurisdictions, our business prospects could be substantially harmed, especially internationally.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Proprietary
trade secrets and unpatented know-how are also very important to our business. Although we have taken steps to protect our trade secrets
and unpatented know-how by entering into confidentiality agreements with third parties, and intellectual property assignment and protection
agreements with officers, directors, employees, and certain consultants and advisors, there can be no assurance that such agreements
will not be breached or enforced by courts, that we would have adequate remedies for any breach, including injunctive and other equitable
relief, or that our trade secrets and unpatented know-how will not otherwise become known, inadvertently disclosed by us or our agents
and representatives, or be independently discovered by our competitors. If our trade secrets are independently discovered, we would not
be able to prevent their use and if we or our agents or representatives inadvertently disclose trade secrets and/or unpatented know-how,
we may not be allowed to retrieve these trade secrets and/or unpatented know-how and maintain the exclusivity we previously held.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>We
may not be able to protect our intellectual property rights throughout the world.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Filing,
prosecuting and defending patents on our product candidates does not guarantee exclusivity. The requirements for patentability vary between
countries, particularly developing nations. In addition, the laws of some countries do not protect intellectual property rights to the
same extent as the laws of all other countries or jurisdictions, especially when it comes to granting use and other types of patents
and what kind of enforcement rights will be allowed, especially injunctive relief in a civil infringement proceeding. Consequently, we
may not be able to prevent third parties from using our inventions or even in launching an identical version of our product even if we
hold a valid patent. Competitors may use our technologies in jurisdictions where we have not obtained patent protection, or they may
produce copy products, and, further, may export otherwise infringing products to territories where we have patent protection but enforcement
against such activities is inadequate or where we have no patents. These products could compete with ours, and our patents or other intellectual
property rights may not prevent them from competing.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 30; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->26<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&nbsp;</p></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Obtaining
and maintaining our patent protection depends on compliance with various procedural, document submission, fee payment, and other requirements
imposed by governmental patent agencies, and our patent protection could be reduced or eliminated for non-compliance with these requirements.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Periodic
maintenance and annuity fees on any issued patent are due to be paid to applicable patent agencies, which require compliance with a number
of procedures, including certain documentary, fee payment and other similar provisions during the patent application process. Non-compliance
events that could result in abandonment or lapse of a patent or patent application include failure to respond to official actions within
prescribed time limits, non-payment of fees in prescribed time periods, and failure to properly legalize and submit formal documents
in the format and style the country requires. While an inadvertent lapse can, in many cases, be cured by payment of a late fee or by
other means in accordance with the applicable rules, there are situations in which noncompliance can result in abandonment or lapse of
the patent or patent application, resulting in partial or complete loss of patent rights in the relevant jurisdiction just for failure
to know about and/or timely pay a prosecution fee. If we or our licensors fail to maintain the patents and patent applications covering
our product candidates for any reason, our competitors might be able to enter the market, which would have an adverse effect on our business.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>If
we fail to comply with our obligations under our intellectual property license agreements, we could lose license rights that are important
to our business.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Giiant License Agreement pursuant to which we license PALI-2108, and other assets of Giiant, contains certain requirements related to
diligence, milestone, royalty, insurance, expense reimbursement, and other obligations. If we fail to comply with these obligations,
Giiant may have the ability to terminate the license, subject to certain requirements as more fully set forth in the Giiant License Agreement.
If the license granted thereunder were to be terminated, our business, financial condition, operating results, and prospects would be
materially adversely affected.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>We
may be subject to patent infringement claims, which could result in substantial costs and liabilities, and could prevent us from commercializing
our potential products.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Because
the intellectual property landscape in the fields in which we participate is rapidly evolving and interdisciplinary, it is difficult
to conclusively assess our freedom to operate without infringing on third-party rights. If any patent infringement claims are brought
against us, regardless of whether successful, we may incur significant expenses and divert the attention of our management and key personnel
from other business concerns. This could negatively affect our results of operations and prospects. We cannot be certain that patents
owned or licensed by us will not be challenged, potentially successfully, by others.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition, if our product candidates are found to infringe the intellectual property rights of third parties, these third parties may
assert infringement claims against our customers, licensees and other parties with whom we have business relationships, and we may be
required to indemnify those parties for any damages they suffer as a result of such claims. The claims may require us to initiate or
defend protracted and costly litigation on behalf of customers, licensees, and other parties regardless of the merits of these claims.
If any of these claims succeed, we may be forced to pay damages on behalf of those parties or may be required to obtain licenses for
the products they use. If we cannot obtain all necessary licenses on commercially reasonable terms, we may be unable to continue selling
such products.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>We
may be subject to claims that our officers, directors, employees, consultants or independent contractors have wrongfully used or disclosed
to us alleged trade secrets of their former employers or their former or current customers.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
is common in the biotechnology and pharmaceutical industries, certain of our employees were formerly employed by other biotechnology
or pharmaceutical companies, including our competitors or potential competitors. Moreover, we engage the services of consultants to assist
us in the development of our product candidates, many of whom were previously employed at, or may have previously been or are currently
providing consulting services to, other biotechnology or pharmaceutical companies, including our competitors or potential competitors.
We may be subject to claims that our employees or consultants have inadvertently or otherwise wrongfully used or disclosed trade secrets
or other proprietary information of their former employers or their former or current customers. Although we have no knowledge of any
such claims being alleged, if such claims were to arise, litigation may be necessary to defend against any such claims. Even if we are
successful in defending against any such claims, the related litigation could be protracted, expensive, a distraction to our management
team, and not viewed favorably by investors and other third parties.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 31; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->27<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&nbsp;</p></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Other
Risks Related to Our Securities</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>We
will need to raise additional financing in the future to fund our operations, which may not be available to us on favorable terms or
at all.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have used and we intend to use the proceeds from our previous offerings and any future offerings, to, among other things, advance PALI-2108
through preclinical and clinical development and into INDs or their equivalent in foreign jurisdictions, fund our research and development
activities and for general working capital needs. We will require substantial additional capital to fund our operations and conduct the
costly and time-consuming research and development and clinical work necessary to pursue regulatory approval of product candidates. Our
future capital requirements will depend upon a number of factors, including: the number and timing of product candidates in the pipeline;
progress with and results from preclinical testing and clinical trials; the ability to manufacture sufficient drug supplies to complete
clinical trials or any additional preclinical studies required; the costs involved in preparing, filing, acquiring, prosecuting, maintaining
and enforcing patent and other intellectual property claims; and the time and costs involved in obtaining regulatory approvals and favorable
reimbursement or formulary acceptance. Raising additional capital may be costly or difficult to obtain, which could inhibit our ability
to achieve our business objectives. Given our limited cash reserves and the significant amount of capital that we will likely need to
fund our operations and business plan, our stockholders will likely experience significant dilution to their ownership interests. If
we raise additional funds through public or private equity sales of our securities, the terms of these securities may include liquidation
or other preferences that adversely impact the rights of our common stockholders. Further, to the extent that we raise additional capital
through the sale of common stock or securities convertible or exchangeable into common stock, our stockholders&rsquo; ownership percentage
will be decreased. In addition, any debt financing may subject us to fixed payment obligations and covenants limiting or restricting
our ability to take specific actions, such as incurring additional debt, making capital expenditures or declaring dividends. If we raise
additional capital through marketing and distribution arrangements or other collaborations, strategic alliances, or licensing arrangements
with third parties, we may need to relinquish certain valuable intellectual property or other rights to our product candidates, technologies,
future revenue streams or research programs or grant licenses on terms that may not be favorable to us. Even if we obtain additional
funding, there can be no assurance that it will be available on terms acceptable to us or our stockholders.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Our
common stock price may be highly volatile.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Since
the completion of the merger with Seneca on April 27, 2021, the price of our common stock has been subject to significant fluctuation.
Market prices for securities of biotechnology and other life sciences companies historically have been particularly volatile and may
be subject to large daily price swings. Some of the factors that may cause the market price of our shares to fluctuate include, but are
not limited to:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">failure
    of our product candidates to show safety and/or efficacy in our clinical trials;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
    ability to obtain timely regulatory approvals for our product candidates, and delays or failures to obtain such approvals;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    results of our clinical trials, including our decision to pause or terminate any such trials;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">failure
    of our product candidates, if approved, to achieve commercial success;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    entry into, or termination of, or breach by partners of key agreements, including the Giiant License Agreement, and employment agreements
    with our named executive officers;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    initiation of, material developments in, or conclusion of any litigation to enforce or defend any intellectual property rights or
    defend against the intellectual property rights of others;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">announcements
    of any financings;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">announcements
    by commercial partners or competitors of new commercial products, clinical progress or the lack of, significant contracts, commercial
    relationships or capital commitments;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">failure
    to elicit meaningful stock analyst coverage and downgrades of our stock by analysts; and</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    loss of key personnel.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Moreover,
the stock markets in general have experienced substantial volatility in the biotechnology industry, particularly in the micro-cap and
nano-cap companies, that has often been unrelated to the operating performance of individual companies or a certain industry segment.
These broad market fluctuations may also adversely affect the trading price of our shares. In the past, following periods of volatility
in the market price of a company&rsquo;s securities, stockholders have often instituted class action securities litigation against those
companies. Such litigation, if instituted, could result in substantial costs and diversion of management attention and resources, which
could significantly harm our profitability and reputation.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 32; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->28<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&nbsp;</p></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Our
common stock could be delisted from the Nasdaq Stock Market if we are unable to maintain compliance with the Nasdaq Stock Market&rsquo;s
continued listing standards.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
common stock is listed on the Nasdaq Stock Market. There are a number of continued listing requirements that we must satisfy in order
to maintain our listing on The Nasdaq Stock Market, including the requirement to maintain a minimum bid price of at least $1.00 (the
&ldquo;Bid Price Rule&rdquo;). In October 2023, we were notified that we were no longer in compliance with the Bid Price Rule and had
180 days to cure such deficiency. On April 5, 2024, we effected a 1-for-15 reverse stock split and we were notified by the Nasdaq Stock
Market that as of April 19, 2024, we were back in compliance with the Bid Price Rule. On April 30, 2025, we received the Notice from
Nasdaq advising us that we were no longer in compliance with the Bid Price Rule. The Notice has no effect on the listing of our common
stock at this time, and our common stock continues to trade on The Nasdaq Capital Market under the symbol &ldquo;PALI.&rdquo; If at any
time during the Compliance Period the closing bid price of our common stock is at least $1.00 for a minimum of 10 consecutive business
days, we will regain compliance with the Bid Price Rule and our common stock will continue to be eligible for listing on The Nasdaq Capital
Market absent noncompliance with any other requirement for continued listing. If we do not regain compliance with the Bid Price Rule
by the end of the Compliance Period, we may be afforded an Additional Compliance Period if on the last day of the Compliance Period we
are in compliance with the market value of publicly held shares requirement for continued listing as well as all other standards for
initial listing of its common stock on The Nasdaq Capital Market (other than the Minimum Bid Price Requirement), unless we do not indicate
our intent to cure the deficiency, or if it appears to Nasdaq that it is not possible for us to cure the deficiency. If we do not regain
compliance with the Bid Price Rule by the end of the Compliance Period, or the Additional Compliance Period, if applicable, our common
stock will be subject to delisting. The delisting of our common stock would likely adversely affect the market liquidity and market price
of our common stock and our ability to obtain financing for the continuation of our operations and/or result in the loss of confidence
by investors. We intend to monitor the closing bid price of our common stock and may, if appropriate, consider implementing available
options to regain compliance with the Bid Price Rule.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>We
take advantage of reduced disclosure and governance requirements applicable to smaller reporting companies, which could result in our
common stock being less attractive to investors.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of the last business day of our most recently completed second fiscal quarter, our public float was less than $250 million and therefore,
we qualify as a smaller reporting company under SEC rules. As a smaller reporting company, we can take advantage of reduced disclosure
requirements, such as simplified executive compensation disclosures and reduced financial statement disclosure requirements in our SEC
filings. Such reduced disclosures in our SEC filings may make it harder for investors to analyze our results of operations and financial
prospects. We cannot predict if investors will find our common stock less attractive if we rely on these exemptions. If some investors
find our common stock less attractive as a result, there may be a less active trading market for our common stock and our stock price
may be more volatile. We may take advantage of the reporting exemptions applicable to a smaller reporting company until we are no longer
a smaller reporting company, which status would end once we have a public float greater than $250 million. In that event, we could still
be a smaller reporting company if our annual revenues are below $100 million and we have a public float of less than $700 million.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>We
do not anticipate paying any dividends in the foreseeable future.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
do not anticipate paying any dividends in the foreseeable future. We currently plan to retain our future earnings, if any, to fund the
development and growth of our business. As a result, capital appreciation, if any, of our shares will likely be the sole source of gain,
if any, for our stockholders for the foreseeable future.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>If
equity research analysts do not publish research or reports, or publish unfavorable research or reports, about us, our business or our
market, our stock price and trading volume could decline.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
trading market for our common stock is and will be influenced by reports that equity research analysts publish about us and our business.
Equity research analysts may elect not to provide research coverage of our common stock, and such lack of research coverage may adversely
affect the market price of our common stock. In the event we do have equity research analyst coverage, we will not have any control over
the analysts, or the content and opinions included in their reports. The price of our common stock could decline if one or more equity
research analysts downgrades our stock or issues other unfavorable commentary or research. If one or more equity research analysts ceases
coverage of us or fails to publish reports on us regularly, demand for our common stock could decrease, which in turn could cause our
stock price or trading volume to decline.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>


<!-- Field: Page; Sequence: 33; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->29<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&nbsp;</p></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Future
sales of substantial amounts of our common stock, or the possibility that such sales could occur, could adversely affect the market price
of our common stock.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Future
sales in the public market of shares of our common stock, including shares issued upon exercise of our outstanding stock options or warrants,
or the perception by the market that these sales could occur, could lower the market price of our common stock or make it difficult for
us to raise additional capital.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Anti-takeover
provisions in our charter documents and under Delaware law could make an acquisition of us more difficult and may prevent attempts by
our stockholders to replace or remove our management.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Provisions
in our certificate of incorporation, as amended (&ldquo;Certificate of Incorporation&rdquo;), and bylaws, as amended (&ldquo;Bylaws&rdquo;)
may delay or prevent an acquisition or a change in management. In addition, because we are incorporated in Delaware, we are governed
by the provisions of Section 203 of the Delaware General Corporation Law, which prohibits stockholders owning in excess of 15% of our
outstanding voting stock from merging or combining with us. Although we believe these provisions collectively will provide for an opportunity
to receive higher bids by requiring potential acquirors to negotiate with our Board of Directors (&ldquo;Board&rdquo; or &ldquo;Board
of Directors&rdquo;), they would apply even if the offer may be considered beneficial by some stockholders. In addition, these provisions
may frustrate or prevent any attempts by our stockholders to replace or remove management by making it more difficult for stockholders
to replace members of the Board, which is responsible for appointing the members of management.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>If
we fail to maintain proper and effective internal controls, our ability to produce accurate financial statements on a timely basis could
be impaired.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are subject to the reporting requirements of the Exchange Act, the Sarbanes-Oxley Act and the rules and regulations of Nasdaq. The Sarbanes-Oxley
Act requires, among other things, that we maintain effective disclosure controls and procedures and internal control over financial reporting.
We must perform system and process evaluation and testing of our internal control over financial reporting to allow management to report
on the effectiveness of our internal controls over financial reporting in our Annual Report on Form 10-K filing for that year, as required
by Section 404 of the Sarbanes-Oxley Act. This has required that we incur substantial professional fees and internal costs to expand
our accounting and finance functions and that we expend significant management efforts. We may experience difficulty in meeting these
reporting requirements in a timely manner.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
management identified a material weakness in our internal control over financial reporting. If we do not remediate this material weakness,
or if we identify further material weaknesses in our internal controls, our failure to establish and maintain effective internal financial
and accounting controls and procedures could result in material misstatements in our consolidated financial statements and a failure
to meet our reporting and financial obligations.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
we are not able to comply with the requirements of Section 404 of the Sarbanes-Oxley Act, or if we are unable to maintain proper and
effective internal controls, we may not be able to produce timely and accurate consolidated financial statements. If that were to happen,
the market price of our common stock could decline and we could be subject to sanctions or investigations by Nasdaq, the SEC or other
regulatory authorities.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 34; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->30<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&nbsp;</p></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Our
Board has broad discretion to issue additional securities, which might dilute the net tangible book value per share of our common stock
for existing stockholders.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are entitled under our Certificate of Incorporation to issue up to 280,000,000 shares of common stock and 7,000,000 &ldquo;blank check&rdquo;
shares of preferred stock. Shares of our blank check preferred stock provide our Board with broad authority to determine voting, dividend,
conversion, and other rights of such preferred stock. As of June 30, 2025, we had outstanding, common stock or securities convertible
into common stock, totaling 9,769,406 shares. As a result, we are authorized to issue up to an additional 270,230,594 shares of common
stock or common stock equivalents under our Certificate of Incorporation. Additionally, pursuant to the initial issuance of (i) 1,000,000
shares of Series A 4.5% Convertible Preferred Stock, of which 200,000 shares are outstanding and (ii) 1,460 shares of Series B Convertible
Preferred Stock, of which no shares are outstanding, we are authorized to issue up to an additional 6,800,000 shares of preferred stock.
We expect that significant additional capital will be needed in the future to continue our planned operations. To the extent we raise
additional capital by issuing equity securities, our existing stockholders will likely experience substantial dilution. We may sell common
stock, convertible securities or other equity securities in one or more transactions at prices and in a manner that we determine from
time to time. If we sell common stock, convertible securities or other equity securities in more than one transaction, investors will
likely be materially diluted by the initial and subsequent sales. Additionally, new investors may gain rights superior to existing stockholders,
depending on the terms of such transactions and types of securities. Pursuant to our equity incentive plans and employee stock purchase
plan, management is authorized to grant stock options, restricted stock units and other equity-based awards to employees, directors and
consultants, and to sell common stock to employees, respectively. Any increase in the number of shares outstanding as a result of the
exercise of outstanding options, the vesting or settlement of outstanding stock awards, or the purchase of shares pursuant to the employee
stock purchase plan will cause stockholders to experience additional dilution, which could cause our stock price to fall.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>General
Risk Factors</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Our
business could be adversely affected by the effects of health pandemics or epidemics, such as the COVID-19 pandemic, which could cause
significant disruptions in our operations and those of our current or future CMOs, CROs, and other third parties upon whom we rely.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Health
pandemics or epidemics, such as the COVID-19 pandemic, have in the past and could again in the future result in quarantines, stay-at-home
orders, remote work policies, or other similar events that may disrupt businesses, delay our research and development programs and timelines,
negatively impact productivity and increase risks associated with cybersecurity, the future magnitude of which will depend, in part,
on the length and severity of the restrictions and other limitations. More specifically, these types of events may negatively impact
personnel at third-party manufacturing facilities or the availability or cost of materials, which could disrupt our supply chain. Moreover,
our trials may be negatively affected. Clinical site initiation and patient enrollment may be delayed due to prioritization of hospital
resources. Some patients may not be able or willing to comply with trial protocols if quarantines impede patient movement or interrupt
healthcare services. Our ability to recruit and retain patients, principal investigators, and site staff (who as healthcare providers
may have heightened exposure) may be hindered, which would adversely affect our trial operations. Disruptions or restrictions on our
ability to travel to monitor data from our trials, or to conduct trials, or the ability of patients enrolled in our trials or staff at
trial sites to travel, as well as temporary closures of our trial partners and CMOs&rsquo; facilities, would negatively impact our trial
activities. In addition, we rely on independent clinical investigators, CROs, and other third-party service providers to assist us in
managing, monitoring, and otherwise carrying out certain of our preclinical studies and clinical trials, including the collection of
data from our trials, and the effects of health pandemics or epidemics, such as the COVID-19 pandemic, may affect their ability to devote
sufficient time and resources to our programs or to travel to sites to perform work for us. Similarly, our trials could be delayed and/or
disrupted. As a result, the expected timeline for data readouts, including incompleteness in data collection and analysis and other related
activities, and certain regulatory filings may be negatively impacted, which would adversely affect our ability to obtain regulatory
approval for and to commercialize our product candidates, increase our operating expenses, and adversely affect our business, financial
condition, results of operations, and prospects. In addition, impact on the operations of the FDA or comparable foreign regulatory authorities
could negatively affect our planned trials and approval processes. Finally, economic conditions and business activity may be negatively
impacted and may not recover as quickly as anticipated.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 35; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->31<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&nbsp;</p></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Global
economic conditions may have an adverse effect on our business.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Financial
instability or a general decline in economic conditions in the U.S. and other countries, caused by political instability, conflict, and
economic challenges resulting from general health crises, has led to market disruptions, including significant volatility in commodity
prices, credit and capital market instability, and supply chain interruptions. Such volatility, instability, and interruptions have contributed
to record inflation globally and could adversely affect our operations. Increased inflation may result in higher operating costs (including
labor costs), reduced liquidity, and limitations on our ability to access credit or raise capital on acceptable terms, if at all. Existing
free trade laws and regulations, such as the United States-Mexico-Canada Agreement, provide certain beneficial duties and tariffs for
qualifying imports and exports, subject to compliance with applicable classification and other requirements. However, changes in trade
laws or policies, particularly increased trade restrictions, tariffs, or taxes on imports from countries where we manufacture products,
such as Canada, China, and Mexico, could have a material adverse effect on our business and financial results. Since February 2025, the
U.S. government has enacted, and continues to enact, a series of new tariffs, including a tariff on all imports and additional &ldquo;reciprocal&rdquo;
tariffs targeting imports from specified countries. These tariffs and other changes in U.S. trade policy have triggered, and could continue
to trigger, retaliatory actions by affected countries, including retaliatory measures on U.S. goods and other protectionist measures
that could limit our ability to offer our products and services outside of the U.S. The tariff policy environment has been and can be
expected to continue to be dynamic. The ultimate impact of these newly enacted and potential future tariffs or other restrictions on
international trade will depend on various factors, including the ultimate levels of such tariffs, how long such tariffs remain in place,
and how other countries respond to the U.S. tariffs. Consequently, we cannot assure that any strategies we implement to mitigate the
effects of such tariffs or trade actions will be successful. In addition, the U.S. Federal Reserve has raised, and may continue to raise,
interest rates in response to concerns about inflation. Inflation, combined with reduced government spending and volatility in financial
markets, may further increase economic uncertainty and heighten associated risks. Economic conditions and uncertainty regarding the broader
macroeconomic environment are beyond our control and may make obtaining necessary debt or equity financing more difficult, costly, and
dilutive. While we believe we have adequate capital resources to meet current working capital and capital expenditure requirements, an
economic downturn or a significant increase in expenses could necessitate additional financing under less favorable conditions, including
unattractive interest rates or excessively dilutive terms for existing stockholders. Failure to secure necessary financing in a timely
manner and on favorable terms could materially and adversely affect our stock price and force us to delay or abandon clinical development
plans.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Inadequate
funding for the FDA, the SEC and other government agencies, including from government shutdowns, or other disruptions to these agencies&rsquo;
operations, could hinder their ability to hire and retain key leadership and other personnel, prevent new products and services from
being developed or commercialized in a timely manner or otherwise prevent those agencies from performing normal business functions on
which the operation of our business may rely, which could negatively impact our business.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
ability of the FDA to review and approve new products can be affected by a variety of factors, including government budget and funding
levels, the ability to hire and retain key personnel and accept the payment of user fees, and statutory, regulatory and policy changes.
Average review times at the agency have fluctuated in recent years as a result. In addition, government funding of the SEC and other
government agencies on which our operations may rely, including those that fund research and development activities, is subject to the
political process, which is inherently fluid and unpredictable.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Disruptions
at the FDA and other agencies may also slow the time necessary for new product candidates to be reviewed and/or approved by necessary
government agencies, which could adversely affect our business. If there are significant employee reductions at the FDA or a prolonged
government shutdown occurs, it could significantly impact the ability of the FDA to timely review and process our regulatory submissions,
which could have a material adverse effect on our business. Further, future reductions in force and government shutdowns could impact
our ability to access the public markets and obtain necessary capital in order to properly capitalize and continue our operations. For
example, over the last several years the U.S. government has shut down several times and certain regulatory agencies, such as the FDA
and the SEC, have had to furlough critical employees and stop critical activities. Currently, federal agencies in the U.S. are operating
under a continuing resolution that is set to expire on September 30, 2025. In addition, federal employees recently have been subject
to termination in connection with cost reduction efforts by the federal government. If a prolonged government shutdown or significant
reduction in force of federal employees occurs, including those working for the FDA, it could significantly impact the ability of the
FDA to timely review and process our regulatory submissions, which could have a material adverse effect on our business. Further, future
government shutdowns and cost-cutting efforts could impact our ability to access the public markets and obtain necessary capital in order
to properly capitalize and continue our operations.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 36; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->32<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&nbsp;</p></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>If
our information systems or data, or those of third parties upon which we rely, are or were compromised, we could experience adverse consequences
resulting from such compromise, including but not limited to regulatory investigations or actions; litigation; fines and penalties; disruptions
of our business operations; reputational harm; loss of revenue or profits; loss of customers or sales; and other adverse consequences.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
the ordinary course of our business, we may process, as defined above, proprietary, confidential, and sensitive data, including personal
data (such as health-related patient data), intellectual property, and trade secrets (collectively, sensitive information). We may rely
upon third-party service providers and technologies to operate critical business systems to process sensitive information in a variety
of contexts, including, without limitation, third-party providers of cloud-based infrastructure, employee email, CROs, and other functions.
Our ability to monitor these third parties&rsquo; information security practices is limited, and these third parties may not have adequate
information security measures in place. We may share or receive sensitive information with or from third parties.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
risk of a security breach or disruption, particularly through cyber-attacks, cyber-intrusion, malicious internet-based activity, and
online and offline fraud, are prevalent and have generally increased as the number, intensity, and sophistication of attempted attacks
and intrusions from around the world have increased. These threats are becoming increasingly difficult to detect and come from a variety
of sources, including traditional computer hackers, threat actors, personnel (such as through theft or misuse), sophisticated nation
states, and nation-state-supported actors. Some actors now engage and are expected to continue to engage in cyber-attacks, including
without limitation nation-state actors for geopolitical reasons and in conjunction with military conflicts and defense activities. During
times of war and other major conflicts, we and the third parties upon which we rely may be vulnerable to a heightened risk of these attacks,
including cyber-attacks that could materially disrupt our systems and operations, supply chain, and ability to produce, sell and distribute
our products.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
and the third parties upon which we rely may be subject to a variety of evolving threats, including but not limited to social engineering
attacks (including through phishing attacks), malicious code (such as viruses and worms), malware (including as a result of advanced
persistent threat intrusions), denial-of-service attacks (such as credential stuffing), personnel misconduct or error, ransomware attacks,
supply-chain attacks, software bugs, server malfunctions, software or hardware failures, loss of data or other information technology
assets, adware, natural disasters, terrorism, war, and telecommunication and electrical failures. Ransomware attacks, including by organized
criminal threat actors, nation-states, and nation-state-supported actors, are becoming increasingly prevalent and can lead to significant
interruptions in our operations, loss of data and income, reputational harm, and diversion of funds. Extortion payments may alleviate
the negative impact of a ransomware attack, but we may be unwilling or unable to make such payments due to, for example, applicable laws
or regulations prohibiting such payments. Similarly, supply-chain attacks have increased in frequency and severity.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Furthermore,
our remote workforce poses increased risks to our information technology systems and data, as most of our employees work from home, utilizing
network connections outside our premises.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Any
of the previously identified or similar threats could cause a security breach or disruption. While we have not experienced any such security
breach or other disruption to date, if such an event were to occur, it could result in unauthorized, unlawful, or accidental acquisition,
modification, destruction, loss, alteration, encryption, disclosure of, or access to our sensitive information and cause interruptions
in our operations, including material disruptions of our development programs and business operations.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
may expend significant resources or modify our business activities (including our clinical trial activities) to try to protect against
security breaches and disruptions. While we have implemented security measures designed to protect against security incidents, there
can be no assurance that these measures will be effective. We may be unable in the future to detect vulnerabilities in our information
technology systems because such threats and techniques change frequently, are often sophisticated in nature, and may not be detected
until after a security breach or disruption has occurred. Despite our efforts to identify and remediate vulnerabilities, if any, in our
information technology systems, our efforts may not be successful. Further, we may experience delays in developing and deploying remedial
measures designed to address any such identified vulnerabilities.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 37; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->33<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&nbsp;</p></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Applicable
data privacy and security obligations may require us to notify relevant parties of certain security breaches and disruptions. Such disclosures
are costly, and the disclosure or the failure to comply with such requirements could lead to adverse consequences. If we (or a third
party upon whom we rely) experience a security breach or other disruption, or are perceived to have experienced such events, we may experience
adverse consequences, including: government enforcement actions (for example, investigations, fines, penalties, audits, and inspections);
additional reporting requirements and/or oversight; restrictions on processing sensitive information (including personal data); litigation
(including class claims); indemnification obligations; negative publicity; reputational harm; monetary fund diversions; interruptions
in our operations (including availability of data); financial loss; and other similar harms. In particular, since we sponsor clinical
trials, any breach or disruption that compromises patient data and identities could generate significant reputational damage, which may
affect trust in us and our ability to recruit for future clinical trials. Additionally, the loss of clinical trial data from completed
or future clinical trials could result in delays in our regulatory approval efforts and significantly increase our costs to recover or
reproduce the data.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
contracts may not contain limitations of liability, and even where they do, there can be no assurance that limitations of liability in
our contracts are sufficient to protect us from liabilities, damages, or claims related to our data privacy and security obligations.
Furthermore, we cannot be sure that our insurance coverage will be adequate or sufficient to protect us from or to mitigate liabilities
arising out of our privacy and security practices, that such coverage will continue to be available on commercially reasonable terms
or at all, or that such coverage will pay future claims.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Our
business and operations would suffer in the event of system failures, cyber-attacks or a deficiency in our cybersecurity.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Despite
the implementation of security measures, our internal computer systems, and those of our current and future CROs and other contractors
and consultants, are vulnerable to damage from computer viruses, unauthorized access, natural disasters, terrorism, war and telecommunication
and electrical failures. Although we have not suffered any material incidents to date, the risk of a security breach or disruption, particularly
through cyber-attacks or cyber-intrusion, including by computer hackers, foreign governments, and cyber-terrorists, has generally increased
as the number, intensity and sophistication of attempted attacks and intrusions from around the world have increased. While we have not
experienced any such material system failure, accident or security breach to date, if such an event were to occur and cause interruptions
in our operations, it could result in a material disruption of our development programs and our business operations. In addition, since
we sponsor clinical trials, any breach that compromises patient data and identities causing a breach of privacy could generate significant
reputational damage and legal liabilities and costs to recover and repair, including affecting trust in us to recruit for future clinical
trials. For example, the loss of clinical trial data from completed or future clinical trials could result in delays in our regulatory
approval efforts and significantly increase our costs to recover or reproduce the data. To the extent that any disruption or security
breach were to result in a loss of, or damage to, our data or applications or inappropriate disclosure of confidential or proprietary
information, we could incur liability and the further development and commercialization of our products and product candidates could
be delayed.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 38; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->34<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&nbsp;</p></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><A NAME="sk_001"></A>NOTE
REGARDING FORWARD-LOOKING STATEMENTS</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 12.5pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
prospectus and any applicable prospectus supplement or free writing prospectus, including the documents that we incorporate by reference
herein and therein, contain &ldquo;forward-looking statements&rdquo; within the meaning of Section 27A of the Securities Act of 1933,
as amended, or the Securities Act, and Section 21E of the Securities Exchange Act of 1934, as amended, or the Exchange Act. These statements
relate to future events or to our future operating or financial performance and involve known and unknown risks, uncertainties and other
factors which may cause our actual results, performance or achievements to be materially different from any future results, performances
or achievements expressed or implied by the forward-looking statements. Forward-looking statements may include, but are not limited to,
statements about:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 12.5pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    results of our pre-clinical studies and clinical trials;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">estimates
    about the size and growth potential of the markets for our product candidates, and our ability to serve those markets, including
    any potential revenue generated;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">future
    regulatory, judicial, and legislative changes or developments in the U.S. and foreign countries and the impact of these changes;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
    ability to successfully develop our licensed technologies;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
    ability to build a commercial infrastructure in the U.S. and other markets;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
    ability to compete effectively in a competitive industry;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
    ability to identify and qualify additional manufacturers to provide API and manufacture drug product;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
    ability to enter into commercial supply agreements;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    success of competing technologies that are or may become available;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
    ability to attract and retain key scientific or management personnel;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    accuracy of our estimates regarding expenses, future revenues, capital requirements and needs for additional financing;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
    ability to obtain funding for our operations; and</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
    ability to attract collaborators and strategic partnerships.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 12.5pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
some cases, you can identify forward-looking statements by terms such as &ldquo;may,&rdquo; &ldquo;will,&rdquo; &ldquo;intend,&rdquo;
&ldquo;should,&rdquo; &ldquo;could,&rdquo; &ldquo;would,&rdquo; &ldquo;expects,&rdquo; &ldquo;plans,&rdquo; &ldquo;anticipates,&rdquo;
&ldquo;believes,&rdquo; &ldquo;estimates,&rdquo; &ldquo;projects,&rdquo; &ldquo;predicts,&rdquo; &ldquo;potential&rdquo; and similar
expressions intended to identify forward-looking statements. These statements reflect our current views with respect to future events
and are based on assumptions and are subject to risks and uncertainties. As such, our actual results may differ significantly from those
expressed in any forward-looking statements. Given these uncertainties, you should not place undue reliance on these forward-looking
statements.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 12.5pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">These
forward-looking statements are based on the current beliefs and expectations of our management and are subject to significant risks and
uncertainties. If underlying assumptions prove inaccurate or unknown risks or uncertainties materialize, actual results may differ materially
from current expectations and projections. Factors that might cause such a difference include the risk factors identified under the caption
&ldquo;Risk Factors&rdquo; in this prospectus, as well as those identified under the caption &ldquo;Risk Factors&rdquo; in our Annual
Report on Form 10-K, filed with the SEC on March 24, 2025.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">You
are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this prospectus or,
in the case of documents referred to or incorporated by reference, the date of those documents.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">All
subsequent written or oral forward-looking statements attributable to us or any person acting on our behalf are expressly qualified in
their entirety by the cautionary statements contained or referred to in this section. We do not undertake any obligation to release publicly
any revisions to these forward-looking statements to reflect events or circumstances after the date of this prospectus or to reflect
the occurrence of unanticipated events, except as may be required under applicable U.S. securities law. If we do update one or more forward-looking
statements, no inference should be drawn that we will make additional updates with respect to those or other forward-looking statements.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 39; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->35<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&nbsp;</p></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><A NAME="sk_002"></A>USE
OF PROCEEDS</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
estimate that the net proceeds from the sale of securities in this offering will be approximately $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; million, based on an assumed public
offering price of $&nbsp;&nbsp;&nbsp;&nbsp; per Unit (the closing price of our common stock on The Nasdaq Capital Market on&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; , 2025), after deducting the underwriting
discounts and commissions and estimated offering expenses payable by us. If the underwriters exercise the over-allotment option in full,
we estimate that our net proceeds will be approximately $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; million, after deducting the underwriting discounts and commissions and estimated
offering expenses payable by us. We will only receive additional proceeds from the exercise of the warrants issuable in connection with
this offering if the warrants are exercised and the holders of such warrants pay the exercise price in cash upon such exercise and do
not utilize the cashless exercise provision of the warrants.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
expected use of the net proceeds from this offering represents our current intentions based upon our present plans and business condition.
As of the date of this prospectus, we cannot predict with certainty all of the particular uses for the net proceeds to be received upon
completion of this offering, or the amounts that we will actually spend on the uses set forth above. However, we currently plan to use
the net proceeds from this offering to, among other things, advance PALI-2108 through preclinical and clinical development and into INDs
or their equivalent in foreign jurisdictions, fund our research and development activities and for general working capital needs.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
amounts and timing of our actual use of net proceeds will vary depending on numerous factors, including the relative success and cost
of our research and development programs and our ability to gain access to additional financing. As a result, our management will have
broad discretion in the application of the net proceeds, and investors will be relying on our management&rsquo;s judgment regarding the
application of the net proceeds of this offering. In addition, we might decide to postpone or not pursue certain development activities
if the net proceeds from the offering and any other sources of cash are less than expected.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pending
the uses described above, we plan to invest these net proceeds in short-term, interest-bearing investments, investment-grade instruments,
certificates of deposit or direct or guaranteed obligations of the United States. We also may use a portion of the net proceeds from
the offering to fund acquisitions or other business development opportunities. However, we have no current commitments or obligations
with respect to any such acquisitions or business development opportunities at this time.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 40; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->36<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&nbsp;</p></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><A NAME="sk_003"></A>MARKET
INFORMATION</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
common stock is listed on The Nasdaq Capital Market under the symbol &ldquo;PALI.&rdquo; On&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; , 2025, the last reported sale price for
our common stock on The Nasdaq Capital Market was $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; per share. As of June 30, 2025, we had approximately 135 stockholders of record.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 41; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->37<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&nbsp;</p></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><A NAME="sk_004"></A>DIVIDEND
POLICY</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
do not anticipate declaring or paying, in the foreseeable future, any cash dividends on our capital stock. We intend to retain all available
funds and future earnings, if any, to fund the development and expansion of our business, and we do not anticipate paying any cash dividends
in the foreseeable future. Any future determination regarding the declaration and payment of dividends, if any, will be at the discretion
of our Board and will depend on then-existing conditions, including our financial condition, operating results, contractual restrictions,
capital requirements, business prospects and other factors our Board may deem relevant.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 42; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->38<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&nbsp;</p></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><A NAME="sk_005"></A>CAPITALIZATION</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table sets forth our cash and cash equivalents and capitalization as of March 31, 2025 on:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 12.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">an
    actual basis;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">a
    pro forma basis after adjusting for an aggregate of 399,000 shares that were issued pursuant to the exercise of pre-funded warrants
    issued in our December 2024 underwritten offering subsequent to March 31, 2025; and an aggregate of 4,601 shares that were issued
    pursuant to the ESPP; and</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">a
    pro forma as adjusted basis, giving effect to the sale of &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Units, at the assumed public offering price of $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; per Unit (the last reported
    sale price of our common stock on the Nasdaq Capital Market on&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; , 2025), no exercise of the warrants sold in this offering and no
    exercise by the underwriters of the over-allotment option, after deducting underwriting discounts and commissions and estimated offering
    expenses payable by us.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 12.5pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
pro forma as adjusted information below is illustrative only, and our capitalization following the closing of this offering will be adjusted
based on the actual public offering price and other terms of this offering determined at pricing. You should read the following table
in conjunction with our consolidated financial statements, including the related notes, and &ldquo;Management&rsquo;s Discussion and
Analysis of Financial Condition and Results of Operations&rdquo; from our Annual Report on Form 10-K for the year ended December 31,
2024, which are incorporated by reference into this prospectus.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 12.5pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="10" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">As of March 31, 2025</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="10" STYLE="border-bottom: Black 1pt solid; text-align: center"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>(unaudited)</B></FONT></P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>(in thousands)</B></FONT></P></TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Actual</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Pro Forma</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Pro Forma</B></FONT></P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>as Adjusted</B></FONT></P></TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 52%; text-align: left; padding-bottom: 2.5pt">Cash and cash equivalents</TD><TD STYLE="width: 2%; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="width: 1%; border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="width: 12%; border-bottom: Black 2.5pt double; text-align: right">&nbsp;</TD><TD STYLE="width: 1%; padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="width: 2%; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="width: 1%; border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="width: 12%; border-bottom: Black 2.5pt double; text-align: right">&nbsp;</TD><TD STYLE="width: 1%; padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="width: 2%; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="width: 1%; border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="width: 12%; border-bottom: Black 2.5pt double; text-align: right">&nbsp;</TD><TD STYLE="width: 1%; padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Stockholders&rsquo; equity:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 10pt">Series A Convertible Preferred Stock, $0.01 par value per share, 7,000,000 shares authorized as of March 31, 2025, actual, pro forma and pro forma as adjusted; 200,000 shares issued and outstanding as of March 31, 2025 actual, pro forma and pro forma as adjusted</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 10pt">Common stock, $0.01 par value; 280,000,000 shares authorized as of March 31, 2025 actual, pro forma, and adjusted pro forma, 4,396,646 shares issued and outstanding as of March 31, 2025, actual,&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares issued and outstanding as of March 31, 2025, pro forma, and&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; shares issued and outstanding as of March 31, 2025, pro forma as adjusted</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Additional paid-in capital</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1pt">Accumulated deficit</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1pt">Total stockholders&rsquo; equity</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 2.5pt">Total capitalization</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
foregoing table is based on 4,396,646 shares of common stock which were outstanding as of March 31, 2025, adjusted for an aggregate of
399,000 shares that were issued subsequent to March 31, 2025 pursuant to the exercise of pre-funded warrants issued in our December 2024
underwritten offering and for an aggregate of 4,601 shares that were issued pursuant to the ESPP, for an aggregate of 4,800,247 shares
of common stock outstanding as of June 30, 2025, but excludes:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">shares
    of common stock issuable upon the exercise of pre-funded warrants issued in this offering;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">shares
    of common stock issuable upon the exercise of Representative Warrants issued in this offering;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 43; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->39<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&nbsp;</p></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">shares
    of common stock issuable upon the exercise of Series 1 warrants issued in this offering;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">shares
    of common stock issuable upon the exercise of Series 2 warrants issued in this offering;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">427
    shares of common stock issuable upon exercise of outstanding stock options as of June 30, 2025 granted under the 2013 Plan, with
    a weighted-average exercise price of $15,144.99 per share;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">146,155
    shares of common stock issuable upon exercise of outstanding stock options as of June 30, 2025, granted under the 2021 Plan, with
    a weighted-average exercise price of $12.89 per share;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">12,679
    shares of common stock issuable upon exercise of outstanding stock options as of June 30, 2025 granted under the 2021 Inducement
    Plan, with a weighted average exercise price of $11.72 per share;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">89,400
    shares of common stock issuable upon vesting of restricted stock units outstanding as of June 30, 2025, all of which were issued
    under the 2021 Plan and vest in equal amounts on an annual basis over three years from the date of grant;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2,952
    shares of common stock issuable upon vesting of restricted performance stock units outstanding as of June 30, 2025, all of which
    were issued under the 2021 Plan and vest subject to certain milestones;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">49,834
    shares of common stock reserved for future issuances under the 2021 Plan as of June 30, 2025, as well as any future automatic increases
    in the number of shares of common stock reserved for future issuance under the 2021 Plan;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">43,394
    shares of common stock reserved for future issuance under the ESPP, as of June 30, 2025, as well as any automatic increases in the
    number of shares of common stock reserved for future issuance under the ESPP;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">50,341
    shares of common stock reserved for issuance under the 2021 Inducement Plan as of June 30, 2025;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4,717,538
    shares of common stock issuable upon exercise of outstanding warrants as of June 30, 2025 with a weighted-average exercise price
    of $5.64 per share; and</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">8
    shares of common stock issuable upon conversion of the 200,000 outstanding shares of our Series A 4.5% Convertible Preferred Stock
    as of June 30, 2025, as well as any future shares of common stock issuable upon conversion of additional shares of Series A 4.5%
    Convertible Preferred Stock that may be issued as payment-in-kind dividends thereon in accordance with their terms.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 44; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->40<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&nbsp;</p></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><A NAME="sk_006"></A>DILUTION</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
you invest in our securities, your ownership interest will be diluted to the extent of the difference between the public offering price
per share of our common stock and the pro forma as adjusted net tangible book value per share of our common stock immediately after the
closing of this offering.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
historical net tangible book value as of March 31, 2025 was $ million, or $&nbsp;&nbsp;&nbsp;&nbsp; per share. Our historical net tangible book value is the
amount of our total tangible assets less our liabilities. Our historical net tangible book value per share is our historical net tangible
book value divided by the number of shares of common stock outstanding on March 31, 2025. As of March 31, 2025, we had 4,396,646 shares
outstanding and subsequent to March 31, 2025, we issued an aggregate of 399,000 shares pursuant to the exercise of pre-funded warrants
issued in our December 2024 underwritten offering as well as an aggregate of 4,601 shares pursuant to the ESPP. Accordingly, our pro
forma net tangible book value was $&nbsp;&nbsp;&nbsp;&nbsp; million, or $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; per share as of March 31, 2025. The dilution information set forth in the table below
is illustrative only and will be adjusted based on the actual public offering price and other terms of this offering determined at pricing.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pro
forma as adjusted net tangible book value dilution per share to new investors represents the difference between the amount per share
paid by purchasers of shares of common stock in this offering and the pro forma as adjusted net tangible book value per share of common
stock immediately after completion of this offering. After giving effect to the sale by us in this offering of &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Units at an assumed public
offering price of $&nbsp;&nbsp;&nbsp;&nbsp; per Unit, which was the last reported sale price of our common stock on the Nasdaq Capital Market on&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; , 2025, and
no exercise of the warrants included in the Units and no exercise by the underwriters of the option to purchase additional shares of
common stock and/or warrants, and after deducting the estimated underwriting discounts and commissions and estimated offering expenses
that we will pay, our pro forma as adjusted net tangible book value as of March 31, 2025 would have been approximately $&nbsp;&nbsp;&nbsp;million or $&nbsp;&nbsp;&nbsp;
per share of common stock. This amount represents an immediate increase in net tangible book value of $&nbsp;&nbsp;&nbsp;&nbsp; per share to existing shareholders
and an immediate dilution of $&nbsp;&nbsp;&nbsp;&nbsp; per share to investors in this offering.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT>&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table illustrates this dilution on a per share basis to new investors:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 60%">Assumed public offering price per share of common stock</TD>
    <TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 16%">&nbsp;</TD>
    <TD STYLE="width: 1%">&nbsp;</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 16%; text-align: right">&nbsp;</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD>Pro Forma net tangible book value per share as of March 31, 2025</TD>
    <TD>&nbsp;</TD>
    <TD>$</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-bottom: 1pt; text-align: left">Increase in pro forma net tangible book value per share attributable to new investors in this offering</TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid">$</TD>
    <TD STYLE="border-bottom: Black 1pt solid">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1pt">Pro forma as adjusted net tangible book value per share after giving effect to this offering</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">$</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 2.5pt">Dilution per share to new investors participating in this offering</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
foregoing table is based on 4,396,646 shares of common stock which were outstanding as of March 31, 2025, adjusted for an aggregate of
399,000 shares that were issued subsequent to March 31, 2025 pursuant to the exercise of pre-funded warrants issued in our December 2024
underwritten offering and an aggregate of 4,601 shares that were issued pursuant to the ESPP; for an aggregate of 4,800,247 shares of
common stock outstanding as of June 30, 2025, but excludes:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
    shares of common stock issuable upon the exercise of pre-funded warrants issued in this offering;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
    shares of common stock issuable upon the exercise of underwriter warrants issued in this offering;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
    shares of common stock issuable upon the exercise of Series 1 warrants issued in this offering;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
    shares of common stock issuable upon the exercise of Series 2 warrants issued in this offering;</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 45; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->41<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&nbsp;</p></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">427 shares of common stock issuable upon exercise of outstanding stock options as of June 30, 2025 granted under the 2013 Plan, with a weighted-average exercise price of $15,144.99 per share;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">146,155 shares of common stock issuable upon exercise of outstanding stock options as of June 30, 2025, granted under the 2021 Plan, with a weighted-average exercise price of $12.89 per share;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">12,679 shares of common stock issuable upon exercise of outstanding stock options as of June 30, 2025 granted under the 2021 Inducement Plan, with a weighted average exercise price of $11.72 per share;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">89,400 shares of common stock issuable upon vesting of restricted stock units outstanding as of June 30, 2025, all of which were issued under the 2021 Plan and vest in equal amounts on an annual basis over three years from the date of grant;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">2,952 shares of common stock issuable upon vesting of restricted performance stock units outstanding as of June 30, 2025, all of which were issued under the 2021 Plan and vest subject to certain milestones;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">49,834 shares of common stock reserved for future issuances under the 2021 Plan as of June 30, 2025, as well as any future automatic increases in the number of shares of common stock reserved for future issuance under the 2021 Plan;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">43,394 shares of common stock reserved for future issuance under the ESPP, as of June 30, 2025, as well as any automatic increases in the number of shares of common stock reserved for future issuance under the ESPP;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">50,341 shares of common stock reserved for issuance under the 2021 Inducement Plan as of June 30, 2025;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">4,717,538 shares of common stock issuable upon exercise of outstanding warrants as of June 30, 2025 with a weighted-average exercise price of $5.64 per share; and</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">8 shares of common stock issuable upon conversion of the 200,000 outstanding shares of our Series A 4.5% Convertible Preferred Stock as of June 30, 2025, as well as any future shares of common stock issuable upon conversion of additional shares of Series A 4.5% Convertible Preferred Stock that may be issued as payment-in-kind dividends thereon in accordance with their terms.</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 46; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->42<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&nbsp;</p></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><A NAME="sk_007"></A>CERTAIN
RELATIONSHIPS AND RELATED PARTY TRANSACTIONS</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 22pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"><B>Related
Party Transactions Procedures</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">In
2021, we adopted a written Related-Person Transactions Policy that sets forth our policies and procedures regarding the identification,
review, consideration and approval or ratification of &ldquo;related persons transactions.&rdquo; For purposes of our policy only, a
&ldquo;related person transaction&rdquo; is a transaction, arrangement or relationship (or any series of similar transactions, arrangements
or relationships) in which we and any &ldquo;related person&rdquo; are participants involving an amount that exceed the lesser of (a)
$120,000 or (b) 1% of the average of our total assets for the fiscal years ended December 31, 2024 and 2023. Transactions involving compensation
for services provided to us as an employee, director, consultant or similar capacity by a related person are not covered by this policy.
A related person is any of our executive officers, directors, or more than 5% stockholder, including any of their immediate family members,
and any entity owned or controlled by such persons.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">Under
the policy, where a transaction has been identified as a related-person transaction, management must present information regarding the
proposed related-person transaction to the Audit Committee (or, where Audit Committee approval would be inappropriate, to another independent
body of the Board) for consideration and approval or ratification. The presentation must include a description of, among other things,
the material facts, interests, direct and indirect, of the related persons; the benefits to us of the transaction; and whether any alternative
transactions were available. To identify related-person transactions in advance, we rely on information supplied by its executive officers,
directors and certain significant stockholders. In considering related-person transactions, the Audit Committee takes into account the
relevant available facts and circumstances including, but not limited to (a) the risks, costs and benefits to us, (b) the impact on a
director&rsquo;s independence in the event the related person is a director, immediate family member of a director or an entity with
which a director is affiliated, (c) the terms of the transaction, (d) the availability of other sources for comparable services or products
and (e) the terms available to or from, as the case may be, unrelated third parties or to or from employees generally.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"><B>Certain
Related Party Transactions</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">Other
than compensation arrangements for our directors and executive officers, and except as set forth below, there were no transactions since
January 1, 2022 to which we were a party or will be a party, in which:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    amounts involved exceeded or will exceed the lesser of (a) $120,000 or (b) 1% of the average of our total assets for the fiscal years
    ended December 31, 2024, December 31, 2023 and December 31, 2022; and</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">any
    of our directors, executive officers or holders of more than 5% of our capital stock, or any member of the immediate family of, or
    person sharing the household with, the foregoing persons, had or will have a direct or indirect material interest.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">The
proposed or undertaken transactions are:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
    August 16, 2022, J.D. Finley, our Chief Executive Officer and Chief Financial Officer, participated in the Company&rsquo;s underwritten
    offering. Pursuant to the offering, Mr. Finley invested $25,000 in exchange for 133 units at $187.50 per unit consisting of an aggregate
    of (i) 133 shares of Common Stock, (ii) 133 Series 1 Common Stock purchase warrants and (iii) 133 Series 2 Common Stock purchase
    warrants. The Series 1 warrants had a term of one year from issuance and expired on August 16, 2023. The Series 2 warrants have a
    term of five years from issuance. Both Series 1 and Series 2 warrants initially had exercises prices of $187.50 but have been subsequently
    reduced as a result of adjustments to the exercise prices for future offerings contained in the warrants. As of the date of this
    prospectus, the Series 2 warrants have an exercise price of $6.31 per share.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">Pursuant
    to a registered offering in April 2023, we sold an aggregate of 50,421 shares of our common stock at a purchase price per share of
    $39.60 to certain institutional and accredited investors. In a concurrent private placement, we also sold (i) 30,349 unregistered
    shares of common stock, (ii) 70,744 prefunded warrants to purchase common stock with a perpetual term and exercise price of $0.0015
    per share, and (iii) 151,514 unregistered shares of common stock purchase warrants with a term of five (5) years and an exercise
    price of $39.60 per share. Armistice Capital LLC, a then holder of greater than 5% of our outstanding common stock, purchased (i)
    25,210 shares in the registered offering and (ii) in the concurrent private placement: (a) 5,076 unregistered shares of our common
    stock, (b) 45,470 prefunded warrants, and (c) 75,757 warrants to purchase common stock in exchange for an aggregate of $2,999,930.11.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">Pursuant
    to a registered offering in December 2024, we sold an aggregate of 158,000 Class A Units and 3,120,688 Class B Units to Armistice
    Capital LLC, a then holder of greater than 5% of our outstanding common stock, for $1.525 per Class A Unit and $1.525 per Class B
    Unit, except that the purchase price of each Class B Unit was reduced by $0.0001, which is representative of the exercise price of
    each prefunded warrant, for an aggregate purchase price of $4,999,687.13. Each Class A Unit consisted of (i) one (1) share of our
    common stock and (ii) one (1) common warrant and each Class B Unit consisted of </FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(i)
    one (1) prefunded warrant and (ii) one (1) common warrant. Each prefunded warrant was initially exercisable for one share of our
    common stock at an exercise price of $0.0001 per share. The prefunded warrants were exercisable immediately.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 47; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->43<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&nbsp;</p></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><A NAME="sk_008"></A>SECURITY
OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table sets forth information regarding beneficial ownership of our capital stock as of June 30, 2025 by:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">each
    person, or group of affiliated persons, known by us to beneficially own more than 5% of our common stock;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">each
    of our directors;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">each
    of our named executive officers; and</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">all
    of our current executive officers and directors as a group.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
information in the following table is calculated based on 4,800,247 shares of our common stock outstanding as of June 30, 2025. Beneficial
ownership is determined according to the rules of the SEC. Beneficial ownership means that a person has or shares voting or investment
power of a security and includes any securities that person or group has the right to acquire within 60 days after the measurement date,
including upon the exercise of common stock purchase options or warrants or the conversion of preferred stock.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font-weight: bold; border-bottom: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Name of Beneficial Owner <SUP>(1)</SUP></B></FONT></TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Number of Shares Beneficially Owned</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Percentage of Shares Beneficially Owned</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: left">Greater than 5% Stockholders</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="width: 60%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Armistice Capital, LLC <SUP>(2)</SUP></FONT></TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 16%; text-align: right">471,906</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 16%; text-align: right">9.83</TD><TD STYLE="width: 1%; text-align: left">%</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: left">Directors and Named Executive Officers</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Donald Williams <SUP>(3)</SUP></FONT></TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">7,178</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</FONT></TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Binxian Wei <SUP>(4)</SUP></FONT></TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">4,115</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</FONT></TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Margery Fischbein <SUP>(5)</SUP></FONT></TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2,517</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</FONT></TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">J.D. Finley <SUP>(6)</SUP></FONT></TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">33,526</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</FONT></TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Mitchell Jones, M.D., Ph.D. <SUP>(7)</SUP></FONT></TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">12,890</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</FONT></TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>All directors and executive officers as a group (5 persons) <SUP>(8)</SUP></B></FONT></TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">60,226</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1.24</TD><TD STYLE="text-align: left">%</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in">*</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">Represents less than one percent</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in">(1)</TD>
    <TD STYLE="text-align: justify">Except as otherwise indicated in the footnotes to this table, this table is based upon information supplied by officers, directors and principal stockholders and Schedules 13D and 13G, and Forms 4, filed with the SEC. Unless otherwise indicated in the footnotes to this table and subject to community property laws where applicable, we believe that each of the stockholders named in this table has sole voting and investment power with respect to the shares indicated as beneficially owned. Shares of our common stock underlying options, warrants, restricted stock units, and convertible securities that are currently exercisable or exercisable within 60 days of June 30, 2025 are deemed to be outstanding for the purpose of computing the number of shares held and the percent of total ownership of the person holding those options, warrants, restricted stock units, or convertible securities, but are not treated as outstanding for the purpose of computing the percent of total ownership of any other person. Applicable percentages are based on 4,800,247 shares of common stock outstanding on June 30, 2025, adjusted as required by rules promulgated by the SEC. Unless otherwise indicated, the address of the beneficial owner is c/o Palisade Bio, Inc. 7750 El Camino Real, Suite 2A, Carlsbad, CA 92009.</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>(2)</TD>
    <TD STYLE="text-align: justify">Includes 471,906 shares of common stock as reported by Armistice Capital, LLC on Schedule 13G, filed with the SEC on May 15, 2025. The address of beneficial owner is 510 Madison Avenue, 7th Floor, New York, NY 10022. Excludes common stock purchase warrants and pre-funded warrants held by Armistice Capital, LLC that are subject to beneficial ownership limitations.</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>(3)</TD>
    <TD STYLE="text-align: justify">Includes (i) 3,728 shares of common stock and (ii) 3,450 shares of common stock underlying stock options.</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>(4)</TD>
    <TD STYLE="text-align: justify">Includes (i) 855 shares of common stock and (ii) 3,260 shares of common stock underlying stock options.</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>(5)</TD>
    <TD STYLE="text-align: justify">Margery Fischbein was appointed to the Board on May 7, 2024. Includes 2,517 shares of common stock underlying options.</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>(6)</TD>
    <TD STYLE="text-align: justify">Consists of (i)(a) 13,472 shares of common stock held by Mr. Finley, (b) 134 shares of common stock that may be acquired pursuant to the exercise of outstanding warrants held by Mr. Finley, (c) 19,867 shares of common stock underlying options held by Mr. Finley, (ii)(a) 51 shares of common stock held by FCW Investments LLC, and (b) 2 shares of common stock underlying warrants held by FCW Investments, LLC. The address for FCW Investments LLC is 19 Cherrymoor Dr, Englewood, CO 80113. Does not include 2,166 performance stock units (PSUs), which vest based on volume weighted average trading price of the Company&rsquo;s common stock.</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>(7)</TD>
    <TD STYLE="text-align: justify">Includes (i) 3,852 shares of common stock, and (ii) 9,038 shares of common stock underlying options.</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>(8)</TD>
    <TD STYLE="text-align: justify">Includes the securities described in footnotes (3)-(7) above.</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>


<!-- Field: Page; Sequence: 48; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->44<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&nbsp;</p></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><A NAME="sk_009"></A>DESCRIPTION
OF CAPITAL STOCK</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following summary is a description of the material terms of our capital stock. This summary is not complete and is qualified by reference
to our Certificate of Incorporation and our Bylaws, which are filed as exhibits to this prospectus and are incorporated by reference
herein. We encourage you to read our Certificate of Incorporation, our Bylaws and the applicable provisions of the Delaware General Corporation
Law for additional information.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of the date of this prospectus, our authorized capital stock consists of 280,000,000 shares of common stock, par value $0.01 per share,
and 7,000,000 shares of preferred stock, par value $0.01 per share.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Common
Stock</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Shares
of our common stock have the following rights, preferences and privileges:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Fully
Paid and Non-Assessable. </I>All outstanding shares of common stock are duly authorized, validly issued, fully paid, and nonassessable.
All authorized but unissued shares of our common stock are available for issuance by our Board without any further stockholder action,
except as required by the listing standards of the Nasdaq Stock Market.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Voting
Rights.</I> Our common stock is entitled to one vote for each share held of record on all matters submitted to a vote of the stockholders.
Any action at a meeting at which a quorum is present will be decided by a majority of the voting power present in person or represented
by proxy, except in the case of any election of directors, which will be decided by a plurality of votes cast. There is no cumulative
voting.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Dividends
and Distributions.</I> Subject to preferences that may be applicable to any then outstanding preferred stock, holders of our common stock
are entitled to receive dividends when, as and if declared by our Board out of funds legally available for payment, subject to the rights
of holders, if any, of any class of stock having preference over the common stock. Any decision to pay dividends on our common stock
will be at the discretion of our board of directors. Our Board may or may not determine to declare dividends in the future. The Board&rsquo;s
determination to issue dividends will depend upon our profitability and financial condition any contractual restrictions, restrictions
imposed by applicable law and the SEC, and other factors that our Board deems relevant.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Liquidation
Rights.</I> In the event of a voluntary or involuntary liquidation, dissolution or winding up of the company, the holders of our common
stock will be entitled to share ratably on the basis of the number of shares held in any of the assets available for distribution after
we have paid in full, or provided for payment of, all of our debts and after the holders of all outstanding series of any class of stock
have preference over the common stock, if any, have received their liquidation preferences in full.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Other</I>.
Holders of shares of our common stock are not entitled to preemptive rights. Shares of our common stock are not convertible into shares
of any other class of capital stock, nor are they subject to any redemption or sinking fund provisions.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Preferred
Stock</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Under
the terms of our Certificate of Incorporation, our Board has the authority, without further action by our stockholders, to issue up to
7,000,000 shares of preferred stock in one or more series pursuant to a resolution or resolutions providing for such issue duly adopted
by our Board. Our Board is further authorized, subject to limitations prescribed by law, to fix by resolution or resolutions the designations,
powers, preferences and rights, and the qualifications, limitations or restrictions thereof, of any wholly unissued series of preferred
stock, including without limitation authority to fix by resolution or resolutions the dividend rights, dividend rate, conversion rights,
voting rights, rights and terms of redemption (including sinking fund provisions), redemption price or prices, and liquidation preferences
of any such series, and the number of shares constituting any such series and the designation thereof, or any of the foregoing.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
Board may authorize the issuance of preferred stock with voting or conversion rights that could adversely affect the voting power or
other rights of the holders of our common stock. The issuance of preferred stock, while providing flexibility in connection with possible
acquisitions and other corporate purposes, could, among other things, have the effect of delaying, deferring or preventing a change in
our control and may adversely affect the market price of the common stock and the voting and other rights of the holders of our common
stock.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 49; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->45<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&nbsp;</p></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Series
A 4.5% Convertible Preferred Stock</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
December 2016, we designated a series of our preferred stock as Series A 4.5% Convertible Preferred Stock consisting of 1,000,000 designated
shares (which is subject to increase without the consent of all of the holders of the Series A 4.5% Convertible Preferred Stock in the
event such additional shares of Series A 4.5% Convertible Preferred Stock are issued solely to the holders as payment of accrued dividends).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of June 30, 2025, we had outstanding 200,000 shares of Series A 4.5% Convertible Preferred Stock with a stated value of $12.79 per share
held by one holder and which are immediately convertible into an aggregate of 8 shares of common stock. The Series A 4.5% Convertible
Preferred Stock have no provisions regarding subsequent securities issuances or so called &ldquo;price protection provisions.&rdquo;
The holders of Series A 4.5% Convertible Preferred Stock shall be entitled to receive dividends in cash or additional shares of Series
A 4.5% Convertible Preferred Stock if and when declared by our Board in preference to the payment of any dividends on our common stock.
The holders of Series A 4.5% Convertible Preferred Stock shall have no voting rights but shall be entitled to appoint one member to our
Board. This right to appoint a member of the Board will terminate when there are less than 200,000 shares of Series A 4.5% Convertible
Preferred Stock outstanding. As long as any shares of Series A 4.5% Convertible Preferred Stock are outstanding, we shall not, without
the affirmative vote of the holders of a majority of the then outstanding shares of the Series A 4.5% Convertible Preferred Stock, alter
or change adversely the powers, preferences or rights given to the Series A 4.5% Convertible Preferred Stock or alter or amend the Certificate
of Designation, other than to authorize and issue additional shares of Series A 4.5% Convertible Preferred Stock. In addition, holders
of Series A 4.5% Convertible Preferred Stock are subject to certain beneficial ownership limitations.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Options</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of June 30, 2025, we had outstanding stock options to purchase an aggregate of 159,261 shares of common stock issued pursuant to (i)
Leading BioSciences 2013 Amended and Restated, Employee, Director and Consultant Equity Incentive Plan, (ii) the 2021 Plan, and (iii)
the 2021 Inducement Plan, each as amended. The options have a remaining weighted average term remaining of approximately 9.2 years and
an average weighted exercise price of $53.37 per share.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Restricted
Stock Units</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of June 30, 2025, we had an aggregate of 89,400 time-based restricted stock units issued pursuant to the 2021 Plan that vest in equal
amounts on an annual basis over three years from the date of grant, subject to continuous service, and have a remaining average term
of approximately 2.6 years.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Performance
Restricted Stock Units</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of June 30, 2025, we had an aggregate of 2,952 restricted performance stock units issued pursuant to the 2021 Plan that vest (a) 50%
when the volume weighted average price of our Common Stock over 20 consecutive trading days is $48.00, and (b) 50% when such volume weighted
average price of our Common Stock over 20 consecutive trading days is $63.75.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Warrants</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of June 30, 2025, we had outstanding common stock purchase warrants to purchase an aggregate of 4,717,538 shares of common stock, with
a remaining average term of 4.7 years and a weighted average exercise price of $5.64 per share.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 50; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->46<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&nbsp;</p></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Limitations
on Liability and Indemnification of Officers and Directors</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
Certificate of Incorporation and our Bylaws limit the liability of our officers and directors and provide that we will indemnify our
officers and directors, in each case, to the fullest extent permitted by the Delaware General Corporation Law.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have entered into separate indemnification agreements with each of our directors and executive officers. Insofar as indemnification for
liabilities arising under the Securities Act may be permitted to directors or executive officers, we have been informed that in the opinion
of the SEC such indemnification is against public policy and is therefore unenforceable.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Certificate
of Incorporation and Bylaw Provisions</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
Certificate of Incorporation and our Bylaws include a number of anti-takeover provisions that may have the effect of encouraging persons
considering unsolicited tender offers or other unilateral takeover proposals to negotiate with our board of directors rather than pursue
non-negotiated takeover attempts. These provisions include:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Board
Composition and Filling Vacancies. </I>Because our stockholders do not have cumulative voting rights, the holders of a plurality of the
voting power of the shares present in person or represented by proxy at the meeting and entitled to vote on the election of directors,
can elect all of the directors standing for election, if they so choose, other than any directors that holders of any preferred stock
we have or may issue may be entitled to elect. Our Bylaws also provide that subject to the rights of the holders of any series of preferred
stock then outstanding, any director or the entire Board may be removed from office at any time, with or without cause, by the affirmative
vote of the holders of at least a majority of the voting power of the issued and outstanding shares of capital stock of the Company then
entitled to vote in the election of directors.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Special
Meeting of Stockholders. </I>Our Bylaws also provides that a special meeting of stockholders may be called only by our chairperson of
the Board, chief executive officer or president, the secretary or any two directors.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Advance
Notice Requirements. </I>Our Bylaws establish advance notice procedures with regard to stockholder proposals relating to the nomination
of candidates for election as directors or new business to be brought before meetings of stockholders. These procedures provide that
notice of stockholder proposals must be timely and given in writing to our corporate Secretary. Generally, to be timely, notice must
be received at our principal executive offices not fewer than 120 calendar days prior to the first anniversary date on which our notice
of meeting and related proxy statement were mailed to stockholders in connection with the previous year&rsquo;s annual meeting of stockholders.
The notice must contain the information required by the Bylaws, including information regarding the proposal and the proponent.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Amendment
to Bylaws. </I>The Board is expressly empowered to adopt, amend or repeal the Bylaws. The stockholders shall also have power to adopt,
amend or repeal the Bylaws; provided, however, that, in addition to any vote of the holders of any class or series of stock of the Company
required by law or by the Certificate of Incorporation, the affirmative vote of the holders of at least a majority of the voting power
of all of the then outstanding shares of capital stock of the Company entitled to vote generally in the election of directors, voting
together as a single class, shall be required to adopt, amend or repeal any provision of the Bylaws.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Exclusive
Forum Provision</I>. Our Bylaws provide that unless we consent in writing to the selection of an alternative forum, the sole and exclusive
forum for (i) any derivative action or proceeding brought on behalf of the Company, (ii) any action asserting a claim of breach of a
fiduciary duty owed by any director, officer or other employee of the Company to the Company or the Company&rsquo;s stockholders, (iii)
any action asserting a claim arising pursuant to any provision of the DGCL or the Certificate of Incorporation or Bylaws (as either may
be amended from time to time), or (iv) any action asserting a claim governed by the internal affairs doctrine shall be the Court of Chancery
in the State of Delaware (or, if the Court of Chancery does not have jurisdiction, the federal district court for the District of Delaware).
If any action the subject matter of which is within the scope of the preceding sentence is filed in a court other than a court located
within the State of Delaware (a &ldquo;Foreign Action&rdquo;) in the name of any stockholder, such stockholder shall be deemed to have
consented to (i) the personal jurisdiction of the state and federal courts located within the State of Delaware in connection with any
action brought in any such court to enforce the preceding sentence and (ii) having service of process made upon such stockholder in any
such action by service upon such stockholder&rsquo;s counsel in the Foreign Action as agent for such stockholder.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 51; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->47<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&nbsp;</p></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Delaware
Takeover Statute</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are subject to Section 203 of the DGCL which, subject to certain exceptions, prohibits a Delaware corporation from engaging in any &ldquo;business
combination&rdquo; (as defined below) with any interested stockholder for a period of three years following the date that such stockholder
became an interested stockholder, unless: (1) prior to such date, the board of directors of the corporation approved either the business
combination or the transaction that resulted in the stockholder becoming an interested stockholder; (2) on consummation of the transaction
that resulted in the stockholder becoming an interested stockholder, the interested stockholder owned at least 85% of the voting stock
of the corporation outstanding at the time the transaction commenced, excluding for purposes of determining the voting stock outstanding
those shares owned (x) by persons who are directors and also officers and (y) by employee stock plans in which employee participants
do not have the right to determine confidentially whether shares held subject to this plan will be tendered in a tender or exchange offer;
or (3) on or subsequent to such date, the business combination is approved by the board of directors and authorized at an annual or special
meeting of stockholders, and not by written consent, by the affirmative vote of at least 66 2&frasl;3% of the outstanding voting stock
that is not owned by the interested stockholder.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section
203 of the DGCL defines generally &ldquo;business combination&rdquo; to include: (1) any merger or consolidation involving the corporation
and the interested stockholder; (2) any sale, transfer, pledge or other disposition of 10% or more of the assets of the corporation involving
the interested stockholder; (3) subject to certain exceptions, any transaction that results in the issuance or transfer by the corporation
of any stock of the corporation to the interested stockholder; (4) any transaction involving the corporation that has the effect of increasing
the proportionate share of the stock of any class or series of the corporation beneficially owned by the interested stockholder; or (5)
the receipt by the interested stockholder of the benefit of any loans, advances, guarantees, pledges or other financial benefits provided
by or through the corporation. In general, Section 203 defines an &ldquo;interested stockholder&rdquo; as any entity or person beneficially
owning 15% or more of the outstanding voting stock of the corporation and any entity or person affiliated with or controlling or controlled
by such entity or person.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Transfer
Agent and Registrar</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
transfer agent and registrar for our common stock is Equiniti Trust Company, LLC. We act as the transfer agent and registrar for our
Series A 4.5% Convertible Preferred Stock to the extent any shares are outstanding.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Listing
on the Nasdaq Capital Market</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
common stock is listed on The Nasdaq Capital Market under the symbol &ldquo;PALI.&rdquo;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 52; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->48<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&nbsp;</p></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><A NAME="sk_010"></A>DESCRIPTION
OF SECURITIES WE ARE OFFERING</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>The
following summary of certain terms and provisions of the securities that are being offered hereby is not complete and is subject to,
and qualified in its entirety by, the provisions of the underlying securities, the forms of which are filed as exhibits to the registration
statement of which this prospectus forms a part. Prospective investors should carefully review the terms and provisions of the forms
of securities for a complete description of the terms and conditions.</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Units
</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are offering Units, with each Unit consisting of one share of common stock, one Series 1 warrant and one Series 2 warrant, each to purchase
one share of our common stock at an exercise price per share of $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, together with the shares of common stock underlying such warrants,
at an assumed public offering price of $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;per Unit (the closing price of our common stock on The Nasdaq Capital Market on&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2025). The
Units will not be certificated and the shares of common stock and warrants constituting such Units are immediately separable and will
be issued separately in this offering.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are also offering to those purchasers whose purchase of Units in this offering would result in the purchaser, together with its affiliates
and certain related parties, beneficially owning more than 4.99% (or, at the election of the purchaser, 9.99%) of our outstanding common
stock following the consummation of this offering, the opportunity to purchase, if such purchasers so choose, Units consisting of pre-funded
warrants to purchase shares of common stock, in lieu of shares of common stock that would otherwise result in any such purchaser&rsquo;s
beneficial ownership exceeding 4.99% (or, at the election of the purchaser, 9.99%) of our outstanding common stock. Each pre-funded warrant
is exercisable for one share of our common stock. The purchase price of each pre-funded warrant is equal to the price at which a share
of common stock is being sold to the public in this offering, minus $0.0001, and the exercise price of each pre-funded warrant is $0.0001
per share. The pre-funded warrants are exercisable immediately and may be exercised at any time until all of the pre-funded warrants
are exercised in full. This offering also relates to the shares of common stock issuable upon exercise of any pre-funded warrants sold
in this offering. For each pre-funded warrant that we sell, the number of shares of common stock that we are offering will be reduced
on a one-for-one basis.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Common
Stock</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
material terms and provisions of our common stock and each other class of our securities which qualifies or limits our common stock are
described under the caption &ldquo;Description of Capital Stock&rdquo; in this prospectus.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Pre-Funded
Warrants</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>The
following summary of certain terms and provisions of pre-funded warrants that are being offered hereby is not complete and is subject
to, and qualified in its entirety by, the provisions of the pre-funded warrant, the form of which is filed as an exhibit to the registration
statement of which this prospectus forms a part. You should review the form of pre-funded warrant for a complete description of the terms
and conditions applicable to the pre-funded warrants.</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>General</I>.
Pursuant to a warrant agency agreement between us and Equiniti Trust Company, LLC, as warrant agent, the pre-funded warrants will be
issued in book-entry form and shall initially be represented only by one or more global warrants deposited with the warrant agent, as
custodian on behalf of The Depository Trust Company (&ldquo;DTC&rdquo;), and registered in the name of Cede &amp; Co., a nominee of DTC,
or as otherwise directed by DTC.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Exercisability</I>.
The <FONT STYLE="background-color: white">pre-funded warrants </FONT>will be exercisable, at the option of each holder, in whole or in
part, by delivering to us a duly executed exercise notice accompanied by payment in full in immediately available funds for the number
of shares of our common stock purchased upon such exercise (except in the case of a cashless exercise as described below). A holder (together
with its affiliates) may not exercise any portion of the <FONT STYLE="background-color: white">pre-funded warrant </FONT>to the extent
that the holder would own more than 4.99% (or, at the election of the holder, 9.99%) of the outstanding common stock immediately after
exercise, except that upon at least 61 days&rsquo; prior notice from the holder to us, the holder may increase the amount of ownership
of outstanding stock after exercising the holder&rsquo;s <FONT STYLE="background-color: white">pre-funded warrants </FONT>up to 9.99%
of the number of shares of our common stock outstanding immediately after giving effect to the exercise, as such percentage ownership
is determined in accordance with the terms of the <FONT STYLE="background-color: white">pre-funded warrants</FONT>. Purchasers of <FONT STYLE="background-color: white">pre-funded
warrants </FONT>in this offering may also elect prior to the issuance of the <FONT STYLE="background-color: white">pre-funded warrants
</FONT>to have the initial exercise limitation set at 9.99% of our outstanding common stock. No fractional shares of common stock will
be issued in connection with the exercise of a <FONT STYLE="background-color: white">pre-funded warrant</FONT>. In lieu of fractional
shares, we will either pay the holder an amount in cash equal to the fractional amount multiplied by the exercise price or round up to
the nearest whole share.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 53; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->49<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&nbsp;</p></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Duration
and Exercise Price</I>. The exercise price per whole share of our common stock purchasable upon the exercise of the <FONT STYLE="background-color: white">pre-funded
warrants </FONT>is $0.0001 per share of common stock. The <FONT STYLE="background-color: white">pre-funded warrants </FONT>will be immediately
exercisable and may be exercised at any time until the <FONT STYLE="background-color: white">pre-funded warrants </FONT>are exercised
in full. The exercise price of the <FONT STYLE="background-color: white">pre-funded warrants </FONT>is subject to appropriate adjustment
in the event of certain stock dividends and distributions, stock splits, stock combinations, reclassifications or similar events affecting
our common stock and upon any distributions of assets, including cash, stock or other property to our stockholders.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Cashless
Exercise</I>. If, at any time after the holder&rsquo;s purchase of <FONT STYLE="background-color: white">pre-funded warrants</FONT>,
such holder exercises its <FONT STYLE="background-color: white">pre-funded warrants</FONT>, then in lieu of making the cash payment otherwise
contemplated to be made to us upon such exercise in payment of the aggregate exercise price, the holder shall instead receive upon such
exercise (either in whole or in part) only the net number of shares of common stock determined according to a formula set forth in the
<FONT STYLE="background-color: white">pre-funded warrants</FONT>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Transferability</I>.
Subject to applicable laws, the <FONT STYLE="background-color: white">pre-funded warrants </FONT>may be offered for sale, sold, transferred
or assigned at the option of the holder upon surrender of the <FONT STYLE="background-color: white">pre-funded warrants </FONT>to us
together with the appropriate instruments of transfer.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Exchange
Listing</I>. We do not plan on applying to list the <FONT STYLE="background-color: white">pre-funded warrants </FONT>on the Nasdaq Capital
Market, any other national securities exchange or any other nationally recognized trading system. Without an active trading market, the
liquidity of the <FONT STYLE="background-color: white">pre-funded warrants </FONT>will be limited.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Fundamental
Transactions</I>. In the event of a fundamental transaction, as described in the <FONT STYLE="background-color: white">pre-funded warrants
</FONT>and generally including any reorganization, recapitalization or reclassification of our common stock, the sale, transfer or other
disposition of all or substantially all of our properties or assets, our consolidation or merger with or into another person, the acquisition
of more than 50% of our outstanding common stock, or any person or group becoming the beneficial owner of 50% of the voting power represented
by our outstanding common stock, the holders of the <FONT STYLE="background-color: white">pre-funded warrants </FONT>will be entitled
to receive upon exercise of the <FONT STYLE="background-color: white">pre-funded warrants </FONT>the kind and amount of securities, cash
or other property that the holders would have received had they exercised the <FONT STYLE="background-color: white">pre-funded warrants
</FONT>immediately prior to such fundamental transaction.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Rights
as a Stockholder</I>. Except by virtue of such holder&rsquo;s ownership of shares of our common stock, the holder of a <FONT STYLE="background-color: white">pre-funded
warrant </FONT>does not have the rights or privileges of a holder of our common stock, including any voting rights, until the holder
exercises the <FONT STYLE="background-color: white">pre-funded warrant</FONT>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Warrants</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>&nbsp;</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>The
following summary of certain terms and provisions of the Series 1 warrants and Series 2 warrants that are being offered hereby is not
complete and is subject to, and qualified in its entirety by, the provisions of the Series 1 warrant and Series 2 warrant, the form of
which is filed as an exhibit to the registration statement of which this prospectus forms a part. You should review the form of Series
1 warrant and Series 2 warrant for a complete description of the terms and conditions applicable to the Series 1 warrant and Series 2
warrant.</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>&nbsp;</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>General</I>.
Pursuant to a warrant agency agreement between us and Equiniti Trust Company, LLC, as warrant agent, the warrants will be issued in book-entry
form and shall initially be represented only by one or more global warrants deposited with the warrant agent, as custodian on behalf
of DTC, and registered in the name of Cede &amp; Co., a nominee of DTC, or as otherwise directed by DTC.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 54; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->50<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&nbsp;</p></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Exercise
of Warrants</I>. The warrants are not exercisable without the Warrant Stockholder Approval, provided however, if the Pricing Conditions
are met, the Warrant Stockholder Approval will not be required and the warrants will be exercisable on the Initial Exercise Date. If
required, we intend to promptly seek stockholder approval for issuances of shares of common stock issuable upon exercise of the warrants
but we cannot assure you that such approval will be obtained. Each Unit includes two warrants: a Series 1 warrant to purchase one share
of our common stock exercisable until to the earlier of (i) the one year anniversary of the Initial Exercise Date and (ii) within 30
days of reporting positive clinical data from a cohort of FSCD patients in our ongoing Phase 1 study and a Series 2 warrant to purchase
one share of our common stock exercisable until the five year anniversary of the Initial Exercise Date, each with an exercise price equal
to $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;per share.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
warrants issued in this offering will be governed by the terms of a global warrant held in book-entry form. Subject to obtaining Warrant
Stockholder Approval, if applicable, for issuances of shares of common stock issuable upon exercise of the warrants, the holder of a
warrant will not be deemed a holder of our underlying common stock until the warrant is exercised. No fractional shares of common stock
will be issued in connection with the exercise of a warrant. Instead, for any such fractional share that would have otherwise been issued
upon exercise of warrants, we will at our election, either pay a cash adjustment in respect of such final fraction in an amount equal
to such fraction multiplied by the exercise price or round up to the next whole share.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Subject
to limited exceptions, a holder of warrants will not have the right to exercise any portion of its warrants if the holder (together with
such holder&rsquo;s affiliates, and any persons acting as a group together with such holder or any of such holder&rsquo;s affiliates)
would beneficially own a number of shares of common stock in excess of 4.99% (or, at the election of the purchaser prior to the date
of issuance, 9.99%) of the shares of our common stock then outstanding after giving effect to such exercise.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
exercise price and the number of shares issuable upon exercise of the warrants is subject to appropriate adjustment in the event of recapitalization
events, stock dividends, stock splits, stock combinations, reclassifications, reorganizations or similar events affecting our common
stock. The warrant holders must pay the exercise price in cash upon exercise of the warrants, unless such warrant holders are utilizing
the cashless exercise provision of the warrants.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Assuming
Warrant Stockholder Approval, if applicable, upon the holder&rsquo;s exercise of a warrant, we will issue the shares of common stock
issuable upon exercise of the warrant within one trading day following our receipt of a notice of exercise, provided that payment of
the exercise price has been made (unless exercised to the extent permitted via the &ldquo;cashless&rdquo; exercise provision). Prior
to the exercise of any warrants to purchase common stock, holders of the warrants will not have any of the rights of holders of the common
stock purchasable upon exercise, including the right to vote, except as set forth therein. Warrant holders may exercise warrants only
if Warrant Stockholder Approval is obtained, if applicable, and if the issuance of the shares of common stock upon exercise of the warrants
is covered by an effective registration statement, or an exemption from registration is available under the Securities Act and the securities
laws of the state in which the holder resides. We intend to use commercially reasonable efforts to have the registration statement, of
which this prospectus forms a part, effective when the warrants are exercised. The warrant holders must pay the exercise price in cash
upon exercise of the warrants unless there is not an effective registration statement or, if required, there is not an effective state
law registration or exemption covering the issuance of the shares underlying the warrants (in which case, the warrants may only be exercised
via a &ldquo;cashless&rdquo; exercise provision).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Fundamental
Transaction</I>. In the event we consummate a merger or consolidation with or into another person or other reorganization event in which
our common stock are converted or exchanged for securities, cash or other property, or we sell, lease, license, assign, transfer, convey
or otherwise dispose of all or substantially all of our assets or we or another person acquire 50% or more of our outstanding shares
of common stock, then following such event, the holders of the warrants will be entitled to receive upon exercise of such warrants the
same kind and amount of securities, cash or property which the holders would have received had they exercised their warrants immediately
prior to such fundamental transaction. Any successor to us or surviving entity shall assume the obligations under the warrants. Additionally,
as more fully described in the warrants, in the event of certain fundamental transactions, the holders of the warrants will be entitled
to receive consideration in an amount equal to the Black Scholes value of the warrants on the date of consummation of such transaction.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 55; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->51<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&nbsp;</p></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Exchange
Listing</I>. There is no established public trading market for the warrants, and we do not expect a market to develop. In addition, we
do not intend to list the warrants on any securities exchange or nationally recognized trading system. Without an active trading market,
the liquidity of the warrants will be limited.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Right
as a Stockholder</I>. Except as otherwise provided in the warrants or by virtue of such holder&rsquo;s ownership of shares of our common
stock, the holders of the warrants do not have the rights or privileges of holders of our common stock, including any voting rights,
until they exercise their warrants.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Description
of Representative Warrants</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>The
following summary of certain terms and provisions of the Representative Warrants that are being offered hereby is not complete and is
subject to, and qualified in its entirety by, the provisions of the Representative Warrants, the form of which will be filed as an exhibit
to the registration statement of which this prospectus forms a part. You should review the form of Representative Warrant for a complete
description of the terms and conditions applicable to the Representative Warrants.</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Form</I>.
The Representative Warrants will be issued in certificated form by the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Exercisability</I>.
The Representative Warrants will be exercisable, at the option of each holder, in whole or in part, by delivering to us a duly executed
exercise notice accompanied by payment in full in immediately available funds for the number of shares of our common stock purchased
upon such exercise (except in the case of a cashless exercise as described below). A holder (together with its affiliates) may not exercise
any portion of the Representative Warrant to the extent that the holder would own more than 4.99% (or, at the election of the holder,
9.99%) of the outstanding common stock immediately after exercise, except that upon at least 61 days&rsquo; prior notice from the holder
to us, the holder may increase the amount of ownership of outstanding stock after exercising the holder&rsquo;s Representative Warrants
up to 9.99% of the number of shares of our common stock outstanding immediately after giving effect to the exercise, as such percentage
ownership is determined in accordance with the terms of the Representative Warrants. Holders of the Representative Warrants may also
elect prior to the issuance of the Representative Warrants to have the initial exercise limitation set at 9.99% of our outstanding common
stock. No fractional shares of common stock will be issued in connection with the exercise of a Representative Warrant. In lieu of fractional
shares, we will either pay the holder an amount in cash equal to the fractional amount multiplied by the exercise price or round up to
the nearest whole share.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Duration
and Exercise Price</I>. The exercise price per whole share of our common stock purchasable upon the exercise of the Representative Warrants
is 165% of the public offering price per Unit sold in this prospectus. The Representative Warrants will be exercisable from the date
of issuance, at any time and from time to time, in whole or in part, during the five-year period commencing from the commencement of
sales of the offering. The exercise price of the Representative Warrants is subject to appropriate adjustment in the event of certain
stock dividends and distributions, stock splits, stock combinations, reclassifications or similar events affecting our common stock and
upon any distributions of assets, including stock or other property to our stockholders.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Cashless
Exercise</I>. If, at any time after the issuance of the Representative Warrants, such holder exercises its Representative Warrant and
a registration statement registering the issuance of the shares of common stock underlying the Representative Warrants under the Securities
Act is not then effective or available (or a prospectus is not available for the resale of shares of common stock underlying the Representative
Warrants), then in lieu of making the cash payment otherwise contemplated to be made to us upon such exercise in payment of the aggregate
exercise price, the holder shall instead receive upon such exercise (either in whole or in part) only the net number of shares of common
stock determined according to a formula set forth in the Representative Warrants. Notwithstanding anything to the contrary, in the event
we do not have or maintain an effective registration statement, there are no circumstances that would require us to make any cash payments
or net cash settle the Representative Warrants to the holders.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Transferability</I>.
Subject to applicable laws, the Representative Warrants may be offered for sale, sold, transferred or assigned at the option of the holder
upon surrender of the Representative Warrant to us together with the appropriate instruments of transfer.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Exchange
Listing</I>. We do not plan on applying to list the Representative Warrants on the Nasdaq Capital Market, any other national securities
exchange or any other nationally recognized trading system. Without an active trading market, the liquidity of the Representative Warrants
will be limited.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Fundamental
Transactions</I>. In the event of a fundamental transaction, as described in the Representative Warrants and generally including any
reorganization, recapitalization or reclassification of our common stock, the sale, transfer or other disposition of all or substantially
all of our properties or assets, our consolidation or merger with or into another person, the acquisition of more than 50% of our outstanding
common stock, or any person or group becoming the beneficial owner of 50% of the voting power represented by our outstanding common stock,
the holders of the underwriter warrants will be entitled to receive upon exercise of the Representative Warrants the kind and amount
of securities, cash or other property that the holders would have received had they exercised the Representative Warrants immediately
prior to such fundamental transaction. Any successor to us or surviving entity shall assume the obligations under the Representative
Warrants. Additionally, as more fully described in the Representative Warrants, in the event of certain fundamental transactions, the
holders of the Representative Warrants will be entitled to receive consideration in an amount equal to the Black Scholes value of the
Representative Warrants on the date of consummation of such transaction.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Rights
as a Stockholder</I>. Except by virtue of such holder&rsquo;s ownership of shares of our common stock, the holder of a Representative
Warrant does not have the rights or privileges of a holder of our common stock, including any voting rights, until the holder exercises
the Representative Warrant.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 56; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->52<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&nbsp;</p></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><A NAME="sk_011"></A>UNDERWRITING</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are offering the securities described in this prospectus through the underwriters named below. We have entered into an underwriting agreement
dated&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2025 with Ladenburg Thalmann &amp; Co. Inc., as the representative of the underwriters in this offering. Subject to the terms
and conditions of the underwriting agreement, the underwriters have agreed to purchase the number of our securities set forth opposite
its name below.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font-weight: bold; border-bottom: Black 1pt solid">Underwriters</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Number of Units Including Shares of Common Stock</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Number of Units Including Pre-Funded Warrants</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 60%; text-align: left">Ladenburg Thalmann &amp; Co. Inc.</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 16%; text-align: right">&nbsp;</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 16%; text-align: right">&nbsp;</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD>Totals</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
copy of the underwriting agreement will be filed as an exhibit to the registration statement of which this prospectus is part.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have been advised by the underwriters that they propose to offer the securities directly to the public at the public offering prices
set forth on the cover page of this prospectus. Any securities sold by the underwriters to securities dealers will be sold at the public
offering price less a selling concession not in excess of $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; per share of common stock, $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; per pre-funded warrant, $ &nbsp;&nbsp;per Series 1 warrant
and $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; per Series 2 warrant.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
underwriting agreement provides that the underwriters&rsquo; obligation to purchase the securities we are offering is subject to conditions
contained in the underwriting agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">No
action has been taken by us or the underwriters that would permit a public offering of the securities in any jurisdiction outside the
United States where action for that purpose is required. None of our securities included in this offering may be offered or sold, directly
or indirectly, nor may this prospectus or any other offering material or advertisements in connection with the offer and sales of any
of the securities offering hereby be distributed or published in any jurisdiction except under circumstances that will result in compliance
with the applicable rules and regulations of that jurisdiction. Persons who receive this prospectus are advised to inform themselves
about and to observe any restrictions relating to this offering of securities and the distribution of this prospectus. This prospectus
is neither an offer to sell nor a solicitation of any offer to buy the securities in any jurisdiction where that would not be permitted
or legal.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
underwriters have advised us that they do not intend to confirm sales to any account over which they exercise discretionary authority.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Underwriting
Discount and Expenses</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table summarizes the underwriting discount and commission to be paid to the underwriters by us.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: center">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Per Unit Including Shares of Common Stock</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Per Unit Including Pre-Funded Warrants</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Total Without<BR> Over-
    Allotment</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Total With Full<BR> Over-
    Allotment</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 44%">Public offering price (1)</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 10%; text-align: right">&nbsp;</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 10%; text-align: right">&nbsp;</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 10%; text-align: right">&nbsp;</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 10%; text-align: right">&nbsp;</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Underwriting discounts and commissions (2)(3)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Proceeds to us, before expenses</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    public offering price and underwriting discount corresponds, in respect of the securities of (i) a public offering price per share
    of common stock of $&nbsp;&nbsp;&nbsp; ($&nbsp;&nbsp;&nbsp;net of the underwriting discount), (ii) a public offering price per pre-funded warrant of $&nbsp;&nbsp;&nbsp;($&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; net of the
    underwriting discount), (iii) a public offering price per Series 1 warrant of $&nbsp;&nbsp;&nbsp; ($&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;net of the underwriting discount), and (iv) a
    public offering price per Series 2 warrant of $&nbsp;&nbsp;&nbsp;($&nbsp;&nbsp;&nbsp;&nbsp;net of the underwriting discount).</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 57; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->53<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&nbsp;</p></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
    have also agreed to reimburse the accountable expenses of the representative, including a pre-closing expense allowance of up to
    a maximum of $25,000 and an additional closing expense allowance up to a maximum of $95,000.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(3)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
    have granted a forty-five day over-allotment option to the underwriters to purchase up to an aggregate of additional shares of common
    stock, and/or Series 1 warrants to purchase up to&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; additional shares of common stock and/or Series 2 warrants to purchase up to&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; additional
    shares of common stock, in any combination, at the public offering prices per security set forth above less the underwriting discounts
    and commissions solely to cover over-allotments, if any.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Assuming
gross proceeds of $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; , we estimate the total expenses payable by us for this offering to be approximately $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; , which amount includes (i)
the underwriting discount of approximately $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; , (ii) the management fee of approximately $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, (iii) reimbursement of the accountable expenses
of the underwriters, including the legal fees of the representative of the underwriters, in an amount not to exceed $120,000 and (iv)
other estimated company expenses of approximately $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; , which includes legal, accounting, printing costs and various fees associated with
the registration and listing of our securities.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
securities we are offering are being offered by the underwriters subject to certain conditions specified in the underwriting agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Over-allotment
Option</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have granted to the underwriters an option exercisable not later than forty-five days after the date of this prospectus to purchase up
to an aggregate of an additional &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares of common stock, and/or Series 1 warrants to purchase up to additional shares of common stock
and/or Series 2 warrants to purchase up to&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; additional shares of common stock, or any combination thereof, as determined by the underwriters,
at the public offering price per security set forth on the cover page hereto less the underwriting discounts and commissions. The underwriters
may exercise the option solely to cover overallotments, if any, made in connection with this offering. If any additional shares of common
stock, Series 1 warrants and/or Series 2 warrants are sold, the underwriters will offer such securities on the same terms as those on
which the other securities are being offered.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Representative
Warrants</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have agreed to issue certain common stock purchase warrants (&ldquo;Representative Warrants&rdquo;) to the representative, or its designees,
of the underwriters, upon the closing of this offering, which entitle it to purchase up to&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; shares of common stock, or&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; shares of common
stock assuming the exercise of the over-allotment option in full. The Representative Warrants will have an exercise price equal to $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
per share of common stock, will be exercisable immediately upon issuance, at any time and from time to time, in whole or in part, during
the five-year period commencing from the commencement of sales of this offering. The Representative Warrants and the shares of common
stock underlying the Representative Warrants are being registered on the registration statement of which this prospectus is a part. See
the form of Representative Warrant for a more complete description of the terms of such Representative Warrants which has been filed
as an exhibit to the registration statement of which this prospectus is part.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Listing</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
shares of common stock are listed on The Nasdaq Capital Market under the symbol &ldquo;PALI.&rdquo;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
last reported sale price of our shares of common stock on The Nasdaq Capital Market on&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; , 2025, was $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; per share. The final public offering
price will be determined between us, the underwriters and the investors in the offering, and may be at a discount to the current market
price of our common stock. Therefore, the assumed public offering price used throughout this prospectus may not be indicative of the
final public offering price. There is no established public trading market for the warrants or pre-funded warrants, and we do not expect
such markets to develop. In addition, we do not intend to apply for a listing of the warrants or pre-funded warrants on any national
securities exchange or other nationally recognized trading system. Without an active trading market, the liquidity of the warrants and
pre-funded warrants will be limited.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 58; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->54<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&nbsp;</p></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Lock-up
Agreements</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Each
of our officers, directors and each of their respective affiliates and associated partners, and certain affiliated stockholders have
agreed with the underwriters to be subject to a lock-up period of&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; days following the Warrant Stockholder Approval, if applicable. If
the Warrant Stockholder is not applicable, such lock-up period shall run from the closing of this offering, subject to certain exceptions.
This means that, during the applicable lock-up period, such persons may not offer for sale, contract to sell, sell, distribute, grant
any option, right or warrant to purchase, pledge, hypothecate or otherwise dispose of, directly or indirectly, any shares of our common
stock or any securities convertible into, or exercisable or exchangeable for, shares of our common stock. Certain limited transfers are
permitted during the lock-up period if the transferee agrees to these lock-up restrictions. We have also agreed, in the underwriting
agreement, to similar lock-up restrictions on the issuance and sale of our securities from the date of this prospectus for a period of&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
days following the Warrant Stockholder Approval or the closing of this offering, as applicable and subject to certain exceptions. The
representative may, in its sole discretion and without notice, waive the terms of any of these lock-up agreements.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Right
of First Refusal</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant
to our investment banking agreement with the representative, provided that the Company consummates transactions during
the term of our agreement (&ldquo;Term&rdquo;) resulting in at least $18 million of gross proceeds, from the twelve (12) months following
the date of such closing and expiration of the Term, should we propose to effect an additional financing, we have agreed to offer the
representative the opportunity to participate as sole bookrunner, exclusive placement agent or exclusive sales agent or financial advisor
in respect of such financing. Alternatively, in the event the Company consummates transactions during the Term resulting in less than
$18 million of gross proceeds, from the nine (9) months following the date of such closing and expiration of the Term, should we propose
to effect an additional financing, we have agreed to offer the representative the opportunity to participate as a joint bookrunner or
co-exclusive placement agent (or exclusive sales agent for an &ldquo;at the market&rdquo; offering) in respect of such financing.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Transfer
Agent and Registrar</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
transfer agent and registrar for our common stock is Equiniti Trust Company, LLC.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Determination
of Offering Price</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
common stock is currently traded on The Nasdaq Capital Market under the symbol &ldquo;PALI.&rdquo; On &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2025, the closing price of our
common stock on The Nasdaq Capital Market was $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; per share. We do not intend to apply for listing of the warrants or pre-funded warrants
on any securities exchange or other trading system.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
public offering price of the securities offered by this prospectus will be determined by negotiation between us and the underwriters.
Among the factors that will be considered in determining the public offering price:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
    history and our prospects;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    industry in which we operate;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
    past and present operating results;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    previous experience of our executive officers; and</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    general condition of the securities markets at the time of this offering.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
public offering price stated on the cover page of this prospectus should not be considered an indication of the actual value of the securities
sold in this offering. That price is subject to change as a result of market conditions and other factors, and we cannot assure you that
the shares of common stock, pre-funded warrants and warrants sold in this offering can be resold at or above the public offering price.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 59; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->55<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&nbsp;</p></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Stabilization,
Short Positions and Penalty Bids</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
underwriters may engage in syndicate covering transactions stabilizing transactions and penalty bids or purchases for the purpose of
pegging, fixing or maintaining the price of our common stock:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Syndicate
    covering transactions involve purchases of securities in the open market after the distribution has been completed in order to cover
    syndicate short positions. Such a naked short position would be closed out by buying securities in the open market. A naked short
    position is more likely to be created if the underwriters are concerned that there could be downward pressure on the price of the
    securities in the open market after pricing that could adversely affect investors who purchase in the offering.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Stabilizing
    transactions permit bids to purchase the underlying security so long as the stabilizing bids do not exceed a specific maximum.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Penalty
    bids permit the underwriters to reclaim a selling concession from a syndicate member when the securities originally sold by the syndicate
    member are purchased in a stabilizing or syndicate covering transaction to cover syndicate short positions.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">These
syndicate covering transactions, stabilizing transactions, and penalty bids may have the effect of raising or maintaining the market
prices of our securities or preventing or retarding a decline in the market prices of our securities. As a result, the price of our common
stock may be higher than the price that might otherwise exist in the open market. Neither we nor the underwriters make any representation
or prediction as to the effect that the transactions described above may have on the price of our common stock. These transactions may
be effected on The Nasdaq Capital Market, in the over-the-counter market or on any other trading market and, if commenced, may be discontinued
at any time.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
connection with this offering, the underwriters also may engage in passive market making transactions in our common stock in accordance
with Regulation M during a period before the commencement of offers or sales of shares of our common stock in this offering and extending
through the completion of the distribution. In general, a passive market maker must display its bid at a price not in excess of the highest
independent bid for that security. However, if all independent bids are lowered below the passive market maker&rsquo;s bid that bid must
then be lowered when specific purchase limits are exceeded. Passive market making may stabilize the market price of the securities at
a level above that which might otherwise prevail in the open market and, if commenced, may be discontinued at any time.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Neither
we nor the underwriters make any representation or prediction as to the direction or magnitude of any effect that the transactions described
above may have on the prices of our securities. In addition, neither we nor the underwriters make any representation that the underwriters
will engage in these transactions or that any transactions, once commenced will not be discontinued without notice.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Other
Relationships</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">From
time to time, certain of the underwriters and their affiliates may provide in the future, various advisory, investment and commercial
banking and other services to us in the ordinary course of business, for which they will receive customary fees and commissions.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Indemnification</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have agreed to indemnify the underwriters against certain liabilities, including certain liabilities arising under the Securities Act,
or to contribute to payments that the underwriters may be required to make for these liabilities.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Electronic
Distribution</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
prospectus in electronic format may be made available on the websites maintained by the underwriters, if any, participating in this offering
and the underwriters may distribute prospectuses electronically. Other than the prospectus in electronic format, the information on these
websites is not part of this prospectus or the registration statement of which this prospectus forms a part, has not been approved or
endorsed by us or the underwriters, and should not be relied upon by investors.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>


<!-- Field: Page; Sequence: 60; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->56<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&nbsp;</p></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><A NAME="sk_012"></A>LEGAL
MATTERS</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
validity of the securities being offered hereby is being passed upon for us by Gunderson Dettmer Stough Villeneuve Franklin &amp; Hachigian,
LLP, San Diego, California. Ellenoff Grossman &amp; Schole LLP, New York, New York, has acted as counsel for the underwriters in connection
with this offering.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 61; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->57<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&nbsp;</p></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><A NAME="sk_013"></A>EXPERTS</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
consolidated financial statements of Palisade Bio, Inc. for the year ended December 31, 2024, incorporated by reference in this prospectus,
have been audited by Baker Tilly US, LLP, an independent registered public accounting firm, as stated in their report, which is incorporated
herein by reference. Such consolidated financial statements have been so incorporated by reference in reliance upon the report of such
firm given their authority as experts in accounting and auditing. The report on the consolidated financial statements contains an explanatory
paragraph regarding the Company&rsquo;s ability to continue as a going concern.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 62; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->58<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&nbsp;</p></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><A NAME="sk_014"></A>WHERE
YOU CAN FIND MORE INFORMATION</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have filed with the SEC a registration statement on Form S-1 under the Securities Act, with respect to the securities being offered by
this prospectus. This prospectus does not contain all of the information in the registration statement and its exhibits. For further
information with respect to us and the securities offered by this prospectus, we refer you to the registration statement and its exhibits.
Statements contained in this prospectus as to the contents of any contract or any other document referred to are not necessarily complete,
and in each instance, we refer you to the copy of the contract or other document filed as an exhibit to the registration statement. Each
of these statements is qualified in all respects by this reference.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are subject to the information and periodic reporting requirements of the Exchange Act, and we file periodic reports, proxy statements
and other information with the SEC. You can read our SEC filings, including the registration statement, over the Internet at the SEC&rsquo;s
website at www.sec.gov. You may also request a copy of these filings, at no cost, by writing us at Palisade Bio, Inc., 7750 El Camino
Real, Suite 2A, Carlsbad, CA 92009 or telephoning us at (858) 704-4900. We also maintain a website at www.palisadebio.com, at which you
may access these materials free of charge after they are electronically filed with, or furnished to, the SEC. The information contained
in, or that can be accessed through, our website is not incorporated by reference in, and is not part of, this prospectus and any references
to this web site or any other web site are inactive textual references only.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 63; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->59<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&nbsp;</p></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><A NAME="sk_015"></A>INCORPORATION
OF CERTAIN INFORMATION BY REFERENCE</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
SEC allows us to &ldquo;incorporate by reference&rdquo; the information we file with it, which means that we can disclose important information
to you by referring to those documents. The information incorporated by reference is an important part of this prospectus, and information
that we file later with the SEC will automatically update and supersede this information. This prospectus omits certain information contained
in the registration statement, as permitted by the SEC. You should refer to the registration statement, including the exhibits, for further
information about us and the securities we may offer pursuant to this prospectus. Statements in this prospectus regarding the provisions
of certain documents filed with, or incorporated by reference in, the registration statement are not necessarily complete and each statement
is qualified in all respects by that reference</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
incorporate by reference the following documents we filed with the SEC pursuant to Section 13 of the Exchange Act and any future filings
we will make with the SEC under Sections 13(a), 13(c), 14, or 15(d) of the Exchange Act after the date of this prospectus until the termination
of the offering of the securities covered by this prospectus (other than information furnished under Item 2.02 or Item 7.01 of Form 8-K):</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
    Annual Report on <A HREF="https://www.sec.gov/Archives/edgar/data/1357459/000095017025043859/pali-20241231.htm" STYLE="-sec-extract: exhibit">Form 10-K</A> for the year ended December 31, 2024, filed with the SEC on March 24, 2025, including the Part III information
    contained therein;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
    Quarterly Report on <A HREF="https://www.sec.gov/Archives/edgar/data/1357459/000095017025069204/pali-20250331.htm" STYLE="-sec-extract: exhibit">Form 10-Q</A> for the quarter ended March 31, 2025, filed with the SEC on May 12, 2025;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
    Current Report on <A HREF="https://www.sec.gov/Archives/edgar/data/1357459/000164117225008346/form8-k.htm" STYLE="-sec-extract: exhibit">Form 8-K</A> filed with the SEC on May 2, 2025; and</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    description of our common stock which is registered under Section 12 of the Exchange Act, in our registration statement on <A HREF="https://www.sec.gov/Archives/edgar/data/1357459/000114420415040378/v414630_8a12b.htm" STYLE="-sec-extract: exhibit">Form 8-A</A>
    filed with the SEC on July 1, 2015, including any amendments or reports filed for the purpose of updating such description, including
    <A HREF="https://www.sec.gov/Archives/edgar/data/1357459/000095017022004093/pali-ex4_2.htm" STYLE="-sec-extract: exhibit">Exhibit 4.2</A> to our Annual Report on <A HREF="https://www.sec.gov/Archives/edgar/data/1357459/000095017022004093/pali-20211231.htm" STYLE="-sec-extract: exhibit">Form 10-K</A> for the year ended December 31, 2021, filed with the SEC on March 17, 2022.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">You
may access the Annual Report on Form 10-K, Quarterly Reports on Form 10-Q and Current Reports on Form 8-K, Proxy Statements, and amendments,
if any, to those documents filed or furnished pursuant to Section 13(a) or 15(d) of the Exchange Act with the SEC free of charge at the
SEC&rsquo;s website (www.sec.gov) or our website (www.palisadebio.com) as soon as reasonably practicable after such material is electronically
filed with, or furnished to, the SEC. The reference to our website does not constitute incorporation by reference of the information
contained in our website. We do not consider information contained on, or that can be accessed through, our website to be part of this
prospectus or the related registration statement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
will provide to each person, including any beneficial owner, to whom a prospectus is delivered, without charge upon written or oral request,
a copy of any or all of the information that is incorporated by reference into this prospectus but not delivered with the prospectus,
including exhibits which are specifically incorporated by reference into such documents. You should direct any requests for documents
to 7750 El Camino Real, Suite 2A, Carlsbad, CA 92009, Attn: Secretary or may be made telephonically at (858) 704-4900.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 64; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->60<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&nbsp;</p></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;<IMG SRC="formdrs_001.jpg" ALT="" style="width:300px"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Units
consisting of&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; shares of common stock or pre-funded warrants to purchase up to &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares of common stock, Series 1 warrants to purchase up
to &nbsp;&nbsp;&nbsp;&nbsp;shares of common stock and Series 2 warrants to purchase up to&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; shares of common stock </B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Representative
Warrant to purchase up to&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; shares of common stock</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>(and
up to &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares of common stock underlying pre-funded warrants, Series 1 warrants, Series 2 warrants, and Representative Warrants)</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>PRELIMINARY
PROSPECTUS</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 14pt"><B>Ladenburg
Thalmann</B></FONT></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>The
date of this prospectus is&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; , 2025</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 65 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>PART
II</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>INFORMATION
NOT REQUIRED IN PROSPECTUS</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Item
13. Other Expenses of Issuance and Distribution</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table sets forth the expenses to be incurred in connection with the offering described in this registration statement, all
of which will be paid by the registrant. All amounts are estimates except the SEC registration fee.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Amount</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 80%; text-align: left">SEC registration fee</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 16%; text-align: right">&nbsp;</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">FINRA filing fee</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Printing expenses</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Legal fees and expenses</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Accounting fees and expenses</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Transfer agent fees and expenses</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1pt">Miscellaneous fees and expenses</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">$</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-bottom: 2.5pt">Total</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Item
14. Indemnification of Directors and Officers</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are incorporated under the laws of the State of Delaware. Sections 145 and 102(b)(7) of the General Corporation Law of the State of Delaware
provide that a corporation may indemnify any person made a party to an action by reason of the fact that he or she was a director, executive
officer, employee or agent of the corporation or is or was serving at the request of the corporation against expenses (including attorneys&rsquo;
fees), judgments, fines and amounts paid in settlement actually and reasonably incurred by him or her in connection with such action
if he or she acted in good faith and in a manner he or she reasonably believed to be in, or not opposed to, the best interests of the
corporation and, with respect to any criminal action or proceeding, had no reasonable cause to believe his or her conduct was unlawful,
except that, in the case of an action by or in right of the corporation, no indemnification may generally be made in respect of any claim
as to which such person is adjudged to be liable to the corporation.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
Certificate of Incorporation contains provisions that eliminate, to the maximum extent permitted by the General Corporation Law of the
State of Delaware, the personal liability of directors and executive officers for monetary damages for breach of their fiduciary duties
as a director or officer. Our amended and restated Certificate of Incorporation and Bylaws provide that we shall indemnify our directors
and executive officers and may indemnify our employees and other agents to the fullest extent permitted by the General Corporation Law
of the State of Delaware.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have purchased and intend to maintain insurance on behalf of any person who is or was a director or officer of our company against any
loss arising from any claim asserted against him or her and incurred by him or her in any such capacity, subject to certain exclusions.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have entered, and intend to continue to enter, into separate indemnification agreements with our directors and executive officers to
provide these directors and executive officers additional contractual assurances regarding the scope of the indemnification set forth
in the registrant&rsquo;s Certificate of Incorporation and amended and restated Bylaws and to provide additional procedural protections.
At present, there is no pending litigation or proceeding involving a director or executive officer of the Company regarding which indemnification
is sought. The indemnification provisions in our Certificate of Incorporation, amended and restated Bylaws and the indemnification agreements
entered into or to be entered into between us and each of our directors and executive officers may be sufficiently broad to permit indemnification
of our directors and executive officers for liabilities arising under the Securities Act. Insofar as indemnification for liabilities
arising under the Securities Act of 1933 may be permitted to directors, officers or persons controlling the registrant pursuant to the
foregoing provisions, the registrant has been informed that in the opinion of the Securities and Exchange Commission such indemnification
is against public policy as expressed in the Act and is therefore unenforceable. We carry liability insurance for our directors and officers.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.75in; text-align: justify; text-indent: -0.75in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.75in; text-align: justify; text-indent: -0.75in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 66; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">II-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.75in; text-align: justify; text-indent: -0.75in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.75in; text-align: justify; text-indent: -0.75in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Item
15. Recent Sales of Unregistered Securities</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Set
forth below is information regarding securities sold by us since January 1, 2022 that were not registered under the Securities Act. Also
included is the consideration, if any, received by us for such shares and options and information relating to the section of the Securities
Act, or rule of the Securities and Exchange Commission, under which exemption from registration was claimed.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>(a)
Issuances of Securities</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Effective
    January 31, 2022, we and Altium Growth Fund, LP (&ldquo;Altium&rdquo;) entered into a Waiver and Amendment Agreement, pursuant to
    which Altium agreed to waive any adjustment to the exercise price of the existing warrants held by it from and after such date for
    issuances of equity or equity-linked securities at a price below the exercise price of the warrants. The Waiver Agreement also includes
    agreement to, among other things, (i) restrict Altium&rsquo;s ability to sell our securities through a &ldquo;leak out&rdquo; provision
    whereby sales are restricted by applying a volume limitation, (ii) shorten the notice period for Altium&rsquo;s participation rights
    related to certain future securities offerings, (iii) restrict our ability to conduct a primary offering of our securities for a
    specified period of time, and (iv) provide registration rights for the shares underlying the warrant issued to Altium in consideration
    of the foregoing. As consideration for the foregoing, pursuant to the Waiver Agreement, we issued Altium an additional warrant to
    purchase up to 3,000 shares of our common stock. The warrant is exercisable beginning six months following January 31, 2022 and the
    exercise price is $825.00 (the closing price of our common stock on January 28, 2022), subject to customary adjustments for stock
    splits, stock dividends, stock combinations, reclassifications and similar transactions.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
    May 6, 2022, we entered into a securities purchase agreement with certain institutional and accredited investors, pursuant to which
    we agreed to sell and issue, in a registered direct offering, an aggregate of 4,862 shares of our common stock at a purchase price
    per share of $412.50, for aggregate gross proceeds to us of approximately $2.0 million, before deducting fees payable to the placement
    agent and other estimated offering expenses payable by us. The shares were offered pursuant to an effective shelf registration statement
    on Form S-3. In connection with such offering, in a concurrent private placement, we also agreed to sell and issue to such purchasers
    warrants to purchase up to 4,862 shares of common stock at an exercise price of $532.875 per share, the closing bid price of our
    common stock on May 5, 2022. Such warrants are not exercisable until six months following the date of issuance and expire five and
    a half years from the date of issuance. In addition, pursuant to a placement agency agreement dated as of May 6, 2022, we engaged
    Ladenburg Thalmann &amp; Co. Inc. (&ldquo;Ladenburg&rdquo;) to act as our exclusive placement agent in connection with the aforementioned
    registered offering and private placement offering. We agreed to pay Ladenburg a cash fee equal to 7.75% of the aggregate gross proceeds
    raised in the aforementioned registered offering and private placement offering and to reimburse its expenses up to an aggregate
    of $85,000. In addition, we issued Ladenburg warrants on substantially the same terms as the warrants issued to the purchasers in
    an amount equal to 6.0% of the aggregate number of shares sold in the offering, or 292 shares of common stock, at an exercise price
    of $532.95 per share and a five-and-a-half year term. The placement agent warrants are not exercisable until six months following
    the date of issuance.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
    December 30, 2022, we entered into securities purchase agreements with certain institutional and accredited investors, pursuant to
    which we agreed to sell and issue, in a registered direct offering, an aggregate of (i) 31,789 shares of our common stock at a purchase
    price per share of $35.63 and (ii) registered prefunded warrants to purchase 2,466 shares of common stock at an exercise price of
    $0.0015 per share. The transaction closed on January 4, 2023. The shares were offered pursuant to an effective shelf registration
    statement on Form S-3. In connection with such offering, in a concurrent private placement, we also agreed to sell and issue to such
    purchasers (i) prefunded warrants to purchase 35,919 shares of common stock at an exercise price of $0.0015 per share and (ii) warrants
    to purchase 70,175 shares of common stock at an exercise price of $35.63 per share. Such prefunded warrants and warrants are immediately
    exercisable and the prefunded warrants have a perpetual term and the other warrants expire five years from the date of issuance.
    Gross proceeds for the registered offering and concurrent private placement were approximately $2.5 million, before deducting fees
    payable to the placement agent and other estimated offering expenses payable by us. In addition, pursuant to a placement agency agreement
    dated as of December 30, 2022, we engaged Ladenburg to act as our exclusive placement agent in connection with the aforementioned
    registered offering and private placement offering. We agreed to pay Ladenburg a cash fee equal to 7.75% of the aggregate gross proceeds
    raised in the aforementioned registered offering and private placement offering and to reimburse its expenses up to an aggregate
    of $105,000. In addition, we issued Ladenburg warrants on substantially the same terms as the warrants issued to the purchasers in
    an amount equal to 6.0% of the aggregate number of shares sold in the offering, or 4,210 shares of common stock, at an exercise price
    of $44.53 per share and a five-year term.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
    April 3, 2023, we entered into securities purchase agreements with certain institutional and accredited investors, pursuant to which
    we agreed to sell and issue, in a registered offering, an aggregate of 50,421 shares of our common stock. The transaction closed
    on April 5, 2023. Concurrently, in the a private offering we offered and sold an aggregate of: (i) 30,349 unregistered shares of
    common stock, (ii) prefunded warrants to purchase 70,744 shares of common stock at an exercise price of $0.015 per share and (iii)
    warrants to purchase 151,514 shares of common stock at an exercise price of $40.35 per share. Such prefunded warrants and warrants
    were immediately exercisable and expire five years from the date of issuance. In addition, pursuant to a placement agency agreement
    dated as of April 3, 2023, we engaged Ladenburg to act as our exclusive placement agent in connection with the April 2023 Offering.
    We agreed to pay Ladenburg a cash fee equal to 7.75% of the aggregate gross proceeds received from the April 2023 Offering or $465,000
    and we reimbursed its expenses of $85,000. In addition, we issued Ladenburg 9,090 placement agent warrants with terms substantially
    similar to the warrants issued in the offering.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 67; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">II-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
    September 5, 2023, pursuant to his appointment as Chief Medical Officer, the Company issued Mitchell Jones, M.D., Ph.D. (i) options
    to purchase 5,000 shares of common stock with a term of ten (10) years and an exercise price of $10.35 per share and (ii) 3,646 restricted
    stock units. The options vest quarterly over three (3) years from the grant date and the restricted stock units vests as follows:
    (a) 303 shares on November 6, 2023, and (b) the remaining 3,343 shares vest over eleven (11) equal quarterly periods after the initial
    vesting date. The options were valued at $33,267 and the restricted stock units were valued at $37,727, respectively from the grant
    date. The equity grants were issued from the 2021 Inducement Plan.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">6.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
    September 7, 2023, we entered into securities purchase agreements with certain institutional and accredited investors, pursuant to
    which we agreed to sell and issue, in a Registered Offering, an aggregate of 155,959 shares of our common stock. The transaction
    closed on September 11, 2023. In addition, pursuant to a placement agency agreement dated as of September 7, 2023, we engaged Ladenburg
    to act as our exclusive placement agent in connection with the September 2023 Offering. We agreed to pay Ladenburg a cash fee equal
    to 7.75% of the aggregate gross proceeds received from the September 2023 Offering or $152,294 and we reimbursed its expenses of
    $75,000. In addition, we issued Ladenburg 9,357 placement agent warrants. The placement agent warrants have a term of five (5) years
    and an exercise price of $15.75 per share.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">7.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
    December 15, 2023, we entered into an engagement letter with MDM Worldwide Solutions, Inc. for the purpose of providing us with business
    advisory services. Pursuant to the agreement, in the event that we chose to renew the six (6) month term, we would be obligated to
    issue the consultant $50,000 of common stock based on the closing price of the Company&rsquo;s common stock on the date of the agreement,
    or an aggregate of 5,603 shares of common stock, which occurred on June 17, 2024. The shares issued were fully vested on the grant
    date and valued at $26,222.04.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">8.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
    January 30, 2024, we entered into warrant inducement agreements (the &ldquo;Warrant Inducement Agreements&rdquo;) with certain accredited
    and institutional holders (collectively, the &ldquo;Warrant Holders&rdquo;) of certain of our remaining outstanding common stock
    purchase warrants issued pursuant to: (i) the May 2022 Offering, (ii) the January 2023 Offering, and (iii) the April 2023 Offering,
    as well as certain outstanding common stock purchase warrants outstanding from the August 2022 Offering (the &ldquo;August 2022 Warrants&rdquo;)
    (collectively, the &ldquo;Existing Warrants&rdquo;). Pursuant to the Warrant Inducement Agreements, the exercise price of each Existing
    Warrant was reduced to $10.97 per share. Each of the Warrant Holders that exercised their Existing Warrants pursuant to the Warrant
    Inducement Agreements received one replacement warrant for each Existing Warrant exercised with each such replacement warrant having
    a term of five years from issuance and an exercise price per share of $10.97 (in its entirety, the &ldquo;February 2024 Warrant Inducement&rdquo;).</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    Warrant Holders collectively exercised an aggregate of 228,162 Existing Warrants. As a result of the exercises of the Existing Warrants,
    we issued an aggregate of 228,162 shares of our common stock and 228,162 Replacement Warrants. The February 2024 Warrant Inducement
    closed on February 1, 2024. In addition, we issued to the solicitation agent, Ladenburg, warrants on substantially the same terms
    as the Replacement Warrants in an amount equal to 6.0% of the aggregate number shares issued pursuant to the exercise of the Existing
    Warrants, or 205,337 warrants, with an exercise price of $10.97 per share, and a term of five years from issuance.</FONT></P></TD></TR>
</TABLE>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0"></P>

<!-- Field: Page; Sequence: 68; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">II-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">9.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
    May 6, 2024, we completed a private placement with an institutional investor whereby we sold (i) 85,100 shares of common stock, (ii)
    530,142 prefunded warrants at a price per share or prefunded warrant of $6.5015. Each prefunded warrants has a perpetual term and
    an exercise price of $0.0001 per share. Additionally, we issued the purchaser warrants to purchase 922,863 shares of common stock,
    with an exercise price of $6.314 per share, and a term of seven (7) years from issuance. We received gross proceeds of approximately
    $4 million pursuant to the offering. We agreed to pay Ladenburg, our exclusive placement agent, a cash fee equal to 7.75% of the
    aggregate gross proceeds received from the offering or $310,000 and we reimbursed its expenses of $75,000. In addition, we issued
    Ladenburg 36,914 placement agent warrants. The placement agent warrants have a term of five (5) years and an exercise price of $10.727
    per share.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
    May 28, 2024, we issued 10,000 restricted shares of common stock to consultants as partial payment for rebranding and website services.
    The common stock shares were fully vested on the grant date and valued at $47,600 on the date of issuance.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">11.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
    September 4, 2024, we issued 14,029 restricted shares of common stock to a consultant as partial payment for financial advisory services.
    The common stock shares were fully vested on the grant date and valued at $50,644.69 in aggregate on the date of issuance.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">12.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
    October 1, 2024, we issued 3,000 restricted shares of common stock to a consultant as partial payment for services. The common stock
    shares were fully vested on the grant date and valued at $10,650 in aggregate on the date of issuance.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">13.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
    December 13, 2024, we completed an underwritten public offering (the &ldquo;December 2024 Offering&rdquo;) to sell (a) 158,000 Class
    A Units at a public offering price of $1.525 per Class A Unit (the &ldquo;Class A Units&rdquo;), with each Class A Unit consisting
    of (i) one share of our common stock, par value $0.01 per share, and (ii) one warrant to purchase one share of our common stock at
    an exercise price per share of $1.40 and a term of five years from the date of issuance (&ldquo;December 2024 Offering Common Stock
    Warrant&rdquo;) and (b) 3,120,688 Class B Units at a public offering price of $1.5249 per Class B Unit (the &ldquo;Class B Units&rdquo;,
    and collectively with the Class A Units, the &ldquo;Units&rdquo;), with each Class B Unit consisting of (i) one pre-funded warrant
    to purchase one share of our common stock being immediately exercisable, having an exercise price of $0.0001 per share, and a perpetual
    term (&ldquo;December 2024 Offering Pre-funded Common Stock Warrant&rdquo;) and (ii) one December 2024 Offering Common Stock Warrant.
    We issued warrants to representatives of the sole underwriter in the December 2024 Offering to purchase an aggregate 196,721 shares
    of common stock (the &ldquo;December 2024 Underwriter warrants&rdquo;). The December 2024 Underwriter warrants have substantially
    the same terms as the December 2024 Offering Common Stock Warrants, except that the exercise price of each of the December 2024 Underwriter
    warrants is $2.51625 per share. On December 12, 2024, we entered into a warrant amendment agreement (the &ldquo;Warrant Amendment
    Agreement&rdquo;) whereby contemporaneously with and contingent with the closing of the December 2024 Offering we reduced the exercise
    price of 1,040,217 outstanding common stock warrants (the &ldquo;Repriced Warrants&rdquo;) held by an investor that participated
    in the December 2024 Offering which expire between July 31, 2027 and May 6, 2031. The Repriced Warrants had their exercise price
    reduced to $1.40 per share. Other than the reduction in exercise price, the terms of the Repriced Warrants remain the same and unchanged.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">14.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">On
    February 11, 2025, we granted J.D. Finley, our Chief Executive Officer and Chief Financial Officer, (i) options to purchase 47,000
    shares of our common stock with a term of 10 years and an exercise price of $1.13 per share, valued at approximately $47,400 on the
    grant date and (ii) 40,000 restricted stock units valued </FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">at
    approximately $45,200. <FONT STYLE="background-color: white">The options to purchase our common stock granted to Mr. Finley vest
    in 12 equal installments on a quarterly basis over three years. The restricted stock units granted to Mr. Finley vest in 3 equal
    installments on a yearly basis over three years. The equity grants were issued from our 2021 EIP.</FONT></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">15.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">On
    February 11, 2025, we granted Mitchell Jones, our Chief Medical Officer, (i) options to purchase 29,000 shares of our common stock
    with a term of 10 years and an exercise price</FONT> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">of
    $1.13 pe<FONT STYLE="background-color: white">r share, valued at approximately $29,200 on the grant date and (ii) 24,000 restricted
    stock units valued at approximately $27,120. The options to purchase o</FONT>ur common stock granted to Dr. Jones vest in 12 equal
    installments on a quarterly bas<FONT STYLE="background-color: white">is over three years. The restricted stock units granted to Dr.
    Jones vest in 3 equal installments on a yearly basis over three years. The equity grants were issued from our 2021 EIP.</FONT></FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 69; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">II-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
offers, sales and issuances of the securities described in this section (a) of Item 15 were deemed to be exempt from registration under
the Securities Act in reliance on Section 4(a)(2) of the Securities Act or Rule 506 of Regulation D promulgated under the Securities
Act as transactions by an issuer not involving a public offering. The recipients of securities in each of these transactions acquired
the securities for investment only and not with a view to or for sale in connection with any distribution thereof and appropriate legends
were affixed to the securities issued in these transactions. Each of the recipients of securities in these transactions was an accredited
investor within the meaning of Rule 501 of Regulation D under the Securities Act and had adequate access, through employment, business
or other relationships, to information about the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>(b)
Issuances of Equity Awards</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
    February 6, 2023, the Company granted J.D. Finley, our interim Chief Executive Officer and Chief Financial Officer: (i) an option
    to purchase 3,813 shares of common stock valued at approximately $87,853, having an exercise price of $36.00 per share, a term of
    10 years, and which vests quarterly over a three year period, (ii) 2,780 restricted stock units valued at approximately $100,080
    which vests in 12 equal installments quarterly over a three year period, and (iii) 2,166 restricted performance stock units valued
    at approximately $78,000, which vest (a) 50% when the volume weighted average price of the Company&rsquo;s common stock over 20 consecutive
    trading days is $48.00, and (b) 50% when such volume weighted average price of the Company&rsquo;s common stock over 20 consecutive
    trading days is $63.75. All of the grants issued to Mr. Finley as described in this paragraph were issued on a conditional basis
    and were subject to the receipt of shareholder approval of the grants, which was subsequently received on June 8, 2023.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
    February 6, 2023, the Company granted Robert McRae, our Chief Operating Officer: (i) an option to purchase 800 shares of common stock
    valued at approximately $18,431, having an exercise price of $36.00 per share, a term of 10 years, and which vests quarterly over
    three years, (ii) 586 restricted stock units valued at approximately $21,120 which vests in 12 equal installments quarterly over
    a three year period, and (iii) 1,193 restricted performance stock units valued at approximately $42,960, which vest (a) 50% when
    the volume weighted average price of the Company&rsquo;s common stock over 20 consecutive trading days is $48.00, and (b) 50% when
    such volume weighted average price of the Company&rsquo;s common stock over 20 consecutive trading days is $63.75. All of the grants
    issued to Mr. McRae as described in this paragraph were issued on a conditional basis and are subject to the receipt of shareholder
    approval of the grants, which were subsequently received on June 8, 2023.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
    February 6, 2023, the Company granted certain non-executive employees, an aggregate of (i) options to purchase 820 shares of common
    stock valued at approximately $18,891, having an exercise price of $36.00 per share, a term of 10 years, and which vest quarterly
    over three years, (ii) 600 restricted stock units valued at approximately $21,600 which vest in 12 equal installments quarterly over
    a three year period, and (iii) 1,220 restricted performance stock units valued at approximately $43,920, which vest (a) 50% when
    the volume weighted average price of the Company&rsquo;s common stock over 20 consecutive trading days is $48.00, and (b) 50% when
    such volume weighted average price of the Company&rsquo;s common stock over 20 consecutive trading days is $63.75. All of the grants
    issued to such employees as described in this paragraph were issued on a conditional basis and are subject to the receipt of shareholder
    approval of the grants, which was subsequently received on June 8, 2023.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
    June 11, 2023, the Company granted Mr. Finley: (i) options to purchase 9,900 shares of common stock with a term of ten (10) years
    and an exercise price of $24.00 per share, valued at $151,978 on the grant date and (ii) 4,446 restricted stock units valued at $106,720.
    Each of the options and restricted stock units granted to Mr. Finley vest in twelve (12) equal installments on a quarterly basis
    over three (3) years. The equity grants were issued from the Company&rsquo;s 2021 Plan, which such shares were registered under the
    2021 Plan on September 14, 2023.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 70; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">II-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
    June 11, 2023, the Company granted to its non-executive employees an aggregate of: (i) options to purchase 6,477 shares of common
    stock with a term of ten (10) years and an exercise price of $24.00 per share, valued in aggregate at $99,436 at the grant date and
    (ii) 3,022 restricted stock units valued at $72,528. Each of the options and restricted stock units granted to the employees vest
    in twelve (12) equal installments on a quarterly basis over three (3) years. The equity grants were issued from the Company&rsquo;s
    2021 Plan, which such shares were registered under the 2021 Plan on September 14, 2023.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">6.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
    June 11, 2023, the Company granted to the non-employee members of the Board of Directors, as supplemental grants, an aggregate of:
    (i) options to purchase 5,158 shares of common stock with a term of ten (10) years and an exercise price of $24.00 per share and
    (ii) 2,756 restricted stock units. Each of the grants vests fully on the one (1) year anniversary of the grant date. The aggregate
    options were valued at $78,136 and the aggregate restricted stock units were valued at $66,120. The equity grants were issued from
    the 2021 Plan, which such shares were registered under the 2021 Plan on September 14, 2023.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">7.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
    September 5, 2023, pursuant to his appointment as Chief Medical Officer, the Company issued Mitchell Jones, M.D., Ph.D. (i) options
    to purchase 5,000 shares of common stock with a term of ten (10) years and an exercise price of $10.35 per share and (ii) 3,646 restricted
    stock units. The options vest quarterly over three (3) years from the grant date and the restricted stock units vests as follows:
    (a) 303 shares on November 6, 2023, and (b) the remaining 3,343 shares vest over eleven (11) equal quarterly periods after the initial
    vesting date. The options were valued at $33,267 and the restricted stock units were valued at $37,727, respectively from the grant
    date. The equity grants were issued from the 2021 Inducement Plan.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">8.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">On
    February 11, 2025, we granted J.D. Finley, our Chief Executive Officer and Chief Financial Officer, (i) options to purchase 47,000
    shares of our common stock with a term of 10 years and an exercise price of $1.13 per share, valued at approximately $47,400 on the
    grant date and (ii) 40,000 restricted stock units valued </FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">at
    approximately $45,200. <FONT STYLE="background-color: white">The options to purchase our common stock granted to Mr. Finley vest
    in 12 equal installments on a quarterly basis over three years. The restricted stock units granted to Mr. Finley vest in 3 equal
    installments on a yearly basis over three years. The equity grants were issued from our 2021 EIP.</FONT></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">9.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">On
    February 11, 2025, we granted Mitchell Jones, our Chief Medical Officer, (i) options to purchase 29,000 shares of our common stock
    with a term of 10 years and an exercise price</FONT> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">of
    $1.13 pe<FONT STYLE="background-color: white">r share, valued at approximately $29,200 on the grant date and (ii) 24,000 restricted
    stock units valued at approximately $27,120. The options to purchase o</FONT>ur common stock granted to Dr. Jones vest in 12 equal
    installments on a quarterly bas<FONT STYLE="background-color: white">is over three years. The restricted stock units granted to Dr.
    Jones vest in 3 equal installments on a yearly basis over three years. The equity grants were issued from our 2021 EIP.</FONT></FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
offers, sales and issuances of the securities described in this section (b) of Item 15 were deemed to be exempt from registration under
the Securities Act in reliance on Section 4(a)(2) of the Securities Act or Rule 506 of D promulgated under the Securities Act as transactions
by an issuer not involving a public offering. The recipients of securities in each of these transactions acquired the securities for
investment only and not with a view to or for sale in connection with any distribution thereof and appropriate legends were affixed to
the securities issued in these transactions. Each of the recipients of securities in these transactions was an accredited investor within
the meaning of Rule 501 of Regulation D under the Securities Act and had adequate access, through employment, business or other relationships,
to information about the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 71; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">II-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.75in; text-align: justify; text-indent: -0.75in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Item
16. Exhibits and Financial Statement Schedules</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.75in; text-align: justify; text-indent: -0.75in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>(a)
Exhibits</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify; width: 0.75in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Exhibit
    Number</B></FONT></TD>
    <TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify; width: 0.1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Description
    of document</B></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.1&amp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Form
    of Underwriting Agreement</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.1</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="https://www.sec.gov/Archives/edgar/data/1357459/000149315224013336/ex3-1.htm" STYLE="-sec-extract: exhibit">Amended and Restated Certificate of Incorporation of the Registrant (Incorporated by reference to Exhibit 3.1 to the Registrant&rsquo;s Current Report on Form 8-K, filed with the SEC on April 5, 2024).</A></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.2</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="https://www.sec.gov/Archives/edgar/data/1357459/000149315224009042/ex3-1.htm" STYLE="-sec-extract: exhibit">Amended and Restated Bylaws of the Registrant (Incorporated by reference to Exhibit 3.1 to the Registrant&rsquo;s Current Report on Form 8-K, filed with the SEC on March 6, 2024).</A></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.01&amp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Form
    of Pre-Funded Warrant</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.02&amp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Form
    of Representative Warrant</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.03&amp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Form
    of Series 1 Warrant</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.04&amp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Form
    of Series 2 Warrant</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.05&amp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Form
    of Warrant Agency Agreement</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.1&amp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Opinion
    of Gunderson Dettmer Stough Villeneuve &amp; Hachigian, LLP.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.1#</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="https://www.sec.gov/Archives/edgar/data/1357459/000117184320008771/exh_1018.htm" STYLE="-sec-extract: exhibit">License Agreement, dated August 19, 2015, by and between Leading BioSciences, Inc. and The Regents of the University of California, as amended on December 20, 2019 (Incorporated by reference to Exhibit 10.18 to the Registrant&rsquo;s Registration Statement on Form S-4 (File No. 333-251659), filed with the SEC on December 23, 2020, as amended).</A></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.2#</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="https://www.sec.gov/Archives/edgar/data/1357459/000117184320008771/exh_1020.htm" STYLE="-sec-extract: exhibit">Co-Development and Distribution Agreement, dated February 27, 2018 by and between Leading BioSciences, Inc. and Newsoara Biopharma Co., Ltd. (as successor-in-interest to Biolead Medical Technology Limited), as amended on November 27, 2018 (Incorporated by reference to Exhibit 10.20 to the Registrant&rsquo;s Registration Statement on Form S-4 (File No. 333-251659), filed with the SEC on December 23, 2020, as amended).</A></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.3+</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="https://www.sec.gov/Archives/edgar/data/1357459/000117184318008473/exh_1003.htm" STYLE="-sec-extract: exhibit">Form of Indemnification Agreement (Incorporated by reference from Exhibit 10.03 to the Registrant&rsquo;s Current Report on Form 8-K, filed with the SEC on December 18, 2018).</A></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.4+</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="https://www.sec.gov/Archives/edgar/data/1357459/000117184320008771/exh_1024.htm" STYLE="-sec-extract: exhibit">Leading BioSciences, Inc. Amended and Restated 2013 Employee, Director and Consultant Equity Incentive Plan and Forms of Stock Option Grant Notice, Stock Option Agreement and Notice of Exercise of Stock Option thereunder (Incorporated by reference to Exhibit 10.24 to the Registrant&rsquo;s Registration Statement on Form S-4 (File No. 333-251659), filed with the SEC on December 23, 2020, as amended).</A></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.5+</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="https://www.sec.gov/Archives/edgar/data/1357459/000149315223020669/ex10-01.htm" STYLE="-sec-extract: exhibit">Palisade Bio, Inc. 2021 Equity Incentive Plan, as amended (Incorporated by reference to Exhibit 10.01 to the Registrant&rsquo;s Current Report on Form 8-K, filed with the SEC on June 9, 2023).</A></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.6+</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="https://www.sec.gov/Archives/edgar/data/1357459/000095017021004851/pali-ex10_4.htm" STYLE="-sec-extract: exhibit">Form of Stock Option Grant Notice, Stock Option Agreement and Notice of Exercise under the Palisade Bio, Inc. 2021 Equity Incentive Plan (Incorporated by reference to Exhibit 10.4 to the Registrant&rsquo;s Current Report on Form 8-K, filed with the SEC on November 23, 2021).</A></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.7+</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="https://www.sec.gov/Archives/edgar/data/1357459/000095017021004851/pali-ex10_5.htm" STYLE="-sec-extract: exhibit">Form of Non-Employee Director Stock Option Grant Notice, Stock Option Agreement and Notice of Exercise under the Palisade Bio, Inc. 2021 Equity Incentive Plan (Incorporated by reference to Exhibit 10.5 to the Registrant&rsquo;s Current Report on Form 8-K, filed with the SEC on November 23, 2021).</A></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.8+</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="https://www.sec.gov/Archives/edgar/data/1357459/000149315223020669/ex10-02.htm" STYLE="-sec-extract: exhibit">Palisade Bio, Inc. 2021 Employee Stock Purchase Plan (Incorporated by reference to Exhibit 10.02 to the Registrant&rsquo;s Current Report on Form 8-K, filed with the SEC on June 9, 2023).</A></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.9+</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="https://www.sec.gov/Archives/edgar/data/1357459/000095017023041459/pali-ex10_20.htm" STYLE="-sec-extract: exhibit">Palisade Bio, Inc. 2021 Inducement Incentive Plan, as amended (Incorporated by reference to Exhibit 10.20 to the Registrant&rsquo;s Quarterly Report on Form 10-Q, filed with the SEC on August 10, 2023).</A></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.10+</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="https://www.sec.gov/Archives/edgar/data/1357459/000095012321015721/pali-ex99_1.htm" STYLE="-sec-extract: exhibit">Form of Restricted Stock Unit Grant Notice and Award Agreement under the Palisade Bio, Inc. 2021 Inducement Incentive Plan (Incorporated by reference to Exhibit 99.1 to the Registrant&rsquo;s Registration Statement on Form S-8 (File No. 333-261196), filed with the SEC on November 19, 2021).</A></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.11+</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="https://www.sec.gov/Archives/edgar/data/1357459/000095012321015721/pali-ex99_2.htm" STYLE="-sec-extract: exhibit">Form of Stock Option Grant Notice and Award Agreement under the Palisade Bio, Inc. 2021 Inducement Incentive Plan (Incorporated by reference to Exhibit 99.2 to the Registrant&rsquo;s Registration Statement on Form S-8 (File No. 333-261196), filed with the SEC on November 19, 2021).</A></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.12+</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="https://www.sec.gov/Archives/edgar/data/1357459/000095017023009226/pali-ex10_23.htm" STYLE="-sec-extract: exhibit">Non-Employee Director Compensation Policy (Incorporated by reference to Exhibit 10.23 to the Registrant&rsquo;s Annual Report on Form 10-K, filed with the SEC on March 22, 2023).</A></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.13&dagger;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="https://www.sec.gov/Archives/edgar/data/1357459/000095017022004093/pali-ex10_27.htm" STYLE="-sec-extract: exhibit">Asset Transfer Agreement, dated October 18, 2021, by and between Alto Neuroscience, Inc. and Palisade Bio, Inc. (Incorporated by reference to Exhibit 10.27 to the Registrant&rsquo;s Form 10-K, filed with the SEC on March 17, 2022).</A></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.14</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="https://www.sec.gov/Archives/edgar/data/1357459/000095017022009812/pali-ex10_1.htm" STYLE="-sec-extract: exhibit">Office Lease, dated May 12, 2022, by and between AP Beacon Carlsbad, LP, and the Registrant (Incorporated by reference to Exhibit 10.1 to the Registrant&rsquo;s Quarterly Report on Form 10-Q, filed with the SEC on May 13, 2022).</A></FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 72; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">II-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.75in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.15</FONT></TD>
    <TD STYLE="width: 0.1in">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="https://www.sec.gov/Archives/edgar/data/1357459/000095017022017248/pali-ex10_2.htm" STYLE="-sec-extract: exhibit">First Amendment to Office Lease, dated July 14, 2022, by and between AP Beacon Carlsbad, LP, and the Registrant (Incorporated by reference to Exhibit 10.2 to the Registrant&rsquo;s Quarterly Report on Form 10-Q, filed with the SEC on August 15, 2022).</A></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;10.16</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="https://www.sec.gov/Archives/edgar/data/1357459/000149315223000368/ex10-01.htm" STYLE="-sec-extract: exhibit">Securities Purchase Agreement, dated December 30, 2022, by and among the Company and the purchasers named therein (Incorporated by reference to Exhibit 10.01 to the Registrant&rsquo;s Current Report on Form 8-K, filed with the SEC on January 4, 2023).</A></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.17</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="https://www.sec.gov/Archives/edgar/data/1357459/000149315223000368/ex10-02.htm" STYLE="-sec-extract: exhibit">Form of Registration Rights Agreement, by and among the Registrant and signatories named therein (Incorporated by reference to Exhibit 10.02 to the Registrant&rsquo;s Current Report on Form 8-K, filed with the SEC on January 4, 2023).</A></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.18</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="https://www.sec.gov/Archives/edgar/data/1357459/000149315223000368/ex10-03.htm" STYLE="-sec-extract: exhibit">Placement Agency Agreement, dated December 30, 2022, by and between the Registrant and Ladenburg Thalmann &amp; Co. Inc. (Incorporated by reference to Exhibit 10.03 to the Registrant&rsquo;s Current Report on Form 8-K, filed with the SEC on January 4, 2023).</A></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.19</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="https://www.sec.gov/Archives/edgar/data/1357459/000149315223011066/ex10-01.htm" STYLE="-sec-extract: exhibit">Securities Purchase Agreement, dated April 3, 2023, by and among the Company and the purchasers named therein (Incorporated by reference to Exhibit 10.01 to the Registrant&rsquo;s Current Report on Form 8-K, filed with the SEC on April 5, 2023).</A></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.20</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="https://www.sec.gov/Archives/edgar/data/1357459/000149315223011066/ex10-02.htm" STYLE="-sec-extract: exhibit">Form of Registration Rights Agreement, by and among the Company and the signatories named therein (Incorporated by reference to Exhibit 10.02 to the Registrant&rsquo;s Current Report on Form 8-K, filed with the SEC on April 5, 2023).</A></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.21</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="https://www.sec.gov/Archives/edgar/data/1357459/000149315223011066/ex10-03.htm" STYLE="-sec-extract: exhibit">Form of Placement Agency Agreement, by and between the Company and Ladenburg Thalmann &amp; Co Inc. (Incorporated by reference to Exhibit 10.03 to the Registrant&rsquo;s Current Report on Form 8-K, filed with the SEC on April 5, 2023).</A></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.22#</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="https://www.sec.gov/Archives/edgar/data/1357459/000149315223032118/ex10-01.htm" STYLE="-sec-extract: exhibit">Form of Research, Collaboration, and License Agreement with Giiant Pharma, Inc. (Incorporated by reference to Exhibit 10.01 to the Registrant&rsquo;s Current Report on Form 8-K, filed with the SEC on September 8, 2023).</A></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.23</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="https://www.sec.gov/Archives/edgar/data/1357459/000149315223032245/ex10-01.htm" STYLE="-sec-extract: exhibit">Securities Purchase Agreement, dated September 7, 2023, by and among the Company and the signatories named therein (Incorporated by reference to Exhibit 10.01 to the Registrant&rsquo;s Current report on Form 8-K, filed with the SEC on September 11, 2023).</A></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.24</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="https://www.sec.gov/Archives/edgar/data/1357459/000149315223032245/ex10-02.htm" STYLE="-sec-extract: exhibit">Placement Agency Agreement, dated September 7, 2023, by and among the Company and Ladenburg Thalmann &amp; Co Inc. (Incorporated by reference to Exhibit 10.02 to the Registrant&rsquo;s Current Report on Form 8-K, filed with the SEC on September 11, 2023).</A></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.25</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="https://www.sec.gov/Archives/edgar/data/1357459/000149315223032278/ex10-01.htm" STYLE="-sec-extract: exhibit">Employment Agreement, dated September 5, 2023, by and between the Registrant and Mitchell Jones (Incorporated by reference to Exhibit 10.01 to the Registrant&rsquo;s Current Report on Form 8-K, filed with the SEC on September 11, 2023).</A></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.26</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="https://www.sec.gov/Archives/edgar/data/1357459/000149315224017739/ex10-1.htm" STYLE="-sec-extract: exhibit">Form of Securities Purchase Agreement entered into pursuant to the May 2024 Private Placement (Incorporated by reference to Exhibit 10.01 to the Registrant&rsquo;s Current Report on Form 8-K, filed with the SEC on May 3, 2024).</A></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.27</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="https://www.sec.gov/Archives/edgar/data/1357459/000149315224017739/ex10-2.htm" STYLE="-sec-extract: exhibit">Form of Registration Rights Agreement entered into pursuant to the May 2024 Private Placement (Incorporated by reference to Exhibit 10.02 to the Registrant&rsquo;s Current Report on Form 8-K, filed with the SEC on May 3, 2024).</A></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.28</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="https://www.sec.gov/Archives/edgar/data/1357459/000149315224017739/ex10-3.htm" STYLE="-sec-extract: exhibit">Form of Placement Agency Agreement entered into pursuant to the May 2024 Private Placement (Incorporated by reference to Exhibit 10.03 to the Registrant&rsquo;s Current Report on Form 8-K, filed with the SEC on May 3, 2024).</A></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.29</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="https://www.sec.gov/Archives/edgar/data/1357459/000095017024095432/pali-ex10_48.htm" STYLE="-sec-extract: exhibit">First Amendment to Research Collaboration and License Agreement with Giiant Pharma, Inc., dated August 2, 2024 (Incorporated by reference to Exhibit 10.48 to the Registrant&rsquo;s Quarterly Report on Form 10-Q, filed with the SEC on August 12, 2024).</A></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.30+</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="https://www.sec.gov/Archives/edgar/data/1357459/000149315224038547/ex10-01.htm" STYLE="-sec-extract: exhibit">Employment Agreement with J.D. Finley, dated September 25, 2024 (Incorporated by reference to Exhibit 10.01 to the Registrant&rsquo;s Current Report on Form 8-K, filed with the SEC on September 27, 2024).</A></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.31</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="https://www.sec.gov/Archives/edgar/data/1357459/000149315224050203/ex10-01.htm" STYLE="-sec-extract: exhibit">Form of Amendment to Existing Warrants (Incorporated by reference to Exhibit 10.01 to the Registrant&rsquo;s Current Report on Form 8-K, filed with the SEC on December 16, 2024).</A></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">21.01</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="https://www.sec.gov/Archives/edgar/data/1357459/000095017023009226/pali-ex21_1.htm" STYLE="-sec-extract: exhibit">Subsidiaries of Registrant (Incorporated by reference to Exhibit 21.1 to the Registrant&rsquo;s Annual Report on Form 10-K, filed with the SEC on March 22, 2023).</A></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">23.1&amp;</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Consent
    of Baker Tilly US, LLP, Independent Registered Public Accounting Firm.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">23.2&amp;</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Consent
    of Gunderson Dettmer Stough Villeneuve Franklin &amp; Hachigian, LLP (included in Exhibit 5.1).</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">107&amp;</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Filing
    Fee Table</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&amp;
To be filed by amendment</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">+
Indicates management contract or compensatory plan.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">#
Certain portions of this exhibit (indicated by &ldquo;[***]&rdquo;) have been omitted pursuant to Item 601(b)(10)(iv) of Regulation S-K.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&dagger;
Certain schedules and exhibits have been omitted pursuant to Item 601(a)(5) of Regulation S-K. A copy of any omitted schedule and/or
exhibit will be furnished to the Securities and Exchange Commission upon request.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 73; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">II-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>(b)
Financial Statement Schedules</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">No
financial statement schedules are provided because the information called for is not required or is shown either in the financial statements
or related notes, which are incorporated herein by reference.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Item
17. Undertakings</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
undersigned Registrant hereby undertakes:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)
To file, during any period in which offers or sales are being made, a post-effective amendment to this registration statement:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(i)
To include any prospectus required by section 10(a)(3) of the Securities Act of 1933;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(ii)
To reflect in the prospectus any facts or events arising after the effective date of the registration statement (or the most recent post-effective
amendment thereof) which, individually or in the aggregate, represent a fundamental change in the information set forth in the registration
statement. Notwithstanding the foregoing, any increase or decrease in volume of securities offered (if the total dollar value of securities
offered would not exceed that which was registered) and any deviation from the low or high end of the estimated maximum offering range
may be reflected in the form of prospectus filed with the Commission pursuant to Rule 424(b) if, in the aggregate, the changes in volume
and price represent no more than 20% change in the maximum aggregate offering price set forth in the &ldquo;Calculation of Registration
Fee&rdquo; table in the effective registration statement; and</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(iii)
To include any material information with respect to the plan of distribution not previously disclosed in the registration statement or
any material change to such information in the registration statement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2)
That, for the purpose of determining any liability under the Securities Act of 1933, each such post-effective amendment shall be deemed
to be a new registration statement relating to the securities offered therein, and the offering of such securities at that time shall
be deemed to be the initial bona fide offering thereof.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(3)
To remove from registration by means of a post-effective amendment any of the securities being registered which remain unsold at the
termination of the offering.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(4)
That, for the purpose of determining liability under the Securities Act of 1933 to any purchaser: each prospectus filed pursuant to Rule
424(b) as part of a registration statement relating to an offering, other than registration statements relying on Rule 430B or other
than prospectuses filed in reliance on Rule 430A, shall be deemed to be part of and included in the registration statement as of the
date it is first used after effectiveness; provided, however, that no statement made in a registration statement or prospectus that is
part of the registration statement or made in a document incorporated or deemed incorporated by reference into the registration statement
or prospectus that is part of the registration statement will, as to a purchaser with a time of contract of sale prior to such first
use, supersede or modify any statement that was made in the registration statement or prospectus that was part of the registration statement
or made in any such document immediately prior to such date of first use.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(5)
That, for the purpose of determining liability of the registrant under the Securities Act of 1933 to any purchaser in the initial distribution
of the securities: The undersigned registrant undertakes that in a primary offering of securities of the undersigned registrant pursuant
to this registration statement, regardless of the underwriting method used to sell the securities to the purchaser, if the securities
are offered or sold to such purchaser by means of any of the following communications, the undersigned registrant will be a seller to
the purchaser and will be considered to offer or sell such securities to such purchaser:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(i)
Any preliminary prospectus or prospectus of the undersigned registrant relating to the offering required to be filed pursuant to Rule
424;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 34.5pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 74; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">II-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(ii)
Any free writing prospectus relating to the offering prepared by or on behalf of the undersigned registrant or used or referred to by
the undersigned registrant;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 34.5pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(iii)
The portion of any other free writing prospectus relating to the offering containing material information about the undersigned registrant
or its securities provided by or on behalf of the undersigned registrant; and</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(iv)
Any other communication that is an offer in the offering made by the undersigned registrant to the purchaser.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 34.5pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(6)
That, for purposes of determining any liability under the Securities Act of 1933, each filing of the registrant&rsquo;s annual report
pursuant to section 13(a) or section 15(d) of the Securities Exchange Act of 1934 (and, where applicable, each filing of an employee
benefit plan&rsquo;s annual report pursuant to section 15(d) of the Securities Exchange Act of 1934) that is incorporated by reference
in the registration statement shall be deemed to be a new registration statement relating to the securities offered therein, and the
offering of such securities at that time shall be deemed to be the initial bona fide offering thereof.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(7)
For purposes of determining any liability under the Securities Act of 1933, the information omitted from the form of prospectus filed
as part of this registration statement in reliance upon Rule 430A and contained in a form of prospectus filed by the registrant pursuant
to Rule 424(b)(1) or (4) or 497(h) under the Securities Act shall be deemed to be part of this registration statement as of the time
it was declared effective.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(8)
For the purpose of determining any liability under the Securities Act of 1933, each post-effective amendment that contains a form of
prospectus shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of such securities
at that time shall be deemed to be the initial bona fide offering thereof.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Insofar
as indemnification for liabilities arising under the Securities Act of 1933 may be permitted to directors, officers and controlling persons
of the registrant pursuant to the foregoing provisions, or otherwise, the registrant has been advised that in the opinion of the Securities
and Exchange Commission such indemnification is against public policy as expressed in the Act and is, therefore, unenforceable. In the
event that a claim for indemnification against such liabilities (other than the payment by the registrant of expenses incurred or paid
by a director, officer or controlling person of the registrant in the successful defense of any action, suit or proceeding) is asserted
by such director, officer or controlling person in connection with the securities being registered, the registrant will, unless in the
opinion of its counsel the matter has been settled by controlling precedent, submit to a court of appropriate jurisdiction the question
whether such indemnification by it is against public policy as expressed in the Act and will be governed by the final adjudication of
such issue.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 75; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">II-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>SIGNATURES</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant
to the requirements of the Securities Act of 1933, the Registrant has duly caused this Registration Statement to be signed on its behalf
by the undersigned, thereunto duly authorized, in the City of Carlsbad, State of California on &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2025.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Palisade
    Bio, Inc.</B></FONT></TD>
    </TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="width: 50%">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 3%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 47%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    </TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    </TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">J.D.
    Finley</FONT></TD>
    </TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief
    Executive Officer</FONT></TD>
    </TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>POWER
OF ATTORNEY</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>KNOW
ALL PERSONS BY THESE PRESENTS</I>, that each person whose signature appears below hereby constitutes and appoints J.D. Finley, as his
or her true and lawful attorney-in-fact, proxy, and agent, with full power of substitution, for him or her in any and all capacities,
to sign any and all amendments to this registration statement (including post-effective amendments or any abbreviated registration statement
and any amendments thereto filed pursuant to Rule 462(b) increasing the number of securities for which registration is sought), and to
file the same, with all exhibits thereto and other documents in connection therewith, with the Securities and Exchange Commission, granting
unto said attorney-in-fact, proxy, and agent full power and authority to do and perform each and every act and thing requisite and necessary
to be done in connection therewith, as fully for all intents and purposes as he or she might or could do in person, hereby ratifying
and confirming all that said attorney-in-fact, proxy, and agent, or his substitute or substitutes, may lawfully do or cause to be done
by virtue hereof.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 24.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant
to the requirements of the Securities Act, this registration statement on Form S-1 has been signed by the following persons in the capacities
and on the dates indicated.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: center; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 32%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Signature</B></FONT></TD>
    <TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center; width: 46%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Title</B></FONT></TD>
    <TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center; width: 18%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Date</B></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief
    Executive Officer and Director</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;,
    2025</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">J.D.
    Finley</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>(Principal
    Executive Officer)</I></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief
    Financial Officer</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;,
    2025</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">J.D.
    Finley</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>(Principal
    Financial and Accounting Officer)</I></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chairman
    of the Board and Director</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;,
    2025</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Donald
    A. Williams</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;,
    2025</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Binxian
    Wei</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;,
    2025</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Margery
    Fischbein</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 76; Options: Last -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">II-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>2
<FILENAME>formdrs_001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 formdrs_001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0@)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" !. 2P# 2(  A$! Q$!_\0
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HH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH __V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>formdrs_002.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 formdrs_002.jpg
M_]C_X  02D9)1@ ! 0$ 9 !D  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" #P IX# 2(  A$! Q$!_\0
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MOQP//_@^/O7Z(_9W]!_WW)_\<H^SO[#_ (')_60TUXD^(B:?^M&>?^$G#/\
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M#_@V,N6?#^'IOHJJXFI*5FHM4Y5N(J4*CA)J%54IU949RC"O&A.<(3_.@_\
M!-3X>D8/[2_[?O\ P']MOX]@_@3XB_\ UBF_\.TOAV?^;E_^"@(_[O>^/?\
M3Q%7Z3^3+_L_Y_&CR9?]G_/XUM_Q$KQ,_P"BTSSYX?AA_P#P/$+_ % X,_Z$
M&#_\&\0__1,?FL?^":'P[)_Y.9_X*!_A^V_\? /U\14G_#L_X=_]',_\%!/_
M !.#X^?_ #15^E7DR_[/^?QH\F7_ &?\_C51\2_$U/3C7.HNV[H<,)?^NZE^
M7S#_ % X,_Z$&#_\&\0__1,?FB?^"9GPZ))_X::_X*$<Y.!^W)\?1^ QXCP!
MZ<<#UIA_X)D_#@C'_#3/_!0D=.1^W/\ '_/!!_Z&'VP?;(K],?)E]5_S^-)Y
M$O\ >'Y"K_XB=XHPVXVSAW_ZA^&'^7ARBX\!<&*__"!@UM_R^XA7_OS'YFG_
M ()C_#@_\W-?\%"O_$Z/V@/Z>(A3?^'8OPX/7]IS_@H9^'[=/[0 '_J1&OTT
M\B7^\/R%'D2_WA^0I?\ $4/%+_HM<Y_\)^&?_I<E_P"HG!G_ $(L'_X.X@_^
MB4_,K_AV'\./^CG?^"A_T'[=O[00 ^@'B(#_ .O1_P .P_AQ_P!'/?\ !1#_
M ,3N_:#_ /FCK]-O)E]%/ONQ^F#1Y,OHO_?7_P!C1_Q$_P 4O^BUSC_PGX7_
M /I=#_U)X06BR+"66B_?9]LO7B,_,@_\$POAPPQ_PT]_P41&>X_;O_:#!XYZ
M_P#"1\4G_#K_ .''_1T'_!1+_P 3R_:#_P#FDK]./)E]%_[Z_P#L:@N'-LGF
M2*6'.%C.YVP"Q"J<9(4$X&3@$XP#@7B;XI2:2XTSAMM)+ZOPO=M[+_DW:#_4
MKA&Z7]A83648K]_GJO*4E&*UXC2O*4HQ6JNVEU/S._X=?_#C_HZ#_@HE_P")
MY?M!_P#S24?\.O\ X<?]'0?\%$O_ !/+]H/_ .:2OTI-];J\<<LB023,R6Z7
M$D<37+(F]A;*S;IRJ?,1&I(7YB *KMJ^GJ]Q$;JW,EJ8EGC%S!YD+7"![99H
MS()(3=9*VWFHGGNK*F< G&7BKXE1BIRXZS.$)2IP4IT^%81<JJ3I1O/P]BE*
M:DG%/E?*^9\L;R50X(X4J6Y.'\/+FORVGQ#=J-7V$FD\_3<56_=.:3@JGNN=
MVK_F]_PZ_P#AQ_T=!_P42_\ $\OV@_\ YI*/^'7_ ,./^CH/^"B7_B>7[0?_
M ,TE?H]-K5A;S1V\\R0W,REHK:66&&>8["X2WBGEB>[=@" MH)\-A6*DBI%U
M6S9YHQ*@>W,8N(VE@66#S2!$9X3+YL/F@AXS*B!X_G4X!P/Q5\2DI-\=YBE"
M<J4VX\(I0JPC*<Z4V^ 4HU(TX3J.G)JI[.$ZBA*G"=2"?!/":DX/A^@I*,9-
M-\2).$JCHQJ1D\\5.=-UE['VL*E2DJS5)U(U)0A/\W?^'7_PX_Z.@_X*)?\
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MBH#,N?OJOMR3^/RFD\Y?^>B_D?\ XFM+O_GW5_\ !<@=>DFU[2GI_P!/(?\
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M']AF,N))2RG#X>GAL/4G@\$^(7+"U,RD\9A5@J>%I8W,\-B95\MVZ*I?:?\
M:'_?#_\ Q-!N2.A4^Q60#]$-?IOM%MK]S_\ D#\G]I3ZU:27=U:=O_2B[15'
M[4WI'^4W_P ;H^U-Z1_E-_\ &Z?.NS?W_K /:4?^?^'_ /!]+_Y(O451^U-_
MTS_*;_XW0+OKED&.P$G0'G.4R*EU+?9D_3_]D/:T?^?^'_\ !]/_ .2+U%4C
M='J"ASV*R >O!"9/Y=.:3[4WI'^4W_QNCVB[/\?_ ) :G3?_ "]HKUJTU\]]
MGNO(O451^U-Z1_E-_P#&Z/M3?],_RF_^-T>T79_U_P!NCYJ?_/ZC_P"#J?\
MF7JH7V<VWW-OFMNW]<>3)C9[YQNS\NS=FG?:C_L?]\R__$5!<,ERFR0[1SAH
M_,5UR"I*L8VVD@D9 S@D9Y-#<)\J<W!*I3FY14FTJ=2%1JW(KWY.5J^J;74E
MSI-<OML+:346YU*<XQBY14I\JFFY0CS3IJZ_>1INZM<_.7]M[_A,!\3OV+F\
M$0^&)_&2?&O77\(1>,KF_L_#+W8\!WWGC5[C2+'4-8C0 /Y1TRW>YD8F-=J$
MM7PO\3F\7OJO[:K?%2+P-!X_/[3/[!AUN+P5/K5SX$75/^$-\$C2?['F\36U
MGJKW+:1_8[78N[:.X346N(XM]JD,C_ORUK:.\;RQQW#0NTD!N(A,UNSIL)@=
M[<O#A>!Y3(>@8D9!@;3-,9YY3:6PDN3$UQ(+=/,F:W0);&60VQDF-J 6MO-=
MQ [,T8&0!^6\1>'M7/,7G..CG52A/.<=A,4\#7IU<3EV#A2X>PV15*=.A!TG
M4C-T'B:\(NE]:A5Q%!.E*LJL?VGA#QCH<,9?PO@)\/Y=CO\ 5S"U<,\;5S##
MQS+&<_B7B>/U)8Q8>JJ%&%'$?V53HNAB)TH0513J*3HP_G\^,-_X'TRZ^.TG
MQ3\':?XQ_:GN?CUJ2^%]/UOQ5XL\#>.+;X8VEM+<?#_4O@-JFC^'/$$FJ2QG
M^R+0:?I%K ]W/JMU+J5_ VE^5<>YVMW\=I_CW^T[<> =+^%5AJ=U\)O@A/\
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M94:^%PF8YO@*DN?'4Z]/9^.64PXEJ<5T^$85L?5RBGEE7 5N(,OIX*#H\?\
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M !%'VH_['_?,O_Q%'M(]_P#TK_Y6'M*7_/\ H?\ @ZG_ /)%VBL][IN,/$F
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MRA]*3QZC"$)<?59.G3C#VDLDR.K4J<J4>:K/$X&K>;23;@H7;;E>ZM^F#_\
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MK/S_ )1U _0?7^AKHA]'3P@NG_JC2[Z9QQ%V_P"QNRE])[QT;2_U\KI-Z_\
M"%PUY_\ 4J\C]23_ ,%2]=XQ\#=*;_=^).J<?7_BAQ^'XU&W_!4SQ IQ_P *
M)TSIW^)>J*?R/@?^M?EKV?\ [9_^AFL^4#R^G\/_ +(Y_GS73#Z.G@_)V_U1
MI]-\YXBZV[9LC3_B9SQSZ<>XC_PQ<-__ #L/U2/_  55\0 D?\*'THX)&?\
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M_P %@/$<<4S6O[.VBSSI&##%)\5]1A6:; WQ!_\ A7S?=.0&"MG&0.:\L?\
MX+C>)HBZ2?LOZ*)HY?)D3_A<FLX#8SG<WPO'ODGKCK7YFW/(0>K'_P!!/Z5Y
M/XYT#S#_ &W:1J@4&.^C7)D89 %P!@Y0D@;R>_;%>UE'T7_ *KB/J^/X%IS]
MKR^QJ+B#B>GR26CBTLWLU-N-G=<K6KU1Y^9_24\>J='V^!X]Q$524O;0>0\-
M3YD[.+3>5Z<J4NCO?I8_863_ (+E>)E4'_AE_1#EL<?&;6/0GJOPP)[=^/QQ
MF+_A^?XD7[W[+VB<]/\ B\NM'^?PO-?A*^?,P1QD\G!SRW.1UXP3CC)]:CD
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MRO-,V56,HX"I%4(87)\=SSE9^TA"$4^=2/U;_P"(FWQ5_P!&7>%O_$D-;_\
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MTEELTIQI86SI1J3;G4@HR:E!R_2K_B)M\5?]&7>%N.#_ ,9(:WU]/^2%4?\
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MC=ZVUN^G:3H=Q</<P13]=XWN/V]M(\/ZE\)?B9IG[:&@^&M:T;Q+X]E^&7Q
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M_8+\&:)\0_V>;GX^^//&.C?MC?%?]H[Q;\1_B5J'A30M=\.6&D:YIFM?#_\
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M)!XN\0*=(U+3=#\)^+/#OA.XFUJ-#K]C;^,-(\;:=&UM':W5E<VLUQ&?5_\
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MV;2H2EEM:<ZBE[F'C)\RI3DU9P6C3LG9Z[O3HNSC&/.Y/#1]?=B?YU5;J/\
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M "+C\4?7]&1=G_[9_P#H9K/E_P!7_P !'_H$E:'9_P#MG_Z$:SYON?\  ?\
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M'#[K8SZPLM4<)BE/+,'@:.822^J5<_GB5!S48S_9?1/VC]$T+XC:;H)_:/\
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M_P#1=3_\MX_^!?\ HI:@G^]+]6_]%U]+'XH^J_4Q*'=O]YO_ $(U7E_U;?\
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M0HP0W$ ,:LV&N8II8I)=H+*3?V\:+J4D4"O$([Z[C:\AB: K,D+8?]T_!/\
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MXR^(.M>(?CU\3W\8Z_X[_9=\37W[05I^S=\,8O%7Q4\ ?";1-;L_BI\$M?\
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M7ON,Z=2G3C"<ZM.?-2C3JS5&A4<W&*Y*^(:PU.23O5;E)0P\9XF%.7_5_P#
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M)7^U90N\_*W)7[3_ ."=&QOVO/ &P(WV?P_X_=EA(=_W?@_5OE 1BV<LH&,
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M;.[5S2,Z+;7MZ*T_F;V?HB$D'H1U'?W%5)2 PR<<=_\ =CJQD#^(_P#?1_\
MB:J3.K'<""/7*=PGU[YZ?R%==+G3=J<G\UYFL9T8IKV])W=_B:Z6ZHBD(PO(
M^]Z_[+5 Y!4X(/*]_P#:%.DD0 <@?,/X@.QXR /8_A4#2H5(R.H_CST(/0GV
MKNIN=E>G+=]C>%2ER_QJ6[^W_P  KKT'T%0=V_WF_P#0C2[T'\8'3C?CL/8U
M TB98;UY+  ,.^?]GD_4\GK77%2LER2V79E>TI?\_J7_ ('_ , I_P#+>/\
MX%_Z*6H)_O2_5O\ T73RZ"5"2 !NSEE'6,#GYLCGC@'\L5!+(FZ0CG=NP0<Y
MR/8D]?4#KP3@5V1A*\='NGMYV[_\'RMJ='M*7_/ZE_X'_P  IDC+<C[S=_\
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M^;3TV2W_ &?BF?[7^-QYZCPM\,^<G(Y_M\9[?Y-5?LO[/W_06^-W_A*_#/\
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MW_9W))_MCX\#)/ T'P* ,GH,^-" .< = ,#I5)K?]G?[K:K\=UW=2N@?#\G
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M-QC,\*.L1D96<$ QJTB^WZ?^P%\=QXGM-,URW^&^G^%1X1\!?$*_^)D7Q?\
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MD\/FY=-0OEOXREM>7\!%]Y/E$J+CQW]M#Q3HNO\ Q0T<Z+XAMO%/B#PC\*O
M7@_QYX^TR^ENE\1?$+PYX1EL?%>IV&OLUI=ZG!:S72VW]HV\TL5_>S>9]HE-
MM+&GF4G@/1KD+*MW<2;&Y=S9L00S29 =6.\,[L6.3\Q7.T "F_@'1A L0N[M
M45@%C5;-D16;=Y<>% 5&.?D4;>0,9.:^MR/A+*LLXB>>XG,E/+WB^*I8'):'
M"E/"UZ&&XO>4RS'*\WQ='$RAC<NPD\EPU7+,(\/3P]*=656I&M)1BO*XAXKS
M?.^%)<.T,IPM3%O"<#X?&9YC^+YXW"8Z? #SO!Y7F614\72Q"PF9XS_6:MA\
MTS&G)9A7^J48RQJ4+O\ 4;Q9X=\)>*/C-XEU"XL/!?Q!U'PY^QY\)9?#^BZM
MH7@[XA:P/$6IN-/NKW0='\>7^E>!-2N]&L[EKS58_$D^L0:'I"+J LI<M92>
M>^.--^$OPUU+]K;Q9H_PN^!>KZGX.^%/[*_B+P3H?BGP3X!\4^%M%\:>([36
M%\72Z1IFERW.@:9,I2";4=/\'ZDFB7$T,-_IZZ@(3(WYWMX!T!R2\EW+F<K\
M_P!A96G)+LY1XF'F.Q)D8@E\E9&*Y%9P^'.DXP\UW'E)D5MFGP^5Y^?.*R-;
MRK&)V.9<1L)6PKJW6ODLJ\),%@ZF!J_ZZ9C]5PN6Y!A,1E#PF9Y3A<1B,NS7
M*LPS:O.."S_ 8:=7,,%A\PP^)E3PE*K)8VK&K6E32<?N<7XP5,9A<QP^'\/<
M)1KXO-N(,PHY[7S7*\TQU.CF^35\MRCZA#&9+C<7B88#&2P6(I4ZN-Q$*-7"
MX64(1DYQJ?JIXO\ !FD>!/@YXEA\'_"K3](LM7^ ?P/B\;ZYX,\-_ K0M=\$
M>%KNU\$ZW\</%6L>)I_$-I\<_%-CJ^@7-]9^(['Q;\/]%D5)7U&VCM;=(=4$
M/Q7M_A3\.+ZV\7Z9\$_@IX)\$>!?C1\(W^&?Q'N=2^$X/B3PO+K45OJFHZ/X
M7\)>'K_7/'FD1:#+=>*=3G^).K6EUX7U:.RUB*;^V='N8K+XM\1_&/XH>)-$
MU[0=6\7QS#Q7X3MO WB/7[?P1\.[#QYXB\/06MI92Z-K?C*'P?:^)-3MKFRT
M^QT^5+W5+BTGL8(X[BTG,-M)!\Z2?#[1T+S1_P!IQ.Q&8@UE&8?G:62W%S%9
MVD<H$C--+&@9%>>0N 9VW^+D'A)C4J_^N'%\,KC#'8S%U*5',\WQ2QV25^6G
MBL56Q%?BC+73K83!/^Q\)/'8?%Y91RO&XJEF2CCJU*;^JS_QCPJ6%GPAP;AL
MTQ3R_ T/:8^EEG#=?#9UAJ$Y83+Z>6X?A'&2J8+&8]?VS.IAL3A\YS''X.AB
M<LS+ 8/"5\'B?TO^+^C:GK7BW_@HI!XI\/>"M'T&Z\ >!_%'@W4_"&E>$;"R
M\1W,_P 3C+\,/%&KWGA2ZNGU?Q3=W5_XBDN=4U64ZU>1);R7ODPJEL?SOTG3
MX=,LK2VA(Q&H+.%*AYE!WS@.I8/,PW/OW,2>1SBNJT'6[OPQX"UGX<Z*8;/P
M[XL\2Z/XD\0*(T@U37;[P_8W5IH^EWVJ0%47P_I!O9]:73V1A+J?EW*,ISG(
M!#X);>"/O;2F2><[?X=V<[1R.AQ@U^I<#\,X[AG!9OE]6MA_[-KU<@HX&.#5
M:EAZ]/)^$<#P_B,>\/6Q>.J4*V9YAAECL13ECL2WB(NM&M[*I0I8;\[XOXCP
MG%6-RC,J=Y9K1H<08O,W5K8?%556SOBOBOB++J$L7AL#EE+$QRO)*-+*,+5A
ME^#2P6&I494'4I5Z]>O)]X?3_P!EC_QJ,]5^O]#4DGWQ]/\ V6.HSU7Z_P!#
M7Z8MH_X?T9\CN[O5WW^2*'_/3_>7_P!&M51.A^O]!5O_ )Z?[R_^C6JHG0_7
M^@KMCO\ +_(N'Q?)_H0W/W5^K?\ H#577H/H/Y58N?NK]6_] :JZ]!]!6]/K
M\OU.J'7Y%)_]8WX_^AO44GW#]5_]"%2N1O;GU/X;WYJ*0C:>>Z_^A"NJ'P_-
MFA3'^HSZ;OYMD?D?3'(S[\[KVJPZ38S74[9>,9@@!.^5F' 0=24_B'ISCK6\
M\J102&0E5CA>9B!R54$MGN0.X[CCCDU\_P#B37VUV_\ -CREE"&CLQDA5=/E
M,Z\X$D@7<[#!))!Q7MY/@'CL1&F]*<5SU+VMRJS275\UK-JUE?6[1YV:YA'
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M#X?FRBO0?0?RJ#NW^\W_ *$:G7H/H/Y5!W;_ 'F_]"-=4?A7HBS-_P"6\?\
MP+_T4M03_>E^K?\ HNI_^6\?_ O_ $4M03_>E^K?^BZZ8_%'U7ZG04.[?[S?
M^A&J\O\ JV_ZZ#_T(58[M_O-_P"A&J\O^K;_ *Z#_P!"%=E'^(BZ?Q/_  O\
MT57SM; !.TX!Y!.#P1Z>M:7A/QEK_P //%GA3QWX4UF;P[XL\">(M&\9>%M=
MM8;*671?$?AN^M]5TC5XX=2MKW3IO[-O[2WO!#?6L]HPAQ+&R9!SCT/T->R_
MLV_#'0?C1^T#\&_A/XJ\1R^$?#7Q%^(7@SPAK>N6\FFPZG:6&N:E9VT\&C7.
ML13Z1;:WJV_^QM"N-5AETVWUG4M/EOHI+595;P>,<RRK*.',^S7/8JKDF59!
MG>99OA_J]/%RQ668;+L55S##?5JU'%4,1#$9;1S+"U</5PE:.*HXNKAI2H0K
MSK4O>R'"9EB\XR6EE<Y4<=B<ZRW"8#$TVHU<-F,\9E\,%7I.4:D(U:-?&T:E
M.4J511G&+Y=+/UO5/V__ (V7/B'PYJW@OP;\"/@SJ7ASXI6GQGUJQ^$OPDT+
MPO!XZ^).DV=]::;KOQ&\_4-:F\16^FV7B'6X[#PZS:1H%JGB?5;C2=+BDVW%
MKY_XL_:Y^)_B+PWJ7@C3O#OPU\$?#^Z^#'BKX#Z;\/\ P/X=UC3/"GA[P/XW
M^(GA?XG^*[S0K75/%&MW\/BO6/%/@[0B_B#5-2U22QT6U30=,MK+3;?3H+']
M8?$?["WA'QQX!_8S^&NH?"#]HCX86/A7X2_MO?$;5_ 7BG4?"<7[1FHW6A_&
MKX=:3H5MK'B#PY\$]0N=6T2X?6K;4[&VTGX">*O$VG>%;J);*SNM,2YUE^&^
M(?\ P3S^#WAO5_&WP%\-^!?C-XJU[PS^WW\$/@IJ/Q?B\7^%%\0>$_AS\9/A
M/\.?%NDV?C'1!\(=.TB!=2U'Q1<^#O"[ZCJO@2TUWXCW&F:I97<D\T7PGUK^
M,,C\8/HRTZ^&P4O#^. Q6%K5XRPU')EF5+ Y/AN+<ZR7!9U/-*?B$J<Z_P!3
MR*C5P_)C,\Q>582>$R[).(L9A*4,OH_T!BN"/%G]_5GQ+BZ>'Q$,%5C2E.K0
M^O8]8*CC>5T*.!P<-'CE34U1I3FU*5?WU&:^,/A__P % OB=X=^-.E_%;X@>
M'O#'B/0Y_C#^SY\9?&7AOPUIUQX;O=5U']F_P1<?#OP'8^'-1^W:[9^&;>Y\
M-W%S'XGN;_2[VX\3:G>R7%S<Q0R3"3S>7]N3XH3:):^&=#\#? SPMX"L_@WX
M\^$R_#_P;\+I?"7P^M],^)?C/P?\0?'/BO1-&TGQ+#>Z1X\O?''@'P9K5K-I
M^HVVGZ$/#.C:=:^'+/2K$:?7U[\8_P!B+X7_ +.7[3'[!^ES:=\2]>^'W[1'
MC;08?&/PT^(VK6$?C#3;K0_CW:_#+4M/F\0:S\'? 5N=#U[1KWPU>7_A#Q%\
M'-#ULP6_B?3HO%*Q7EGKFC^F_$O]CSX9_'O7_CC\;-1L_C]H)O\ XB?MY6_B
M#Q[8^*_A?<_!?]G*?]EZ^FM? ?@[XF6UE\$_"DZ-\3[V*2R\"Z"?$WP]N?#V
MAW>CZ5I%Y\0[JSU&[ONC_7'Z,T<5PQQ)6\.ZN+R#/.&J>(R_.I8?$TL!EKPG
M&4^#\)AZG"4.*W3>94*V1YCB_KU+&YGF/)D6597PW7S+.\\PF2XOHP^2^+/U
M7-LF_P!9*T,\R_/YX?&8>GB*G-B*>8\-X;.82<E@YU)TY>RJU'2:A2EB6Z^)
MIU)QC.'P!J7_  4$^-5U\1?!WQ.MO"GP2\/^,M \?W/Q-\0^(-)^'"VLGQ0\
M8ZAX,N/ >I7_ ,3WN=9OQ?:;JGAC4=8M+[0?#0\(>&/[3U[5_$ITZUUV8:S:
M\K+^V[\5;SP5H'@C3- ^$FF/X2\*^'OA]X&\=:7X1O-2^(G@?P-H'Q%O/BCX
M/\!>%/$/B3Q=XCTO3](\-^+I)/\ A'M0U+2-2\9:E8/+HMUX@U33M0U$7/T1
MX:^"_P 'OA9_P4/_ &,?A)X.LOB)KDB_%;]B?7/BK;_%2]\%:[I.OZC\:='^
M"GQ2N=$\'Z1H/A;PU(/"<&D^-KC0[C3O%;:EJ=W<&6WE5K"WO=0U7['\0?%'
M]GCXE>/?B%X!\476L_&_Q%\+OA]^WYXD\>_$+P;\&_!WP)U_PO\ "Q?#WA_3
MM!^!O@U;G2_$VAZ[KGA;7= U36=$^*GC3P[KM]HUSJUU::3I,MA-+#7I<3<8
M>$>1XOA..2> M#BK(\7PG5XMIXV-"-"EEN$J\>YGPED[> KYGQ+@_:_VI&5#
M!T,=Q'@H8B>:91DN&RFM7CB,BX3RR;)>,LSA5PN-X]Q.6YCC<\J\'0RS&5L1
M4J8[&U<FR7'5*5Y46G.6$S6E"5J+4OJTY\SJ<LI?E5\=?VU/B7\:?"[^%-:\
M,?"3P5X>NOBWX@^.FIP_#7P9+X6;Q%\6?&^FMIWB3Q?K"7?B;5H=6D\1RF\U
M&^T^.T-CIFJS7VHKIM@;MH![-XA_X*G_ +2.L:CX9U&_L?A+9W/ASQ[=?%*&
M]B\*^*KA+WQ=J?PYUOX276I:@NM>.[_3],M7\(:Y<P6GA;08](TBUU"RTG4-
M/TBW:U^SR_67[/\ \+_A]\(OC+\<OA'X'\%:5XJ\ ?%G_@G)XA_:4\/^(OB[
MX>TGQ-\;O!%EXW_9NM_B';>"+'QEI]EI'A&&VC\1ZC;S:UK/A_X<:-J%Y/80
M)"MA#'\WFO\ P2QTOQ)J7A/XW6'AKX1>+_&.IW?B7X3%OB/\(/!_PE^+?Q5^
M'$!?Q),\FO\ P7^*>F:C<>.O@+K5Q';P?$8^&-5\.:ZQT[2-+MM<TNX\0KY&
MF?<2>#E/@?B;.\/X*Y%C^'.!'PKF_#<<WQF'RQXW ^*. K8JOFF-EFF=XRIE
M.9Y9CN!\SR[.,HJ8_B#'YA_9>%JY;6RZIA\-2JO+\MX^Q.=Y9@'QMC8X[B:K
MG.78JLJTN>O/A##QC0E4E3H4IUOJV'SS&5J"BH1BG/GA-M2A\>>$OVT?B?X2
M\,^'OAHVC?"GQ-X$T7X3> ?@[HW@OQMX$34M,UW1/A1\1O$7Q1^'GBS6+:'Q
M!9:W-XN\ >./&7B.[T35H+JWT>]M]<OM/UCPYJ%N]R).-\5?M6?$[QOXZ_:9
M^)&IW?A.;Q7^U+X9\4>"?B,EMH]Y]ADT3Q9XS\'^.]1NO"NGW.NSSZ#=Q:GX
M!\.76CWC/?0:?:PW]O;6RQ741MOV]\$_LR?#3P_X(^/G[/7CSQ5^SI+\;/VX
M/BU\<7^'5OX8T?4M-U75/#GP=7Q;9?! _LXZ*Q\5:=HFD>,/CVOBNQU236?%
M&F60\,6C>&K35M8U701?/%<>!/B#%X(^ UO\6/A3H6D?\$]+C_@E7\(/$/QN
M^(.O?#WP;X?L=$^*4O[-.MZSX5U_P'\3VTJR\3V_QCOOCC_PK72].L]+O]?O
M-3NM2*&SNUNCCYS">-G@WE>9XRKP_P"$^3K%XS'58PS'&YO3R"IQ7DF25.$N
M,)YSPE1SO!8*?&.8YGXA57E&7Y7@G6JYYQ1P/3IX[-J.*KX;*LN]O_47C^M2
MRS$KB[,ZU+#3RO&PE2PU;'X;!YK.IQ%EE'%U9NG46&H/AW#T,QS/$RJS6&RC
MB#&8ETXQ:J/\R?AS_P %$/&/A+X@_!7QK\1_!7PX\:M\,_$7P)U#QCXNT#2/
M^$<^+OQ"T+X!W-[)X&\+:_XSU/6-6T.V73+"[FMFN=&\(Z7/KLT&F3>*[[4&
MTVRN;?SF/]N#XK:8-&\.0^ /@#X=^'NC_#3XE_"[5?@CX<^&EYIGPD\5>&OC
M/JWA_P 2_$F75O"VG:VGB)M1\2^)O!'@SQ';ZMH7B/PU)HJ^ O#]EX>&A:/9
MW&D3^[?\$X?AAXM^&/[=?@GP]\1OAY8IXE\/_"?XC?$*Z\%^.]!L-6TV_EO_
M (#Z[X\\%RZYI/G76F/H6L:6=&\011[9+U;:_662ZT6[\N(_7OA7X=_LW_M5
M?LL^*?A%^R1\+O$?A;P]XW_;&_9@U+Q%XK\=:;%)XU\+W?QATWXC:QX[\"Z7
MXEMM'O98/A-\(? ND1>%O"FH"TLUU:WTR?Q/JWB&_BU0@?1\:Y_X%<#<8+"+
MPNP^9</3PG >,S7CW+L0L1PAE>$XFSSCS'XS,7AL!Q-5P&"SS+JG#>/Q>58W
M!8;&9IBX8_%9)D6+X4JY7B,?C^#(,'QOG&1494^-L9A:^&EF^$PF5XW"QP.<
M8K%95@>%8Y?@J4?8<U/+*&59C.OC(RC..6973P.<5JE:GF$(Q_*_QS^V?\8O
MB->ZK?:WJO@C1WOOB!\)/B19S>%_#,FA:;X,USX'^"X? GPR\/>#[:2]N-&\
M/^$?#GANWM])G\,R27@N;ZTDU"YE;4I[V\N>T?\ ;[^+&H#Q1,? 7[/.I_\
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MY7C.(J%?%O#<*4/[6H9%E57&XW.\)2Q/%,,3' UL?">&HPQ.%PF83KU*-*6
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MCZ\L/#,JKQ,,'"M]7JU94G7G0I6J.-"7+R7E/E:CS>RJ2I_GLEB")V6*(QR
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MA8>K3JXB&#Q?$.:QRZ:K4I8'"8RMAJ:E&1ZIX#_:*^/?PFT*?PQ\-/C'\0_
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M4?VA)[Q-&\%6OP2BTOX6_'S4_@=J.E7D+"7Q\L&IW6GQ:W'-]N:STBW1=/\
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M:P^'YLK3_P"K/_ O_0'JK5J?_5G_ (%_Z ]5:WI_"OF7_P #\T9]Q_\ $_\
MM*H4^_\ \!;^:U-<?_$_^TJA3[__  %OYK7IQ^%>C_0Z7N_5_F4I/NM_O_\
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M KF,1;RB(FU(8MFT@G!2+: <L-H4J=H8_,[&OE[4UD7QI\0%E^^/%2'[RO\
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M^MV4Y_O#\/\ T8:C[/\ ]L__ $,U)/\ >'X?^C#4?9_^V?\ Z&:ZX_"O6/\
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M9-)<<9TGY9)PF_SR;T[LTAC\ W_R3W#6W7..+.Z_ZGIZ[_PKKX6_]'*> O\
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MW<:1*I^&7[1)&V.*6$,Y_P"%6;I)62>?S))&9I3-+YA<.17AWFW7_/<?F/\
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!V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>4
<FILENAME>formdrs_003.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 formdrs_003.jpg
M_]C_X  02D9)1@ ! 0$       #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" %E IX# 2(  A$! Q$!_\0
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M/*J9:ZC53E?L^656$K)*2A)1;3;ULW;5<W5)K5</9RM" #P@P6/L"QW8')Y
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MJIU?5I996 "X#'KC<<#.!SEB%('//3'3Z4^,GC?4=9N&MEG\S<9$*19!ZY!
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ME/M?LOO/CG2JN@YJ$G'EMS;)M**?GNGTW/.FADB7!);Y&&!_"V]<CD]<^^,
M<Y//-OI\[N6SLR?N\9XP!_%W !Z=Z]#>PN,LK1MU+ A3P"26Z]\$<<C!((Z$
M0?V1<[%<1E@<]4;. <$GKU/'7^E;)IJZU6UUW_KR."=.<8IR@[-I;I*^K[^1
MYBMO+;3[MQ9=V<CH3SD#U)/(.1@C&>Z]9H]OYK*"JDE\$.IP"5 QR<9(&1G^
M$_-G-:3^';FX8*D;$NP& KYR3DX./Y\XQD]Z[30/!FJ(_F^3*X=D;YN J@?>
MZ8SR,'T;MD5SXJK*E'EVNF]UWM??I:_KW.S!4?:R_O*5EY:7\D_^!YG2:?H<
MGEP+& NY48*@^;(#<@XQN(X) R !@D@&N]\/^%+FYF4E7X4@@X !RX&/FZ=0
M<^AYY)KNO"/A<M' )XUR& SC@ *@VG@8.=V"3A1CGEL>XZ)X:LX"Q$2@ #()
M')YP<$9ZM@]P1C&1S\?B<3+V]7_'TMVC^?KOYGVV79;&:BEK.VL5HT[O=MVV
MM;5WO\CS?1/!KE54P@'( V@!L[=V2<X'J03N^\<]*W[CPVT;[&A8 #C@=#SV
M89ZDDGOZXKUZUL51VCCC4!#C<H[[B,@$9Z<$YP0""#QB]<:;;!\R1]<<#! )
M&3U&#Z9'H1ZUZ.5XQTTNDKW46[7=G=ZZ*S\^QZE;+*?*X77,U91;WU3]%MU?
M0_+/1O">EVNJZGJVHZ/<^(O"<.MZKHUA#H3))>->07-Y%;K)IT4_VG;=)!&+
M69)3&N9&<.H*KV/AJ+POI/@.T3QAXCMM!T;4-:N]:T/0;Z&5KJ'4=.M8+JST
M[43#;S7+6IN96M[GRYX@N8U,BE7+W/#=^D?PY^W0:4FESZ.=$N)KG0IS'?ZG
M*U_/':C3+A&CG@OY(IWN+@HZ2NBL'.UCG(\/:Q+:>,M5L-,U"YATO1=.NKCP
M[X7^)ND7&IR:C]OA6[UJ&T@<7,7FW<BI#%,^W[JL3M -?VS0PF$P3PJIPEB*
M^8T?:\TJ%6/LD]+5)U(6OUO'W=5U9_!CJ3::<E'NVG9.Z>OG97>QT'AW2-8\
M2:O)I$<^C:;X>U73--U^QN?"<]GJ[>'#I*316RW,MZ;J33K)[BR:]N)+V&>(
M37]UY4L63%#XUK=W>:M\0]0G\9>,?#>@ZMIEG;1P>)M!M[>_T>[DLK)H+()'
MIK7L#R31JJ7DDKL);MBX\J)FBKZ#MO!VEKH2V.K:!HVC^:^M->Z9=:O'H]Z+
M6YT47\-C:NBO<2?9;BY%W''(ZP 7$2*BO\QX]HO"EOXJU7X<1>']*L= L-(T
MRYFU*ZMUOIK\:E EPTK21J1(97U&)I) @7?;%R%\D[>S'95*5'"X>4*:G*O*
MI3E&$K>]1M9Z7;5[Z75]M=3T,#B&O:0YTVX):7LO>_X;M^9]^?\ !-/PA\.?
MCC\0M1TWXD^"_"/QX\=V_P &?CG\4O@M\#_B##<76C?'+]I;P'X,O=3\ ^!]
M4T.QFTZ#7].MK6\\2>([/P)&;>/QM/X:T+PI(NH?;+O3]8_1K]EG]GS1/BUX
MB_8 \8_MX?LD?"?X4?M-^+_^"BMW\$_"W@W1?V>]$^!VB?M%_LRZ-\$-6\>^
M.+WQI^SMH.F^&_"_B+2_@]X_31/#UA\3;+P-HLFHZ7>2>&M6O_$6JO#J5M_/
MZ=.\1Z!XGT.X\)Z:^B>&8[#2]>\+7+ZN^EWMKXHT^73;J"]L-4LG6_T744EB
MENK?2+:2"W:T$UY'_I:+G9\;^(OB+\:KGPYX]U;XB>+(_$NF7T-SH/BZ_P#'
M?B75==T6WN8H%-OI>I3Z@^IVZSW,\B1VMO=P-9_8)<(OF29^)SK@K-LSQUJ5
M2$'3PU.*C)5[-1E6^%0E&-I*>O,N9.,=TERZ24I-N5=Q7]UR4>^MFKNW77IV
M/U_\6_L5?"W]K_Q=_P $H]"1O@QXM\+?&.Z^+_Q@_:7_ &TO@)\%=!_9+^$G
MB+]D;P'JFDZQX\^'_B'P;H']@Z5I7Q:^!OACPA\1++QQXHUCPQI/B31E\;^$
MWUF/6](BCU*Z]8UO]D'X5_%__@HA_P $_?V@]'_9Z_9OLOA?^U!X=_;5^$_Q
M8^ /[-]YX0^*'P(\$?M'_ ;X'?&/Q5X(\+P0?#]-7\-Q^,_$WPI\0_!KXB6-
MC87=SK3>-?#GB2ZT6UB@@M8X_P  ;GP]?2QV_AZQ\5>(M)O+VWUG3M M?!^O
M^*M(TDV>JP16OBV[.BK?1:9$NIZ7Y&D>*;J5(TUFSB6TN/M=M&(A<L+7QUX&
MN)K?P1I'Q#UKP]:7]KXE7Q+I\WCKP_>:?X@O[!/#VK^(-&MM(GCU6>Y&B&VT
M%/%>G317VH>'Y9K%9S9R&WKY'&\ 9CAW"-;%86E+FA%>TJ/5\[YN9.?-&\I1
MNGJDFMVK:QYDHN.812BHZ.4VW%.[B]?M-+KITW8_]B#X >*O#_\ P4#_ &!?
MA%^T9\&/%_AFT^(O[3/[+EIKGPW^,/P_USPF?%O@#QK\8_#WA&_:Z\)^*-%T
MN[U'PEKVH66OZ'=ZG+I=YHE_#8:S9)=LVB74EW^Q&N_"34?B'X;^(/B?]K']
MC?X7_ 36/AQ_P4C_ &9/@[^R5XMT/]F?2_V7K_X\^ O'/[0>M>%?BA\(+_PI
MH^G>%O#WQP\!Z-\,;.Q\4#QG;>&=1U'0YW6#5_$.IQZQ_9\OY&>/OA3\;OB]
M)I?Q)\/0?&KQ;\1_"ES9VFJ:Q>V?Q*NM6T]+.YGUS0]5\%Z_XGEO=:TZWLKF
M6]N((](>W2WU":^N8'@N+V5Y?./''A;X^V_A'0?&/Q:^%?[2NJL="G;PSXS^
M(VI?$.X_L2_36)[F/5_!TNM7MQ<Z39I?(CWD6FQV\L4SI<L%++(?+Q_#&:4I
MTZ'UG".%*$W.<*[2480<FTN9MJRNTUO?N==64\7"BHXRG^[BT_>J*3E9*ZL[
M-+=J75M]=/Z%O'GP6T?Q9_P5L^"WP*UO]GJ"[^"B?%?]O+PUX;\#:S_P3*\%
M_LF>$-7;PK\#OC'<^#/#/AOQ=X?TE1^TM:>&(=*T+Q+X9U35(3>BXTW3?%,5
MG%>:NEQ)^17[-GP=\5_"G]DW_@I7XX^,G[/&HZ7\5/@IX%_8V^(?PTTGXX_"
MK6=+UG0!XA_:SBT776BTSQCHNEWUKX9\8:787_@+6KUT:SO+>:;2-*O;N5'N
M:_-[QO\ &[Q[K>M^&[^U^(GQ;LM1\-6<?V,^(/BMXYUC4=)\0SVMO;ZKJ7A?
M4M0UEKS15U..,071T][.:6W(LI3+$NQJ%_XN^(WB/[=>>*/'WQ!\1G5K:QT?
M4Y?$GBWQ/K0U:QT>>>_TS1]3EU;4;D:C9Z3>75U>:?I]XTT&G7=S<75M!#/,
M\I^?H8'&SJ.-*M3='FE%XGVCJ4N:-TTHQ;FFKWNU9M66S9VT,/B(T^7ZU"*E
M&WN3FY-I-)^]ILU+6^J2LTKO^B;]JOX!_LV_ WPKXN_:(\'_  V\":UX$_X*
ML?M:?L?^(?V'M&U32-*D@^%G[-WBRW\*?M*?M2:/X,M["&QTWPK/X9^*GQ$T
M#]F#4=+LA;7/ACPYX>UOPG*;+4KK5)&^L/B;\$O"6K?\%G_V9O@/JW[/>CP_
MLYI^W=\?_!@\+:W_ ,$Q_A]^S=\-XM%\+^%/&3_#_P ):)\9='T&2;]JCP[=
M6.GZQK-M#XDEN%N8?!^GZ[;V%W%K[7$'\BTFH:W>Q:'IMQK6N75AX:6Y?PSI
MUQK&I36?AM+^]_M.Z?P[93W+VVA)>ZGNU"X_LB.S6YOP;N0/.OFUZI)X\^+N
MKOI5]K7Q7^*FL2Z/=M>:'-J_Q)\::K+HVH26-QILE_HLU]KMQ)I=^VG7MYIK
M7NGO;W7V*[NK02_9[B:.31Y974G?$J<5HZD'54':ZT3?,G9VE=M6VO9WSI91
MCZU505>4G;6<I5&GORM>]S7LU&5V]+VO=M_O!\;=>_9Q^%GBK_@E]X_^(WPI
M^!O[1?PW_:6\-?&S0_CU\?\ X'?LQ^&?V=_A-\3_ ()_%KQIX6^#^A>#?!/P
M^M-.TRSTG]KS]C'6D\8^,[O7I_#^@^,O#=]XG\!0WZ^)O#VM1:S!^>O_  4J
M\*?#+X&?M"6W[&WPE\-V5MX?_8J\--\!?&?Q+O?#_P#87CCX_?&^/4IO&'QI
M^,'C>>\C;6+T7WBG7+?P=X$T&_U"ZA\-> _!^D3:1%'9Z[>VUE\$2-JJZ?:Z
M(^IZL^CZ==W5_I^D'4KYM)L-1OVBEOM0T_36N#96-_?20P27E[:00W=T\$+7
M$TAACVUM4O-2U+4KO5-7U'4=7U?4+B>YO]6U6^NM2U34;F=FEN+F]U*_DGO+
MVYFD&^6XN9Y978Y=R 158?"QHU+UJTJB4G;WI*SO9.7,W=;W5E^![N$R"IAI
MTJLL35G.E+VCC>I[U12C)7N[6T<91=T]'OH2REG0%4Y!/4=, +TR<;CVST'
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M.][*_6R\U^8G[>/_  35^*'[$GACX$_$RV^)/PS_ &G?@-^TSIMU-\$OC/\
M VYNI]#\;:[8V]K=MX9M=#U*2YU>WU>Y@G9]/(^TV=TMIJ*O<6]_I\^FU]1?
MML_\&^GQ]_8V_9/U_P#:H\2?&GX9?$6?P%%\*+GXN_";PEHNMZ9XI^&ME\28
M+.TGU'5K_5+N6RFL= UN[M;*::.'R[VR:XU2-DM[.<#Z\_8=_:)T#_@KW^VY
M_P $W_V)/@?^S+;_ +-_[ W_  3PM]<^/]E\+[_QGJ7Q(\1S1>!=.@%KJOC_
M ,6ZA);"\?6/'FO>'-*A%Q87K3ZAXB\2ZIJSS+J$T2_LC^S]\=/V ?V[_P!L
MK_@H]\#-"_X*$:;\>;O_ (*,_#>_^'>B_L]?\*&^,?@F#X66_P #_!6I>$;7
M5/"/Q"\6Z%I7A?Q;JGAK2FU[Q7)#8:A;#4==BCOM#ECLEBA7E=&G*2G)IMR2
M4F];VUT>K]YQ\K-WWNO#J\9\2X;"93A,5%)99)8K,(T\.YSK8:K75&,'**DJ
M35.4ZTI2;@Y4G&+T:7\6GPG_ .";'CGXN_L!_M2_M_6'Q%\+Z'X2_97\8:%X
M,\1?#J_T/7+SQ+XLNM>/@L0:CHNMV1;1[&TC3Q?#,R7HE7;;$-/&V%EYS_@G
M9_P3F\;_ /!23]I9?V:O ?Q"\.?"O6CX \:?$)?$_C#2-3US26LO!LVD1SZ=
M]BT>6UOS=7B:H##-&9(XG0M(@C!%?T<?\$[OV2OVB/B#_P $5O\ @KG^QYX.
M^&TGB?\ :+TG]K'2/AE=_#F/5=%TF6_\:?#R^^%MEXSM;75==OM.T1+**#PU
MJUQ92W6H0V5Q:P%+>60R(KP_\$*_V.OV@_V*O^"N'AKP!^TI\+[KX8^._$'[
M'_Q<\<Z/H.I>(O!7B"_U;PO>^(H/#-OJMO/X0\0:VMCY^M>%/$-O(DQ@D,2V
M4LA$<D)>JU.G*"LG;2/5IMN6ETK*6EMTW9\JT/4KY_4=#B^G#%P>-P4\)/*[
M1=.4J=2C@ZU;V=.HU4FZ?MYJI-)P2UDU"S/XSO$&A77A[6/$&ES2K-_8&K:[
MI+7"A3%<#0[N[MI+F-!)(6#+##*MMNBF/G!,H4?'[V_ #_@W^\9?%+X8_LW^
M,_CM^VQ^SC^R?\2OVQK2"_\ V8/@1\1VU'6/'?Q%@U%K>7P_%,-,O;6'3[W7
M[>_T_P"RV$*W5Q;7E_IFES";5=16RM_GK2/&W[#'AWX%?M+?#[XL_L@^+_B?
M^U/KWC#X]K\)_P!H?2/C5X@\(>%?AS'K-C'IGP]AUOP FJ6VA>(X/!OCZSUS
M5;R6]LII[R#Q(;2;?:VD1B_HP_8/_P""9G[2OPX^&O[,7_!0_P#:R\.?'C_@
MH/\ &7X->&[#6_\ @G_^QKX1^(FC:EX<^$]M<P+K7@;Q5X]^*?Q!\5:5X.\(
MZ/HUO#H^MZ/X3TG5+BQ\.:I8:)%I^FZU>6=SH.G^12HTJM6<(VKN.\(WBX;7
MYO=W2>T%)<S770];B_,<RP.58?$TI5,KK25!488B,95LSYL/1G[7#.E/V4*;
MJNJI_6'3FHTJEH7LS^>#X)?\$6OVFOB=^U[^T+^Q;X@^*O[-_P %_BM^S=XN
M\&^#O$\GQ6^(-WX<L?'=_P#$&VFU+P7-\)]/GTU-6\;-XBT(Z=J^GZ=:6\=\
MUIK>CML9KLQQ^>>-_P#@EE\?[/\ X*4>(?\ @E_\,[S0?BU\;]#\8:%X2_X2
MFPCO?#/@N>UG^%WAOXJ>)_%NH#5!<ZGH/AWPCH7B5'U">ZCNGE73IH8!+J5_
MI-A>?I3^SY^RI_P4O_:9_P""]<'Q[^._[-NH67Q;^%?[2OP&^./[5&C:;XH^
M&LL'P0\ ^+-'TJY^&T>ZV\<SQ:MHVE_#[1;.ST\:(+S5)4THW-U#!.X%?L)X
M9\$^.OV-O^#H;XA_M2_M->#)_A9^SC^V5+X]^"?[.7QF\7:]X:A\,^,OB+<?
M!/X#SV&G6ATW7[G4=&BU"\^'OB+PQIMUXIL=/TV2_P!3TZU8PZC-ITD>RP,;
MWG%P@IKFDWKRMM+>*LT[)WO[V^NAX6(XVSG+JTE'%T,=5K<-X?$4*-"G*2AF
M$Y495'.\I2FU2=6J_91BY4DU;EO47X _&+_@A1XE\+?"O]I+XA?LS_MH?L[?
MMF^,?V,!=W7[4WP7^$1U;3/'GPUL-%&I7'BJYM#JMQ<6/B*3P]:Z'XA^TV]F
MZ/<3:'K-G8&[UK2YM$E\Y_9R_P""37_"??LF_#C]M']J/]LKX!_L4?!#XZ>,
M[KX>? +4_B=I/BGQ1JGQ2\1VMWKMC<3QV7A1K@>&])^T^'-6$%S?272"TL)+
M^^FLH9H8V_9W_@F!^PO^T9_P1^\5_P#!6#]J[]OBQLOAW\"M'_9P^+?P5\"^
M*];\7>&M0L_VI/%OBGQS_P )#X1\1^"-,T_Q!>:OJQ\8PZ5'#H]OXA@M-8FU
MGXHS6-TEKJ&FZ_/'T_['_AOXV>"?^"*/[ ]C^R!^R'\.?^"PFI:[\:=2\?\
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M&5_M:W2:UOZ]SM_#UO<714; ?DZ8(QDL#R3R<CC!Q@G/!.?IWP=;-$BAH^A
M&1V7<PW=,L2-I88&.2!D&O'_  #96UU(S,R[M^2V >.A!QVR?S_,?2FDZ6+:
M-#L&0Q)*@9'!SSVX!&2>IXYQCQ<=43Y]'JI:Z=FU^A]-D-",W&:LFI4WJO\
M#)[=?4]H\,3+F/#(&*_-G(48!'R@'C)ZY)SP> .?I#PMK=[IVFDVETD1*,6
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MJ2"0N1MQRPSG@9QR#CGMT'K@9QQZ/H'B_P 7VOA_4_"%GXL\4VOA'7[ZWO\
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M_@I/^P#9ZA>VVG_LW?MM>,M,@NI4TWQ)K/Q__9\\!ZOJ^G,$DM;_ %;P9;?
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M'_#'ASX@>(=>TPC2?&FI6UQJMGKL1:WO++PKKDOV:?0K6!M/DFGM[JTC@_F
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M/>74FE6;R.$**2)9(E4JK%1"B8"%FVG&:^POV(?A7X<\;Z_X;TW0M0N]*O\
MQWXCB\*WOBG6;:SO9_#&CV22OKNKZ7;02&)K;3K==3UAH9 MY?PVEM;/*()
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M$MX04HRE>RLI<FEMWKLFO7PNR_9Z^*\LOF/X!OPI)&U[_1=QQVXO<$9(P<#
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M23LK)6MY'F&A?#;XKV<XG;P9>8=0R2-J.D*AW2(0,M=E"=J$[?O#DYP#7O\
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MN'4Y(SS@;E ]NYY'L16EIT)4I(,B%?F8G/4DY.3C@'GN.".U<K8WK7-PL;L
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MKOR>JEE;E1@[?7.-VZ^U7T=Q]BMY[I[:%KJX: *1%#&,'SBSKL23E05#$L"
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MTC6]TJS6L:/WQDHT8MM-3<91<7S72WO:_*_)V9YTZ$I5K2BU%J=[V716T?\
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MG1Q#K6A*C3I+V=1WY9*+:5I(_F2_X)N7-WJ_[=GP&MY6<^?=_$ *D;%&5O\
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M81$?F.:^PX5_A59?SJZ\O=7WZ-_>?QSXV06'SB,6^9QP\M;6O;$UME=VZHZ
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MWKEU!JRVEW$\UK/?VL6EWIMGN8D,D' $T8'E.X= W4S?L!?&M\G^W/AH06*
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M &=JKDURMY:K?.6)"^:2$.2,D=> 0.<$XX]3D@8NZ?I4BVVYR#C)QT.>H'S
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M3C%+V2CU:2O?U^[].Q\N^-?"-Q<P[2%8[^5R>/N\]@>!]"<$CFOF]YKCPCK
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M2ZG)J'BQO&/B!^T_^U5>V]O\+_B''H^F>*?A]H/BKX,^.6U;PYJ$/C*[.G^
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M(IM^?F?R:L13BO<TC)N<59;3U7VEV??R;1^!UQ=0X 2YM3ERF/M$'RD#J"7
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ML^7$K_%?PF2=A$^HA@P("[-$UB)F\T_N2N9U8 ON*HQ*@[0WU[^WGI4^K_\
M!/[5(85+21_M@_!&?(4N)%@^$OQV$JHZ!D8QJ,.6<(BO&K,"V!^E'P/_ &'O
MV8OA9X@T^XN9_$/BOQ'H#ZW>)XCU2Y2SLM^E:=<6]_8OI WQ7.H:7=W.F1SV
MP ^VR:G;HD> X?1_X*_^!?"OA[]BOP1IOAG1;'2+>Z_:2\#ZL]G9P*J22_\
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M(M1\,W(A:0+KL4LJ*>R_X9D^%/B.2-_A1^V!\$=>MKUI?[,T/XP:5XL_9_\
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MS-IMS%/!@A%VCS/E);(/&1@ <X].F*_0RXTK3I;MI[BX\@@*R16YQY@)Q@
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MUGP#9:Q'>:H9[#0O#YL-.L+^2QL[J*]O;BXEN$N+-3 \D4T2:=(8XIMOU?\
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MM4N)T=&9%\XR+(J+NB<9)RW3:<\@ @XQ7SP/$-SJ3!BWF2!0ID'/RK@ 9_A
M&T''7!ZU^O7_  5Q\ ?"+P!\1+ ^ ;VPN'O]/L;K48-/\BW6WGO()))))+2$
M!+629G$C02;)P6):,8./QH\)P6EUJ'EB4*LG#AF *A25R=P&<8[$\<CN!^XX
M#$TL=E<<31HU(.5FTX.*LXOI9*]_+\S^)*\GE>=ULLGC9XGV%6;E.K2]F[QD
MX:U9)-M_R2F[[VO%M?MW_P $RH6E\1_#AUP1'XE\?NI_N;O!WB#<PQW?&#TQ
MZ9K^;3PR0/#?AU3PX\/Z-ST)']G1#\R<<=N*_J._X)L:5:6U]X&EB7E=4^(K
M*0>W_"&>(CD]#T+<?3(Z _RV^&%;_A&_#8V\C0M*/4<9TS3R#U]#]1T(SD5^
M@\,65!\UK<NB?\UME?JEVU/YK\8ZBJ9I&6G\"T7I[R^L5'?SZZKS.E@>2WNK
M:^MI9K2_LKA+FRO[262UO[*XB$J136=[;M%=6TBI-*-\$R%@Y#$X&.I@^(/Q
M"5Y,?$7XAI\AC)'CSQ<NZ-F.Z-C_ &R-Z, "R'*DX)!(&.58C<>1T^G\3'O[
M$4TE2,'!'IGJ.X/7@C(/MFOH'&[3DKM:)R5VM]$VG;[T?BT752LG52=FTG-)
MNRU:32;\V>H^"KGXS_$CQ?X5\ >"_%'Q)\0>+/&?B#1_"WAS1;+QQXLBEU#7
M?$.I6VD:59F:/4WCM(KB_OK>![BX465N'66[Q;QL1]/^/+3XB?$#P_XB?3M9
M\>^$_P!H_P#9XTR\\)?'WX6Z7XP\4Z1#\3/ GPR:Y\(G]H;P1X?M-57SM9T/
M2-*MM!_:"TCPVMQI>K6ITWX_:/YL%[\0;J\^=?V?/C_\5?V8/B[X0^-7P>\6
M:IX5\:^#-9LM3CDL-1U#3+7Q'80:K8ZEJOA77I]-EBOI?#'B86%M8:[8P21-
M?:-]NL&>,7 (['7_ -K'XQ_$#]I6R_:B^*'C'QMXQ^(=CXI?Q):Z@OC35M)U
M[2-.AUW4-4TKPEX<\27*^(I=(TC1H-=U6PTR*:QU+3VT8W^@ZUI^NZ=K<\%O
M#C%:J$;JRTBKZM+I'I?_ (8Z*=2].2E5DF[)/G?,KRZ7E?739K3R=CYHMHXX
M@(X ODRE;D,(DC:X-XIOC.YA!AEDG>X:830-)#+&Z/;R20*CF^@8EF^?=E\$
M[AR!QM.%(;@<^F2,94U^\]EX8^#W[3/[+/Q]_;=^%/[&GPHD\5_"9_@E\#="
M^$OQ>\;^*]0^"?P]\*Z"DFI^//B-I/AKP/9^$]5UW5?&7B/Q)%X0\-^%(-8M
M+/P)X?\ $-@D%\;30K+39?TFU[]G7_@F'X.U2[\,?$W_ ()OZ3HOBK0_$V@?
M#[Q-_P (Q?>,_%_@'3_BEKUCH=UJ7A!?B#;>*M'T:WM8KN^MH=,\4:G>06,G
MAO3M>\1Z[<:%9>')9M2]S"99B*M-N#<8U4D^>_+9.^E[Q];)66UWM]#@>$<5
MFL?;4YQI\L5)5,191DI/E:A*HVG)-7ERN]G=Z'\AFFZGJNFR/-IFJ:AI]U/%
M);^=97+022K<(8I()6R=T$@X< *[  +)G.?T(_9<\5_"_P"(L%YX#^(W@WX)
M>"IM-T*PCTKXCZMXB'AG5KFZL]229+Z>X\3:AJD,U_<31*#=Z*FGO:^6XEBF
M>:%HOZ3OAI^P/_P2F_:#N_C)X+\(?LN> M+U+X<>*KGX>:]KVB>)?%-OJ+KJ
MFC:M'I7Q"\%ZQ8^-]4MM+TE?$GAGQUH.F1:C;OJC:]X,O[J/29K*ZTZZO/Y>
M->_8JU_PKIGB+Q]XP^)7@+P=\&M/^)'Q)\":!XNU,>,?B3XENS\/_'GB/P>T
M'C'1/@_\/O&VB?#_ ,:W4>D07&K_  ]\?>.O!GC$I-9>)9/#5GH_B#3=1O?T
M?@OCCB/PNQN$QV%QJQV K3Q+J9/5G-8.=7EIVJ5)RJ>Q4IN,%&,HMP:O&UT?
M'<>^&JQ."HT\;-)J<G3Q.&45*+J:3C3K4U&49222J*$TVFN9/0_1SXQ_M[^$
M?">LW&A>$]1\#:K+I6G>'[_0-6^$,M[XT@N;F.T6V:VUOQKXE2WTVZO;.*$7
MEWI5LD=O'"@L%9S!YC_#7[7/[7$7[2L_PQCTSPV/"UMX1TN[O=9FF%M::MXP
M^('B-X8/$6OQ:=9Q3E;-[2W@%B]K;SNDT<8A0C&?&;6U_9+\+JLUUXE^-/QH
MO<,5L/".D>&/@?X3O$4LLD<^J^))OB+XUNK1""K3Z;I>CR"2-ED1%4UM6O[2
MNL>%-UO\#_ 'PT^ , S';^(O!^D3>+_BY+&004F^,/Q1N?&/BBPW8WM#X0_L
M*9) #82V(5(T]3C'QQXOXRP%7 5X8?+<KQ#FZV&P]=QQD95'*^'E4A.-:M0I
M\W(^><X2BM4T]?A<A\.LCX=E/&4)2KXAI0JPQ-JDW**7O-5>:349)--IVM=6
MW/9?@IX.^*/PCTO6O%7CO3?@Y\)?!?Q \+R^'8M=_:?^%NA>-_$MWI<SSW":
MK\&?A+XHT3Q#X]O_ !'=P30>;XB\.>'-*:".-KP>(=*@+K=Y6G?&+P7\*8H]
M/_9LT+4K/Q!]D,%[^T'\36T74?BE<O(AD:Q^%7@[3R?#WP-T0"40W&HV5QXF
M^*.LV8"MX\TVW-OI%C\R647C'XA>)M4O1;^+/'_C'5K+5O$&K7HC\2>-?%NH
M6.AZ5>Z_KVL7UVD5[J5_IF@Z%I^IZ[KNHWT<B>'=&T^\U"[N+#2;6]D62S='
M1'1E=&+%71@R.!* =K E6QM;H?NX?[CJS?CD%&4XW46X\[BW9N+:][EO>SDM
M)6LVOBNCZ^2?NN:?PJ,')/X5M&+E]E+9+1=$CLH[DW-U/?SSSWE]?S_;=0U"
MZN)+B]O[\R--)>7ER[R7%W.TY>19[R:XO2%B:ZN9[B(ROTUBY+%V8;N0S/R"
M?P(QV7&<$D<] .,MW4; 6P2,C@]"&&>!ZGO70QRJEM/("P\F%I/E*HY:+=((
MU8I)M,A54S'%+*-Q:WC>?RE;I]HL/0Q.)>'A76'HSJN$J_L4W",I)<O-%5;\
MKT:?+KMS:\$X.=2G[SBW44(ZM-\[@O=LTWRNVVU[[[]U97BGA=I56QYD<4CJ
M7!(9"ZJ5SD-D;@<KT&"I[.TG&P$[\EBH8K/&2<8QMV'."K<\GY67&5)']G_@
M'XF^.O@-\=OV ?V./AA^QC\+=1_9C^)W[*-S\0/''Q5MKSP5:>.]&UCPWHGP
MW'C#Q?X?T'4M0:XO]%\%^(_'NC0?$6PU]+SQ_P"*[CQS=:O\.Q/+H,FGW/O6
MJ_MQ?!/0W\"/JGP0NFB^)=Y8S>"(]"LOA/XAU+4M%U;7(O"^CZIK&D^&-3U;
MQ/X-O+C7;Z.V@T7Q7%H6I0SR7^@6_C'5-2LM3TVW_G7,_I%YIDV+A1P_"E'$
MX>M6K4H3AF32M1Q%7#OFIPG%4Y1G2E>+5[.,F[31^@0\,Z>,A3Q%7,I0J5*=
M-N,Z"K27[N,E:I4YYM-/W5?W5=)*)_"U(RNAW&0H4)"B&4@K@Y"ML((P" W)
M !;J"![Q^R[KVEZ-\9-+@U)=.MD\0Z)XD\)W-[J5I?7\>G/K.C7AL]1^R6&E
M:I>S20ZDEG,J):!$N(XS-=62 W$?]H'PW_;/^#7Q'\8_!?P-:_ [7_#5Q\;]
M'L];\/:OK_PULM-T/1[?5- ^(FK:!!XEU&[\'^&]/T>]UJ#X;Z\FE02W=E=:
MUK4L=CX3A\;:-/)KDORU_P %O_#&@>&OV2?#/QC\)>'M#\)?%KX9_'_X?P^!
M/B%X8TRP\/\ B?0[;Q.?&5GK.GP:EIMM:23Z=J45I8WR6>L6\\<%R5>%A<1H
MRY\/?2,6?\24>&<7PTL+5Q56$:&)A)N,:M6IRW4TK5%2FWS.[NXMM]\L5X;/
M*LLQ&;0SA2C34ZD\.J,*;Q"HMVA-1MS-\JBU*\HW5E;;XA_8'FETG]H[X6:/
MK^F>+=%-W<:K?0WNJV5O#-J^FW?AKQ+:W<FHBXU"]U"+3)?LVH-9SI)BR2.V
MS;1&0AO?OBIJ>J! /%D'AZVEFTO[1X=M="FAFETV"*:.&/0-02^?^U-;UC4(
M-FJ7>H+'#;6[R.EM&T84GY2_8W\0:SXC_:5^%?C#P_X?\6)X%UKP+K%[IFL^
M*=$:ROKVYO\ X;ZJ+Z[MY=2O[G4-2L;S7([J2'6+9%TF:25Q;K (Y<X'Q!^*
M5S?:WX2L=3>>W,_AU@PG29"N;I?ER8^ ,KC) (Y%>_XJT_WF$J1]]UJ"GI[W
M(^5V77E>NBT?W']??0XQ,</3XGG-Q=2MB:$9*=G.=H\L9/FO*;A'W8R?-RJ3
M2<4SZU^'XLK\W,-V46)8Y@JY4HNZ-@VUFX ;KNQP#T->0_&OPQ93SRVMNJR6
M\D.&BAD$BX9_F;R!!.LC!&<A?+!) PZX(;;\(ZF(-,2ZB>/]Y_JF+ -B-!@L
MI.Y >J[U7S ?DW$\\=XIU.YN[EP\@"'!8A0^>>>"3D_,<E>2<BOR*C5C1H*Z
MBJEKMV2J+=;Z2OY7_*Y_;+A..8?69QFZ>C=*2DZ<]6V^1WA-:V3<79>[MHOR
M2_;7_9P\ _\ "/Q:SX.>]N->:XAD-S.ZOYP,&Z[@N+=+.U-JT,R[84^?>BK(
M6 &*_)W2O!=Z)_(N;2:%XB5<X.[=EBQP1T;[P'3&W.>M?TVZWX8TO7[>>UNX
M=Z2(48M$RDYY_A5@1P3N(X/&1P:\EO?V1?A]KGACQ!JR0W,6K0+.;0P-;;(/
M(C$T+-&[":?[=,3:X@601$;I1'%M>O6PF:*.$G&3_>*_*Y.\WJ[6D[R_'16W
MT1S9AD[X@SB%:EA\+AZ-/ M<JHT:49UD[+F4:45*KI=7BYVMK:Q^(6B> 99)
M(PRS,?,&3@'&0>,8((P".F<]<DU[_H7P@ANTM_/A.PJ&^Z#S\N <@'D9/7L!
MQDU]&>'_ (+Z_-JMY#:Z%=2):$B5Y(5S&P/\+%PIP >8RX'K7J%MX(UC3[F.
MU?22LR-&C[82SKYH8H656)PV Q(X!P&*G .%;&5^>"4I*S]U2<N1.SU:;Y5>
M[W7XG#@\IC"2DXJZ?VHK6Z:ZK=W=^C^\\*T3X/VEO:+((U+(&V%T7>"RJ#CD
M94A1G((!SGKBN8U[PY+HLH97?:CAD&[*K\V/N$E4/&!CG'"@'%?;,_P[\3VD
M+O-IP"*BR,DB1L\.X%4D*K*6PRJ. I;.2VT8JAJ/P"\4>([*UNB(($OIC:!S
M&@!==K%6(?<N%;=N("9^ZV125>I5?[]TVDM&G"]]5O9::[._EK8]S#8>>'I5
M?81G"C5CR3C13A2F^92Y9QI<L)=6U)2[VZGSQX)U<HB*1O=MRKU!^XW&.#@=
M>@Z8!SC'O^C175Z$=4D8D1D;3SEL$@Y]3T Z$=^ #1/V9?%6C^(+331;M<QW
M6UEND+-$90CEE$JGRVR%P=KX7<=Q"@8^W/ WP3&AHUM?1V;74>QI(F<RO$WS
M-_"3&I;D!@_S <'.36-5KF7*U:R^%JU[O^72YA&G-MQ4)MWLHJ,MK+9);;[*
MUSR7P/HR6S"6ZM68[-V2 < E&[@\'![_ $Y()[;4_$FF6+-:(_V>4JROYA !
M=1L(4=0"05 SCH5'6O7-0\,QV$2")$"37*V2 #?FY=2%0*F2H(QAB%C&.7 .
M*\%^+?P=\1WT)NM(2WMK^)W+0MJ"([2%F959/.V@/)PRKG'W1P:<>6LE!N,.
M56<FU%R:ZWT;OMN2Z=>E)R]G4E=WY7"3Y;NS333MZ6T[(Y34-8>XFD\J:)H^
MS_,<#(XX(X((!Z9!&.HK"LM0+3NBNIQP"F< DL"&ZYR02.>!\V, BL?PQ\%/
MC[?V5Q,^AF2QLIVC::"52BL02"&$L@<%.245P.5W!N1Z[X8_9J^,$MJ+RXL;
M:W#R1-*T]Y$SQQRD^6X42(L88A@3,.3M  S@U&/LWSPG&4EM&,KMW5F[+717
M;MLNQ;3G[OL7&_7V;C:VNZBO^#L<4VF+?02LZ!R2V,KD#DCK@Y.3W'4#CO7G
M-QX)GN+MMJ3[5RZH"<<$]..G!!Q_LGKQ7W=HG[,_BAH7GU35(+>QC203.6(F
MCN8P2R&V^;<%P&62)2A!!+!F(7H(?@SX6L+NWL]?\4Z3:>9IES<$'4K675?M
MJ)(;.&VL%'VB2*=A'OMBH+;RIVGD9U<6W9.SY6[IN]KI:ZWM\]?-A_9]6O*"
MIQJ>ZVWR*<KWTVBM?G=>1^==OX4OQ)Y"PS9#C *F4#'R@[1W.>">H.!WSZ+X
M?^$.KZQ=*RZ?>7;(JR^7#;, R[L#.5ZEC@=AGKP:^T)F^%WA#09?$D'A^;6M
M4M]'M[V73!$\5[:36%S&ETALB))$E:%Q>!?)#20)*8F8Y5NEN/B791:2+_7_
M  _I6ARVZLFKVL=O.;JRM-4MY+K1+J80[0SV]D@U/[/&LMU+_!$\C+&>26+H
M-MR4F[;P^'T]V25^_7O<]:GP_CI03@IP6R4X-2OU=I*]GO\ EY?/%O\  CQC
M9R1P1>%-4@#!2DDMK\HRHD^7MG#@[23A1T!))]('[(&K:U8037VO6ND7TENE
MY<Z5-$'NM,A>5%\B[4$!IP23R!PIX&#7IUY\0OB-X9\=1:GK.JZ18?#Y])\/
M6VE+/*R37&I:1?&VU_4OLKRF<?VC"]O$X$/R "1L*'*\):?$76GM]'TO6_%F
MG:2]_8OH_C#7XX[N2;4+G3O+M-"CT2_^T7,5E<SZQJ?V?4-9O!'+%-LE?RXB
M)*:QDHN.LXQTY;N4?=5K;NVUNNATX?AO&XA3<HI1I*3G[EKJFVY;0NVXQ=]]
M6EJKR. L/V-_@OXHA\,W?B3QNNOVVN6L\JPVMU#IECJ5WIU[-:7VFQW85RLX
M0&9N2Q,.-N.3U/@CX)_L^> ;S7HM)\,'5K7P_?:U;._B#6#<PVTUCI%IJL.9
M(8534+!XUFMXDR LRSJ[$E177_"?P1X6^&?PZTOPSHEFMCI7@&6XTK18O$FI
MKK$UI_;5[/=V7C6ZO+=IIK@W\LMN]O?7BQ+Y7G0!T>&X6.GIWBWP5#J7Q%\(
M0"32-<\*WR>%;O3KBSCM2]CKVW6]6O\ 1Y+BV6#4[75XM6DO)7LY[JUM# HO
MWMY9XEFRQ6-JU/<56IR-I_Q9N',MM.?EOKII=;(]#!Y!AHU(\T(5)WY;0A!5
M+2:OK&*E:*:Y]TUJ^:[MIZ9KFCZY)?:5\/O"^F67A;3_ !EX1TO5;C3VE,.I
M:/XAT@7VH1V]G&$:RU+2;UEM)8P_[@QLA7*\)\6/'?B"X^'GQ(\"?#FQU :M
MI]M;W&CEITDD@:QO[-+J>WN;F1525+*.Y9&9FP,A<L*A^'GB3P-I6F:3I_E/
MJ>L6MO8>,]>UP6\5N-5UJYM5U^TDO7L96@26/^UTCFGC!MDG?R _GDQC+E^(
M_AK6=(D/BGPU9I=Z?HOB*XO+O2IGCM%T=8+^RN(KXH9'N9$L=02>.XD0)=1R
M)<637 .^N+VDW=\\GR[OGD^6_GS:7]==STJ>3T?K-:*P"Q%-RI^[6E&E&#5U
M%QC/E4G):W2TT5KW13U#Q?K5C;3WVL>+)]+\1:Y)I6M66@VLC7VOW\FL:%JU
MC%IGD"0PR1V_A^PBU>)H@S1R02$G#8?TU]/L;JS^S7FGZ/J303>']16?4S=P
MQZSKWARVL_$/@_6(E1BL$NIB%)+WRL'S;>U &593XMK/B#P+I7Q&^&<MWHVG
M2>*)H_"'AGP?=WGV>ZT^YTS3M!UW4TU32_-8217EO911Z!<2H5<R"W=U$30N
M>\U;QIKNH_$_Q'X,T006%KX.T[P!=SZK=Z1<78AUS5O$OB"&SAFA3[/(MEIO
MAG1;R6YO$=[*WFBB,UQ&TT22IRYO>E+F3TYI.Z=MUS-M.UN^GX+OJY<Z<HTY
M82."3A>"Y=+:13A4Y8N<6]':_(VXZ<IU7[/JZ5)=:WXM@NKPZ]=^*KWQ3J?@
MOQ!:"ZEM?$GAG63'\1='\/K+IP*Z6EA<Z'=Z=>B=O-%O:7;R2!-P\)_X*R>+
M%UO]D'3M*N;OPY?7VG?M7>&KV*?P_>-=P/X4\2^"OB9>^$_.5B3:WJ:=93VM
MS&C K-!<$!1(HKOO"NF6WB'QO\&/B#X>\0:W=>!_!UU;:T]W#-)$SVGCC3O$
MFK6VF1:9")?[3LI+$^'--B21)9H87CC3S"'*\G^WE\%OA]JW[(.ESZ[^T/X!
M^&6CZO\ M$^"/%-UJ/B+2?B=XPTVWEL? GCJ-[/0SX0\.22:GXTUN+6XIKC2
MY]5T[3A;:-'%>7]HMQ:B7[3A6HY3Q,(+W72:<H1T7NP]YRBDDMTWLK7[G\P>
M/=.CEU.AC*^-Q5>K+-L%&G1A0J6O%U(^S;@FHVLI*32;NM6V?S5&\"QL79\#
M;+DRM\A *^<"S$H0J(H<%6.T!6'-:F@>'?%GC.=++PAX-\9^,9[F5(I+3PAX
M5\0>);F[F;!CC?\ LC2KJ.6-D"AQ)-*A<-YFUP4'O,GQ/_9M^##K!\&/A>?C
MUXTM-@/QB_:7T=E\%6E\N[?=>!?V>] U.TT*.T@=_P#0+GQYK_B2XDC#27.G
M)(S0RNO?^"A_[:#1-;Z9^T9XW\'Z9&O[CPW\.H= ^&WA6PA4@?9=*\/>!M)\
M.Z?8:<'#30VLBWC,)&FG)GDE(^M3PT>;V^.J48Z14J#]K-SYD^1QC)M)QYI7
MZ.-NI^ U7FF*PSJX' PKXEVE@:6*CR1^L:<LY>TA[T8P<U).\6I7:LC^@K_@
MDS\"_C/\ ?V4?CYXH^(,FN_LT>._B-XOT_5?A):>-]%US2?$<MAX*\,K##J6
ML>#+Z:.&X\)>)+Y7L--M6T+2KKS'C<ZB2?G[2[_X*)^.M?M?!/PU^"GPV:X_
M;+OMFE:HTUM+KFHS3W]\\^J3-H[8FM+1K>*2\R\@CBLFFMR09$9/QJ^#G_!4
M;]JOQ3IOA;X6Z9;:)JGB/PCX+\8/J7Q,T_P/>^//'FM^%+"TTV[U;7/B#'>Z
MA?Q2WNEV^DV<FL>(7M--FL8_+C6=+DK&??OA6UOX%\ ?$+]KW]I7XG:_X$^-
MWQA\.Z9!^R_J<-Z_A[QW'X(US3K]W\4:GX?%G!JOA+1==-G"WA*7Q*(M2\0Z
M2U[=VGG6]M,U?OG"6(RF.68:%'$O&3Y8^TE4IQC.%3D4?9RCI)IQ:D[WND[6
M>I_"_BSE?$<>*\TEF="CA)UYPJ3>$DY8*,N7D?+*G%4*=1--."46_B:6Y^\7
MA[XR?!+X<>+)/#WQV^*>C:=K&A?#I;+7]9\<:CI^C^(KOQ)XZ=HO$EOI.FM+
M*L.D^'X;&:+2F5%EC:[NHI#(5#CR'2?VD_@EXO\ BK\3O _AL:W\2?"%QH7@
M^R\':E_PA7B+QSX7@N-,GN)H5UNY\$ZOX>\2S:((S$ZVEM>20,IE0,JRRJW\
MO_P_\3^#-<U?Q"/BW>^*_BC\3/$GB,Z'H=S#;/XAU"XT^YVR6\N@R3AY;O\
MM"YEN/MAL6FDM)@SW:P>;&7ZS0/B#XO^!/B/6Y/#NL_$CX7^--,62VM;*VEU
M/2;FYLWMIHK43!"&6((-C7C,EJH1Y#,D2%Q])C\1E-##XG$UYUF^?WHSJ7A3
M?+'3WG:&B6BLK/;6Y\%D'#6=8['8"AE?+4Q;QK<Y0A*=6K2M%\SE%.<Z>C5W
M*4?=LMM.R^*-]^QIX!NOBMX8^'/@'XB_&7QYK.I^+='T?QAXTNI?A)\+OAK<
M7>HSP:5+\/?A3HO_  D/CK4]0T*07%GH:?%'QSJ,4UA$EHFBVUVT5Y'\G:=8
M@H<N)"@P7 0QR;PIW1RQGR?E9'62U;]_9REX)"=O'T1?>/? G[0%Q#<_&6];
MP+\6P%MT^+VCZ%>ZOH/BVW15:&/XGZ#I0DUB\OH2'%QXOTR+[=:Q&.:^@U2*
M">6L[6O@=XZ\,V=GK,%II?CWPMJTLD&D>.OA9JL?C_PKJ4\"[Y+1Y]"B_M7P
M]J,46V270?%^@Z)K\2[I3'/;;'K^<L?2]MBJLL+356#^UAX*<):KK2BT^_Y'
M]V95F%++LLC0S!UZ693_ -Y^N2J0P\];_P"S*N^1O;^&MDSX?\5> K[2]E_/
M9&%I]0$5FB$R.\>?O85R,<D'('IG@ 4+O26A=8;W3Y;BWN)(HG_=MM^;H",Y
M(Z'@\\@8/3W_ .'&O:'\1M%M]>O;^#4K=V$-G:P3*\$1VEP9W;)R<#YEVY(
M)[UZ!XY\-:(?#]LNDVGVBZN);<2RV@9GLY2WRR<;MR'Y4"]0QR3U!>84:M&K
M.E.$E*"?,TKPTLM))*ZO;HORO^L9-F\<32@X554IU7:]-J=M+^\D_=6BWN?)
M:;;F]/A_0]'>TCLDQ=7#QLD1&U6#H').=ORAMQ&0>F#44CG36AL-2M9)Y'S+
MYDB,R -\PVG/)"\@G."!@8KL/&6A>,?#]I%>_9I+:VOY(_/NVB?<\-O*Q7(
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MXNK;1IO:\97LY-*]OT/K,E\5L^RC"XK"8+.<PPV'QU6.(QD8QFE*O&"C!O\
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MLE[J;W-K=WFH7:V_C*'[=J%W<6-I??:]3>],&HQ1WT,7GQQ%?RV^&W_!+_\
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M92&_MGNQ"JVMO.H1HW"LLS7$@RB!B\8ZGY;Q84:&+PM)7M&G&-NB:3\]O/\
MI?Z+_0[A"OA<[Q#3=\5A_6S2?2_;[]+['A7B;X=R^&[*.W\/Z-<Q12AHH+".
M[NI]4*VVIR0&\U(2.UI';3VZ++ L<YD6%E @9ALKR"WTZZU&1[@6MY)!;2.D
M[>0_[N1"%9<#E@N=I(XYXZ#'T[+J<-^)K;1-1\3W5A&YO+K5)! RE+=0R01(
MT>QVCDCV1S)$KN</D.<GD-8\6^#_ (=VMN][>:SK=[JNL)I$&@Z;IY%^^L38
M40S0I#+F(JWF2S#:D:KN/'RU^,1E*'-^[C-.5TVTK;^7S/\ 0'$4Z<G&T92Y
M8I/W-=6FK7=]?.VJ^9\\>)=&\3VBRW&FZ->/''")?-$+! G"XY'!.<C.<<D#
M)-<'J]C\29=.MH_#FF:FTVL0OY;Q1K\C1LZ2!0SA3L>,Y! W'..>#]IZ[K]W
MIZ6T2:'JFO:1)I]A_:B0S6]O>V^JZE>-&UG!!( ;BRLH]HDN NT[6&<U':ZU
M+!-*LGP[U?3#I%_):64LEU"T)LY[=$:_>*!I,QF8.^X%<%WSR2!E.\I-\O+=
M[+5+3O:W2Y="'LDJE-<LGTE:+T;W36CT_'[_ (MA\ _&RST>TTS0?#LS:_?W
M9:XEN)8(XVB1@9 6:4@%U+;/WB@MA,G)KV_PIX(US2[BVLO$^A:M>:S+IZZG
M>:M8Z98W?A;3(A*6^S:CK$FIVMQ:ZE;Q0RF>W.FO%&-RB:1]JGU#3_$_B 7.
MN>%K#PN-*U;1_"]W.UW>WDDEM<-?RS6\<INS($C&P9ADCD9H[CRWYQ@\[X!%
MW -(%YXJTE+V+PU8MX\TO7+N'6O$S:+IDCK'=7]]):6L$IMVN@A1$@:6"0F<
MS21JXR56I6J1E&,N1/WKII[/2SO=WMU/4PV'PWL:D*T*,JLHV@Z/[S7RERP2
MM;3LI;#;CX+ZWXBUG49M*\1Z3-9RVD%Q*X5I8(K>5"Z;3) IR Q)2,LN#D,<
MX%[PU\ 98;IX-2\66VJW%I<'[!I^F03&,'[+]I\VZC6-A#)(/W<7VDV\%P%W
M0W!!8'D/%/[4'A+PS=^%_P#A#=6O]:M[CQG9^'M82R6*."VTS5(?M5H]Y"S%
M_,L%>*&80!;8PH@1!(9,SZ?\4_!OAC6?'%_HUW;1>+_BCX6LO$6M1ZA;M;VE
MEJ6CZN_AJ.??<M).D3VV+R*W\S[+M4RK"@8YZFW&UXS2;LGRO1VTN8T,#4CA
MZC48J#J-P3DE*_5M7LK0;WDN9KE33DF>QW'@O>JPZ#XBTO4I])9I+C3TB6U,
M-^596MVO7"K;KECMDW.A( .0Y!XW7+2UDUZ'1["]OK[7IFG6\%ENDT^WEM$1
MI5%[$-ERH8F/*, K*<$=L#1O&T7C71YM.L_#LFEP:9<Q&VN-*N;HW5X\&IC3
M=4MM<EF*B1WBBN=0MY7)WV\EO$H,C"0>@6GAMOAW8?\ "2:5>W5SI-O#J,J6
M=VB23K:ZW.UUEW!5Y'6-U\E_E"8.1)C)V5"<E=."]96_0\3$UL+A9*/.O;2?
MNPC9RUE972:MK?H]+.UT<._AW6M5N-/TY[.73;U91?Z2MS=8^W7UBDC26Q&X
M--YT*F7<!MA6(A]Q(-1WFH:3<V&H^*]6T1M5T^QMV6]U+2)I;FUDUA&A-QI\
M"I,";M@]Q<"(1D(;9H""QP//O$FLWFM^/O /Q!D\9-H.F>#9KZ],%U-LAN;>
M;_039-;+(SW,\\-Q*5<(JQA&.&Z!WAWXT?#O1G&F3^*="M['4M4U+4++3K:V
MFN+*TET^]O3ILUUY4!!DU6QG47;;&FW.K HT8!ETI)V]UOR=_P E_78WACH2
MHSY:4*M2DG"K&-O:QG9J3<9NFFTFFW&3VZGU"TEZE[?1WMUI6C6-MINEPP^'
M;.=8[:XBN)(ECU$M$S/-/+%( Y5B(YD:-P3S6-JUSXUTJW\2CQ5=V.E^ I9[
MYK?5M)NDDGNM$TI;*\@G@%N9+@2;3<$Q/^]58G!SYJ[?F*'X^_"F#P]I^H7O
MB:[F\1Z?J&L6^GZ+HEE/=W%Q:O<BXBBO9KU3(UK#-A[5-B-$I9=Y!!KSO6/V
MLULK&"TL-#U&W2>YN9[S2]3=);:2WWPAUMK$K/(1+&9(W"N BR[2K[QBO8S5
MG)3Y;I-TXN<E=I:1]V]F]=5979Y,<72G&K*G4I1G17,XUZE.FW;5I>_.[:5D
MNK:74^U_%5SXENEF@CTZ[U^-+"695TZYN@DHO=,2_L9&:!H]SBSG@6X7_EE.
M)$?#*17RW/H]EX1U-_$'Q!DTS[%J%OX>TS1]*:\OM2U#0O$=Q?QF[U6[O[<&
M1;%8)8PRL%6Q*N97**:OZC_P4\TSPEX8?1F^&\5K=W.V2'4=1,MOYI>!(I(T
ME6!"MO*H.^+;D,S%'52H'YZ_$K]NB7Q5J\<D(\,>'%5KW(T>VNM522/4(O)G
MCNQ<7;JZK&2R 1%HI"<9&$JL5A\'AZ5.<:DYU*W,I1<'>'(DTI+F;5W)K7LT
M=>1YWC\7.HYY?2H8>C*,:-:<E%XA\TE+EMS745%2M?[2?4^[Y?&[^"[&Y\5^
M+M1EOO%^BZGX@T"YTZ.W@G%]J$<<MGI\KPQ0-'?:7>VIC$( $T#%(Y':1P:I
M:AK^I^,KFZ\+: =/O_&'CR+3_'%T?$.J6FC6TEK>:/+IMO9QRWKB.V?0DN(X
M+:S"YEM[<<"1@Q_-O6/VA=3UJV"WOB*]C,MS#JBR0PQHUS=07T6H"X9YXF*&
M61%CE ?YK=VB"@_O$\OU#XJ7EWK,6L)?AM7MK3[/%J+SW%S>"W2+RD"K$AB0
MA5#  )^\!8C!7/F0J*FG&-'G7,Y7=D[MZJS3T5M/4^X6.E52G)PA+E2M&2:L
ME9/I>][OO^7V+X[USQWXHTW5_ _C?5/$.MZY9W/C232CX=N+>5H/[1O;BU@T
MRTO!+!;*T6ZSEAN?.EC_ ';X 8KCU3P5::/IOBH6_C?XCG4_^$9;P$ITR_@C
MT"RU6[U2VO(O$#OIGG30SK%?M:75ZLC$?:X8)X2GDXK\S]/\>+<RO<7GB)_,
M#+(%F.HK)'(D_G%O+$RJC221JSA0H<,3@%LB2]\3Z 99KE[F*XNI&\R>ZCO;
MJZF>3(*'_2)9V;#E3@DD;3CM4UE.?+.$4VK2Y7WT:CYZZ?H>DLR]GAYTZ*A"
M56C*#JV4^24Z;C[2VG-RN7.UI>UNI_2K\.O@M\+O%=S?>$=$\5SZOIOB'P6W
M@KQ(BZXNJZA>Z1#J5S?:%/;3Q2-)9:AHL^KZM#%=QJ"UM+91#+6XS[UX_P#V
M;/!NE:3-=Z?<Z@VNZ;HKVUOJ%_+-<W*LFG:1IQGO;B:(2/%<VFA6%O=KO9?+
MA=H=DDDK-_*]\.O'/Q'CU6SG\!ZWXE\/W5J)<:A87NHVDB2*ZR+-))9A9'4,
M >5D0 G$88AJ^\ETG]K3QOI-DEQ^T=JJ:1?6L=W<0WUWK&IR"25624/'&;.X
M9C''&!$\H4$9\O<QSZ^&E0^JM5L))U':W+3ND]?M:6L_+]3\FS_Z_EN:8;$X
MGBR@J$GSO#4YJ%3EO'WI<JBDHI.\7JV[723/HK6/&'ACX:ZCXU\/:6]G++9^
M(_A_<"'4[^R2T3PC=Z1;ZEX]TZVO/OR)H\5FNH:;#*!/,OV9$7Y'SY?XG^(U
MUXMU#XR^'?!5E8:3XMNOA%I,?@VYN6C@\//>_8[GP?/H>K3PO,+;4+ZUN-!O
MW B?R]+M;J5]LA#Q\IH?[,S7-L__  G_ ,9]>U&YNRD4MMH^@Z3H\]W(MLNG
MBXN=1UQKZY8R6*"T210LRVQQM,PW5] ^"?@=X(\+ZD-9\*1ZG:ZTM]#<VUZW
MBG6+EH[F"VNK:XRMU>O#-'=)<R7%W%.DHEN(H3"(84,+^5[&I*I-2I*E2;]V
MVDI+6[<;=+]UOV1Z]?C[A^E@:D</];S3&KD:JP7+"G*,4FG/V^JFTI+W7:SU
MULM/4_!=MK=[XKT/5+.SM==T_P ,W_B7PIH6^&(>$OB;X-,.G2>'/#7B$E9[
MW2_$J:GXC^SQML@N$T2QO4D:*_BB3U_Q)>:7-?MJV@?\)2=*UOX;^)-3OKJ]
MTNZ6>[N] /VNTBU<K ?]-:TU74[&VLR1YDL323+*LBK6U-;ZO<7]GJGB2>XU
M016*:99:E=7MK/\ 9K.U2-7L84=?-2.)6BV7#R27C[Y=UT<*%ZKP?XNUKPUK
M%R^CVD6NZ%J2P6<VDZE,9[=I(Y"V=,CM_,FB(+>3.TH=)H\ [N6JOJL')PY9
M>Q7P.,6Y:J\M-+>\[7717ZGRW_$1I5JDZM7"5)5XJ*IX>IBI1C'EBHKF?[RW
M,DIK5KWMG9)8OP[N/""7/@ZS36&TVV_L'PMJ]SH5EIDMA:ZM9KI.B'P_+:6K
MQ6[:;/:V,$S75G&)#:FZ\B-28,'P7_@K;I7]G?L8:+,MW:O9:S^UGX6\0V5C
M9?9K>'1H9/A/K&@1Z;%!:IY:6ZVOAZUNT)57DOKN]:7<Z.3^C=AXL\/:EXDT
M>'Q'X0T/0]=MI%33[2_L)=0N?L_]F2W#7,;V]MY=C8@1K%#%+*KQ8(PF./SE
M_P""T^M^#-/_ &.?#\/AZ;3)I(_VG? C7!T^Y,C26FK> /B-)I32V[_-!.]U
M:ZM_HQ 9 '<G:4V?59#2>#K5E%P<94G=0=Y6<5NM-;-)J^C372Y^2>*O$$L\
MP.#E5P.(O_;6":;IN5-/WY.,97]Y1>G-]J-MEH?S$ZK/;)YTFYG.6W*JEY0.
M%7"C'F,)"HVC:0'R>!QT7P;^#/Q*_:-^(^G_  G^$NBVFL>)[_3-4UK5=1UG
M4+/PWX2\$^$= L;O5?%/CGQ[XOUF>RT'PKX1\*:7875YJFIW]]YMRMN]EI%O
MJFJJ]@-GX(_L_P#C7X^+XE\;76NZ9\*/V??ALLU_\7_VA_&UM?6_@CP18H[6
MS:?I$,*F_P#''Q!UB5O[/\&^!?#:W6IZSK4D$<SVUFEU<Q=J?V^/ GPQUJY^
M&O[/7PUU+2_V3_\ A%/B7X5\6^'M3UC3/"7QK_:4_P"%B_#3Q+\-I?B;\8_B
M!I^DZ\+'4]'7Q)#X@^'WP]T.VU'P3X':STN34!J_B*RU/4+SW*>'A!RJXAQ]
MG*=X*#4IJ6K5XV5E;F3=WKIK>Y^=UL=BZM#ZKEE&C.<J'(ZRE[F%UBG)2BKN
MM%NRIIQ<HN3YO==_HOXQ?%SQ/^REH?B;]E;]CSPOKFFZ))X1T[Q%\?OVK=/T
M'3]=\8_M*:'J;3K;^)O!?C'2WUS0O!/[,0U$21_#_2]"U&RFU".VFG\3B:2T
MO+:W^%M+U#XPPV-GX<U;PY\0->TSXA2Z+>:7I/B?P[XDO9/$LOA.P&H:1)X9
MNM1M9;Z]&CZ9J\<S?\(N]S97FC:RE[!;R0R1HWIG@G_@H?JW@+P9=_"WP;\)
M] T+P#HWA'P_X0^&5G;>)+/6?%OAR'0;#XP/KX\;^+_%?@;6)_'ND>,/$OQP
M\>>,]?T"VTKX>VNB>(+K3+;1([72-.L+6TT+;]O7Q[JD-\?$_@77]9\%>.8_
M!_A#3VTGQ7XTTS7- T/PG^RUI7[+FN^'_@KXQ@T*^D\&^(M5TK2]+\:7T/A-
M+:>36M0NM U+2YM+NFU"W]2AFE7#6^KXFO1M:T81:3>UW::UMIKT6_;YROP_
M]8PTX9GP[E^9.3G.6+KU(>TE4:TYO:4;[<K>ME=VNEK]??L<>'OBOH7[4=H/
M'NAZCHHL?AYXZ\6Z_?RVB:7I?A:-O@_<_$OP[9WFM/91Z9X7UR"WMM,,OAJ^
MO-/UPWDTUB]K)J"W-M%K?&SQ!KGQ.^!7@WQ'\8O 7B3P=^U/X+U?PAY%Q)X;
M.BZ1\9_V>?C1;0:M\,=?%O)*GV_QMX.\>7NO6NF6^EI-_:/AC7H+:_2XN[2"
MQKPN^_:V^/OB9- ^(^G?"74M*\ _#CQS\5O$&KZ%K'Q&UN_CU?6/AQ^SG\&?
MA'XGL_&CZM9:)K>I^(?AQX9/@WQ9<>)M1T2RO]7O?&%_;6-CI(B2"/R[P[_P
M4&USPMJ'AG7(O <.LZUI_@#X/>"->N-?\::U?66IP?"BVOM+T#4O![3:++K?
M@'4O$VDI$;F6SFUEM/\ 'MU:^+M.@N;BR>)NRMGN,Q6'="MBJJIU-:DZC<5-
M[73<K/X4F[^31\IA.!:#S!8_+<NP6&Q.'=IT,'.G+V4ND8\M).2Y>5V=E>3M
M=ZE2XNKK0]4N-&U_3KW3=4L&BBU#2=;TJ_TS4+<36EM>1)>Z;K&GV]]8O<VM
MY;RP1WUM:781S<1(DL*L/<?A]\6O$7@87MUX/\6:SX=N=32)-2GTJ[N8Y+Q8
M6(@2[62<K,UNJB.*9OWBQKL!PS9^$_'7Q77QYXLBU?1]/\4Z9I=CX<\,>'M-
MA\8^/M;^*/BE[#PMI2:%;WWB#QGK]KI]S=:E?) EQ)I^BZ;IGAC2X[BVL+:W
MN;B!KEHK?QC>6XVF5\$#CY@.IY&UP.V/?&:\[#XZ5-?[//2][+27R2N[^G1'
MUN-X.>9TH1Q,%&K%ZM2NUINGRZ_AOL?$OPF^,OB'X017&GK?2:AX?G9"MLTD
MJR6B#@O$7?"L,KN,9!*[P>*_<'X)_$GPMX@\#:!KD=Q!/'?1I/<R7'D.?.&T
M_9W5V;#HV&5F&>" 0QP/YT=0MWO21')Y<D:G<K L@XR0>S!AQQTSZ8-?07[+
MOQ*U;P[X[\+>&+W5)QX2U'6H(KZUN9F:*)F=0L<98E45B ,X QG/:OV#.<LI
MX[#3Y*,:=6,6U*"4G-IIV?-:VB;TOJ?CO!/$U;+:D(U9N5&I.,73E4G:-]-&
M[MZRCNO+J?TD:GX!\:_%?P)JFL>"? 5]XB\-:4=3LM5:WGT2*]N9-'\.7WC'
M7XO#VG:C?6U]KVI:%X2TV_\ $EW8:9;W+QZ3;W5Q$/MQLU/REXS_ &._COX8
M\<Z7X:N_AOJ@FUV?6K31(1KWAD:8VJ^'/"=_XWU3P]K6J1^(%MO"&H:?X;TO
M6=8N;#Q V@N=+T'5KMWNK73;R2+[6\#?M3?\('\.+_P%X=;1]-M+_6]4UNXU
M=8;*YU2:SUKP7+X(U#1[*6YL[B2Q74-'O-2M;J\MI!++!?O"?E5L^@I^V?I%
MOXDU'QYX?^%$.FV6J>/?%OCCQAI]WXQN9KC7M2\4_#KXH?#J:UT2XN_!VH:1
MX3TO2K+XHZS=Z6&\/^([JXO6N+;59I]*E4U^85Z$:;E&JN5QFXZ=TF^VY^\8
M?,\[A5A/#X>C+"UZ490J?6*O-S.49+W%#EMRN3UUT2;U/P:\4_!7XJWK?%G5
M=*\+7VLZ;\)])TV_^)VO:7J.BZUX7\&Z1K6HQZ7H,\GB;3=4O-!U=]8B.J7U
MK9>'+NYU6?3M UO4FA:QT/4YK6]^SMHO[6?P0\0>&_VD/@!X/UDZAX#\(P>/
M-.\:P>&] \5Z+I?A7Q[XGU+X&1^)+S0M8NC#<:-J'B#4]9\!/-J$$AAO9#J$
MQ1[@B;Z\^('[1?B.S\-?&3X?^&?ASX.USP+\3?#WC_28X-9M+2\\3:)XF^(E
ME\.]+U+Q2VLZ!HOA73->O='T[P+;V&@12>&-$AT"&6XLM&ACL;[4'U#:^ _Q
MW\4_!SX6>#(H/A[!J%CX0\->#_!6LV/]H:E--XJ\)>'_ (U?$/XM>(M!U_2K
M>"X4:;XKL?B)JOAO4DC2>73YM+T76=-1KRQ@\O@J*$9+V?9>]LT[O;3;1=3V
M\56SG$8#DEA,'6<JTG.-6+J-4G&FG&3DF[:3LM(^\EKK?S?]F3P_^V9\%)?C
M!\'O!OC#XG_L_P"G>/[V]\4?&N\^'NLW'@#XWW^C_L^^/?&?PSUG4;;XG>#=
M5T/XE6?A3P7\1[?Q%H_B/P?X;\1V&FZYJ4EM)J-C?"\#/^O]IXE_;.L+'QIJ
M?CZ+X:_$#5O'-]X3;XI)\3/A%\!/BO?>,/$WP,N5^!WA7X@:[H?Q T/Q#?7W
MB'PK>ZQ_PB6J_%&[@U"XU/6-5GDU/4C?"[U![_P__:7C\4^ ;U8="TNQT?XB
MZ=\8+W4=*N;6TEO--E^,/QDUKXQRAKV\T6+Q)&G@NYUMO#>E:<FNM9:C96<=
MW=QK<!6:C\:?VSM1LAKUO%X+M);/Q+J/BR\E4^(+>VTQH_%?Q5MOBT;VZTX:
M*=7GUO1==L-,@TD_\)*-%M[;2-)=["XG6Z23IPLXMV=6KS;64$U=Z::]6]_,
M_,,UR:MCL96J+*,!1M*4>>G!-3O:\]80Y&M&E%M>ZK-63/G#XK?"O]H7XCWG
MP\UKQ7X:MO$LW@K3M)_9A^'MII%UX$TBZL]+\&>)/$_CV'X:W/AS3-3-S=/X
M9U3QUJWB?7]4\2V$0T7PUJB7NMZHNA6*15Z[\0_B?^W'\6_&_@KQ!XQ\(_L]
M^*_%?PX@\.>)O!_C?5_V?OV4+K23I$::_P#"?P78Z?XSO_#4_AWQAHVEZYJF
MJ6_AKP/=WUWX?T#QSI?ABZT[0]$\3^&=+O;/Y4\8_MCQ>'[^?5W\+Z#<VMY\
M5OB]\2-:TF\UO4[--;T7XV_#33?A3XQ\&_;[6UN]3TG31X:LKFXL]9L[.^U:
MWNM0N#;V<Q2/''?"C_@I)I'P^?0_"'PW^'_A&V\':$=(N-(\-^,-6/Q&O)]1
MA^)>E?$;Q;-XGUK5_"L-I-=>+)M'TOP]8OI_A:S'AC3M*M-7TYWUR:^:3UXY
M?B9TW5A"LU%+6,+NSTTO=M)6M?9+0\/&Y3AH>RP]:&%C5A)*#E42?OR;FUMR
MN7-)NWQ-MMN]E]7Z;\<_V[_%7BKXH?%33].^&VJ>+]:\9^')?B1I^K? ']G2
M"ROOC;X$L?$&M>$_'%CX"\5:+%H^J?M*>$M.C\2S6'CW1(;SXC?V5:W4-OK&
MK:=9Z-;O\Z:KJW_!3OPWX/;P;X$G2ZN?%NI?%2WT?QIXI\%_!;Q[\7OA_=?M
M"^'I?B#\<;3PO\:-;M-1\?\ P';XO>'EO_B'\4=#NM:\'P7T,?BC78[6XBAU
M6P3#\*?M/>*+2Q\1^!O"3-H5_P#$OXI'XAW?CC4#9>(O%NC2G0/%FDWEA;ZK
MJVGSRR:I?VWBVYFN-=TN\T"YFG!,<-NK>4OW7J?[5-_K=IIUMK7@?P[<>'K&
MUUO0+O1-(OE\/2:KX1\2_##0OAOK%EJ6KZ/I&GWNH>(],;P[%K?@[Q??P7NJ
MZ+I^OZYX5GAGL;N6XG\G$5*E*<83]O&SE=RC9K3I>U];_P# ZW#AZKAN:>&P
MF Q2:I3E.IRU/9.-^1QC[T;O;II"*=TDE^ %[^PC^T_8W-WIP^%MK.=!M_"=
MU-JLWCOP'I6@>([+Q5)J6F^"5\.^*]5\3V?AWQ1'XLU'PIJ>E6%SX8\37KW<
MNFZH^K1POH5U:PNT?]E;X[S:!I>KV'P[\46]S>ZNGAI+2[NO#UGXM2_7X@)\
M*1=ZS\/Y]8M/&7AZU/Q+>+P=K&H:MHS:+X<\0K/HFI6MJTUJUY^WNL:I\+_'
M7PVN/A5X_P#A)<ZO\*I+/P*-*\)Q?$S6[#5(G\)>)O'WBV[N-;\51Z-<ZAK+
M^+=8^(6MS7%O%9V"Z/"MHMC(,3H^!\0?CYXI\2Z3XBMM<\-^"].\3:[XWC^)
M-QXLT33;:.Z_X3.V_:#US]H5+&:^ATK2_$NN_#.[UCQ-J>AZ[X"U'6[73-3;
M1/!/BC[.VOZ#,MUA*6'D[N]31>_/W9::6LG:RO9/K?74^BPV)QU>I3HU<#2O
M%1A.JE*E",(V4;1C!0;4;MZJ^[:/Q'\)_ CXN>+HK'4+3X=_;K>8_$BWGU_6
M[_P[H/A_2;/X7W7@[3/'.H>(?$NM:E:Z;X>LO#6I>-_".D:IK>K7441UG4I+
M+PYINJW=VT3X/C#X4Z?X5US5O!_C#0KKPEXPT*>"PUC1KZ.TMY[.2>U@N;*Y
MM9K&[U+3M7TG5+:]_M/2_$&GW\MCJ>E3Z;?65U<V<UI))^B7C;XVV<FB:EX(
MT[X"HGPDO+SXB^*-5\,WOQ.UV\U"7QM\0/B]X#^,6O>+-,\>:KX/OK?29=#U
MSX5^ ]-\/>&]4\)ZQH]YH]E*FINTDLZGY+^,^MP?&CXGZA\0].\!>#/AB=3L
MO#UN/ WA%;>'PGIMUX5\(Z3X5FU;3X;?2K&);SQ(VC6^M:U]FL])COM>O+YH
MH(;&.SM).=U8*]JC25[*^R5[+>^EDCZ3"<.XC%8ATW2HJG+WXSI2523C.THM
MQ=DG9IM7T?4^7;OX5^'Y)XK6>]-NY)$4D@!@E!!829;Y&RN1OR#@8#$#%=MX
M5_8M^+'Q"T+6O%'PZT"#Q)H6AZB^CW<T6J>']/U"YU>+0=1\5S:-H6DZIJ>F
MW_B;5O\ A&=*U+6)-+T2*\U#^S[.YDL('U 6ZGK[62R$EK#J8W7R7T4+VCPY
MB=68+N@7;^Y0@?<;@#YQUS7U1HOQ0\7>%?A5XV^&?PODB\)RZSXXM?%VK>-K
M.QTFY\1V%NW@'5_ LVB>&[_5=.U3^Q+JYL]7GNI-7L%TRZ@A$EO'>[IU\O-8
MB#>LVEW<K[;>7SZ&V-X2Q-.FU1I.I-M>[**C[NMW=<VJLOUM8\K\0_ ;]O:2
MP_9B^''B+X>6NM:3^S_J)\/_  (\-36'PN\1Z9X*U#QCXR\0?M07'AWXH:>F
MOS6;S:OK6K:[\0(K'XO^59W_ (=M-1\/V]X;"PO]-7T'Q!^U?_P5E^(VH?M!
M76O?&3X@_&O1])\5?";]J;XNVOB+Q;HGQF^$WPSUWX>_$O2?'WPU\;?"VUN_
M$OB#X>_"73[?QI/IR6'A?X-VFGVVI>&])NO#MSH%WH7A"Z%A[=I_[=LGASXB
M3^/-!^!\-MJOC3Q5X4\2_$D7'Q$U#7F\577@3X?>(? VGZ=X3L]4\)WNE^#-
M,$NM'Q%<R7(UZYGU2U>PD2[T>ZG67*T']KZ;2-%^*7AK3/AUX9FT+XC1^+[Q
M],\2)IFH:W!XE\5>#[?P<?$%]KGA_P .^"[74T\.Z786SZ/IDOAM8+22ZUR&
MU@M?[2-T>^CF$4FO:72LG[SVY;)-OT7Y>GS-7@C,.653^QJ$Y1FO9N4I1MSR
M<Y2C:*WDV]T^9\V[/GWXB_M ?\%#OB]X7^-'Q?U#P9X+L[#XL?LR_$S3?CWX
M[^%O[+WP(^'%_P"/OV>OB%\7?!OAGXG>+_B1<> _#&@:KXEFE^*^B^&HKGQS
MKD6L>*O#%UJNIS:3'9:9K%_?2_,OP+\5?\%'_P!@OQ/XT\.?"#PP--NO$=[K
MGQ,\0>"_B3\*OA5\<M'L/''['WBO6M+3XL>&O#7Q9TSQ?IOACXJ_ OQ7#K*>
M'?B1H4]AXKT82O)I;7WV4R/^B_@/]J3Q)\-?!O@WPMH?AW3&U/3OAQ<_#.<W
MTAN=-UOPMJWQP_X6]XET?Q+I3H;;5M%UZQO=1\#:KIMQ^YN=!U.[D#+>6UDT
M/8>-/V^/BAJ,GC'P];> _"NG^%_&^F_M0V6J>#[>6RU73I+K]I7Q=JGC>0MK
M-]H<FN1)X*;5Y-$L#:7:)JUO EYJ$<5S<31);S2C%KFJ2YEOHGTZ.ZZ>;;;O
MMM,_#S'XN-7"_P!DT(1DHM595)+ET4K6:>J;T=[))I[V/@'P-\4O^"S/PR^#
MGQ3T+09M6ET.#Q?^T=X@U3QCXF\,_!KQQ^T3\+/%'Q+&B^$/VK_%/P/\=>)=
M/O?CI\+(/&EWXZTZQ^+7C'X.WFCZ-+<^,9=0N+G3IKC4M0/3RS_\%D]=_9NT
M?]GEM*^R_#[1;GX?_LW1:GH^@_ RU_:>URV^#_CS^VOAA^SUK?Q3TFVN/V@_
M%O@?X2>,H;/7O!?@"^UUO!_AGPWX=T^_D>T\'Z,\47Z,2?MY^*]4^&_Q$TR\
M^$/AN/\ X3K6?C9JU^MOKUM_9UG#\9M0\):GJ%]>Z(?!5MJ^IZGX-O?!VDZ_
MH.L67C'1[$>)=-TC6=7\,ZU_8<%EJ%CPQ^U_XJUOQ[K?C3P]\+M'U*9_C1XC
M^.VI0->:BSRMX^\+W?@W6O",OV:"UN;2WO-'U+4+7^U;25)[$:BUS CR1")X
M><4U=J4NO2RL_1:7U;_#>YPX3PLQ[K1PU? 8;F4X^TA*O*-H+F:DY*[=DH6]
M=[:GY_?'3X=_\%:_VQ-.L?A=\8O"OP^DT)?$M_\ M(^*G^'/A']G/X2>&/BU
M\2B1\*M7^/'Q8\?_  QBT3P]\9/B\U]J]YX+G\4>.=8OO&4 \0^(9)38_P#"
M437E_P#./A[_ ()]_'SPWK-_I/B;PO=:!K>CZCJ6C:WIE]&\5YIFM:/J%SI6
ML:=>PN&9;VPU&SNK.\WS7#&\@F\RYN'W32?OK\+OVF/BW\-[0:;X*^"&@>%/
M V@:#?O:Z3XTU:3Q_P#;]0UGQ[X \:^)=1U&]UGPM_8FI7VKI\-O#_A;3M!M
M/"VCVVFZ-*^IRZA>ZO:M=7/+2ZKXV^(/BK6]<AO-9AOO$WB'4_%M[8ZI<2ZM
MJ.F:=K^KZAK5TVI:Y=K%/K=]%)<2MJ&N7$=O>ZQ<-)JMY:6=S>RVL/EXS-.>
M%X.3E.7(^9R7+%Q;;6KO:26CLGN?IO!_ &+P4U&K2PM#"0G*3=.I&4HRO:[3
M4590TYF[NR5SV'_@FM\!_%OPWT'1(=;MDB;ROB>S"%"P.[P1XBC \UD81R,7
MV(X_>!G!C/FA,?SV_P#!/_\ X)^?$K]M;X9>,?$?PX^)]A\/CX3USX/_  HG
ML+KP?XXU_3/$>M?$_P  ?%3XA:-=>*=3\)ZBA\.?#S2+?X-7FGZEJ]WHOB>Z
M&O:IIEO!X5U5[_"_UM_LD:O%8Q-X<\8:W=:+@^)]+\0P7%D7N='T7Q;I-SH<
MVLQYP)8]/L]5DU)Q"XE*6S) 1-Y=?SH?#S]D+_@KI^PUJFM?#;X3_LRZE\2K
M.'X@?"[XL>%/B7X<^#O@WXX^%[KQ[\$=/\9Z+\'?C;\*_$=]=:A;>$-<\.:=
MXZ\27%BDFCW%YI*:HL$UI)J%K R?9<*8V'U*K2K5(1?UA6<I6DXJE3;LFUY^
M7<_!O'3(,;A\WHUL/A*V(PWL'!5,-3=2+_VJI:4N122GJGRK[*5M]?BWPS^R
M%XY\1^)_A+X3NOBAX6\,>%/%?['7_#?FN>-M5D\77W@SX&_!"QL?'.K>)]4U
M+P_86LNN:]XVT1_ \=E!HOA&QM+SQ-XIU[PS8QZU:N=4G/H4W[#DOA?PBGQX
MO?VH_!OA[]E;7O ?A/Q1X;_: TWP;\3#K?BJ\\;>//B;\.-/^%[?"#28!XM3
MXB:)K?PE^*&I>+#J&KS:9X6\+>%=1\::1JNJW<FCZ97T=HW@+_@LAHUK\,9;
M7]CKXAG6?@]\/?\ A4OASQM>_LT^%M6\<ZK\'-5T;Q7X<OOA)\1/%.IV=[?_
M !+^'>M:/XY\2V&N>&?%,%OI^L6-[=2/+8ZI;Z8(9)/AW_P6"EU>6>__ &)O
M&.H^"+SP)X:^&<'P4UG]D_P=K?P"TCP9X!\7:C\2?!6E^'_@U-86GAG2I_#'
MC;5KWQ9IVOZ9JEAXA.IZUXRGU+6M7C\0S:=)]?[6B]8XFA;=7FDWU=U?1V^Z
MRZ'X6\LS-RO#+<TY';E;PLM8VCO>#>]_T1\Q:S^P'X_T#]F_XK_M@+\:OAEX
MG_9I^$7BWXD>!M2^,7@-?&GB/P;XV\>^ ;KX:V_PV\+>!;F/3;&]U2_^+'B7
MXSFR\,Q:Q::/I?@2+PWXRG\17=A<Z)HMGKGN.I?\$B?VB+=/'VFZ9\5/A_K_
M (>^%O[1GQ&^"OCO1]*A\=RQ>'KKX7_"O3OB#/\ &*^\*WUG&)_A_J5UKF@?
M"V\\168-UX:^)FOZ!HU_+%H^MQK-T6M_"_\ X+3:]!XSL?%/[./[0>LZ;\2+
M3XYZ=XYT74/@O8_\(]XJT?\ :&T;X9:/\1-+U3P^'@T-].ALOA!\+F\"1V6F
M16_P]USP=X:U7PI';7&E2WUQM6/A_P#X+@6OCW6/B/9? +]HBT\6^)+[X[:M
MXBN;3X+:58+XA/[2'@GPA\+OC)I?B#2X5EL]5TSQ3X&\%^&?[,M941-#\1>%
M/#/B.U>+4X;F4X_6-/\ ?*&W\T=_OM:W]6L5+*,RDK2RG-;/>^"GK;;7D[J^
M_P"!\?\ Q$_88\:>!?@/XE^*FK_$FTUG6? GP\^!?Q7^+'PRT[X;_%FZTKP-
MH7[1W@3P)XA\ Z%?_&Z;PK=_!K6?B_%\-_BKX)\9^.OA_+J6F7FG^'+QX-"O
M_$*Z!:Z;;?2?@'_@C_\ &GXE>#_@3X\LOBMH-AIWQ\/[/UU;1^(_AG\5-,TQ
M(/COI'C[7/"^F?#CQ==)J7AS]H/Q9X2'@>>T^(G@OP1<2:[X'N+CPO+;:EJ*
M:A>0C0U3X0?\%B=;^&.K?!O4OV/_ (JWFC:]\)/!'P!\6^+8OV:O"X^*GBWX
M)?#/4O"^K_#SX:>)_B-#9V_BGQ1X1\#3^!/!UOX<TG4]0T[%AI.GZ7>ZG+IF
M@:=:7?!Z7^S9_P %:=$^)7PI^*%O^RO^T%%\1/@O\./#_P .?AUJ.H?"6"__
M .$=\(^$_"6L>!='TU;.]1[37XY/#7B#4M,N+J^T[2KB_A$#ZBI,LB+T0Q3:
MY?K6%]W5.4X*ZM;:^FOETV,%E.94Y2Y<ES:":2YHX2K-MW;=TZ:2[IIN]]7N
M<[X\_P"">FI?"9O$WBWXU_M'>$?AS\,?"/AKX+ZW?>./%7PK^+#?$:U\3_'A
M/B9XE\*?#CQW^S_M7XD_#OQOI^E_";X@^/\ XE6>NW%NNA>#H[?Q38'4[WQ9
M;0W?:>*/^"8OQ<^'OPMO_&'BSXI6MO#H_P ?_$OP%TC0/!7@OXA^.O $^LV'
MC/X*>&+7QG>?$BQNK+P]X*\'_$#2OC#X$\2^$KW4=!N]?U;0K3_A&_$-KIS:
M,SMWFC_#;_@L#ICW;Z_^R-\1_B/IVJ^#?AAX'\1^'?B_^S=X4^*N@^,;?X&V
M,VE?!3Q=XPTWQKI\P\2_$_X<Z)<GPWH7Q&U2]D\6:AX9T_1?#NOW][I.DQP7
MO)>.OV<_^"N?Q'U'PGK7Q$_9K_:&\5:UX-^+OCGX\Z)J6M?#>R%_'\4?B/K?
M@_Q'XI\07GE:>+:Z_M;6_ 'A&[TW3EL;73O#MGHUGH-A;G38UGAKZU3CI4Q&
M&<K:\M16U]--+,)93FL]5E&;M7LG+!5$[+;3E71]?SN>7R?L _$#3?C_ /LX
M?L]R_$'P1-XC_:3\<?%'P/X:U^STW6Y-%\/7WPT_:#^+/[-NJWFKZ44.J7KZ
M]XG^%WB/Q%X?TW3U,T>FW&DV-Q=6&M6,]\GB7QT^#]Q\"/BKK'PMGUS6/$=]
MX?M='N=1U#5_A]K?PTU*&YU70Y=6?3V\+Z[K>OW:6]IY:WO]MMJ$RW=H\=I#
M::?(=P_2&/PG_P %C8;[P#K^I?L?>,;[Q/\ "SQUKGQ"\ >.M?\ V9_"MY\0
MO#6L^-_BOXN^,/BK3=.\37=LUV_@[Q-\1O%^M:OK/A%O,T]K+7=2T[3+^',:
MK\_^./V(/^"@?Q*\57'B.^_87\=>%-3N+#2]-D\._"_X$:3\.?#[-8>9<RWH
M\,: 9],;6'O&(N;^!+>\GM7,;7&YBQZ<+B\.Y:XC#ZO?VBVYE?K_ %]YR5,B
MSAQJ5%D^;.-Y)R^ISLIZI)OEVO9-^=_(^'+,+Y2%@-Y%KDL/G.6_>9)^8Y.-
M^>I^]6_:1EF:3)VI)(,$DAAN)0[<X(P4"G&,>R@'ZLM_^"<W[?0FB@_X8Z^/
M_GRO&B0?\(-<&4R2,@\LH;@.)%VDR!E 0 NS 8ST&F?\$ZOV]KEFAM_V/OCY
M//YC0BVB\$7$MP9H@WGP+#'<,7GM!$SW4 ^>V0J7 W 5ZBQ6$;26+H-O9>TC
MT>NTGL>=+)LZ@G*>3YA&"?O2>&J64>K^#2WG9>9\KVX&^+;C:K,#MQA<E\ X
MX!Y''7FM_D02E,EUBOR,8/S%0JLPPQ,8SF155I6C5Q"K2E ?K6P_X)N?\%!9
M(VFA_8P_:,EAE4/'/%\.-6>%U9<J5D3*D'H".C9'6NALO^"<7_!0&Y9UM?V,
MOVCI9(=K3&V^'.L.]J0SE3-Y+!UVNA+1C!D&$8%9,-TT<1A8J4EBJ+G&4'&/
M.DI)7<M;IW6BT3WUZ7\C%93F56G64<#BU0JTYTZ==4I7YY)Q:E'ELO>ML[M;
MG]0/P]_9^\#_ !F^)O[%W[5OAKP3\'O'WAGP-^S3J.CZKXSF\+^&_$GC$_$F
MQ3X1W_P;UVTU9]#N]2?7OABGA3XE:5H.L3ZK;^*?A\GB"[L] ETU-=NX+CL'
M_8#T66^\276M^+_%_B>Y\3Z]X_\ '6K7'B#P;X5O;B#Q[\2OAU\2?ACXG\2Z
M!)!IAO+2[GT_QQX8$<]\+NY2;X4^!];:>6^T;27T[^6NP_X)U?\ !0&U$,$7
M['/[25F)7"Q0Q^ ?$5DGF32Y=8;2);:&,3.&G?:\DF_)?"X8=7:_\$\_^"@L
M2CS_ -D+]IJWR9) T_@3Q#$GEQL$=E>2[ 8 @A<, <-CN*^KH<3Y52C%57A9
MSY8J=Z[2<E%+6R2;7*EO^)^+9EX1<8XC%8>V(=/GCB:="E6P%.K4]GB:TZRO
M*4I-).;E3BDHI-6C%W;_ *Q=$_9FM_"OBOX1:_X<O-8M])^$'ACQCX6M- U?
MP[8Z]<:EI7BS1M.L;VWL/$DEGH=YH5NFM65EXFO+"WTZYL[W7)K_ %.6YN;^
M6>]D^)?^"Q^IZ;I7[)MGX9U/4(+3Q%XF^,?@6;P[HMTT<>NZC9Z5%XMU76]0
M6U9A=-I<5M;6Q>Z6(VA=;&-I QMA7X8V?_!/_P#;ZD&(_P!DK]HZXVLD9,/@
MG7)U1\!@)7BNWV,.FY@2K9)4L #?;_@G[^W3"X$_[(?[0BN%R)[[P9JCO&[K
M^\2-IX)IMIR5)-S:$]#'*#Y;=N,XSRVMA987#_5Z<9PE&I*->4W[RM+XDE=-
MOT\VCBROP7SW+<ZP&85Y5,37RV=Y48Y93I.2A-N4X2@W)3334+1LWNSU;_@E
M1JE]IG[:_@:?33IL4Y\)_%9#]NTQ[Z>TAB^&GB6X;5-#=(94TK6K">QL9;36
M)'M5M$5PMU'*80?V\^(E[XACTNQDM/B!X=CM;S1I;;6=3TNRL] >>VU,:S.L
MFCZQ'#!J]O-I%II5K8>:TR3>9/(BX$P#?#__  2D_P""=/[6'A?]K?P%\:OB
MS\+?%GP0^&?PMCUS7=>O_B0O_",77C<ZCX8U72;/P9X=TJZN%DUC^U7U5$U:
M>:-K'3;?RTN SWD>W]LOVK? 'P\O]"71_%O@O3;;2A;0PI/IUM_9$,=Q#?*;
M6/2-1TX.L:)<SI.8[MXY9T=X=A;-?S7XI4J68XRC5PM95$HQTBD[U&G:&C=E
MO=^2LM3_ %'^B;G*X=I8O#YI@<11ABJD:M6I5A."HT\.K^[%Q2J-[M-IQ3UV
M=ORP\*?%/QSXCDUC2-&U'3-,ATSX?Z7\28[[2[:W6*Y/BZT\8W]SX7M;?49$
MMK:?PNNB:8MA"T(@LIKJ.X6&*.52R^(/BE?Z19ZE\3=8UFXTG4?#,]]?"RU&
M6PNH;ZSUGX:VOBFZ\1V42Q((;O1H5,4=A&3;V:&ZMI!"UT"?UK\&_LO_  NT
M/P=I^HWWAO1KCQ.^AV-AX@\26!>"^OH[C0+VP:U@NY64S01:?(MI]E\E85G+
MR.0 9#\5_&G]CKPQ\0_&6B0^#M.-YXA'AE/!7ACP[J?B.[T;P;H6G?VM;ZQK
M>OPS0V=[=&[DCBN6U7S;::]O])MX]"L-L5S(I_)Y91B8P@W=59+F5.SWO;=J
M_P ^_31L_M[)O%'A;-<1CZG+.&'P%*NY58QA4A-4IVY9N3;C&HDW:S:LKIMI
M'SW\,/C5-X@U74=3\7:4OAZU'AFS\1:IJ/B+2+/2[WPYX?LM*NKBZTN;3F>X
MFT^\6SGTF_>6:[,EWK=_?0RQ6JV5Y$L7QC^/FE^%O@_XJ\?6\VG>$M9N)[73
M]$MS&MOXHDM[Z:RFL-#NK:826=OJ@TM[S6=0=)=/6PFGBTF0^=9ECZ9K7[$7
MC+X"^ ?$/B3Q=X[\)^)+JTTCXEZYXV\0:=H^M7-U.GB"SM+RYO(;":%;C5G\
M*6NF>*=0T*WFB:2YUG5+%KB..V@D0_S/?'K]KBRU3QA;>#O ]MK_ (Q\':%K
M.L:FLGC'7UN=2O+K4Y'$.J>)5@@^S76O3&5]2NM6M&)M;BZ>VL[=K>&)B\-E
M>)K5'2J4N2479M>\WUMK[K6VV_X'KXCC#),9@:F;994=6"4)4\.U*G%<L8Q:
MD[*HK6;:E%Z2B[:*WZS>&_BQ\3O'G@K3+7PZ+V6[6VT30YQ?:J!HR:38VJ.E
M\=1>6:>:]FNG\V^=UDE>8%Y2S_/72:5\+?B&I\1S^+/&.D:C=^,$N=)O1I>I
MM>W4.D^68Y;>2;[,)S#LVIL#@-PH 0G;^?7[/'[4%AX?\-VEIJOA:6TDM&GD
MM!::MIT CF<L8FD:XTR+<K9(R94(+!V. %/V/K_[;_A-Q'_PCG@?4#;MIUC'
M-=:GK^CW%W+J)M)1?I$;*,".W$XC*LP)? VGY6QV3P-++YQ;BJD5JW-<NG+9
M)\KEU?5[_A\?/C#C7,HRI82CA<)"HG%^PBYS5]4XRE&,D[I*ZMI?S/H2+X-_
M"RX\+:;X4TW0M%M+79%'J'B&-#;ZS%>X6!+^63!G>6)H]YN'E5U5S]T'<_Q#
M^TIK=C^S]\2=+T'6M8\->/KCQ/X-@MK/3?M)GNM%TFSFE6TCU.1S)]DEU,(9
M!I\A0W9"OY<AYKF]8_;/\7W%A'IT'A;1=-C@NC>B9)HI;FY2 C?:2R$(Q25&
M4^9@QD_* 65L?''C[6-0\:Z_)XGU002:A=2F2Z=88I=0FBRSVTGGW<@6&*RW
M^7"%.T $H!P*YL3B<,X)*C33;]VTI/6ST5X_EVML>QPOA.-H8N%?.,;4J824
MW*6'CR+E3=^>7/43LXWCJE9O70^CW_;3UW0HI;2UO(=)6=HRZV,23 N3&B2,
M\9$C,JH@#9;Y(U4D(,#B]=_;+^)?B&46G_"?Z]J6EK%':/9K$UO9I;QJJ0Q"
M%Y_F15!C4",JJCY<)P/F%K0WKLC:9#>$ B57E@_=@!B/,\H,Z ,H9>?O;<_+
MNST/AOP#XE\1W,5AX6\)ZGK5[*^%@TN,7B+@'!!C7"X.1^\.>,#)!%>->O*[
MC!\M]-96_#3[CZ7,7EZKU*]54Z%2G4]V=2M%R:5G?EYK*+;:NGO>W=_5'PW^
M).C^)]6L(_&7B.VTK.I6MO:G4]6O]%MK>*X#8N+>XLDFADN<K*XANT%NAC9E
M( 8C[<T_P?\ #?PUI5T^@ZCX8\1Z8TT\D.O6VL:'KCF.ZWL]SJC2/(;2WN89
M/.@F6.&(1O\ Z+&B"-:^!?@S^S;KOC'4OCU!X_TGQ9X4_P"%2_LO_%CXU:=Y
M&EQD:GX@\!^(_AII>F^&M=><OG1[^#Q=J=P?LB"[-U:1QPML=Q7J'PT\&?";
MX?\ [..D?'7XY6_Q/URT^)7Q6\8_"[X5^ OA.OAG0-?MW^'/A[1];^)GC/7?
M$GBB&]L?#=Q;WGB/2]'T/1=,TJWU76&:XO#J$$-E<W<'?@,+BW-S=*,U/6*G
M)I)7LKM*32O:SMJCX3B[B_AS,ZM#+,9F=?+%@L1EF!E4RFA!UL1+%X;$8B=6
MI+VM%UI05"S7.N>"GS2C+E3]%UKXO_"#P'?SQOXET32;A8S/=6VBV]IKEX8H
M25,[7-I'O56;*Q[YE^SL& &0<^27_P"VA\/(UO\ [-X.UO7KF65K?^TKHV5A
M+)"IDC6.U=GN+J.25F(N"IC9&CC1PS,H7JOBE^RO\$OAE/\ &3XT?%7Q;\2O
M'?P+T2+]G'4_@WX=^%NA^'O!?Q.^*;?M9?#:^^+7PZM_%<_BO_A)?#7PUOO#
M?P[TS4;7QA<6VA:G)J.OM;VOAZSBM+F[:+RSX;?LY?LY?&#XYZF?"OQ8^+5Q
M^RKX$^ ?BC]H?XU>+K[PO!9_&#X6^&O!_AS5+W7/A3!:P6K>#_$OC:;Q1>^'
M_#GAO5]%9O#/B0:](=(M8;U;B(>V\!F479T*%-[-JK*3BM5LTHM.VKO9)W2;
ML?G-/.^!Z,,;CZF8\0X_+Z7))9A'+\=A\(W*4%"%6=3$2<)3G4ITXP5.4I59
M1INTFFODOXN_'75/'3O#=FPT?1K9C<6&G0&-]4AMP&D\JXU)$CG+2;7D#.X!
M7YERHR?FG^U&U&279IS3Q-*@CNHG$$T.3DO(RE7<)D,[9P_))YY_1WXJ?L!G
MP-J7[?&E:IXNU2_;]E?PE\.O'?PODM=.BM+?Q[X6^)WQ&\ Z7X8U?Q5:2;YM
M*LM2\ >-[/6HK/22XMM8NIRG^C(L(^,/V3?@M=_M%_M)_"GX"W,UUH%EXQUN
M^G\<^(EA6_O/!OPZ\'^%M7^(/Q-\7M:2/'!=R^&? 'AW7M4M[67/V[5([#2
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ML9D1#<7>E:Y:7$-Y:M;R*($4EWD:)E<[AG[9T;]J;P7%J5A)=KXAUPI,PO\
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M[\+_ -G[X76D^K#1=&L[;6=4\.V7P62^OM1#S2:U+X@M;>VU'5H-!BOC^?\
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MI]-3PQ#<:3*\>B:=K&HZR;II)EMX+X23-K(A$5LJS;86MV+C]ZK*Z*&Z&/\
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MQ!MX/#_Q'\3>'--\.:W?6.EW&GZ&^EM!+#H-_)' /L[7D]R8GE8PY8C]X=N
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MIU7&OB<=AJDY3C4E6J-J^G(I*7-9)*5E+[3T/KOX:>-?B#X"\4^)/$6B^%]
MUU/$GA/Q!\-=<L?$FE+XK\+ZUX2\17>C:EJT5WI<U[8^47D\/V;W%Q+/)':J
MJ?-/7C?[0GQPUKPEX7M]'C^''[/WBWX>^*/%NF>-/^%9^-?ACIOBCX;:7KJZ
M!#X8G\5^!HFU>SGT+6[RSM+.TUJSM=3GTWQ"EIJ%M?6#"V8RX_AW]IGX53:;
MK7ACQ9#XL\%SZO;2V%QK]O8KJ,-G#E)!/-!I[6]R\"N!%<00E%D1O+E5M^*^
M,?VI/C%HGQ#\/GX4>&;'POXA\'Z+;Z++I'BFR\(ZUX:U"#4[2,12W<&EVT\,
M,7VJ]EDO3!)'(L,MS<*=WFR[M5G6(I5H4Z%;]TX-I>SI.ZM+5MTV]=6K/=*U
MM&GE7A/@*^7X?,<PP^-EFKS&G"M@Y*K4IXJ.#C*G2J>_4?N4Z56JGRJ/M(.?
MM'(=>_M<?$H^,/B_XJ\>ZK\+OBMIOQIN_!TWQ'^%?Q/\%Z;K7PRU-/ATES9_
M#VW\+>"[46W_  B*^ ]&F3PUX1;P]JUDVE^&Q<:6WVA+LRPYU]^W;^U+=W'C
M*Z\%ZG:_"\^+_#/PR\!66H?"[0(_ L_@_P"%_P (+S5]0\)_"KX>7NGS-<>$
M/AZ;S67OM;TB 7U[K>H6>GWEQJ:R6:(WS%X/72-#MH(-4\)VBO<2^5!JLKSK
M/*$SO(:],I@\P$?+&%!'&>U=)<ZS>^6TNDV*W*I>B,0B3[7,JG.Q(DB5<K@L
M9-RLQPNTC:P,QS?$Q:<:TTU?5I;--/>+3NFUKW=M=3ZO_B%G#;LJ61X"&UJ<
M*52%'2S3=%5W1E*/+%Q<J4G%QC*+YHQ:^E;+]NKX]ZE=:]>^.[7X4_%>_P#%
M/P;\ _ ?QU;?$SX?IXYB\?>#/AMXIU'QCX4O?':76IV5YXF\4:5J^I6]NNMS
MWMK))H^@Z%IT\4KV O)/$?!_[0WQ ^$GCGXG?$SX0CPA\,_%_P 3/!OBGP#<
M:AX!\.G0F^'OAOQ=J>F:CXAMOA&TNHW=]X!N]132(-/GO8KO5YX[*XO(;7R1
M,JQ^9ZY:6QG;4-9T;4-.O2H^>TMYXXIP5 02,H&QMNT$CD'&,8&.?+:;+"54
MPKT"^>)A*/E Q&S$?/CHQP2Q!YZ5$\YQ4)PJ1KOG7-:7+3DUS))VO!I7VT.G
M#>&&4X>G7I4LJPD*.(IJE7H\M25*K"[:C.E*<J=D[VM!--]M#WNZ_;^_:AMK
MWP%J7B#QAHWQ#U3P)X)^*'PREU'XE^'(/&MS\1?A=\8[ZUU?QU\+OBV+Z[CB
M\<_#NZUBRTW5-&\/7$=@- O='T:YT^]6]L4O7\T\1_M;?$OQ+XM^">HZ/X9^
M&'PST+]G#Q?+X\^#7PZ^%/@6S\.?#+PMXLO-;TGQ!JWB*[\-RWM[?:SXC\17
MGA_0;;Q%J^HZY)<7NFZ;'9V(TL/YL?FDGAZ75+F.&T@>1G.01N<,,K\KDL55
M3E<L!D%0N<,17?VGP?$R1S:I9W-E--AHS K+&ZX 60%6^;YCCG/(QG  K-YU
MBY-MXBHV]W[O1II?!HDTFK=4M'9&N$\*<IPZYL+D>%2:G'FBJKC:2G&2475<
M4^6I4@WRWY:DXII2DG1/QU^(;:!^T1X:NCX:DL/VJ?&7A[Q]\74.@"%KCQ)X
M6\7Z[XWTAO"\=CJ4+^'M*77?%'B![O3)GU9[RSO+>WDO=]F;BX]MG_X*"_'B
M*^_95U'6/$/@O6[W]CB/=\'+2Y\!V\J/J<.C:%X=TCQ3X[,U^UQXR\8>&="\
M*^%K/PSKVI7<4>CGPYI<Z:=,UN(V\[MO@>C3(&U"ZC4#(>&,"<C)(\P@;C@>
MO10.^#6^/@'<2P1E?M4T97RQ<F*25FN7.U8&:.&:25RQX0I)O) QC<PB&<8J
MDY2IUY\TG=Q]UJ3YN=?%%V7-KHE9VZ))7/PVR#%2;QV PLY4?:0E"49KE7LY
M4:E/W:D?^7*=)[ODNKIW;H^*_P!M/]HKQQX"?P1\1OBEXA^*&C-\1_!WQ7T?
M4?B--)XOU?PMX]\$0:K!IE_X.U(WQE\.:=K-OJ\D'C#1H+3[+XBMK'3(/M%@
MMF!-PGB3]ISXM>+M<_:@US4V\+M<?M>6_P!B^,QM?#GV9)H'^(6D_$D1^$T:
MX63PX6\0Z'IL<V7U-)M*:\M(5MKNY%_;=GJ/[*'Q,-Y_9NC>!_%^L:H]G'?1
MZ;IWA;5I+][>:81)=-;VEB2+9F?8EP\$<9<K\V3@L\-_LI_%K5KR_L+3P7XA
M2\L-232+VTO]/N+6YM=8DLVU&.P\F]%EF9K2"9G20C8A# [E^699QF+?-'VB
MFM$^=[.Z:Y=5M)KK9-VLVV>E1\/>$:>&G2AEF#C"I95(KVKYE*=.;O\ O5)<
MTZ-*7,E'WJ47?37V:']K?XW>,]-\57MUHWP=T_XF_$?P#-\+/'7[0VC?##2=
M(_: \7>!+W0].\*:EIVM?$*.\=8=3UGPEI__  B^N^(]#TC1-=UC1[F2/4[^
M[NI+JZN_:/ /[2WQW\(WOB.[\/ZEX<M6\7?LW>&_V4?$6D6^A*WA_6?A!X.T
MLZ%X2AOM-.HJDWBK0=(:9;7Q/YBW!N;W59(K2VT_5+K23QO@3]D>^U9+*WU#
MXK_#?P[>%[BSO='EU6/4/$FDZNMEJTYT^_T2T6/R(HHK&._FU)M1GL[".00W
M[3$%7M>+OA!X%^'7]G0:E\=].\0ZO?R/)>Z;X!TU]83P_:++;8GO-4ED@L6N
M=DC@Q,XC=W"JC-M%9RS?-)ZSKU:;LTM8^\I7NW[N^K3>^NK9K@_#W@N-=0GD
MV7UU)0DJ56E*:D\-R^Q4>:I)Q]GRQY5#E2<8M+W3R2_\!:W96\-QHUC+(UJC
M(0T@:0+D&%69((58*@\M JL0L9)R& J'PWJ,7]IM%?+%]K0P"6WN)3 8I$R)
M!*QB=8P2<P@!C*N3\G?Z57Q/^SMX7-C;P:G\7_BE<S:9+<268UKP[X9L]%U&
M&XELXH=0&GZ9>W@CGBAAOX4EEA+1W#*QG38D7#77COX76>MZ9J6D?!+P[>W5
MI&1J]OXT\3^)O%EK?ZA+AA-=:;9W>D6\<>X PI#'$@4$ G)KQJM.<YRG?XG=
M[+7KT[ZGZKE"IX>C3A# *FJ?-"$%*HDH1G)04;S=M+)::7UN[GL_P8\2OJGQ
M&\.6-H8=PEU&V2VO&15+OHU]';BUD7:MV22H2!5$K$"-4=B .G_X*?\ A'Q%
MI7[#L::[I6HZ;]N_:I^%U[8?;M,GT^&ZMX_AW\78'DM_/8&6,%0XD0,IW%21
MP3F_!;XE^)E^)VG:AX5T[P?X$TOQ ES;:EX/\+Z!IXT>WEM=#O8_M&FR:G!>
MZU;7$_)E\N^;8VT2.Y!8['_!5+X@>,?%G[$2ZAXK\17^N-:?M2_"2QTL7;H8
M=-M#\._C2\UK:P1!(H8Y)$C9MJ9+ LQ(R*^NX5RVI*MB+ZWI].MTG>[M;?9?
M\$_!?I%XZLLNR^G[!4Z7]LX!OF<G*,K7T:3B^5NUW)J6Z70_FH:SMXY$5F 8
M*I.%  ^9^"2V,Y.,'I@\'K6W;V]L8-T44DDB;E"Q('DG=B62*W2-G=IVR$BA
M=4FNG&RT$[D(>2GG?SD<N"#%G. ",R,!Z<#/'/'(XSSN:)K^I:+?V6LZ/J-W
MI6IZ1>V.IZ7J5E,8+O3K_2[DWMA>6\XYBFLKLM=6[MGRIF+CL#]Q2RJ3E\+U
M[M]UM;6__!\C^<,1CZD*=*=*I2C*-/F?MI.$))0EHFFO>;LTK[)O=77[B_L&
M_P#!*[7OCGKOA+XBZ_\ %+X":_\ "2W6RU#6-'\+>)M;\;ZC#>ZL^BSZ3X1\
M4#X?6NG)\//$NH&YOK1=*\;&X2UU"QA%]X/UJWN)8(O[.K>Y^'U[X \6^&;#
M0-8\:>&O ,7A_P ,6?A'Q!<7-_<:)JOAFR@CCM9;+7[M[/4X?#FH:;IMS9ZC
MHNDVK:9>22RZ>FEV#6FEV7X=_P#!,CX]?MA#X$6/B']H;X(/J7B[XA:KHVH?
M!SXA>+=%\*>&_C'\=;6\M+J3P_XQU.'2].TKQ7<^']*6^M#X1NO&(U!/$\D0
MN-*EU!XOE^M?C!^UE\1].^$E[J47PVO/!^K:5XT\4Z%YFF:K82^,-)UOP=97
M6L>*;FWETR#RWTS4K2XL;K4!/FSO+6T?S"VJ/9R']CX8X8PD<)2JQPT54G*,
MIR<IS;]V*;M*4K-):)<L6V]VC_.GQLXYXFS'B3%9?/$RA@L(ZD*5+!U.6-U7
MG)3E5@HUN9+2SJ-<J3[L^F_CM\)OV5O$^CZIX-O? _PKM/%&J>']?U;6=)M?
M!NA3^*+#Q[\4_"D'PZO?'&O2>?I/AG5M9/A[Q#J!L-<U6VAU2VFL=UIJUK>7
M-Q<I_"I^W/\  /P=^S;^T!XA\#_"^/QS??"E[+3)/A]K_CVWBCU?5TB+:9K]
MN-2TK2K+2KB:TUB%H;F*.2:5+&5+Z.34&\T2?TB>&?BIJ7Q*C\+^//B1\=[3
MPUXMT3P+JWB=]$UO,4>MZY'J,1T+PKI[Z/=3R&WULA[J%=3D&H:0L3"WCMXV
MW/\ G+^W#XMTCXU^!_!ES\2]8^$VAZ7]D\2PV/CWQ;'XSO?!WPMU/5] 70M,
MU/QI#X!L;RY;Q%JQ_MF;P-#KE_:VJW$!\17]G="W6R?UL]R+!4,%.I%QIUHN
MS>]GI96;Y7OOR[M;7L'@IQ[Q/@,]^J8C$8RME^(2<J4ZTY*>BBFIMNI!:/W8
M36U]V?@>MS"J%0RL3W##.W))!&#ZGG(YQWQ4B7T,9);!!  R3U&3V5AR"/KV
MK@KN_6UN[FWBNK.\CMKF\C%]9F66TOK>"\FMH+^QED*>7:72JK)#<1272E"2
MVTDBF^N,,;9'4'N@ /T) _0XKY_"49+WI6M=W5EMKIWZ^O2]G8_KZKFT9J7-
M*[25FFHI;*[2LTK;6[_?\[:/'#J"&W\V)4"D;PZ@'C(&[</XE[8/S=\9JE>>
M'U>X6!'+[Y-P"D$%ERR;RI*_,0, CJ!C&1GF] N;Q5E$9(4<%@!N'RL0!@<C
M<.1D>G<D]1IL5U=,TLLKAH\L,$@[0<'MRRJ"5&<'CD#FOH;J*;<7-)-N*U;L
MGHOS^1^6Y%4K5J$HT6HRT4:C2Y8OI)MKKM>SU:]3]8?V-?BUXLN?!NF?#+2_
M#>O77_".>=&E]I=K/+IJ0RNLX:>Y2*2)9Q))()07R$,.0I;)^Q/%&H^/UU*U
ML]8CN/#UM\[?:[P*R.-I92Q8*$+Y&-QX)P>0,8O[(NO^$_!_PB\(6^A"R>^O
M;-KK5KFWB9[A]19P)([J7R7VO]GBM04#DJ&4E1G)];^*OBVT\<3V\6H/;VJP
MV:-&LBAI&"QG8X$0#$CJ=Y4]L#@5^5Y^_:XN2IX><)*<G)M+6Z:TU[V=D_GN
M?TAP;]<PV64GBZL)J3]R-DVGHW+9^ZT[6T7Y'R9XMU/4+6$7 $.I$73I+$"9
M+B9 3LEA@A;S9"K$-E =V,'(SG]*_@K\9)8?!.@K8Z?K+0:/IEE:S3WFE7MK
M&-JLP\EYX46;:ZNC,I8KL7( 8"OASPG:?#:2WMXO%6I:A8:W'JT1\*:OIZ*8
M;R9[R."XLKJU\X2;9+=ITD8VTHC5FD#D*#7[,>%]>^'$WA>WTV^M[&:.#3+2
M&!"8;=HI/LH6>20(L;-)-(J$X#E2H8E22#X#I36\&GZ*]M.M_P [O1ZM:GVM
M;$2FX\L>:/)%:;7N_*U]CYI^(_[2\]WIT]D%$MP86 >5 ) F &P"2=HP S8P
M<C.1U_.7QOK\&M:A([PB)I6<S%4"+OD9B6) ' +80#MG!KZH^+OPZ^'E]\0+
M?6;2_O8)8=/NXK>W@U!UMGFF(:-A$TB1/L"X)?: P(!8?,?F+6/"AFUF>W75
M4*;8]Q<C).0&R45@TG7<02"W1CD&OVWPWP6%H8.ICY0DZ[2@V][SO&]]=%S=
MTK+[_P K\0*6)QL\/A(SBJ,J:E)*VCM\$M%[SLHNZ>ZU/ Y;,R7DUK>.QM5<
M[3 K,TL3L05 BP788/(S@$[C6)=61T^\\O2O,CM#(%;SHI8C'D$DR>:.%.6(
M;(Z'D#:*]P?P"\\_GQ7F5CD*J2P4;PQ().""ORL?HP 7)K.O?#UC(WV;6;M1
ML)\J2!29$5#\^50*K[B5.7.0 5"X/'Z7-Q47MT[=_+4_'\3PQ5E*T)*@U[_M
M9V5.*B^:5[-[I67NO5ZGEPU.]MT5)OFC,W$@/1%)(8N/NJP&<@@$D,#@@U^C
M_P"P'\#O WQ-\82:QK?@;Q'XK9-.OS=S:_%IH^'JF-H<:A'()XM0M-1M@546
MV9)&0NRPD=/BO_A"])UF">'2-;M7O2R1PV]W&(W8JBJ=A ;() .3@8QC=C!^
MD/V7OB#HGPC?QKI7B6V^(_B+Q;%+;W7A?X>^&)VLO#;P69$NKZYK%_8/#,RV
MZA2;".1X9HV<R3PE!GS<5%U?9P@N;F<KVMHK1WNTN_GH?DWB3EV=9;D688[#
M)XNE3@E"I0@I15D^9Z<LET^REH[7/WLGU;P]X7\/Q^%_A5YE]XM\/P1VUEH[
M:1*FAZ<J3Q)>V=E+<HD-Q;//Y#VTJ2$A8B(OE+$<=\8KSPMXA\*:QIGQ.TV_
MT?7IM#U&"*[L=+9[FVCN],=M0L;4".16G,Y:YAD/[\&<8.-AKX;L/VND\1P:
M'9:?K_P[M];\926PTJUL=2U.UL?#5M;7$3_VGK^HW2V]NLVFR11^?&]S,97+
M;E9-SK\N?'/]J#XA>"M<\<65[XYTSXF-_:MM!:2:=J,FJ^'KR\*1M<7&E?9Y
MHVFCFC,&Z.,_95&4$Q((7AJY#&M3NKS;;NFE*S6ZM+MMY6ZG\L\.\49KA\WH
M8AXO'T)8>:J*-&$W%3;;DDTU)3NK26EGLW<_2C]GWQA8W_A7P1\(OA1)JOBJ
M]TN"#0+:.]@==2@FD7,XU<LN8+:,.!-<2JD88$.P/-?9FH_L7+K]I:ZK\5/'
M4T<EPD[_ -AZ%)"L"*L4CH+^X8N+F,2!68Q$ ; 7!0&ORF_8._:?GTKXD_$#
MQ+\4%\&Z%JGBW1/#MKX#TKPYH\>C6VG6]DD@U=;J[>9WNM5U8!5GN)!F(*NR
M4<U^GNK?M.:7JK".9F^RRQS1R3I#/*D)\F3RV1< .DDABC8J<1I([OE4)'\Z
M<<9-/)\YQ%%TYJE6IUJZE*#Y7.ISU.6]FM'.RT2TNGU/]?O!3B/-N,N$<BQ,
M<;2H5<)3I4,1[648UY0C2I04ZMWS\TU'F=Y3:<FM'=+\<_VT_@?IOP1NM7\4
M:?XJU"7X>:1-;7-ZD.E"]U*SNY65(5BBV[7TY7D#2W&QHD5P7*@;A^6\7B+3
M_%&FZYXH\#VNH:[%I\@GN;C4B(=>TV.20"6;2_#J(KZG9V\;-,TNV5$-PF=J
MK'7ZU?M(?&[3;K4;32KC_A']>U;5M<M(XM"U/3;KQ!I36D-V6SK&F:>)7FAD
M@11' XR95Z <CR7QC+XYOWT[Q1IG@"P\,:#+*8=7G\'_  PT3X:64VG)$R+:
MWFIZ_JGVJZTQG0^5LL5>0LY SD#\_A%QFVU96M=^=K6MZ6?R[7/Z?56M'"T<
M.Z\9U)14)58R?(M-4]4TY6T;3O9ZH_,KPY^T@/#OBN'P9H_AB[NM'U[5H-+'
MB[Q9I%Y9O=ZA>RK 89+B\1++3I8+J01F:218K212))%2-B/Z&_\ @G[X*\8:
M!I>CSSZ/\4O!7B+0]<N=6\0:9J_AN?5_!GBF"Q5HY]9\/^(+"&2VGTS4DN(;
MNQ:.XEMK@0&2%F"[A^>WP \+^"?VM/BI9_"SQOJ4OPY\)^"_'%M(+[PK#X76
MWUO79KA_L_AG69+MVOM0;4]-BN/ME]I5O(OGR-,RVY8&/^O+2?&_P^\+:-:Z
M!IEM!8Z+I6F6FE:786[QVT$4-C9VUE;K/';1O%-(JP^?+YLI96^8%VZ=M*"C
M*-1NSC\*>G,GUVU2MU/SKB[,,Q4(9;0RZGFD.=PFE=SC&4HIV:<;JUVVY-W2
MT/B_Q=\?-#72I-,ENS;"W>Y!MY5$4J2R2$SEDD"S*9!Y>Y7'\"KC@"OR_P#B
M;^TKI/ANZG74?$W]CVLM].MJ+NTU27S7>3Y4C%M Z2[C\T:1NY (PH.17V9^
MUUI6A7D%WXG\*0V$M^9)6>!U;$TVP&-HEAN$ 6.0YEW@;@5(7Y<5^2FJZY8^
M&[4V?C3[!?\ B*>ZAU9IKFS6+3HMFV5+2RO[D^5:LB!(W8>87D4O((SE!^F<
M%<,RXJKU)3A-8:G.-.I6LN2$VDE!MRTE):I<K6KN[[?+9KC\LX.RY.A@%#$X
MVG&4\+2U<9->]%<UI.]VVF]Y-;'L6D?$K76T76]=L-3NKB'Q#/%<Z7H]Q$;"
M6Y50%%U"EYY)@>=@/LBSA%=B@DSEJ\3\0_$'QKXMN3X9L?#>OZ=)<DR:CKNM
MFPBM='@=P+B:U"R.;J<'RHXK<*ZE9I9A\T(Q/<>)/ _BVS6\T?QN^BZ]"7>]
M\,:M>0JRVD*F59]/U*-I;*[@W9)M1/!<-$%2*)G*K7#2>+IIK<D2ET<S1BX!
M@#2&)MBLS0RR,4;.0<$'Y21N(S^X83P^X=PU*@W2O4HU%)QLF[QYE>SCU;;\
MOF?C&<>)?$U'$UI86K+#+%TW1E9<U6$7HG!7:4DHQM[RZ[':>,X/$&GZ%I</
MPF^)FJ:5X@M(A'>:3X\T:T\3>#]2D)'GSV]S:.NMZ:SO\X53)"C$DE?NUY[\
M./@/^TEXH^).C?$[Q!^UA\-?"NM>$;N.[TBQ@7Q']AN;>?:+C2X]+MK"2SNX
M2BCSA>21NT8$<C.%!-K3M=N),DQK+M#$%))DPH^8EF>$(/FY^^3@8 )-2R^,
M!;2+''<K'*DF]Q;R[V7 'R[B(T) (&0S ;L$@@D>E+A3(.62>%3YHN*_=PW?
MK'I_6I^=XCCOB:FW3EFF)K*I7]JU6<H0INTES.2FGUM;5:W:NCV/XN?M'?%S
MX<RZYIWB#X,^+?%UW9R_9UUSP3JMC>>%[I[D%;>:6*^(U*S:1R#Y$$+O)&K#
MR]@;&S^SM_P4CU_6_"-UX(^+>ES?"O4O#U\UGH-[?K<1>'KW0)O^0=:ZAJ4Z
MB.TUBPD-P+U9)HU2.6-9$#-&*\7M_&U_$LL[:E=23.T;*[W(/S0*P@E*_O,R
M*6^?YP &+ LPQ7)ZC/H6LG4+36K&VU*UU2W*7C21F\2X:1?WL4D<TH1=S\[U
MVNH& >BGYW$^''#=>%6/L)0JU&W&JK)15K6TL][MHZ\/XX<7Y;C,-*KCXXC#
M82FJ=/ **^JUHJ;DZDYV4HS;?([6]V/=NWW3K?[8WP?T3Q+X"L_''Q1T._T[
MQ'\0?!FF3Z?H=\=<EDM=6\1:=I\]Q<?8?.@M-+MH&DN+V::2)8((IIIR(55C
M^^_BW]H?0M(TYK"RU"U2RA58+6"UDB-K+91*JVIA1'*2P&%8GCP7#H<#<&&?
MX9/%G[*N@W=U)>>%=8.C&X/FC0M@D6 ><\N-.N803;K.R1*LK)]JMWMV96=7
MC"_2&C_M/_M!?!CP)::;\1-!/Q;T'0!':Z?K5CJTVC>*K*TA1+>RM+J*2"?3
M-354$:/>W<7VB4?O#M?D?!<0>$TL-057)ZCG-QE.:C[SM:;=[N+V3TOI;>]C
M])X>\=,GXBSC"PXVRZCE^71C'V']E-59:M*/M8U(N-W-/F?*W:6^A_2GXA^*
M.J_$?4K/P[X0M;_Q7K.I7T<ATG2;:XFN%MX+A)Y9+AVC$-I:I'#(\S3NB21J
MT:[I)%1OO'XDZOX^TWP2T5KIFE6;+IH6YTM=5A>Y@D33VMPL<.[RHV;"[8X2
MQS@E?NY\8_9&B\)?"GX&^!_$QTJU7QS\0/"FE>+/%6HWSQ7EU;RZQ96M]9Z*
MMPSP*8],L+Z. 2):1^<8)7?,BKOROBI\:(;V*^6&[0KB4H%9DQ,X"[V)1E:+
MY<1EBN-I^4C(K\0E">6PG1IRMBE:\)I\UN976MU+W7*[N[6>^Y^]Q;XJS+"5
M\OPDL)DV7U5.A6DE&GB+)M\CM!**?+RW?-)*Z23M+^<W]I3Q7X:TGXZWNK_$
M_P 73> ](MX;AK?08K>^O_$WB2]:-4:2V@L8)(;31;<%XC=7!MK1)),2REC@
M?$NG2> K_P"(T.L^#+R+Q!%K5UJUS9:&2;.#0I+6*0V \2ZE?W+6MHJ2K!J-
MW!H+74NIWT<MNH#O$#^BW[5/Q _8=\5_$WP98?M#/+/)X;_M'5=9\2:!XGUF
MWG6+[5&L/@ZX\/Z'8W4^NKJ;AKF38$>+R3&TB%E0_GU^V;\>_P!F""ZT:Z_9
M6TGQ=X2B\,/++X<T^R\ 7_A?P_XCNT-K%JWB?6]9\?VL>H7%A#:_Z&(=&M;F
M<R/*Z6]L3%+7/&/M9:4I>VJ*U1J*]Y=$E_B;MILS]CEF<848N<U&.&P\(IWN
MO=26ZYMU'ITMJ?+R?M%:[K'BVS_X3:#5+*'2-?&D^%;EK8:;HW^AWNRY"7NI
M)'/?01#:T&2Z1@*!M)&?U$MYM.\>R> _"&A^,]%N;95GN]*F\3:C;:9#I]]J
M@MY]4M=1)>-&M;R:VMQIMQ,5B6X5FB)D<,/Q"^+/Q'T?XK>/O#?B:>7PNVB7
M7A^.VMK>T^VZ?9V&L$K%=7,\%S<RK+?><I?SH%MD#9(B;.*^A?V8_'_BCX9?
M$+P;J,B7GB_PM9^+-$A\1++X5D\7Z5;>&+V]5-3>_M5@G1+.UT];F[4BZM+K
MRK26:V+/$5K'%Y/[.*YDX\ZYDGM=Z66K.S(N(56>+4I1M3HN=.3:?.VGHG+F
MOHDDM-]-S^K[]FOX&WFH'P[&=0U#PIXMUO2;[P]X<U*ZAL]7TVZN-/A34+:>
M[@V(VJ::=K-;1.CW,T.V6W=HV\QOTBT#X&?$+PC?^%/%6M?$C2;W6]#4/XAT
MGPKI%YX?\,:U+=VSPWTCZ3<7]U]ES"(PX^2/S]S%0QP/*_@/\0/"EMK6FP:.
M]EJ>CZ?X.T^ZTC4M,U5KGP[I>G:GNN=$_L_3M51]9T^XU?27B7[/<N?LTOVF
MTA:.WCA2OI3Q)\8],DTRVM[F>T"VRR"$;&C8E@Q5Y&* -M!^ZSE20>0.MX3#
MX6GAJE&49JK&;4KRDK<M[RM=*RU:>JTTON?D'%&8<39EG7L,'.+R^KSRQ,%&
ME.+ISDY5*<E)RO-4U."7+=2:?,N5(^=_B3\8[33KJYLKB[6UN8))/,0OD,V6
MC#!F8EMSNHRK$G* $8Y^+/&WQ8@O[;65FU6ZC6"RE 5(3)"99;E(Y)KF0@I#
M]DB4R0AF G<O'\VUA6G^U)XC2[LM;\0:1-:VEYHFG7^K>9*D+6UQ'9V=Q+-#
M*K3PC9=0EH&?>C(':5 73C\<KV^_:(^)&I6FG>-+OPUH.CZ@\4VD_#?P8+.P
MM[Z!85N8+3Q)XKUJ>.;RHK=X_.MFO[.W,Q:2-IG=G/W7!/ .,XHQ*KNK[+!T
M*J?O+244TTD]6U+S6K/%XR\0\F\.LCHJIA/]KQ.%K*B[*//6C3=TN2*NXNS?
M,T_/>_V!X?\ &_B.RT+Q!-?^,K!]&G\7W$FA^'[R1+C7-$\-7P$!;1K"22*T
MNE&IPWNJ/%>S+]G@OX=JK 8Z[_X%75K;2_M!:QING:G;:U<_LI_$Z?6?%.IW
M4-UJMY>V,WAJXGM;$2*+#P[I=K"&DBTK3?.M[B+?=FYE,89?SZUOX@ZQHEY+
M!'I^B1W$:[7/S:HUNUOBW:WL[NTNY@/+,90%89$(4%9'!W'W_P#9\\3:_P#V
M/^TK<:G>"XMF_8^^/DT5A'#JEMJMJ]I8^'5:ZCWVWV3[,\*S1J[7#2.7\L1
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M/BB\U"ZL[B=+.4K#=V>F0Q!C]GU&0O+;W4ZB3[#"N?GF(KF/C5/9:;H6G7T
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M]GCX3S^-_#VOP6=OXL^$&F?\*1UJXNVLV?\ M27PEX2U6[^%<$B1@W,BZ?\
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MKM-J,DC1ZC=:H%6]U'6((]3OR0ZNSQW5T7>%Y"%#% "5;'&<C]:?C_\ L^>
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M<J"N0#G/UWX]_9LMM1\"SO:^-M7L[B2"9;>[$EM,R/$ I\RU+;8AN(.T#:.
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M^9P<^L?"CPOXF\>^*=(\*>#=#U#Q'XEUB:9=/TW3;2265ETNUN]7U&ZEDC&
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MEVT1XW#^08S/<RIX++:<:E>7+-K=IQ]G)V2;W:;VZ]]OO;]E/]OC2?C!\ /
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MR56K5A%_#6LKRM-:2Y7\,7:+U=K&3XM^,$&I)/+/+91[@,I;I'"A&Q1GY')
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M]QM7E7,QS\Q!Y&,9[ '!W]$U6W1IK-)8KI]3LVTX1RSO;8:X9F\_SUX$<(B
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MX6VOP2UOP_XX^,.NGP?K7AS5M"\3Z!\)_"_V37OBAJUYI%S'>Z=-XICBAO\
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MNQ;:AX7O;Z: :A-X/UN,B]T]-5$0-SI=_P"9HR2K+<>5!/>W4LG[&^-/VOO
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M>Q4LS,"05W9%?6'[=^JLW_!.R\A4RQ06'[:OP/6"*YD$LT?VOX-_&ZXD57&
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MWU?4?AK['R<J,=L-GC_OLX_3O700VA=E.^4HJ;466:>15PI.0&D"CC*[ #&
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MJ]%>^^K76[TU3V_J]8C'8RA4YL/"B^5-*"BMFI?947NMO+?4_&+]L/\ :?\
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MO[>&*2>'EQ?B'DE&C*E*511BZU.A.T4ZDZ<(NK:\6^6,94WSZJ7-:/-9V\3
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MB'Q5\,M3O?#$@=8_$OA66'Q7I3+&QWG.G)'=0J#F1FN(R$B9'(.:^7A8*Y)
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M7MKS02Y4GIJKN^_?U/DJM.I&+51>R[0E?GEMMM9W\MD>9M!>.NUX8V!P1C(
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M'7@7PQX,^&>B:EX/^%NDZFVGZ/HCJ]G_ &O<:;O^T:CXDU *L6L^)+56+ZI
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MHZB#$P7PS/I<T6KW<=]'/?\ ]IV45DR017!UOVCO'FM:=\1M1^&WPFB?XF>
MVA\-3Q>-/[-BTVXL?L_@N?PM?M#&?*B?4VFDFUF^2.(Q/K"3J@6)Q(MTL!"'
MO>UBY=;VMU2T^[J?S!D>4\28G,::IY1C*"O*SJ0J?S-/7E7NW3Y>T;+6UWX_
MHND^$8= TVPFMM4TR2V%W=V,FK7D40NK'4[IYK2]MX9+%)3ISQDBPG:[)FR0
M54\US\GAOPB\5_,1#>BVL[Z2X\ERQC\N!WQ*^2K9*@*@0,S8QC!KS=/V??BQ
MJ=RVJW'B7Q,\\Z"!K75;U=1TR.. AK9;.UQ;M8VPVEHK5'F2WY6-G#&O1/"?
MPI^+>CWD.EM<:!);7^&NKBXM96<,2(\R*-X$7ENZ.P?!;:#DG-8X^I"G0K*G
M\3@XI2]Z[E:&VFEI.W9VWL?WYP-@88#)LOJXVM[.OAJL:M:$Y>_-0O)*-]4^
M91NM?=4E;JN,^#V@Q2>'K^?_ (1674VEU6Z>UD:W$8CMS:V31*DLRC(5F8YV
M%=[,-Q(8#W'P2U^DM[X:>P&E7%P9[S2K:\7:EQ(/^/BRAGB9(8KM]@-L0VZ?
MJ,'%?6GA7X#ZU_8]K;7.N6L(2,$1Z;8H(W'!&S(R 3E!C)&W(/%9GB;X#?9[
M62\AU&_O;H213" .D:13VXQ',$9HVCE7/)5_FQSC&"954CAL%A\+5493HR<D
MVY<T82=]&I1?-S-)>5U9GI9SG6$S#-I8U2Y8Z*]-\B=2*4-5[R:Y(]]]>Q\M
M:UXIC>S>UN[JX638UE>V<\TTDD>R5$4.LK&021S&.6, Y&P. <$-V_@?PQX.
MU7X/>*]1UOXBZTUW<O+/HFFW^Q].M%M))(2KRM"DT,GFHJ/$P9PAC,6XE@M?
M5/!5]!<2V]SIUGJ%C=,'GFOT4W27 0E+K[3'(LID6X$,X7:!YD:J2REJ\JU#
MP1>Z$CQGQ#J3:++?V]U?:.DO_']%#,9F@27=)]F9V9EBN%C)MA)(?+F9PJ_H
M&6<08.AA<90JSK5H3H2<:/M6VZCARZ7YFE:*5EU3UNVS7#9I1IU*TG4G*E5P
M[BH5)<T/:MR>VG1QT\MS@?&GP<\5>#?A)%\5/&D4&DZ9XT\5V?A#PII]S$\>
MI^)DM+:XUS4M3LX_G#Z7IMG!#YM]$7C^T7%O ZAW^3=\0_M%>%?%_P"S9X!^
M ?C3]G;P;XQU/X6^ _B+\/\ X?\ Q?3Q=\1_#_BSPUI_Q'\:ZUX[U'59_"VE
MZT/!^K:I8ZQXDU&6SDOK+:TMM \L)2:6,<G^T5\<O%?Q"UC0AXA%O9^'_ VA
MOX8\">#](_Y _AK0LX9DB((N=8O$5QJ&J2A)[@N&,:*BH? O"7BE=<\2^&[2
M6(3Q:CXH\*VE[9!_*:6WNO$&GVE[;'R667==0S2QMY;1R*S;8V4[67\IS9?6
MZ=7%8F@E3I2J/#T^7EE&FN=QC.]^::5US6CK):::_.8N*E)55=2M[J6D4FY6
M273>ZU=GU[_?5_\ \%.OCA;?%OQ]\8M'^&_@:#6_B'^TA\$?VC]9TNWDUB[\
M.7&I?!/X7^*_A9<_#BXAFO)1)X)^)/@'QCX@T/QHMU*'":U-'I\ZR".-. N?
M^"G'QI_X63\,OB9??#GP;J&M?#/XK_M0_$_P[HZS>(8='AB_:P^#7A_X&W?@
M6&"UO)&M/ WPN\#>&-)L_ <\%PBQ7$$5KXCO(V@ADG_4_P#;4^"WP$>X_:3T
MSP1\,_AVVH_L^_MV_ ;P%:'PQ^SM\0/V>'\$?!WQ]\1?$WA#6?A_?>-O$4S>
M#_VH!K>JZ?I5O<7WA=Q>^&+!5\0RL+?4XHAX?^T/\/?#'[.VE_'WXA?L]_LC
M_#GX^^+M5_X*$_M6? KQ5I_C+X:^)?C'X:_9_P#AW\,;S1!\'_AMX<^&>AZM
M9_\ "/-\87UGQ!J%QXVOUN+S4-/\+3>'M O=)NIWU!?@?K&7.49QRJTY14HS
MG[T5&25^9>ZM8M+=ZM-7=D<#ISBN9MM*VLG=Z[:_/\_E^%,_QX\2V7[,>E?L
MO+X?TM/#.D?M#ZO^TW_PF+G4D\4R^,-5^$7@[X0WN@2QEUL)M!LO#7@+0-0E
MO4MFU1;S6[I8VC"!J^J_B'_P4@L_&GQ_\"?M2:5^RI\-O"?[07@[XX_";X^7
M_C&S^*OQIUW1?%/BGX7'0-6CT.3P/X@\5:CX5\,Z!XDM_"<%A?S:%96]V$MM
M:M; F>6(/^LGA/\ 8H^!WP^_:G_:F^+NM? #X:^)O@W\)_"O[*OAZQ_9U^)/
MQ-\-Z+X&\+?M _M+Z3X#\;_''X:V'C+QIXUTF"^O_P!G/P!#\3]3\*^'Y->O
M-9LM<311K$UVEJL)^?\ 1/\ @F-X'\=^.?B_^Q['H>GZ;XU_91_;\\!>,?&7
MQATIGGU_Q5_P3@^,>EVFOW_CK7M22_33]9\+> _ ?A#PWXVTS4;2WMY)(/&<
MR6-Q)+J1WNIF6$Q*]G/ SIJESS;DO=DYJ*J<D;:R25-3LV[2IZ)-%4I.+E:U
MFE=-75DWT^9^5_QB_;D7Q[\+OB'\&_A7\ OA)^S=X%^,OQ)\/_$_XU'P1K7Q
M)\:^,OBMXH\&:EJ%[X(TS7_%_C_QCKMY8^"= \2ZK=^,[#P7X=TJRM9=:;3+
MR=HTL=Z=?\&O^"CE[\$? EAIG@SX%?"6R^+ND_!7QG^SC8?'.R\0>.O#-]KW
MPK\<1:O9W=C\6_AGX5U[P_\ #/XR>-=&L-9U2S\,>._&VDZB^EG^SX[BTN)+
M-+Y_U2_9:_8W_9W_ &A_!7Q"^)&N_ WX.^$O#G_!2']I']H7X?\ [/#:WXU\
M.>!=6_91^ OA'P%\2= ^"OCGX+^'?%/C/0=2\0^)?$W[1NI_"_PIXCUW0(?$
MDEWHOA;XC6,.CVR:D&T_S3]E?]@GPK?^$_V$-+^+'P/T6Y\=:UJ7_!5'0OC-
M8^)-/FM_$'BCQ/\ "KP)X;A^%NGZMID%Z]Q=M\/_ !:-8D\+Z586Z7-K-%_I
M4.HQMY SABL'/]PL'*4DV[S46_>5WKHDH\JAZQ:3M>1UTJ?MVXQ2C-[J*Y8Z
M;/E5[O35]7Z'Y*ZE^TOXC\4?L]?L_P#[.EQ8Z;#X;_9X^(OQ7^)_@[7D\[4]
M7O/$/Q6'@V[N!XET'5+J[T*\MM ;P%"EC ENNGZG_;^KV=PS65S'7U1\:/VV
M8/C5\%?B#\"/#?[/'PE^"'@WXU_$_0OC9\4]&^'FK_$[7O"6I_$;0K37)M#D
M^%GP[\8^,/$_@_X,:$NH^)=9UF_T#X4Z+I8U+[5##<:D;#3K:T7T'_@G3^Q'
MKUAXC^,_QV^*?P6\&_$W3/V<?@FGB7P[\&OCUJ1^%/@#XL?'#XAWP\._"SPK
MXM\1>/[SP9I\>FW<6B^-/%EQ:W5]9PM%X7F@@M&MKQ#'][:'^Q'X _9M^*?_
M  4SEN?"O@K6OA5X<D_9Y\??LD?$CQW\!?$?[67AC1OA;\;/B5XJUV&T\/\
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M*="+Q6&E)S4U&5;3E;Y7*,9QMJGRWM\T?HYXQ^'UI?6SO'$D]VX4*L(^5B&
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M\4OB[IVN:=J FO(;W4)K<6:*;2,"0K"(K9<PQ1Q%DB"*'V^8,#<V0:Y7XA?
M753ITWC+1-6MWM6U+[/?6]C>"+58/M*O(MS+I,Z^7*D;0L'NK5S'<;AN4;%!
M_.3]ICXPZK\%OAO-=>'M-?5?%VJZ\/#T.L:S;BRBT"6XL(Y(]0MHN5DN8V<2
MJNTAV4,?O5])P[D4,YQU##X:;]M)M2A5OKJTERRLWI;=>EU8\;-<VP649-C,
MUQ27L</>RI)73C>Z?+K'5/\ I'P)^V+XLT>^^-6K:79W,$K:=IVCV>I",>;
M-:FLI;JZ&4'R7]M!Y;O,P\\K&(97,&Z.OD"\M+:7?)%+$S$,^'<(&VL,88@
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M'%Q#-&H\S9\VY6*;6 #9# >9WG[8?AR43)9KKSSK(0D,E@BJX8C_ %964Y0
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MBFGL?A#J_B75]9T>]\/:MXNU[5=!NO$-_P",K[1=9\0:AJ-A=^-+O3VT>_\
M%.H6>H7$\5]XEGTTRZ=-K=Z)]1>UDN(C<!+FY$O*ZU\7O'&DWVIZK;_$?QU#
MJ6M>#+?X=:Q?6WCC6X=5UKP%:Z5!H5GX%U&?^T0;WPE;:1;6VCV6@79ETBTT
MRWM;&"UCMH(HX\[]J#P=#X2\;IJOAO4IFT#Q?87%_'#9S3QPQW]O<K'J-JH
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MMN__  3J\2'^T%N)%_;;^ (<+<07(0S?!KX]M*JD22NH9HX^P5?X< D#\?\
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M&GB?C.)\MED^'PD,!A:U_;U8-1EJW=\FDI7NVK._1Z,Y"/6+R"50;B2X7RT
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M(S$"OBW6/B9K'Q N3;+K$MAHJ$Q-Y<C17LY+%"WVA"KE)5 .  ,.,#BM,O\
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M%;),HQ%9)ZOGJ?5KS;DY--MOE:6R/23>Z0DHAC$TLMRX@ABDCLGS)*?+CW8
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MPB.,'8L9Q\N%/RX[# ]3@D8,VR3:"Y89R.-WS'IWP.#R2."NW#3S):7BLEY
MTH(,9.1R&!4MCDX*D\*-V2PP>E<M7!4ZE53IMT5U@O>3E:RD]8[.SM;6UKGV
M^6\7*5-X7,Z<:\8VIQFY>SE"G=1DHODDY-0<[2O=.SMHCF]+\>6]RS0:WIZL
M)"4$BHI3:V SD!2<]>O;C%?2'PS^)UAX$\)?&'PWHFD:3JT7QB\ 'X>WUW._
MDW>B:?-K&GZO/=6T:D"0RS:;#!)N!7;A<8)%?.=WX0A;Y[)A%NY6)GVAER>=
MRC@C'"L1D G'.XY"VE_I<S$1O"R8.8]TL3XP TC+N ( &.>C'/ P/.KXW%Y?
M/EG>I1U4JL8N+7:T4I>GQ:=;GV,>&LBXHPT*F7X^KAJ]-QE2HUJJKPFXR4G?
MGG22:2;6C][6Z-R\^&NF7FX6LP@<NS[TC5'WYVL01Z$$ ]"J@GJQJ/0_ FOZ
M3?+/_:;P6,39DB#'88E;+YW$\' )!SN+<#@4ZS\8ZHDL44L<;*N?G6-SNSNP
M#QN!&0K9&,CIWKO['6HKZ/RA*C3#_6'#(67 ^4B0+C)///3!YP!6V%S/+,1*
MU.K..)=KJ4G%7=TMVNM_ZW6+X:XMR; UL56P]+'X'#J/(X0C&;@K\[O!57K%
M*WGMN9-A\7O%G@_7_M?AZ6XL392H;:<73Q.TD9QE5+B-D<J6*8.<*>@-?<_@
MK_@I!XKLK:&P\8Z=8ZDD<<>;B1GM;@C 3=YL;LI.58!]H.3PN"#7Q-+;VD@Q
M<0&53)D("-P8!CYF"<L!DKE00=R^E8]UX6TJ[9G&^$MP"K#@;@0QX'4DKC'\
M(Z;>>^=?-\/5YJ.(4X<D'&BK6U3N^=-ZRW:Y=&K:GB87%\&9S%T,UP=7"XQ*
MTL1.$ES..BIJG*-))4U=*7/[R=[+8_8OPQ^W9\*]>BC&J->:5<M)\RJ5OHWR
M!P&"J2HXSU[C@=?4],_: ^#OB-Q)9>*M.M7D8C-Y(EMEL%L,DC;!N P-Q(W%
M1Z5^ =QX&N%)>RN(Y%/W5D(B;WRZX9F.2"6&3R1CC%:&U\5:2^Z"ZNXD3./W
MTDJC(QDH5PW/W<C(;YL@BMZ'%.9X.ZQF$YHMM755NT;O72B^BOOWZ[>KA>!>
M'\PA+^Q,YP=.:4O<J2@IN6MH*,JZ][F]U*^CT/Z-Y?%OAV]C1K37=,NH9\B%
MK:]@EWD#(VI'NR<G.&/!QWYKS?Q!X+L_%EPJ,)7MW?>V^/",?FY$;;@00>7
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MCTPN?7@5ZYX=^*'A*62V>?5=-C9F 6.?6=.B\Z0D8C59+I2TA&3M7)(!P,@
M=.&P].E1C"-:#2[OR_Q.VFB/&SO$0Q.(Q&(Q$(UJ]6;J2<:G+&<TN7G2C%\N
MW+RIR]3KI-!\2:]$UOHNGW9AD3:7=W$49.2V,;<X0QDDGOD**X2Y^#_B^UOS
M?W;QEXF8PQ. 002?F;..3QEB#QDX!YKZ-TSQS!<QDPVTDQ8;;>&!)/(\O;E9
M]S*J2 NSJ9XF>%Q&$5]R.!FZ[XBO(F&HWEH3;PIRD>(T YPSRNXB;!Q]V1N
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M.]X4U%<SLG>TDTDV]C\[?CW\)](CC>#0+5I[R5I@6 \X1*V?F#,&PXZ-P,'
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MMEGB$C)ZOXZ^%MO\&=2^#?BWQ+?KXL\#_$+P?X?^+%YI<=E?D?\ "/S,+O\
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M6H-&#&5B"GRE.5.#NV#G(7KDY!Z@]ZSM.U74='N'N]'O;O3+I0[&6UN9HA*
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J!';C"^E.\A?7'T51_(#UHHKGVU6C\M/RL>A[.G:WLX6[<D+?=R6_ __9

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
